Cluster ID;Oligomeric State;PDB ID query;Biological Assembly query;PDB ID target;Biological Assembly target;Type of alignment;Rank of alignment;Structural similarity;Query cover;Target cover;Structurally equivalent residue pairs;Query cover based on alignment length;Target cover based on alignment length;Typical distance error;RMSD;Sequenceidentity;Permutations;Query resolution;Target resolution;Query method;Target method;Query length;Target length;Query name;Target name;Query organism;Target organism;Query ligands;Target ligands;Query description;Target description;Target UniProt ID;Target Gene names;Target Pfam;Query UniProt ID;Query Gene names;Query Pfam;grupo;target pH;target Temperature;query pH;query Temperature;QueryChainID;TargetChainID;maxRMSD-T;maxRMSD-Q
1l3b;4;1l3b;2;1kxz;1;b;1;732;98;98;744;100;100;0.90;0.92;100;0;2.65;2.7;diffraction;diffraction;768;768;Precorrin-6y methyltransferase/putative decarboxylase;Precorrin-6y methyltransferase/putative decarboxylase;METHANOTHERMOBACTER THERMAUTOTROPHICUS;METHANOTHERMOBACTER THERMAUTOTROPHICUS;MSE   selenomethionine;MSE   selenomethionine;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, C2 SPACEGROUP W/ LONG CELL;MT0146, the Precorrin-6y methyltransferase (CbiT) homolog from M. Thermoautotrophicum, P1 spacegroup;O26249;cbiT MTH_146;PF13847;O26249;cbiT MTH_146;PF13847;b;7.50;100;7.5;100;1l3b_F;1l3i_B;1.07;0.92
1l3b;4;1l3b;2;1f38;1;b;1;732;98;98;744;100;100;0.88;0.89;100;0;2.65;2.4;diffraction;diffraction;768;768;Precorrin-6y methyltransferase/putative decarboxylase;PRECORRIN-8W DECARBOXYLASE;METHANOTHERMOBACTER THERMAUTOTROPHICUS;METHANOTHERMOBACTER THERMAUTOTROPHICUS;MSE   selenomethionine;MSE   selenomethionine;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, C2 SPACEGROUP W/ LONG CELL;X-RAY CRYSTALLOGRAPHIC STRUCTURE OF PRECORRIN 8W DECARBOXYLASE, THE PRODUCT OF GENE MT0146 IN THE METHANOBACTERIUM THERMOAUTOTROPHICUM GENOME;O26249;cbiT MTH_146;PF13847;O26249;cbiT MTH_146;PF13847;b;7.50;100;no/data;130;1l3b_F;1l3i_B;1.07;0.92
1l3b;4;1l3b;2;1l3i;1;b;1;732;98;98;744;100;100;0.90;0.92;100;0;2.65;1.95;diffraction;diffraction;768;768;Precorrin-6y methyltransferase/putative decarboxylase;Precorrin-6y methyltransferase/putative decarboxylase;METHANOTHERMOBACTER THERMAUTOTROPHICUS;METHANOTHERMOBACTER THERMAUTOTROPHICUS;MSE   selenomethionine;MSE   selenomethionine| SAH   s-adenosyl-l-homocysteine;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, C2 SPACEGROUP W/ LONG CELL;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, ADOHCY BINARY COMPLEX;O26249;cbiT MTH_146;PF13847;O26249;cbiT MTH_146;PF13847;b;7.50;100;7.50;100;1l3b_F;1l3i_B;1.07;0.92
1l3b;4;1l3b;2;1l3c;1;b;1;734;99;99;744;100;100;0.82;0.84;100;0;2.65;2.31;diffraction;diffraction;768;768;Precorrin-6y methyltransferase/putative decarboxylase;Precorrin-6y methyltransferase/putative decarboxylase;METHANOTHERMOBACTER THERMAUTOTROPHICUS;METHANOTHERMOBACTER THERMAUTOTROPHICUS;MSE   selenomethionine;MSE   selenomethionine;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, C2 SPACEGROUP W/ LONG CELL;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, C2 SPACEGROUP WITH SHORT CELL;O26249;cbiT MTH_146;PF13847;O26249;cbiT MTH_146;PF13847;b;7.50;100;7.50;100;1l3b_F;1l3i_B;1.07;0.92
1l3b;4;1kxz;1;1f38;1;b;1;738;99;99;744;100;100;0.65;0.65;100;0;2.7;2.4;diffraction;diffraction;768;768;Precorrin-6y methyltransferase/putative decarboxylase;PRECORRIN-8W DECARBOXYLASE;METHANOTHERMOBACTER THERMAUTOTROPHICUS;METHANOTHERMOBACTER THERMAUTOTROPHICUS;MSE   selenomethionine;MSE   selenomethionine;MT0146, the Precorrin-6y methyltransferase (CbiT) homolog from M. Thermoautotrophicum, P1 spacegroup;X-RAY CRYSTALLOGRAPHIC STRUCTURE OF PRECORRIN 8W DECARBOXYLASE, THE PRODUCT OF GENE MT0146 IN THE METHANOBACTERIUM THERMOAUTOTROPHICUM GENOME;O26249;cbiT MTH_146;PF13847;O26249;cbiT MTH_146;PF13847;b;7.5;100;no/data;130;1l3b_F;1l3i_B;1.07;0.92
1l3b;4;1kxz;1;1l3i;1;b;1;736;99;99;744;100;100;0.74;0.75;100;0;2.7;1.95;diffraction;diffraction;768;768;Precorrin-6y methyltransferase/putative decarboxylase;Precorrin-6y methyltransferase/putative decarboxylase;METHANOTHERMOBACTER THERMAUTOTROPHICUS;METHANOTHERMOBACTER THERMAUTOTROPHICUS;MSE   selenomethionine;MSE   selenomethionine| SAH   s-adenosyl-l-homocysteine;MT0146, the Precorrin-6y methyltransferase (CbiT) homolog from M. Thermoautotrophicum, P1 spacegroup;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, ADOHCY BINARY COMPLEX;O26249;cbiT MTH_146;PF13847;O26249;cbiT MTH_146;PF13847;b;7.5;100;7.50;100;1l3b_F;1l3i_B;1.07;0.92
1l3b;4;1kxz;1;1l3c;1;b;1;739;99;99;744;100;100;0.55;0.56;100;0;2.7;2.31;diffraction;diffraction;768;768;Precorrin-6y methyltransferase/putative decarboxylase;Precorrin-6y methyltransferase/putative decarboxylase;METHANOTHERMOBACTER THERMAUTOTROPHICUS;METHANOTHERMOBACTER THERMAUTOTROPHICUS;MSE   selenomethionine;MSE   selenomethionine;MT0146, the Precorrin-6y methyltransferase (CbiT) homolog from M. Thermoautotrophicum, P1 spacegroup;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, C2 SPACEGROUP WITH SHORT CELL;O26249;cbiT MTH_146;PF13847;O26249;cbiT MTH_146;PF13847;b;7.5;100;7.50;100;1l3b_F;1l3i_B;1.07;0.92
1l3b;4;1f38;1;1l3i;1;b;1;739;99;99;744;100;100;0.60;0.61;100;0;2.4;1.95;diffraction;diffraction;768;768;PRECORRIN-8W DECARBOXYLASE;Precorrin-6y methyltransferase/putative decarboxylase;METHANOTHERMOBACTER THERMAUTOTROPHICUS;METHANOTHERMOBACTER THERMAUTOTROPHICUS;MSE   selenomethionine;MSE   selenomethionine| SAH   s-adenosyl-l-homocysteine;X-RAY CRYSTALLOGRAPHIC STRUCTURE OF PRECORRIN 8W DECARBOXYLASE, THE PRODUCT OF GENE MT0146 IN THE METHANOBACTERIUM THERMOAUTOTROPHICUM GENOME;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, ADOHCY BINARY COMPLEX;O26249;cbiT MTH_146;PF13847;O26249;cbiT MTH_146;PF13847;b;no/data;130;7.50;100;1l3b_F;1l3i_B;1.07;0.92
1l3b;4;1f38;1;1l3c;1;b;1;741;100;100;744;100;100;0.45;0.45;100;0;2.4;2.31;diffraction;diffraction;768;768;PRECORRIN-8W DECARBOXYLASE;Precorrin-6y methyltransferase/putative decarboxylase;METHANOTHERMOBACTER THERMAUTOTROPHICUS;METHANOTHERMOBACTER THERMAUTOTROPHICUS;MSE   selenomethionine;MSE   selenomethionine;X-RAY CRYSTALLOGRAPHIC STRUCTURE OF PRECORRIN 8W DECARBOXYLASE, THE PRODUCT OF GENE MT0146 IN THE METHANOBACTERIUM THERMOAUTOTROPHICUM GENOME;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, C2 SPACEGROUP WITH SHORT CELL;O26249;cbiT MTH_146;PF13847;O26249;cbiT MTH_146;PF13847;b;no/data;130;7.50;100;1l3b_F;1l3i_B;1.07;0.92
1l3b;4;1l3i;1;1l3c;1;b;1;739;99;99;744;100;100;0.57;0.59;100;0;1.95;2.31;diffraction;diffraction;768;768;Precorrin-6y methyltransferase/putative decarboxylase;Precorrin-6y methyltransferase/putative decarboxylase;METHANOTHERMOBACTER THERMAUTOTROPHICUS;METHANOTHERMOBACTER THERMAUTOTROPHICUS;MSE   selenomethionine| SAH   s-adenosyl-l-homocysteine;MSE   selenomethionine;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, ADOHCY BINARY COMPLEX;MT0146, THE PRECORRIN-6Y METHYLTRANSFERASE (CBIT) HOMOLOG FROM M. THERMOAUTOTROPHICUM, C2 SPACEGROUP WITH SHORT CELL;O26249;cbiT MTH_146;PF13847;O26249;cbiT MTH_146;PF13847;b;7.50;100;7.50;100;1l3b_F;1l3i_B;1.07;0.92
2wzn;12;2wzn;1;2pe3;1;b;1;3932;97;99;3954;97;100;0.52;0.53;100;0;1.9;2.0;diffraction;diffraction;4248;4248;354AA LONG HYPOTHETICAL OPERON PROTEIN FRV;354aa long hypothetical operon protein Frv;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;GOL   glycerol| ZN   zinc ion| CL   chloride ion;no/data;3d structure of TET3 from Pyrococcus horikoshii;Crystal structure of Frv operon protein FRVX (PH1821)from pyrococcus horikoshii OT3;O59485;PH1821;PF05343;O59485;PH1821;PF05343;b;8.5;100;6.8;100;2wzn_A;2pe3_A;0.37;0.53
2yjv;3;2yjv;2;1q5x;1;b;1;468;99;99;470;100;99;0.40;0.41;100;0;2.8;2.0;diffraction;diffraction;27;483;ATP-DEPENDENT RNA HELICASE RHLB;REGULATOR OF RNASE E ACTIVITY A;ESCHERICHIA COLI| SYNTHETIC CONSTRUCT;ESCHERICHIA COLI;no/data;no/data;Crystal structure of E. coli regulator of ribonuclease activity A (RraA) bound to fragment of DEAD-box protein RhlB;Structure of OF RRAA (MENG), a protein inhibitor of RNA processing;P0A8R0;rraA menG yiiV b3929 JW3900;PF03737;P0A8R0;rraA menG yiiV b3929 JW3900;PF03737;a;5.4;100;5.2;103;2yjv_N;1q5x_A;1.72;0.41
4dbe;2;4dbe;1;4dbd;1;b;1;417;98;99;420;99;100;0.55;0.55;100;0;1.789;1.699;diffraction;diffraction;444;444;Orotidine 5'-phosphate decarboxylase;Orotidine 5'-phosphate decarboxylase;SULFOLOBUS SOLFATARICUS;SULFOLOBUS SOLFATARICUS;BMP   6-hydroxyuridine-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion;Crystal structure of orotidine 5'-monophosphate decarboxylase from Sulfolobus solfataricus complexed with inhibitor BMP;Crystal structure of orotidine 5'-monophosphate decarboxylase from Sulfolobus solfataricus;D0KT28;pyrF Ssol_1680;PF00215;D0KT28;pyrF Ssol_1680;PF00215;b;6.5;100;5.6;100;4dbe_B;4dbd_A;0.53;0.55
3wkq;3;3wkq;1;3x1n;1;b;1;889;99;99;891;99;100;0.32;0.32;100;0;1.15;1.55;diffraction;diffraction;969;1056;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS;GEOBACILLUS THERMODENITRIFICANS NG80-2;CU   copper (ii) ion| NA   sodium ion| FMT   formic acid| MPD   (4s)-2-methyl-2,4-pentanediol| EDO   1,2-ethanediol| SO4   sulfate ion;CU   copper (ii) ion| NO2   nitrite ion;Copper-containing nitrite reductase from Geobacillus thermodenitrificans in complex with formate;Nitrite-bound thermostable copper nitrite reductase at 320 K;A4IL26;nirK GTNG_0650;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.5;100;4.5;320;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3wkq;1;3wni;1;b;1;891;99;100;891;99;100;0.08;0.08;100;0;1.15;1.5;diffraction;diffraction;969;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| NA   sodium ion| FMT   formic acid| MPD   (4s)-2-methyl-2,4-pentanediol| EDO   1,2-ethanediol| SO4   sulfate ion;CU   copper (ii) ion| OXY   oxygen molecule| MPD   (4s)-2-methyl-2,4-pentanediol| PEG   di(hydroxyethyl)ether| ACY   acetic acid;Copper-containing nitrite reductase from Geobacillus thermodenitrificans in complex with formate;1.50 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans;A4IL26;nirK GTNG_0650;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.5;100;4.5;100;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3wkq;1;3wi9;1;b;1;886;99;97;888;99;98;0.33;0.35;99;0;1.15;1.3;diffraction;diffraction;969;972;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS;GEOBACILLUS KAUSTOPHILUS;CU   copper (ii) ion| NA   sodium ion| FMT   formic acid| MPD   (4s)-2-methyl-2,4-pentanediol| EDO   1,2-ethanediol| SO4   sulfate ion;CU   copper (ii) ion| ZN   zinc ion| NA   sodium ion| ACY   acetic acid| MPD   (4s)-2-methyl-2,4-pentanediol| SO4   sulfate ion;Copper-containing nitrite reductase from Geobacillus thermodenitrificans in complex with formate;Crystal structure of copper nitrite reductase from Geobacillus kaustophilus;A4IL26;nirK GTNG_0650;PF07731,PF07732;Q5L1X8;GK0767;PF07731,PF07732;b;4.5;100;4.6;100;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3wkq;1;3wnj;1;b;1;891;99;100;891;99;100;0.08;0.08;100;0;1.15;1.2;diffraction;diffraction;969;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| NA   sodium ion| FMT   formic acid| MPD   (4s)-2-methyl-2,4-pentanediol| EDO   1,2-ethanediol| SO4   sulfate ion;CU   copper (ii) ion| NA   sodium ion| OXY   oxygen molecule| MPD   (4s)-2-methyl-2,4-pentanediol| EDO   1,2-ethanediol| SO4   sulfate ion| ACY   acetic acid;Copper-containing nitrite reductase from Geobacillus thermodenitrificans in complex with formate;1.20 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans;A4IL26;nirK GTNG_0650;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.5;100;4.5;100;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3wkq;1;3wkp;1;b;1;885;99;100;885;99;100;0.11;0.11;100;0;1.15;1.901;diffraction;diffraction;969;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| NA   sodium ion| FMT   formic acid| MPD   (4s)-2-methyl-2,4-pentanediol| EDO   1,2-ethanediol| SO4   sulfate ion;CU   copper (ii) ion| NO2   nitrite ion| MPD   (4s)-2-methyl-2,4-pentanediol| PEG   di(hydroxyethyl)ether;Copper-containing nitrite reductase from Geobacillus thermodenitrificans in complex with formate;C135A mutant of Geobacillus thermodenitrificans copper-containing nitrite reductase in complex with nitrite;A4IL26;nirK GTNG_0650;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.5;100;4.5;no/data;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3x1n;1;3wni;1;b;1;892;100;100;894;100;100;0.32;0.32;100;0;1.55;1.5;diffraction;diffraction;1056;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS NG80-2;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| NO2   nitrite ion;CU   copper (ii) ion| OXY   oxygen molecule| MPD   (4s)-2-methyl-2,4-pentanediol| PEG   di(hydroxyethyl)ether| ACY   acetic acid;Nitrite-bound thermostable copper nitrite reductase at 320 K;1.50 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans;A4IL26;nirK GTNG_0650;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.5;320;4.5;100;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3x1n;1;3wi9;1;b;1;883;99;97;885;99;97;0.33;0.34;99;0;1.55;1.3;diffraction;diffraction;1056;972;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS NG80-2;GEOBACILLUS KAUSTOPHILUS;CU   copper (ii) ion| NO2   nitrite ion;CU   copper (ii) ion| ZN   zinc ion| NA   sodium ion| ACY   acetic acid| MPD   (4s)-2-methyl-2,4-pentanediol| SO4   sulfate ion;Nitrite-bound thermostable copper nitrite reductase at 320 K;Crystal structure of copper nitrite reductase from Geobacillus kaustophilus;A4IL26;nirK GTNG_0650;PF07731,PF07732;Q5L1X8;GK0767;PF07731,PF07732;b;4.5;320;4.6;100;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3x1n;1;3wnj;1;b;1;892;100;100;894;100;100;0.34;0.34;100;0;1.55;1.2;diffraction;diffraction;1056;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS NG80-2;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| NO2   nitrite ion;CU   copper (ii) ion| NA   sodium ion| OXY   oxygen molecule| MPD   (4s)-2-methyl-2,4-pentanediol| EDO   1,2-ethanediol| SO4   sulfate ion| ACY   acetic acid;Nitrite-bound thermostable copper nitrite reductase at 320 K;1.20 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans;A4IL26;nirK GTNG_0650;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.5;320;4.5;100;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3x1n;1;3wkp;1;b;1;883;99;100;885;99;100;0.33;0.33;100;0;1.55;1.901;diffraction;diffraction;1056;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS NG80-2;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| NO2   nitrite ion;CU   copper (ii) ion| NO2   nitrite ion| MPD   (4s)-2-methyl-2,4-pentanediol| PEG   di(hydroxyethyl)ether;Nitrite-bound thermostable copper nitrite reductase at 320 K;C135A mutant of Geobacillus thermodenitrificans copper-containing nitrite reductase in complex with nitrite;A4IL26;nirK GTNG_0650;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.5;320;4.5;no/data;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3wni;1;3wi9;1;b;1;884;99;97;885;99;97;0.23;0.24;100;0;1.5;1.3;diffraction;diffraction;969;972;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS;GEOBACILLUS KAUSTOPHILUS;CU   copper (ii) ion| OXY   oxygen molecule| MPD   (4s)-2-methyl-2,4-pentanediol| PEG   di(hydroxyethyl)ether| ACY   acetic acid;CU   copper (ii) ion| ZN   zinc ion| NA   sodium ion| ACY   acetic acid| MPD   (4s)-2-methyl-2,4-pentanediol| SO4   sulfate ion;1.50 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans;Crystal structure of copper nitrite reductase from Geobacillus kaustophilus;A4IL26;nirK GTNG_0650;PF07731,PF07732;Q5L1X8;GK0767;PF07731,PF07732;b;4.5;100;4.6;100;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3wni;1;3wnj;1;b;1;894;100;100;894;100;100;0.09;0.09;100;0;1.5;1.2;diffraction;diffraction;969;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| OXY   oxygen molecule| MPD   (4s)-2-methyl-2,4-pentanediol| PEG   di(hydroxyethyl)ether| ACY   acetic acid;CU   copper (ii) ion| NA   sodium ion| OXY   oxygen molecule| MPD   (4s)-2-methyl-2,4-pentanediol| EDO   1,2-ethanediol| SO4   sulfate ion| ACY   acetic acid;1.50 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans;1.20 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans;A4IL26;nirK GTNG_0650;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.5;100;4.5;100;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3wni;1;3wkp;1;b;1;885;99;100;885;99;100;0.12;0.12;100;0;1.5;1.901;diffraction;diffraction;969;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| OXY   oxygen molecule| MPD   (4s)-2-methyl-2,4-pentanediol| PEG   di(hydroxyethyl)ether| ACY   acetic acid;CU   copper (ii) ion| NO2   nitrite ion| MPD   (4s)-2-methyl-2,4-pentanediol| PEG   di(hydroxyethyl)ether;1.50 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans;C135A mutant of Geobacillus thermodenitrificans copper-containing nitrite reductase in complex with nitrite;A4IL26;nirK GTNG_0650;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.5;100;4.5;no/data;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3wi9;1;3wnj;1;b;1;884;97;99;885;97;99;0.25;0.25;100;0;1.3;1.2;diffraction;diffraction;972;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS KAUSTOPHILUS;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| ZN   zinc ion| NA   sodium ion| ACY   acetic acid| MPD   (4s)-2-methyl-2,4-pentanediol| SO4   sulfate ion;CU   copper (ii) ion| NA   sodium ion| OXY   oxygen molecule| MPD   (4s)-2-methyl-2,4-pentanediol| EDO   1,2-ethanediol| SO4   sulfate ion| ACY   acetic acid;Crystal structure of copper nitrite reductase from Geobacillus kaustophilus;1.20 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans;Q5L1X8;GK0767;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.6;100;4.5;100;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3wi9;1;3wkp;1;b;1;884;97;100;885;97;100;0.24;0.25;99;0;1.3;1.901;diffraction;diffraction;972;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS KAUSTOPHILUS;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| ZN   zinc ion| NA   sodium ion| ACY   acetic acid| MPD   (4s)-2-methyl-2,4-pentanediol| SO4   sulfate ion;CU   copper (ii) ion| NO2   nitrite ion| MPD   (4s)-2-methyl-2,4-pentanediol| PEG   di(hydroxyethyl)ether;Crystal structure of copper nitrite reductase from Geobacillus kaustophilus;C135A mutant of Geobacillus thermodenitrificans copper-containing nitrite reductase in complex with nitrite;Q5L1X8;GK0767;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.6;100;4.5;no/data;3wkq_A;3wi9_A;0.35;0.35
3wkq;3;3wnj;1;3wkp;1;b;1;885;99;100;885;99;100;0.14;0.14;100;0;1.2;1.901;diffraction;diffraction;969;969;Nitrite reductase;Nitrite reductase;GEOBACILLUS THERMODENITRIFICANS;GEOBACILLUS THERMODENITRIFICANS;CU   copper (ii) ion| NA   sodium ion| OXY   oxygen molecule| MPD   (4s)-2-methyl-2,4-pentanediol| EDO   1,2-ethanediol| SO4   sulfate ion| ACY   acetic acid;CU   copper (ii) ion| NO2   nitrite ion| MPD   (4s)-2-methyl-2,4-pentanediol| PEG   di(hydroxyethyl)ether;1.20 A resolution crystal structure of dioxygen bound copper-containing nitrite reductase from Geobacillus thermodenitrificans;C135A mutant of Geobacillus thermodenitrificans copper-containing nitrite reductase in complex with nitrite;A4IL26;nirK GTNG_0650;PF07731,PF07732;A4IL26;nirK GTNG_0650;PF07731,PF07732;b;4.5;100;4.5;no/data;3wkq_A;3wi9_A;0.35;0.35
3ddw;2;3ddw;1;1xoi;1;b;1;1575;98;98;1585;98;99;0.54;0.56;100;0;1.9;2.1;diffraction;diffraction;1696;1692;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;2zb2;1;b;1;1577;98;99;1585;98;100;0.50;0.53;100;0;1.9;2.45;diffraction;diffraction;1696;1698;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;3ceh;1;b;1;1576;98;99;1584;98;100;0.49;0.49;100;0;1.9;2.8;diffraction;diffraction;1696;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;2ati;1;b;1;1576;98;100;1579;98;100;0.30;0.30;100;0;1.9;1.9;diffraction;diffraction;1696;1692;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;Glycogen Phosphorylase Inhibitors;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;no/data;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;1fa9;1;c;1;1360;84;82;1562;97;94;2.60;2.68;96;0;1.9;2.4;diffraction;diffraction;1696;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;8.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;1exv;1;b;1;1565;97;100;1572;98;100;0.45;0.45;100;0;1.9;2.4;diffraction;diffraction;1696;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;1l5q;2;b;1;1573;98;100;1580;98;100;0.45;0.45;100;0;1.9;2.25;diffraction;diffraction;1696;1694;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;1fc0;1;b;1;1578;98;100;1583;98;100;0.38;0.38;100;0;1.9;2.4;diffraction;diffraction;1696;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;3dds;1;b;1;1609;100;100;1611;100;100;0.26;0.26;100;0;1.9;1.8;diffraction;diffraction;1696;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;1em6;1;b;1;1560;97;99;1569;97;100;0.52;0.52;100;0;1.9;2.2;diffraction;diffraction;1696;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;3dd1;1;b;1;1610;100;100;1611;100;100;0.17;0.17;100;0;1.9;2.57;diffraction;diffraction;1696;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;3cem;1;b;1;1575;98;99;1585;98;100;0.55;0.55;100;0;1.9;2.47;diffraction;diffraction;1696;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ddw;1;3cej;1;b;1;1566;97;99;1578;98;100;0.61;0.61;100;0;1.9;3.3;diffraction;diffraction;1696;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 055   (2s)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK055;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;2zb2;1;b;1;1574;98;99;1578;98;99;0.37;0.38;100;0;2.1;2.45;diffraction;diffraction;1692;1698;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;3ceh;1;b;1;1574;98;99;1580;98;99;0.42;0.43;100;0;2.1;2.8;diffraction;diffraction;1692;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;2ati;1;b;1;1574;98;99;1580;98;100;0.43;0.44;100;0;2.1;1.9;diffraction;diffraction;1692;1692;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;Glycogen Phosphorylase Inhibitors;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;no/data;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;1fa9;1;c;1;1321;82;79;1537;96;92;2.72;2.83;95;0;2.1;2.4;diffraction;diffraction;1692;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;8.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;1exv;1;b;1;1565;97;100;1568;98;100;0.30;0.30;100;0;2.1;2.4;diffraction;diffraction;1692;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;1l5q;2;b;1;1573;98;99;1576;98;100;0.30;0.30;100;0;2.1;2.25;diffraction;diffraction;1692;1694;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;1fc0;1;b;1;1577;98;100;1581;98;100;0.34;0.35;100;0;2.1;2.4;diffraction;diffraction;1692;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;3dds;1;b;1;1575;98;98;1587;99;98;0.60;0.62;100;0;2.1;1.8;diffraction;diffraction;1692;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;1em6;1;b;1;1559;97;99;1568;98;100;0.53;0.57;100;0;2.1;2.2;diffraction;diffraction;1692;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;3dd1;1;b;1;1576;98;98;1584;99;98;0.50;0.51;100;0;2.1;2.57;diffraction;diffraction;1692;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;3cem;1;b;1;1576;98;99;1580;98;99;0.37;0.38;100;0;2.1;2.47;diffraction;diffraction;1692;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1xoi;1;3cej;1;b;1;1562;97;99;1577;98;100;0.69;0.70;99;0;2.1;3.3;diffraction;diffraction;1692;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 288   5-chloro-1h-indole-2-carboxylic acid{[cyclopentyl-(2-hydroxy-ethyl)-carbamoyl]-methyl}-amide;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;Human Liver Glycogen Phosphorylase A complexed with Chloroindoloyl glycine amide;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;3ceh;1;b;1;1574;99;99;1580;99;99;0.43;0.44;100;0;2.45;2.8;diffraction;diffraction;1698;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;2ati;1;b;1;1573;99;99;1578;99;100;0.38;0.38;100;0;2.45;1.9;diffraction;diffraction;1698;1692;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;Glycogen Phosphorylase Inhibitors;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;no/data;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;1fa9;1;c;1;1335;84;80;1544;97;93;2.67;2.75;95;0;2.45;2.4;diffraction;diffraction;1698;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;8.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;1exv;1;b;1;1566;99;100;1570;99;100;0.35;0.35;100;0;2.45;2.4;diffraction;diffraction;1698;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;1l5q;2;b;1;1560;98;99;1579;99;100;0.76;0.81;97;0;2.45;2.25;diffraction;diffraction;1698;1694;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;1fc0;1;b;1;1569;99;99;1577;99;99;0.51;0.51;100;0;2.45;2.4;diffraction;diffraction;1698;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;3dds;1;b;1;1575;99;98;1584;100;98;0.52;0.54;100;0;2.45;1.8;diffraction;diffraction;1698;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;1em6;1;b;1;1568;99;100;1573;99;100;0.39;0.40;100;0;2.45;2.2;diffraction;diffraction;1698;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;3dd1;1;b;1;1577;99;98;1584;100;98;0.45;0.46;100;0;2.45;2.57;diffraction;diffraction;1698;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;3cem;1;b;1;1559;98;98;1582;100;100;0.84;0.88;97;0;2.45;2.47;diffraction;diffraction;1698;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2zb2;1;3cej;1;b;1;1568;99;99;1576;99;100;0.49;0.49;100;0;2.45;3.3;diffraction;diffraction;1698;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| A46   5-chloro-n-{4-[(1r)-1,2-dihydroxyethyl]phenyl}-1h-indole-2-carboxamide| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;Human liver glycogen phosphorylase a complexed with glcose and 5-chloro-N-[4-(1,2-dihydroxyethyl)phenyl]-1H-indole-2-carboxamide;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ceh;1;2ati;1;b;1;1576;99;100;1581;100;100;0.40;0.40;100;0;2.8;1.9;diffraction;diffraction;1618;1692;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;Glycogen Phosphorylase Inhibitors;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;100;no/data;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ceh;1;1fa9;1;c;1;1330;84;80;1527;96;92;2.60;2.69;95;0;2.8;2.4;diffraction;diffraction;1618;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;100;8.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ceh;1;1exv;1;b;1;1564;98;99;1570;99;100;0.44;0.44;100;0;2.8;2.4;diffraction;diffraction;1618;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ceh;1;1l5q;2;b;1;1574;99;100;1580;99;100;0.42;0.42;100;0;2.8;2.25;diffraction;diffraction;1618;1694;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ceh;1;1fc0;1;b;1;1577;99;100;1582;100;100;0.38;0.38;100;0;2.8;2.4;diffraction;diffraction;1618;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ceh;1;3dds;1;b;1;1575;99;98;1584;100;98;0.53;0.53;100;0;2.8;1.8;diffraction;diffraction;1618;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ceh;1;1em6;1;b;1;1560;98;99;1569;99;100;0.53;0.53;100;0;2.8;2.2;diffraction;diffraction;1618;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ceh;1;3dd1;1;b;1;1578;99;98;1584;100;98;0.45;0.45;100;0;2.8;2.57;diffraction;diffraction;1618;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ceh;1;3cem;1;b;1;1583;100;100;1587;100;100;0.36;0.36;100;0;2.8;2.47;diffraction;diffraction;1618;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3ceh;1;3cej;1;b;1;1573;99;100;1580;99;100;0.46;0.46;100;0;2.8;3.3;diffraction;diffraction;1618;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| MES   2-(n-morpholino)-ethanesulfonic acid| PLP   pyridoxal-5'-phosphate| AVE   4-[3-(2-chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2ati;1;1fa9;1;c;1;1292;82;77;1508;95;90;2.76;2.88;94;1;1.9;2.4;diffraction;diffraction;1692;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;Glycogen Phosphorylase Inhibitors;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;no/data;100;8.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2ati;1;1exv;1;b;1;1563;99;99;1570;99;100;0.46;0.47;100;0;1.9;2.4;diffraction;diffraction;1692;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;Glycogen Phosphorylase Inhibitors;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;no/data;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2ati;1;1l5q;2;b;1;1573;99;99;1578;100;100;0.40;0.40;100;0;1.9;2.25;diffraction;diffraction;1692;1694;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;Glycogen Phosphorylase Inhibitors;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;no/data;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2ati;1;1fc0;1;b;1;1563;99;99;1581;100;100;0.76;0.80;97;0;1.9;2.4;diffraction;diffraction;1692;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;Glycogen Phosphorylase Inhibitors;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;no/data;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2ati;1;3dds;1;b;1;1574;99;98;1579;100;98;0.41;0.41;100;0;1.9;1.8;diffraction;diffraction;1692;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Glycogen Phosphorylase Inhibitors;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;no/data;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2ati;1;1em6;1;b;1;1535;97;97;1572;99;100;1.09;1.15;94;0;1.9;2.2;diffraction;diffraction;1692;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;Glycogen Phosphorylase Inhibitors;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;no/data;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2ati;1;3dd1;1;b;1;1576;100;98;1579;100;98;0.29;0.29;100;0;1.9;2.57;diffraction;diffraction;1692;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Glycogen Phosphorylase Inhibitors;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;no/data;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2ati;1;3cem;1;b;1;1579;100;99;1582;100;100;0.28;0.28;100;0;1.9;2.47;diffraction;diffraction;1692;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;Glycogen Phosphorylase Inhibitors;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;no/data;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;2ati;1;3cej;1;b;1;1570;99;99;1580;100;100;0.54;0.55;100;0;1.9;3.3;diffraction;diffraction;1692;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;GLC   alpha-d-glucose| IHU   n-(2-chloro-4-fluorobenzoyl)-n'-(5-hydroxy-2-methoxyphenyl)urea| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;Glycogen Phosphorylase Inhibitors;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;no/data;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fa9;1;1exv;1;c;1;1286;77;82;1517;91;97;2.84;3.02;95;0;2.4;2.4;diffraction;diffraction;1692;1694;GLYCOGEN PHOSPHORYLASE, LIVER FORM;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;8.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fa9;1;1l5q;2;c;1;1329;80;84;1529;92;97;2.62;2.71;94;0;2.4;2.25;diffraction;diffraction;1692;1694;GLYCOGEN PHOSPHORYLASE, LIVER FORM;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;8.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fa9;1;1fc0;1;c;1;1333;80;84;1529;92;96;2.60;2.68;96;0;2.4;2.4;diffraction;diffraction;1692;1692;GLYCOGEN PHOSPHORYLASE, LIVER FORM;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;8.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fa9;1;3dds;1;c;1;1355;81;84;1534;92;95;2.47;2.54;95;0;2.4;1.8;diffraction;diffraction;1692;1696;GLYCOGEN PHOSPHORYLASE, LIVER FORM;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;8.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fa9;1;1em6;1;c;1;1304;78;83;1517;91;96;2.72;2.82;95;0;2.4;2.2;diffraction;diffraction;1692;1694;GLYCOGEN PHOSPHORYLASE, LIVER FORM;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;8.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fa9;1;3dd1;1;c;1;1313;79;81;1534;92;95;2.76;2.87;90;0;2.4;2.57;diffraction;diffraction;1692;1696;GLYCOGEN PHOSPHORYLASE, LIVER FORM;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;8.5;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fa9;1;3cem;1;c;1;1331;80;84;1531;92;96;2.62;2.71;96;0;2.4;2.47;diffraction;diffraction;1692;1618;GLYCOGEN PHOSPHORYLASE, LIVER FORM;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;8.5;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fa9;1;3cej;1;c;1;1244;75;79;1468;88;93;2.85;3.00;90;2;2.4;3.3;diffraction;diffraction;1692;1618;GLYCOGEN PHOSPHORYLASE, LIVER FORM;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| GLC   alpha-d-glucose| AMP   adenosine monophosphate| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH AMP;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;8.5;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1exv;1;1l5q;2;b;1;1568;100;99;1570;100;99;0.24;0.24;100;0;2.4;2.25;diffraction;diffraction;1694;1694;LIVER GLYCOGEN PHOSPHORYLASE;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1exv;1;1fc0;1;b;1;1568;100;99;1572;100;99;0.36;0.36;100;0;2.4;2.4;diffraction;diffraction;1694;1692;LIVER GLYCOGEN PHOSPHORYLASE;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1exv;1;3dds;1;b;1;1565;100;97;1572;100;97;0.48;0.48;100;0;2.4;1.8;diffraction;diffraction;1694;1696;LIVER GLYCOGEN PHOSPHORYLASE;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1exv;1;1em6;1;b;1;1559;99;99;1564;99;99;0.40;0.40;100;0;2.4;2.2;diffraction;diffraction;1694;1694;LIVER GLYCOGEN PHOSPHORYLASE;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1exv;1;3dd1;1;b;1;1566;100;97;1572;100;97;0.43;0.43;100;0;2.4;2.57;diffraction;diffraction;1694;1696;LIVER GLYCOGEN PHOSPHORYLASE;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1exv;1;3cem;1;b;1;1566;100;99;1570;100;99;0.35;0.35;100;0;2.4;2.47;diffraction;diffraction;1694;1618;LIVER GLYCOGEN PHOSPHORYLASE;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1exv;1;3cej;1;b;1;1537;98;97;1572;100;99;1.06;1.11;94;0;2.4;3.3;diffraction;diffraction;1694;1618;LIVER GLYCOGEN PHOSPHORYLASE;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-403,700;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1l5q;2;1fc0;1;b;1;1574;100;99;1578;100;100;0.37;0.37;100;0;2.25;2.4;diffraction;diffraction;1694;1692;Glycogen phosphorylase, liver form;GLYCOGEN PHOSPHORYLASE, LIVER FORM;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1l5q;2;3dds;1;b;1;1573;100;98;1580;100;98;0.46;0.46;100;0;2.25;1.8;diffraction;diffraction;1694;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1l5q;2;1em6;1;b;1;1562;99;99;1569;99;100;0.48;0.49;100;0;2.25;2.2;diffraction;diffraction;1694;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1l5q;2;3dd1;1;b;1;1574;100;97;1580;100;98;0.44;0.44;100;0;2.25;2.57;diffraction;diffraction;1694;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1l5q;2;3cem;1;b;1;1576;100;99;1580;100;99;0.36;0.37;100;0;2.25;2.47;diffraction;diffraction;1694;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1l5q;2;3cej;1;b;1;1568;99;99;1578;100;100;0.55;0.56;100;0;2.25;3.3;diffraction;diffraction;1694;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| 700   [5-chloro-1h-indol-2-carbonyl-phenylalaninyl]-azetidine-3-carboxylic acid| CFF   caffeine;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;Human liver glycogen phosphorylase a complexed with caffeine, N-Acetyl-beta-D-glucopyranosylamine, and CP-403700;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fc0;1;3dds;1;b;1;1576;99;98;1583;100;98;0.47;0.47;100;0;2.4;1.8;diffraction;diffraction;1692;1696;GLYCOGEN PHOSPHORYLASE, LIVER FORM;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fc0;1;1em6;1;b;1;1564;99;99;1569;99;100;0.40;0.41;100;0;2.4;2.2;diffraction;diffraction;1692;1694;GLYCOGEN PHOSPHORYLASE, LIVER FORM;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fc0;1;3dd1;1;b;1;1579;100;98;1583;100;98;0.35;0.35;100;0;2.4;2.57;diffraction;diffraction;1692;1696;GLYCOGEN PHOSPHORYLASE, LIVER FORM;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fc0;1;3cem;1;b;1;1578;100;99;1581;100;100;0.32;0.32;100;0;2.4;2.47;diffraction;diffraction;1692;1618;GLYCOGEN PHOSPHORYLASE, LIVER FORM;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1fc0;1;3cej;1;b;1;1564;99;99;1579;100;100;0.69;0.70;99;0;2.4;3.3;diffraction;diffraction;1692;1618;GLYCOGEN PHOSPHORYLASE, LIVER FORM;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE COMPLEXED WITH N-ACETYL-BETA-D-GLUCOPYRANOSYLAMINE;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3dds;1;1em6;1;b;1;1557;97;99;1569;97;100;0.62;0.62;100;0;1.8;2.2;diffraction;diffraction;1696;1694;Glycogen phosphorylase, liver form;LIVER GLYCOGEN PHOSPHORYLASE;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3dds;1;3dd1;1;b;1;1610;100;100;1613;100;100;0.31;0.31;100;0;1.8;2.57;diffraction;diffraction;1696;1696;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3dds;1;3cem;1;b;1;1574;98;99;1585;98;100;0.57;0.58;100;0;1.8;2.47;diffraction;diffraction;1696;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3dds;1;3cej;1;b;1;1563;97;99;1578;98;100;0.68;0.68;100;0;1.8;3.3;diffraction;diffraction;1696;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PO4   phosphate ion| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 26B   o-tert-butyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-l-threonine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;Crystal structure of glycogen phosphorylase complexed with an anthranilimide based inhibitor GSK261;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1em6;1;3dd1;1;b;1;1562;99;97;1569;100;97;0.48;0.48;100;0;2.2;2.57;diffraction;diffraction;1694;1696;LIVER GLYCOGEN PHOSPHORYLASE;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.0;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1em6;1;3cem;1;b;1;1563;99;98;1570;100;99;0.48;0.49;100;0;2.2;2.47;diffraction;diffraction;1694;1618;LIVER GLYCOGEN PHOSPHORYLASE;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;1em6;1;3cej;1;b;1;1535;98;97;1570;100;99;1.04;1.10;94;0;2.2;3.3;diffraction;diffraction;1694;1618;LIVER GLYCOGEN PHOSPHORYLASE;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| CP4   bis[5-chloro-1h-indol-2-yl-carbonyl-aminoethyl]-ethylene glycol| PLP   pyridoxal-5'-phosphate| MPD   (4s)-2-methyl-2,4-pentanediol;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;HUMAN LIVER GLYCOGEN PHOSPHORYLASE A COMPLEXED WITH GLCNAC AND CP-526,423;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3dd1;1;3cem;1;b;1;1580;98;100;1584;98;100;0.34;0.35;100;0;2.57;2.47;diffraction;diffraction;1696;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;no/data;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3dd1;1;3cej;1;b;1;1568;97;99;1578;98;100;0.57;0.57;100;0;2.57;3.3;diffraction;diffraction;1696;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;SEP   phosphoserine| NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| CFF   caffeine| 25D   2-cyclohexyl-n-[(3-{[(2,4,6-trimethylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]-d-alanine| MPD   (4s)-2-methyl-2,4-pentanediol| MES   2-(n-morpholino)-ethanesulfonic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;Crystal structure of glycogen phophorylase complexed with an anthranilimide based inhibitor GSK254;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.0;100;6.5;100;1xoi_B;1fa9_A;1.35;3.02
3ddw;2;3cem;1;3cej;1;b;1;1573;99;100;1580;99;100;0.48;0.48;100;0;2.47;3.3;diffraction;diffraction;1618;1618;Glycogen phosphorylase, liver form;Glycogen phosphorylase, liver form;HOMO SAPIENS;HOMO SAPIENS;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVD   1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;NBG   1-n-acetyl-beta-d-glucosamine| PLP   pyridoxal-5'-phosphate| AVF   1-{2-[3-(2-chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423;Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865;P06737;PYGL;PF00343;P06737;PYGL;PF00343;c;6.5;no/data;6.5;100;1xoi_B;1fa9_A;1.35;3.02
4x1e;2;4x1e;1;3loc;1;b;1;348;89;87;382;98;95;2.14;2.21;99;0;2.4;2.5;diffraction;diffraction;440;424;HTH-type transcriptional regulator RutR;HTH-type transcriptional regulator rutR;ESCHERICHIA COLI O6:H1;ESCHERICHIA COLI;no/data;MSE   selenomethionine| URA   uracil;Crystal structure of unliganded E. coli transcriptional regulator RutR, W167A mutant;Crystal structure of putative transcriptional regulator ycdc;P0ACU2;rutR ycdC b1013 JW0998;PF08362,PF00440;P0ACU2;rutR ycdC b1013 JW0998;PF08362,PF00440;b;8.5;100;7;200;4x1e_B;3loc_A;1.94;2.21
4x1e;2;4x1e;1;4jyk;1;b;1;350;89;88;380;97;96;2.02;2.08;99;0;2.4;1.7;diffraction;diffraction;440;424;HTH-type transcriptional regulator RutR;HTH-type transcriptional regulator RutR;ESCHERICHIA COLI O6:H1;ESCHERICHIA COLI;no/data;SO4   sulfate ion| URA   uracil;Crystal structure of unliganded E. coli transcriptional regulator RutR, W167A mutant;Structure of E. coli Transcriptional Regulator RutR with bound uracil;P0ACU2;rutR ycdC b1013 JW0998;PF08362,PF00440;P0ACU2;rutR ycdC b1013 JW0998;PF08362,PF00440;b;8.5;100;5.5;100;4x1e_B;3loc_A;1.94;2.21
4x1e;2;3loc;1;4jyk;1;b;1;388;97;98;397;99;100;1.05;1.07;100;0;2.5;1.7;diffraction;diffraction;424;424;HTH-type transcriptional regulator rutR;HTH-type transcriptional regulator RutR;ESCHERICHIA COLI;ESCHERICHIA COLI;MSE   selenomethionine| URA   uracil;SO4   sulfate ion| URA   uracil;Crystal structure of putative transcriptional regulator ycdc;Structure of E. coli Transcriptional Regulator RutR with bound uracil;P0ACU2;rutR ycdC b1013 JW0998;PF08362,PF00440;P0ACU2;rutR ycdC b1013 JW0998;PF08362,PF00440;b;7;200;5.5;100;4x1e_B;3loc_A;1.94;2.21
1szz;2;1szz;3;1vez;2;b;1;332;97;97;336;98;98;0.79;0.85;99;0;3.3;2.3;diffraction;diffraction;354;354;Peptide deformylase;Peptide deformylase;LEPTOSPIRA INTERROGANS;LEPTOSPIRA INTERROGANS;ZN   zinc ion| BB2   actinonin;ZN   zinc ion| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| FMT   formic acid;Crystal structure of peptide deformylase from Leptospira Interrogans complexed with inhibitor actinonin;Crystal Structure of Peptide Deformylase from Leptospira Interrogans(LiPDF) at pH8.0;Q93LE9;def pdf LA_2438;PF01327;Q93LE9;def pdf LA_2438;PF01327;b;7.5;293;8.0;100;1szz_B;1vez_A;1.08;0.94
1szz;2;1szz;3;1vev;2;b;1;332;97;97;337;99;99;0.88;0.94;99;0;3.3;2.51;diffraction;diffraction;354;354;Peptide deformylase;Peptide deformylase;LEPTOSPIRA INTERROGANS;LEPTOSPIRA INTERROGANS;ZN   zinc ion| BB2   actinonin;ZN   zinc ion| MES   2-(n-morpholino)-ethanesulfonic acid| FMT   formic acid;Crystal structure of peptide deformylase from Leptospira Interrogans complexed with inhibitor actinonin;Crystal structure of peptide deformylase from Leptospira Interrogans (LiPDF) at pH6.5;Q93LE9;def pdf LA_2438;PF01327;Q93LE9;def pdf LA_2438;PF01327;b;7.5;293;6.5;100;1szz_B;1vez_A;1.08;0.94
1szz;2;1vez;2;1vev;2;b;1;341;100;100;342;100;100;0.42;0.43;100;0;2.3;2.51;diffraction;diffraction;354;354;Peptide deformylase;Peptide deformylase;LEPTOSPIRA INTERROGANS;LEPTOSPIRA INTERROGANS;ZN   zinc ion| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| FMT   formic acid;ZN   zinc ion| MES   2-(n-morpholino)-ethanesulfonic acid| FMT   formic acid;Crystal Structure of Peptide Deformylase from Leptospira Interrogans(LiPDF) at pH8.0;Crystal structure of peptide deformylase from Leptospira Interrogans (LiPDF) at pH6.5;Q93LE9;def pdf LA_2438;PF01327;Q93LE9;def pdf LA_2438;PF01327;b;8.0;100;6.5;100;1szz_B;1vez_A;1.08;0.94
1yta;2;1yta;2;2igi;1;b;1;346;96;96;357;99;99;1.23;1.27;100;0;2.2;1.7;diffraction;diffraction;360;360;Oligoribonuclease;Oligoribonuclease;ESCHERICHIA COLI;ESCHERICHIA COLI;MSE   selenomethionine| FLC   citrate anion;ZN   zinc ion| CD   cadmium ion| ACY   acetic acid;Crystal Structure of Oligoribonuclease, the lone essential exoribonuclease in Escherichia coli;Crystal Structure of E. coli Oligoribonuclease;P0A784;orn o204a yjeR b4162 JW5740;PF00929;P0A784;orn o204a yjeR b4162 JW5740;PF00929;b;7.5;100;7.5;100;1yta_B;2igi_A;1.50;1.27
3orr;2;3orr;1;3orq;1;b;1;723;98;98;732;100;99;0.76;0.79;100;0;2.23;2.23;diffraction;diffraction;754;754;N5-carboxyaminoimidazole ribonucleotide synthetase;N5-Carboxyaminoimidazole ribonucleotide synthetase;STAPHYLOCOCCUS AUREUS SUBSP. AUREUS;STAPHYLOCOCCUS AUREUS SUBSP. AUREUS;MSE   selenomethionine;MSE   selenomethionine| ADP   adenosine-5'-diphosphate| MG   magnesium ion| GOL   glycerol| POP   pyrophosphate 2-;Crystal Structure of N5-Carboxyaminoimidazole synthetase from Staphylococcus aureus;Crystal Structure of N5-Carboxyaminoimidazole synthetase from Staphylococcus aureus complexed with ADP;A0A0H3KFM7;purK NWMN_0934;PF02826,PF02222,PF17769;A0A0H3KFM7;purK NWMN_0934;PF02826,PF02222,PF17769;b;6.5;77;6.5;77;3orq_A;3orq_B;1.17;0.79
1f6k;4;1f6k;1;1f7b;1;b;1;1155;100;100;1156;100;100;0.23;0.23;100;0;1.6;1.8;diffraction;diffraction;1172;1172;N-ACETYLNEURAMINATE LYASE;N-ACETYL-NEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;SO4   sulfate ion| GOL   glycerol;CL   chloride ion| NAV   6,7,8,9-tetrahydroxy-5-methylcarboxamido-4-oxononanoic acid| NAU   4,4,6,7,8,9-hexahydroxy-5-methylcarboxamidononanoic acid;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II IN COMPLEX WITH 4-OXO-SIALIC ACID;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;4.6;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f6k;1;1f6p;1;b;1;1152;100;98;1156;100;99;0.39;0.39;100;0;1.6;2.25;diffraction;diffraction;1172;1172;N-ACETYLNEURAMINATE LYASE;N-ACETYL NEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;SO4   sulfate ion| GOL   glycerol;no/data;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;4.6;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f6k;1;1f73;1;b;1;1140;99;99;1146;99;99;0.51;0.52;100;0;1.6;1.95;diffraction;diffraction;1172;1172;N-ACETYLNEURAMINATE LYASE;N-ACETYL NEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;SO4   sulfate ion| GOL   glycerol;HMN   2,4,6,7,8,9-hexahydroxy-5-methylcarboxamido nonanoic acid| GOL   glycerol;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III IN COMPLEX WITH SIALIC ACID ALDITOL;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;4.6;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f6k;1;1f74;1;b;1;1135;98;97;1138;98;97;0.35;0.36;100;0;1.6;1.6;diffraction;diffraction;1172;1172;N-ACETYLNEURAMINATE LYASE;N-ACETYL-NEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;SO4   sulfate ion| GOL   glycerol;CL   chloride ion| NAY   6,7,8,9-tetrahydroxy-5-methylcarboxamido-2-oxononanoic acid| GOL   glycerol;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II COMPLEXED WITH 4-DEOXY-SIALIC ACID;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;4.6;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f6k;1;1f5z;1;b;1;1153;100;98;1156;100;99;0.33;0.33;100;0;1.6;1.88;diffraction;diffraction;1172;1172;N-ACETYLNEURAMINATE LYASE;N-ACETYLNEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;SO4   sulfate ion| GOL   glycerol;no/data;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM I;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;7.5;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f7b;1;1f6p;1;b;1;1153;100;98;1156;100;99;0.37;0.37;100;0;1.8;2.25;diffraction;diffraction;1172;1172;N-ACETYL-NEURAMINATE LYASE;N-ACETYL NEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;CL   chloride ion| NAV   6,7,8,9-tetrahydroxy-5-methylcarboxamido-4-oxononanoic acid| NAU   4,4,6,7,8,9-hexahydroxy-5-methylcarboxamidononanoic acid;no/data;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II IN COMPLEX WITH 4-OXO-SIALIC ACID;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;4.6;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f7b;1;1f73;1;b;1;1140;99;99;1146;99;99;0.50;0.51;100;0;1.8;1.95;diffraction;diffraction;1172;1172;N-ACETYL-NEURAMINATE LYASE;N-ACETYL NEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;CL   chloride ion| NAV   6,7,8,9-tetrahydroxy-5-methylcarboxamido-4-oxononanoic acid| NAU   4,4,6,7,8,9-hexahydroxy-5-methylcarboxamidononanoic acid;HMN   2,4,6,7,8,9-hexahydroxy-5-methylcarboxamido nonanoic acid| GOL   glycerol;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II IN COMPLEX WITH 4-OXO-SIALIC ACID;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III IN COMPLEX WITH SIALIC ACID ALDITOL;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;4.6;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f7b;1;1f74;1;b;1;1136;98;97;1138;98;97;0.32;0.33;100;0;1.8;1.6;diffraction;diffraction;1172;1172;N-ACETYL-NEURAMINATE LYASE;N-ACETYL-NEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;CL   chloride ion| NAV   6,7,8,9-tetrahydroxy-5-methylcarboxamido-4-oxononanoic acid| NAU   4,4,6,7,8,9-hexahydroxy-5-methylcarboxamidononanoic acid;CL   chloride ion| NAY   6,7,8,9-tetrahydroxy-5-methylcarboxamido-2-oxononanoic acid| GOL   glycerol;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II IN COMPLEX WITH 4-OXO-SIALIC ACID;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II COMPLEXED WITH 4-DEOXY-SIALIC ACID;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;4.6;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f7b;1;1f5z;1;b;1;1153;100;98;1156;100;99;0.34;0.34;100;0;1.8;1.88;diffraction;diffraction;1172;1172;N-ACETYL-NEURAMINATE LYASE;N-ACETYLNEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;CL   chloride ion| NAV   6,7,8,9-tetrahydroxy-5-methylcarboxamido-4-oxononanoic acid| NAU   4,4,6,7,8,9-hexahydroxy-5-methylcarboxamidononanoic acid;no/data;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II IN COMPLEX WITH 4-OXO-SIALIC ACID;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM I;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;7.5;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f6p;1;1f73;1;b;1;1148;98;100;1152;98;100;0.40;0.41;100;0;2.25;1.95;diffraction;diffraction;1172;1172;N-ACETYL NEURAMINATE LYASE;N-ACETYL NEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;no/data;HMN   2,4,6,7,8,9-hexahydroxy-5-methylcarboxamido nonanoic acid| GOL   glycerol;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III IN COMPLEX WITH SIALIC ACID ALDITOL;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;4.6;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f6p;1;1f74;1;b;1;1132;97;97;1136;97;97;0.43;0.43;100;0;2.25;1.6;diffraction;diffraction;1172;1172;N-ACETYL NEURAMINATE LYASE;N-ACETYL-NEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;no/data;CL   chloride ion| NAY   6,7,8,9-tetrahydroxy-5-methylcarboxamido-2-oxononanoic acid| GOL   glycerol;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II COMPLEXED WITH 4-DEOXY-SIALIC ACID;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;4.6;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f6p;1;1f5z;1;b;1;1170;100;100;1172;100;100;0.29;0.29;100;0;2.25;1.88;diffraction;diffraction;1172;1172;N-ACETYL NEURAMINATE LYASE;N-ACETYLNEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;no/data;no/data;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM I;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;7.5;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f73;1;1f74;1;b;1;1132;98;97;1136;99;97;0.41;0.42;100;0;1.95;1.6;diffraction;diffraction;1172;1172;N-ACETYL NEURAMINATE LYASE;N-ACETYL-NEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;HMN   2,4,6,7,8,9-hexahydroxy-5-methylcarboxamido nonanoic acid| GOL   glycerol;CL   chloride ion| NAY   6,7,8,9-tetrahydroxy-5-methylcarboxamido-2-oxononanoic acid| GOL   glycerol;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III IN COMPLEX WITH SIALIC ACID ALDITOL;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II COMPLEXED WITH 4-DEOXY-SIALIC ACID;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;4.6;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f73;1;1f5z;1;b;1;1146;99;98;1152;100;98;0.51;0.52;100;0;1.95;1.88;diffraction;diffraction;1172;1172;N-ACETYL NEURAMINATE LYASE;N-ACETYLNEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;HMN   2,4,6,7,8,9-hexahydroxy-5-methylcarboxamido nonanoic acid| GOL   glycerol;no/data;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM III IN COMPLEX WITH SIALIC ACID ALDITOL;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM I;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;7.5;113;1f74_A;1f5z_A;0.66;0.52
1f6k;4;1f74;1;1f5z;1;b;1;1131;97;97;1136;97;97;0.45;0.45;100;0;1.6;1.88;diffraction;diffraction;1172;1172;N-ACETYL-NEURAMINATE LYASE;N-ACETYLNEURAMINATE LYASE;HAEMOPHILUS INFLUENZAE;HAEMOPHILUS INFLUENZAE;CL   chloride ion| NAY   6,7,8,9-tetrahydroxy-5-methylcarboxamido-2-oxononanoic acid| GOL   glycerol;no/data;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM II COMPLEXED WITH 4-DEOXY-SIALIC ACID;CRYSTAL STRUCTURE ANALYSIS OF N-ACETYLNEURAMINATE LYASE FROM HAEMOPHILUS INFLUENZAE: CRYSTAL FORM I;P44539;nanA HI_0142;PF00701;P44539;nanA HI_0142;PF00701;b;4.6;113;7.5;113;1f74_A;1f5z_A;0.66;0.52
2or3;2;2or3;1;1pdv;1;b;1;373;100;100;374;100;100;0.30;0.30;100;0;1.2;1.8;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;MSE   selenomethionine;Pre-oxidation Complex of Human DJ-1;Crystal structure of human DJ-1, P 31 2 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3cza;1;b;1;371;99;100;372;99;100;0.29;0.29;99;0;1.2;1.2;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;MLA   malonic acid;Pre-oxidation Complex of Human DJ-1;Crystal Structure of E18D DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;1p5f;1;c;1;372;99;100;372;99;100;0.24;0.24;100;0;1.2;1.1;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;no/data;Pre-oxidation Complex of Human DJ-1;Crystal Structure of Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;1j42;2;b;1;369;99;100;370;99;100;0.35;0.35;99;0;1.2;2.5;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;no/data;Pre-oxidation Complex of Human DJ-1;Crystal Structure of Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;1ucf;1;b;1;373;100;99;374;100;99;0.26;0.26;100;0;1.2;1.95;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;no/data;Pre-oxidation Complex of Human DJ-1;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4bte;1;b;1;373;100;100;374;100;100;0.27;0.27;100;0;1.2;1.38;diffraction;diffraction;378;378;Protein DJ-1;PROTEIN DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CU1   copper (i) ion;Pre-oxidation Complex of Human DJ-1;DJ-1 Cu(I) complex;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4mtc;1;b;1;373;100;100;374;100;100;0.32;0.32;99;0;1.2;1.47;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;EDO   1,2-ethanediol;Pre-oxidation Complex of Human DJ-1;Crystal structure of human C53A DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4p2g;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.2;1.35;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;Pre-oxidation Complex of Human DJ-1;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3cy6;1;b;1;371;99;100;372;99;100;0.27;0.27;99;0;1.2;1.35;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;no/data;Pre-oxidation Complex of Human DJ-1;Crystal Structure of E18Q DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3sf8;1;b;1;373;100;99;374;100;99;0.34;0.34;100;0;1.2;1.56;diffraction;diffraction;378;382;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSO   s-hydroxycysteine;Pre-oxidation Complex of Human DJ-1;Structural insights into thiol stabilization of DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4p34;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.2;1.55;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;Pre-oxidation Complex of Human DJ-1;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4oq4;1;b;1;373;100;100;374;100;100;0.31;0.31;99;0;1.2;1.49;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSD   3-sulfinoalanine| NA   sodium ion;Pre-oxidation Complex of Human DJ-1;Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4p35;1;b;1;373;100;100;374;100;100;0.30;0.30;100;0;1.2;1.75;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Pre-oxidation Complex of Human DJ-1;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;2r1u;1;b;1;373;100;100;374;100;100;0.30;0.30;100;0;1.2;1.5;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;no/data;Pre-oxidation Complex of Human DJ-1;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3cyf;1;b;1;371;99;100;372;99;100;0.26;0.26;99;0;1.2;1.6;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSD   3-sulfinoalanine;Pre-oxidation Complex of Human DJ-1;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3bwe;3;b;1;372;99;99;373;100;100;0.43;0.43;100;0;1.2;2.4;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;MSE   selenomethionine| PO4   phosphate ion;Pre-oxidation Complex of Human DJ-1;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4ogf;1;b;1;373;100;100;374;100;100;0.30;0.31;99;0;1.2;1.6;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Pre-oxidation Complex of Human DJ-1;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3f71;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.2;1.2;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSO   s-hydroxycysteine;Pre-oxidation Complex of Human DJ-1;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4n12;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.2;1.478;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Pre-oxidation Complex of Human DJ-1;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3ezg;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.2;1.15;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSD   3-sulfinoalanine;Pre-oxidation Complex of Human DJ-1;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;2rk4;1;b;1;373;100;100;374;100;100;0.29;0.29;99;0;1.2;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;no/data;Pre-oxidation Complex of Human DJ-1;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4mnt;1;b;1;374;100;100;374;100;100;0.25;0.25;100;0;1.2;1.584;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CU   copper (ii) ion;Pre-oxidation Complex of Human DJ-1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;2rk3;1;b;1;373;100;100;374;100;100;0.26;0.26;99;0;1.2;1.05;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;no/data;Pre-oxidation Complex of Human DJ-1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;2rk6;1;b;1;372;99;100;372;99;100;0.24;0.24;99;0;1.2;1.15;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSD   3-sulfinoalanine;Pre-oxidation Complex of Human DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;1pe0;1;b;1;373;100;100;374;100;100;0.36;0.36;99;0;1.2;1.7;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;no/data;Pre-oxidation Complex of Human DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3b38;1;b;1;373;100;98;374;100;98;0.44;0.46;99;0;1.2;1.85;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;EDO   1,2-ethanediol;Pre-oxidation Complex of Human DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4p36;1;b;1;374;100;100;374;100;100;0.25;0.25;99;0;1.2;1.182;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Pre-oxidation Complex of Human DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3cz9;1;b;1;373;100;100;374;100;100;0.29;0.29;99;0;1.2;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;P4C   o-acetaldehydyl-hexaethylene glycol;Pre-oxidation Complex of Human DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;2r1t;1;b;1;374;100;100;374;100;100;0.25;0.25;99;0;1.2;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Pre-oxidation Complex of Human DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;1soa;1;b;1;374;100;100;374;100;100;0.24;0.24;99;0;1.2;1.2;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CSD   3-sulfinoalanine;Pre-oxidation Complex of Human DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;1pdw;3;b;1;373;100;99;374;100;99;0.38;0.39;100;0;1.2;2.2;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;MSE   selenomethionine;Pre-oxidation Complex of Human DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;4n0m;1;b;1;373;100;100;374;100;100;0.32;0.32;99;0;1.2;1.95;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CU   copper (ii) ion| EDO   1,2-ethanediol;Pre-oxidation Complex of Human DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3b36;1;b;1;373;100;100;374;100;100;0.33;0.33;99;0;1.2;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CL   chloride ion| EDO   1,2-ethanediol;Pre-oxidation Complex of Human DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;1q2u;2;b;1;374;100;99;374;100;99;0.22;0.22;100;0;1.2;1.6;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;no/data;Pre-oxidation Complex of Human DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;3b3a;1;b;1;373;100;100;374;100;100;0.39;0.39;99;0;1.2;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;CL   chloride ion| EDO   1,2-ethanediol;Pre-oxidation Complex of Human DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2or3;1;2r1v;1;b;1;374;100;100;374;100;100;0.25;0.25;99;0;1.2;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;SO4   sulfate ion;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Pre-oxidation Complex of Human DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3cza;1;b;1;371;99;100;372;99;100;0.26;0.26;99;0;1.8;1.2;diffraction;diffraction;394;394;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;MLA   malonic acid;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal Structure of E18D DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;1p5f;1;b;1;372;99;100;372;99;100;0.23;0.23;100;0;1.8;1.1;diffraction;diffraction;394;378;DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;no/data;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal Structure of Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;1j42;2;c;1;370;99;100;370;99;100;0.22;0.22;99;0;1.8;2.5;diffraction;diffraction;394;378;DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;no/data;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal Structure of Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;1ucf;1;b;1;374;100;99;374;100;99;0.21;0.22;100;0;1.8;1.95;diffraction;diffraction;394;378;DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;no/data;Crystal structure of human DJ-1, P 31 2 1 space group;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4bte;1;b;1;374;100;100;374;100;100;0.21;0.21;100;0;1.8;1.38;diffraction;diffraction;394;378;DJ-1;PROTEIN DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CU1   copper (i) ion;Crystal structure of human DJ-1, P 31 2 1 space group;DJ-1 Cu(I) complex;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4mtc;1;b;1;373;100;100;374;100;100;0.26;0.26;99;0;1.8;1.47;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;EDO   1,2-ethanediol;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of human C53A DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4p2g;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.8;1.35;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3cy6;1;c;1;371;99;100;372;99;100;0.26;0.26;99;0;1.8;1.35;diffraction;diffraction;394;394;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;no/data;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal Structure of E18Q DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3sf8;1;b;1;373;100;99;374;100;99;0.33;0.33;100;0;1.8;1.56;diffraction;diffraction;394;382;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSO   s-hydroxycysteine;Crystal structure of human DJ-1, P 31 2 1 space group;Structural insights into thiol stabilization of DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4p34;1;b;1;374;100;100;374;100;100;0.25;0.26;99;0;1.8;1.55;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4oq4;1;b;1;373;100;100;374;100;100;0.28;0.28;99;0;1.8;1.49;diffraction;diffraction;394;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSD   3-sulfinoalanine| NA   sodium ion;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4p35;1;b;1;374;100;100;374;100;100;0.24;0.24;100;0;1.8;1.75;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;2r1u;1;b;1;374;100;100;374;100;100;0.25;0.25;100;0;1.8;1.5;diffraction;diffraction;394;374;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;no/data;Crystal structure of human DJ-1, P 31 2 1 space group;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3cyf;1;b;1;372;99;100;372;99;100;0.22;0.23;99;0;1.8;1.6;diffraction;diffraction;394;394;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSD   3-sulfinoalanine;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3bwe;3;b;1;372;99;99;373;100;100;0.37;0.37;100;0;1.8;2.4;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;MSE   selenomethionine| PO4   phosphate ion;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4ogf;1;b;1;373;100;100;374;100;100;0.30;0.30;99;0;1.8;1.6;diffraction;diffraction;394;374;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3f71;1;b;1;374;100;100;374;100;100;0.26;0.26;99;0;1.8;1.2;diffraction;diffraction;394;392;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSO   s-hydroxycysteine;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4n12;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.8;1.478;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3ezg;1;b;1;373;100;100;374;100;100;0.27;0.28;99;0;1.8;1.15;diffraction;diffraction;394;392;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSD   3-sulfinoalanine;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;2rk4;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.8;1.15;diffraction;diffraction;394;394;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;no/data;Crystal structure of human DJ-1, P 31 2 1 space group;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4mnt;1;b;1;374;100;100;374;100;100;0.20;0.20;100;0;1.8;1.584;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CU   copper (ii) ion;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;2rk3;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.8;1.05;diffraction;diffraction;394;394;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;no/data;Crystal structure of human DJ-1, P 31 2 1 space group;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;2rk6;1;b;1;372;99;100;372;99;100;0.22;0.23;99;0;1.8;1.15;diffraction;diffraction;394;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSD   3-sulfinoalanine;Crystal structure of human DJ-1, P 31 2 1 space group;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;1pe0;1;b;1;373;100;100;374;100;100;0.31;0.31;99;0;1.8;1.7;diffraction;diffraction;394;394;DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;no/data;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3b38;1;b;1;372;100;97;374;100;98;0.46;0.49;99;0;1.8;1.85;diffraction;diffraction;394;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;EDO   1,2-ethanediol;Crystal structure of human DJ-1, P 31 2 1 space group;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4p36;1;b;1;373;100;100;374;100;100;0.26;0.26;99;0;1.8;1.182;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3cz9;1;b;1;373;100;100;374;100;100;0.29;0.29;99;0;1.8;1.15;diffraction;diffraction;394;394;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;2r1t;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.8;1.7;diffraction;diffraction;394;374;DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of human DJ-1, P 31 2 1 space group;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;1soa;1;b;1;374;100;100;374;100;100;0.25;0.26;99;0;1.8;1.2;diffraction;diffraction;394;378;DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CSD   3-sulfinoalanine;Crystal structure of human DJ-1, P 31 2 1 space group;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;1pdw;3;b;1;373;100;99;374;100;99;0.31;0.31;100;0;1.8;2.2;diffraction;diffraction;394;394;DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;MSE   selenomethionine;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;4n0m;1;b;1;374;100;100;374;100;100;0.24;0.25;99;0;1.8;1.95;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3b36;1;b;1;373;100;100;374;100;100;0.28;0.28;99;0;1.8;1.5;diffraction;diffraction;394;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human DJ-1, P 31 2 1 space group;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;1q2u;2;b;1;374;100;99;374;100;99;0.22;0.22;100;0;1.8;1.6;diffraction;diffraction;394;378;DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;no/data;Crystal structure of human DJ-1, P 31 2 1 space group;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;3b3a;1;b;1;373;100;100;374;100;100;0.29;0.29;99;0;1.8;1.5;diffraction;diffraction;394;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human DJ-1, P 31 2 1 space group;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdv;1;2r1v;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.8;1.7;diffraction;diffraction;394;374;DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of human DJ-1, P 31 2 1 space group;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;1p5f;1;b;1;372;100;100;372;100;100;0.22;0.22;99;0;1.2;1.1;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;no/data;Crystal Structure of E18D DJ-1;Crystal Structure of Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;1j42;2;b;1;369;99;100;370;99;100;0.26;0.26;99;0;1.2;2.5;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;no/data;Crystal Structure of E18D DJ-1;Crystal Structure of Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;1ucf;1;b;1;372;100;99;372;100;99;0.15;0.15;99;0;1.2;1.95;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;no/data;Crystal Structure of E18D DJ-1;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4bte;1;b;1;372;100;99;372;100;99;0.15;0.15;99;0;1.2;1.38;diffraction;diffraction;394;378;Protein DJ-1;PROTEIN DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CU1   copper (i) ion;Crystal Structure of E18D DJ-1;DJ-1 Cu(I) complex;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4mtc;1;b;1;372;100;99;372;100;99;0.19;0.19;99;0;1.2;1.47;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;EDO   1,2-ethanediol;Crystal Structure of E18D DJ-1;Crystal structure of human C53A DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4p2g;1;b;1;372;100;99;372;100;99;0.22;0.22;99;0;1.2;1.35;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;Crystal Structure of E18D DJ-1;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;3cy6;1;b;1;372;100;100;372;100;100;0.18;0.18;99;0;1.2;1.35;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;no/data;Crystal Structure of E18D DJ-1;Crystal Structure of E18Q DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;3sf8;1;b;1;371;100;98;372;100;99;0.31;0.31;99;0;1.2;1.56;diffraction;diffraction;394;382;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSO   s-hydroxycysteine;Crystal Structure of E18D DJ-1;Structural insights into thiol stabilization of DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4p34;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.2;1.55;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;Crystal Structure of E18D DJ-1;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4oq4;1;b;1;372;100;99;372;100;99;0.16;0.16;99;0;1.2;1.49;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSD   3-sulfinoalanine| NA   sodium ion;Crystal Structure of E18D DJ-1;Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4p35;1;b;1;372;100;99;372;100;99;0.15;0.15;99;0;1.2;1.75;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Crystal Structure of E18D DJ-1;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;2r1u;1;b;1;372;100;99;372;100;99;0.24;0.24;99;0;1.2;1.5;diffraction;diffraction;394;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;no/data;Crystal Structure of E18D DJ-1;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;3cyf;1;b;1;372;100;100;372;100;100;0.10;0.10;99;0;1.2;1.6;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSD   3-sulfinoalanine;Crystal Structure of E18D DJ-1;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;3bwe;3;b;1;371;100;99;372;100;99;0.42;0.42;99;0;1.2;2.4;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;MSE   selenomethionine| PO4   phosphate ion;Crystal Structure of E18D DJ-1;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4ogf;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.2;1.6;diffraction;diffraction;394;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal Structure of E18D DJ-1;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;3f71;1;b;1;372;100;99;372;100;99;0.09;0.09;99;0;1.2;1.2;diffraction;diffraction;394;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSO   s-hydroxycysteine;Crystal Structure of E18D DJ-1;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4n12;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.2;1.478;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of E18D DJ-1;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;3ezg;1;b;1;372;100;99;372;100;99;0.24;0.24;99;0;1.2;1.15;diffraction;diffraction;394;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSD   3-sulfinoalanine;Crystal Structure of E18D DJ-1;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;2rk4;1;b;1;372;100;99;372;100;99;0.20;0.20;99;0;1.2;1.15;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;no/data;Crystal Structure of E18D DJ-1;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4mnt;1;b;1;372;100;99;372;100;99;0.15;0.15;99;0;1.2;1.584;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CU   copper (ii) ion;Crystal Structure of E18D DJ-1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;2rk3;1;b;1;372;100;99;372;100;99;0.17;0.17;99;0;1.2;1.05;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;no/data;Crystal Structure of E18D DJ-1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;2rk6;1;b;1;370;99;99;370;99;99;0.16;0.16;98;0;1.2;1.15;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSD   3-sulfinoalanine;Crystal Structure of E18D DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;1pe0;1;b;1;371;100;99;372;100;99;0.34;0.35;99;0;1.2;1.7;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;no/data;Crystal Structure of E18D DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;3b38;1;b;1;371;100;97;372;100;97;0.29;0.29;99;0;1.2;1.85;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;EDO   1,2-ethanediol;Crystal Structure of E18D DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4p36;1;b;1;372;100;99;372;100;99;0.25;0.25;99;0;1.2;1.182;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal Structure of E18D DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;3cz9;1;b;1;372;100;99;372;100;99;0.19;0.19;99;0;1.2;1.15;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal Structure of E18D DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;2r1t;1;b;1;372;100;99;372;100;99;0.19;0.19;99;0;1.2;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal Structure of E18D DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;1soa;1;b;1;371;100;99;372;100;99;0.26;0.26;99;0;1.2;1.2;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CSD   3-sulfinoalanine;Crystal Structure of E18D DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;1pdw;3;b;1;371;100;99;372;100;99;0.39;0.40;99;0;1.2;2.2;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;MSE   selenomethionine;Crystal Structure of E18D DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;4n0m;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.2;1.95;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of E18D DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;3b36;1;b;1;372;100;99;372;100;99;0.19;0.19;99;0;1.2;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of E18D DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;1q2u;2;b;1;372;100;98;372;100;98;0.24;0.24;99;0;1.2;1.6;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;no/data;Crystal Structure of E18D DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;3b3a;1;b;1;372;100;99;372;100;99;0.21;0.21;98;0;1.2;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of E18D DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cza;1;2r1v;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.2;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MLA   malonic acid;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal Structure of E18D DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;1j42;2;b;1;369;99;100;370;99;100;0.28;0.28;99;0;1.1;2.5;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Crystal Structure of Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;1ucf;1;b;1;372;100;99;372;100;99;0.17;0.17;100;0;1.1;1.95;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4bte;1;b;1;372;100;99;372;100;99;0.14;0.14;100;0;1.1;1.38;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;PROTEIN DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU1   copper (i) ion;Crystal Structure of Human DJ-1;DJ-1 Cu(I) complex;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4mtc;1;b;1;372;100;99;372;100;99;0.20;0.20;99;0;1.1;1.47;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Crystal structure of human C53A DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4p2g;1;c;1;372;100;99;372;100;99;0.14;0.14;99;0;1.1;1.35;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;3cy6;1;b;1;372;100;100;372;100;100;0.22;0.22;99;0;1.1;1.35;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Crystal Structure of E18Q DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;3sf8;1;c;1;371;100;99;372;100;99;0.27;0.27;100;0;1.1;1.56;diffraction;diffraction;378;382;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine;Crystal Structure of Human DJ-1;Structural insights into thiol stabilization of DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4p34;1;b;1;372;100;99;372;100;99;0.14;0.14;99;0;1.1;1.55;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;Crystal Structure of Human DJ-1;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4oq4;1;b;1;372;100;99;372;100;99;0.25;0.25;99;0;1.1;1.49;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| NA   sodium ion;Crystal Structure of Human DJ-1;Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4p35;1;b;1;372;100;99;372;100;99;0.19;0.19;100;0;1.1;1.75;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Crystal Structure of Human DJ-1;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;2r1u;1;b;1;372;100;99;372;100;99;0.19;0.19;100;0;1.1;1.5;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;3cyf;1;b;1;372;100;100;372;100;100;0.18;0.18;99;0;1.1;1.6;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;3bwe;3;b;1;371;100;99;372;100;99;0.40;0.40;100;0;1.1;2.4;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine| PO4   phosphate ion;Crystal Structure of Human DJ-1;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4ogf;1;b;1;372;100;99;372;100;99;0.20;0.20;99;0;1.1;1.6;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal Structure of Human DJ-1;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;3f71;1;b;1;372;100;99;372;100;99;0.19;0.19;99;0;1.1;1.2;diffraction;diffraction;378;392;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine;Crystal Structure of Human DJ-1;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4n12;1;b;1;372;100;99;372;100;99;0.16;0.16;99;0;1.1;1.478;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;3ezg;1;b;1;372;100;99;372;100;99;0.15;0.15;99;0;1.1;1.15;diffraction;diffraction;378;392;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;2rk4;1;b;1;372;100;99;372;100;99;0.16;0.16;99;0;1.1;1.15;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4mnt;1;b;1;372;100;99;372;100;99;0.16;0.16;100;0;1.1;1.584;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion;Crystal Structure of Human DJ-1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;2rk3;1;b;1;372;100;99;372;100;99;0.15;0.15;99;0;1.1;1.05;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;2rk6;1;b;1;370;99;99;370;99;99;0.16;0.16;99;0;1.1;1.15;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;1pe0;1;b;1;371;100;99;372;100;99;0.32;0.32;99;0;1.1;1.7;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;3b38;1;b;1;371;100;97;372;100;97;0.30;0.30;99;0;1.1;1.85;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4p36;1;b;1;372;100;99;372;100;99;0.12;0.13;99;0;1.1;1.182;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal Structure of Human DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;3cz9;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.1;1.15;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal Structure of Human DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;2r1t;1;b;1;372;100;99;372;100;99;0.16;0.16;99;0;1.1;1.7;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal Structure of Human DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;1soa;1;b;1;372;100;99;372;100;99;0.13;0.13;99;0;1.1;1.2;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;1pdw;3;b;1;371;100;99;372;100;99;0.32;0.32;100;0;1.1;2.2;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine;Crystal Structure of Human DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;4n0m;1;b;1;372;100;99;372;100;99;0.21;0.21;99;0;1.1;1.95;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;3b36;1;b;1;372;100;99;372;100;99;0.22;0.22;99;0;1.1;1.5;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;1q2u;2;b;1;372;100;98;372;100;98;0.14;0.14;100;0;1.1;1.6;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;3b3a;1;b;1;371;100;99;372;100;99;0.29;0.29;99;0;1.1;1.5;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1p5f;1;2r1v;1;b;1;372;100;99;372;100;99;0.15;0.15;99;0;1.1;1.7;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal Structure of Human DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;1ucf;1;b;1;370;100;98;370;100;98;0.23;0.23;99;0;2.5;1.95;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4bte;1;c;1;370;100;99;370;100;99;0.24;0.25;99;0;2.5;1.38;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;PROTEIN DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU1   copper (i) ion;Crystal Structure of Human DJ-1;DJ-1 Cu(I) complex;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4mtc;1;c;1;369;100;99;370;100;99;0.27;0.28;99;0;2.5;1.47;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Crystal structure of human C53A DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4p2g;1;b;1;369;100;99;370;100;99;0.28;0.28;99;0;2.5;1.35;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;3cy6;1;b;1;369;100;99;370;100;99;0.27;0.27;99;0;2.5;1.35;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Crystal Structure of E18Q DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;3sf8;1;b;1;369;100;98;370;100;98;0.33;0.33;99;0;2.5;1.56;diffraction;diffraction;378;382;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine;Crystal Structure of Human DJ-1;Structural insights into thiol stabilization of DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4p34;1;b;1;369;100;99;370;100;99;0.26;0.27;99;0;2.5;1.55;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;Crystal Structure of Human DJ-1;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4oq4;1;b;1;369;100;99;370;100;99;0.30;0.30;98;0;2.5;1.49;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| NA   sodium ion;Crystal Structure of Human DJ-1;Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4p35;1;b;1;370;100;99;370;100;99;0.25;0.26;99;0;2.5;1.75;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Crystal Structure of Human DJ-1;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;2r1u;1;c;1;369;100;99;370;100;99;0.29;0.30;99;0;2.5;1.5;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;3cyf;1;b;1;370;100;99;370;100;99;0.25;0.25;98;0;2.5;1.6;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;3bwe;3;b;1;369;100;99;370;100;99;0.37;0.37;99;0;2.5;2.4;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine| PO4   phosphate ion;Crystal Structure of Human DJ-1;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4ogf;1;b;1;369;100;99;370;100;99;0.26;0.26;99;0;2.5;1.6;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal Structure of Human DJ-1;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;3f71;1;b;1;369;100;99;370;100;99;0.26;0.26;98;0;2.5;1.2;diffraction;diffraction;378;392;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine;Crystal Structure of Human DJ-1;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4n12;1;b;1;370;100;99;370;100;99;0.25;0.25;98;0;2.5;1.478;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;3ezg;1;b;1;369;100;99;370;100;99;0.30;0.30;98;0;2.5;1.15;diffraction;diffraction;378;392;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;2rk4;1;b;1;369;100;99;370;100;99;0.27;0.27;99;0;2.5;1.15;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4mnt;1;b;1;370;100;99;370;100;99;0.24;0.24;99;0;2.5;1.584;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion;Crystal Structure of Human DJ-1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;2rk3;1;c;1;369;100;99;370;100;99;0.26;0.26;99;0;2.5;1.05;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;2rk6;1;b;1;369;100;99;370;100;99;0.26;0.26;98;0;2.5;1.15;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;1pe0;1;b;1;369;100;99;370;100;99;0.30;0.31;99;0;2.5;1.7;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;3b38;1;b;1;369;100;97;370;100;97;0.33;0.34;99;0;2.5;1.85;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4p36;1;b;1;369;100;99;370;100;99;0.29;0.29;99;0;2.5;1.182;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal Structure of Human DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;3cz9;1;b;1;369;100;99;370;100;99;0.29;0.29;99;0;2.5;1.15;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal Structure of Human DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;2r1t;1;b;1;370;100;99;370;100;99;0.26;0.26;99;0;2.5;1.7;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal Structure of Human DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;1soa;1;b;1;369;100;99;370;100;99;0.30;0.31;99;0;2.5;1.2;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;1pdw;3;b;1;369;100;98;370;100;98;0.34;0.34;99;0;2.5;2.2;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine;Crystal Structure of Human DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;4n0m;1;c;1;369;100;99;370;100;99;0.27;0.27;99;0;2.5;1.95;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;3b36;1;b;1;370;100;99;370;100;99;0.25;0.26;99;0;2.5;1.5;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;1q2u;2;b;1;369;100;98;370;100;98;0.28;0.28;99;0;2.5;1.6;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of Human DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;3b3a;1;b;1;369;100;99;370;100;99;0.27;0.27;98;0;2.5;1.5;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1j42;2;2r1v;1;b;1;370;100;99;370;100;99;0.25;0.25;99;0;2.5;1.7;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal Structure of Human DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4bte;1;b;1;374;99;100;374;99;100;0.12;0.12;100;0;1.95;1.38;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;PROTEIN DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU1   copper (i) ion;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;DJ-1 Cu(I) complex;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4mtc;1;b;1;374;99;100;374;99;100;0.20;0.20;99;0;1.95;1.47;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of human C53A DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4p2g;1;b;1;374;99;100;374;99;100;0.16;0.16;99;0;1.95;1.35;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;3cy6;1;b;1;372;99;100;372;99;100;0.19;0.19;99;0;1.95;1.35;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal Structure of E18Q DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;3sf8;1;b;1;373;99;99;374;99;99;0.28;0.28;100;0;1.95;1.56;diffraction;diffraction;378;382;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Structural insights into thiol stabilization of DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4p34;1;b;1;374;99;100;374;99;100;0.14;0.14;99;0;1.95;1.55;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4oq4;1;b;1;374;99;100;374;99;100;0.22;0.22;99;0;1.95;1.49;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| NA   sodium ion;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4p35;1;b;1;374;99;100;374;99;100;0.13;0.13;100;0;1.95;1.75;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;ZN   zinc ion| CL   chloride ion| GOL   glycerol;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;2r1u;1;b;1;374;99;100;374;99;100;0.19;0.19;100;0;1.95;1.5;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;3cyf;1;b;1;372;99;100;372;99;100;0.14;0.14;99;0;1.95;1.6;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;3bwe;3;b;1;372;99;99;373;99;100;0.38;0.39;100;0;1.95;2.4;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine| PO4   phosphate ion;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4ogf;1;b;1;374;99;100;374;99;100;0.20;0.20;99;0;1.95;1.6;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;3f71;1;c;1;374;99;100;374;99;100;0.15;0.15;99;0;1.95;1.2;diffraction;diffraction;378;392;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4n12;1;c;1;374;99;100;374;99;100;0.15;0.15;99;0;1.95;1.478;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;3ezg;1;b;1;374;99;100;374;99;100;0.19;0.19;99;0;1.95;1.15;diffraction;diffraction;378;392;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;2rk4;1;b;1;374;99;100;374;99;100;0.18;0.18;99;0;1.95;1.15;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4mnt;1;c;1;374;99;100;374;99;100;0.12;0.12;100;0;1.95;1.584;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;2rk3;1;b;1;374;99;100;374;99;100;0.15;0.15;99;0;1.95;1.05;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;2rk6;1;b;1;372;99;100;372;99;100;0.14;0.14;99;0;1.95;1.15;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;1pe0;1;b;1;373;99;100;374;99;100;0.31;0.31;99;0;1.95;1.7;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;3b38;1;b;1;374;99;98;376;100;98;0.50;0.54;99;0;1.95;1.85;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4p36;1;b;1;374;99;100;374;99;100;0.19;0.19;99;0;1.95;1.182;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;3cz9;1;c;1;374;99;100;374;99;100;0.20;0.20;99;0;1.95;1.15;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;P4C   o-acetaldehydyl-hexaethylene glycol;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;2r1t;1;b;1;374;99;100;374;99;100;0.14;0.14;99;0;1.95;1.7;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;1soa;1;b;1;374;99;100;374;99;100;0.20;0.20;99;0;1.95;1.2;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;1pdw;3;b;1;373;99;99;374;99;99;0.34;0.35;100;0;1.95;2.2;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;4n0m;1;b;1;374;99;100;374;99;100;0.20;0.20;99;0;1.95;1.95;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion| EDO   1,2-ethanediol;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;3b36;1;b;1;374;99;100;374;99;100;0.17;0.17;99;0;1.95;1.5;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;1q2u;2;b;1;376;100;99;376;100;99;0.21;0.21;100;0;1.95;1.6;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;3b3a;1;c;1;374;99;100;374;99;100;0.23;0.23;99;0;1.95;1.5;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1ucf;1;2r1v;1;b;1;374;99;100;374;99;100;0.13;0.13;99;0;1.95;1.7;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;The Crystal Structure of DJ-1, a Protein Related to Male Fertility and Parkinson's Disease;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;4mtc;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.38;1.47;diffraction;diffraction;378;378;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;EDO   1,2-ethanediol;DJ-1 Cu(I) complex;Crystal structure of human C53A DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;4p2g;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.38;1.35;diffraction;diffraction;378;378;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;DJ-1 Cu(I) complex;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;3cy6;1;b;1;372;99;100;372;99;100;0.18;0.18;99;0;1.38;1.35;diffraction;diffraction;378;394;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;no/data;DJ-1 Cu(I) complex;Crystal Structure of E18Q DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;3sf8;1;b;1;373;100;99;374;100;99;0.26;0.26;100;0;1.38;1.56;diffraction;diffraction;378;382;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSO   s-hydroxycysteine;DJ-1 Cu(I) complex;Structural insights into thiol stabilization of DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;4p34;1;b;1;374;100;100;374;100;100;0.15;0.15;99;0;1.38;1.55;diffraction;diffraction;378;378;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;DJ-1 Cu(I) complex;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;4oq4;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.38;1.49;diffraction;diffraction;378;384;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSD   3-sulfinoalanine| NA   sodium ion;DJ-1 Cu(I) complex;Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;4p35;1;b;1;374;100;100;374;100;100;0.12;0.12;100;0;1.38;1.75;diffraction;diffraction;378;378;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;ZN   zinc ion| CL   chloride ion| GOL   glycerol;DJ-1 Cu(I) complex;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;2r1u;1;b;1;374;100;100;374;100;100;0.17;0.17;100;0;1.38;1.5;diffraction;diffraction;378;374;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;no/data;DJ-1 Cu(I) complex;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;3cyf;1;b;1;372;99;100;372;99;100;0.13;0.13;99;0;1.38;1.6;diffraction;diffraction;378;394;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSD   3-sulfinoalanine;DJ-1 Cu(I) complex;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;3bwe;3;b;1;372;99;99;373;100;100;0.38;0.38;100;0;1.38;2.4;diffraction;diffraction;378;378;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;MSE   selenomethionine| PO4   phosphate ion;DJ-1 Cu(I) complex;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;4ogf;1;b;1;374;100;100;374;100;100;0.24;0.25;99;0;1.38;1.6;diffraction;diffraction;378;374;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;DJ-1 Cu(I) complex;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;3f71;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.38;1.2;diffraction;diffraction;378;392;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSO   s-hydroxycysteine;DJ-1 Cu(I) complex;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;4n12;1;b;1;374;100;100;374;100;100;0.13;0.13;99;0;1.38;1.478;diffraction;diffraction;378;378;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;DJ-1 Cu(I) complex;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;3ezg;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.38;1.15;diffraction;diffraction;378;392;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSD   3-sulfinoalanine;DJ-1 Cu(I) complex;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;2rk4;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.38;1.15;diffraction;diffraction;378;394;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;no/data;DJ-1 Cu(I) complex;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;4mnt;1;b;1;374;100;100;374;100;100;0.10;0.10;100;0;1.38;1.584;diffraction;diffraction;378;378;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CU   copper (ii) ion;DJ-1 Cu(I) complex;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;2rk3;1;b;1;374;100;100;374;100;100;0.13;0.13;99;0;1.38;1.05;diffraction;diffraction;378;394;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;no/data;DJ-1 Cu(I) complex;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;2rk6;1;b;1;372;99;100;372;99;100;0.13;0.13;99;0;1.38;1.15;diffraction;diffraction;378;384;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSD   3-sulfinoalanine;DJ-1 Cu(I) complex;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;1pe0;1;b;1;373;100;100;374;100;100;0.30;0.30;99;0;1.38;1.7;diffraction;diffraction;378;394;PROTEIN DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;no/data;DJ-1 Cu(I) complex;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;3b38;1;b;1;373;100;98;374;100;98;0.43;0.47;99;0;1.38;1.85;diffraction;diffraction;378;384;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;EDO   1,2-ethanediol;DJ-1 Cu(I) complex;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;4p36;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.38;1.182;diffraction;diffraction;378;378;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;DJ-1 Cu(I) complex;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;3cz9;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.38;1.15;diffraction;diffraction;378;394;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;P4C   o-acetaldehydyl-hexaethylene glycol;DJ-1 Cu(I) complex;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;2r1t;1;b;1;374;100;100;374;100;100;0.15;0.15;99;0;1.38;1.7;diffraction;diffraction;378;374;PROTEIN DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;DJ-1 Cu(I) complex;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;1soa;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.38;1.2;diffraction;diffraction;378;378;PROTEIN DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CSD   3-sulfinoalanine;DJ-1 Cu(I) complex;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;1pdw;3;b;1;373;100;99;374;100;99;0.34;0.34;100;0;1.38;2.2;diffraction;diffraction;378;394;PROTEIN DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;MSE   selenomethionine;DJ-1 Cu(I) complex;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;4n0m;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.38;1.95;diffraction;diffraction;378;378;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CU   copper (ii) ion| EDO   1,2-ethanediol;DJ-1 Cu(I) complex;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;3b36;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.38;1.5;diffraction;diffraction;378;384;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CL   chloride ion| EDO   1,2-ethanediol;DJ-1 Cu(I) complex;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;1q2u;2;b;1;374;100;99;374;100;99;0.17;0.17;100;0;1.38;1.6;diffraction;diffraction;378;378;PROTEIN DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;no/data;DJ-1 Cu(I) complex;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;3b3a;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.38;1.5;diffraction;diffraction;378;384;PROTEIN DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;CL   chloride ion| EDO   1,2-ethanediol;DJ-1 Cu(I) complex;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4bte;1;2r1v;1;b;1;374;100;100;374;100;100;0.13;0.13;99;0;1.38;1.7;diffraction;diffraction;378;374;PROTEIN DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU1   copper (i) ion;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;DJ-1 Cu(I) complex;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;4p2g;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.47;1.35;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;Crystal structure of human C53A DJ-1;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;3cy6;1;b;1;372;99;100;372;99;100;0.19;0.19;99;0;1.47;1.35;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;no/data;Crystal structure of human C53A DJ-1;Crystal Structure of E18Q DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;3sf8;1;b;1;373;100;99;374;100;99;0.30;0.30;99;0;1.47;1.56;diffraction;diffraction;378;382;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSO   s-hydroxycysteine;Crystal structure of human C53A DJ-1;Structural insights into thiol stabilization of DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;4p34;1;b;1;374;100;100;374;100;100;0.24;0.24;99;0;1.47;1.55;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;Crystal structure of human C53A DJ-1;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;4oq4;1;c;1;374;100;100;374;100;100;0.22;0.22;98;0;1.47;1.49;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSD   3-sulfinoalanine| NA   sodium ion;Crystal structure of human C53A DJ-1;Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;4p35;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.47;1.75;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Crystal structure of human C53A DJ-1;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;2r1u;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.47;1.5;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;no/data;Crystal structure of human C53A DJ-1;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;3cyf;1;b;1;372;99;100;372;99;100;0.17;0.17;98;0;1.47;1.6;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of human C53A DJ-1;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;3bwe;3;b;1;372;99;99;373;100;100;0.41;0.42;99;0;1.47;2.4;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;MSE   selenomethionine| PO4   phosphate ion;Crystal structure of human C53A DJ-1;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;4ogf;1;b;1;373;100;100;374;100;100;0.32;0.33;99;0;1.47;1.6;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal structure of human C53A DJ-1;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;3f71;1;b;1;374;100;100;374;100;100;0.20;0.20;98;0;1.47;1.2;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSO   s-hydroxycysteine;Crystal structure of human C53A DJ-1;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;4n12;1;b;1;374;100;100;374;100;100;0.19;0.19;98;0;1.47;1.478;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of human C53A DJ-1;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;3ezg;1;b;1;373;100;100;374;100;100;0.29;0.29;98;0;1.47;1.15;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of human C53A DJ-1;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;2rk4;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.47;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;no/data;Crystal structure of human C53A DJ-1;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;4mnt;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.47;1.584;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CU   copper (ii) ion;Crystal structure of human C53A DJ-1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;2rk3;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.47;1.05;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;no/data;Crystal structure of human C53A DJ-1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;2rk6;1;b;1;372;99;100;372;99;100;0.21;0.21;98;0;1.47;1.15;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of human C53A DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;1pe0;1;b;1;373;100;100;374;100;100;0.36;0.36;99;0;1.47;1.7;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;no/data;Crystal structure of human C53A DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;3b38;1;b;1;372;100;97;374;100;98;0.47;0.52;99;0;1.47;1.85;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;EDO   1,2-ethanediol;Crystal structure of human C53A DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;4p36;1;b;1;374;100;100;374;100;100;0.25;0.25;99;0;1.47;1.182;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of human C53A DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;3cz9;1;b;1;374;100;100;374;100;100;0.25;0.25;99;0;1.47;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of human C53A DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;2r1t;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.47;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of human C53A DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;1soa;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.47;1.2;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of human C53A DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;1pdw;3;b;1;373;100;99;374;100;99;0.36;0.36;99;0;1.47;2.2;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;MSE   selenomethionine;Crystal structure of human C53A DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;4n0m;1;b;1;374;100;100;374;100;100;0.10;0.10;100;0;1.47;1.95;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of human C53A DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;3b36;1;b;1;374;100;100;374;100;100;0.15;0.15;99;0;1.47;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human C53A DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;1q2u;2;b;1;374;100;99;374;100;99;0.24;0.24;99;0;1.47;1.6;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;no/data;Crystal structure of human C53A DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;3b3a;1;b;1;374;100;100;374;100;100;0.24;0.24;98;0;1.47;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human C53A DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mtc;1;2r1v;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.47;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of human C53A DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;3cy6;1;b;1;372;99;100;372;99;100;0.25;0.25;99;0;1.35;1.35;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;no/data;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal Structure of E18Q DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;3sf8;1;b;1;373;100;99;374;100;99;0.29;0.29;100;0;1.35;1.56;diffraction;diffraction;378;382;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CSO   s-hydroxycysteine;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Structural insights into thiol stabilization of DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;4p34;1;b;1;374;100;100;374;100;100;0.06;0.06;100;0;1.35;1.55;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;4oq4;1;b;1;373;100;100;374;100;100;0.28;0.28;99;0;1.35;1.49;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CSD   3-sulfinoalanine| NA   sodium ion;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;4p35;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.35;1.75;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;2r1u;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.35;1.5;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;no/data;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;3cyf;1;b;1;372;99;100;372;99;100;0.20;0.20;99;0;1.35;1.6;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;3bwe;3;b;1;372;99;99;373;100;100;0.41;0.41;99;0;1.35;2.4;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;MSE   selenomethionine| PO4   phosphate ion;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;4ogf;1;b;1;374;100;100;374;100;100;0.19;0.19;100;0;1.35;1.6;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;3f71;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.35;1.2;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CSO   s-hydroxycysteine;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;4n12;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.35;1.478;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;3ezg;1;b;1;374;100;100;374;100;100;0.08;0.08;99;0;1.35;1.15;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;2rk4;1;b;1;374;100;100;374;100;100;0.13;0.13;99;0;1.35;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;no/data;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;4mnt;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.35;1.584;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CU   copper (ii) ion;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;2rk3;1;b;1;374;100;100;374;100;100;0.14;0.14;99;0;1.35;1.05;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;no/data;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;2rk6;1;b;1;372;99;100;372;99;100;0.18;0.18;99;0;1.35;1.15;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;1pe0;1;b;1;373;100;100;374;100;100;0.32;0.32;99;0;1.35;1.7;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;no/data;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;3b38;1;b;1;373;100;98;374;100;98;0.43;0.45;99;0;1.35;1.85;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;EDO   1,2-ethanediol;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;4p36;1;b;1;374;100;100;374;100;100;0.13;0.13;100;0;1.35;1.182;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;3cz9;1;b;1;374;100;100;374;100;100;0.15;0.15;99;0;1.35;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;2r1t;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.35;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;1soa;1;b;1;374;100;100;374;100;100;0.12;0.12;100;0;1.35;1.2;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;1pdw;3;b;1;373;100;99;374;100;99;0.36;0.36;99;0;1.35;2.2;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;MSE   selenomethionine;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;4n0m;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.35;1.95;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;3b36;1;b;1;374;100;100;374;100;100;0.24;0.24;99;0;1.35;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;1q2u;2;b;1;374;100;99;374;100;99;0.17;0.17;99;0;1.35;1.6;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;no/data;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;3b3a;1;b;1;373;100;100;374;100;100;0.30;0.30;98;0;1.35;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p2g;1;2r1v;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.35;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| 1PE   pentaethylene glycol| EDO   1,2-ethanediol;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of DJ-1 in sulfinic acid form (aged crystal);Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;3sf8;1;b;1;371;100;98;372;100;99;0.33;0.34;99;0;1.35;1.56;diffraction;diffraction;394;382;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine;Crystal Structure of E18Q DJ-1;Structural insights into thiol stabilization of DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;4p34;1;b;1;372;100;99;372;100;99;0.23;0.23;99;0;1.35;1.55;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;Crystal Structure of E18Q DJ-1;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;4oq4;1;b;1;372;100;99;372;100;99;0.19;0.19;99;0;1.35;1.49;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| NA   sodium ion;Crystal Structure of E18Q DJ-1;Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;4p35;1;b;1;372;100;99;372;100;99;0.20;0.20;99;0;1.35;1.75;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Crystal Structure of E18Q DJ-1;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;2r1u;1;b;1;371;100;99;372;100;99;0.26;0.26;99;0;1.35;1.5;diffraction;diffraction;394;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of E18Q DJ-1;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;3cyf;1;b;1;372;100;100;372;100;100;0.13;0.13;99;0;1.35;1.6;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of E18Q DJ-1;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;3bwe;3;b;1;371;100;99;372;100;99;0.44;0.44;99;0;1.35;2.4;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine| PO4   phosphate ion;Crystal Structure of E18Q DJ-1;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;4ogf;1;b;1;372;100;99;372;100;99;0.25;0.25;99;0;1.35;1.6;diffraction;diffraction;394;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal Structure of E18Q DJ-1;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;3f71;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.35;1.2;diffraction;diffraction;394;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine;Crystal Structure of E18Q DJ-1;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;4n12;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.35;1.478;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of E18Q DJ-1;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;3ezg;1;b;1;371;100;99;372;100;99;0.28;0.28;99;0;1.35;1.15;diffraction;diffraction;394;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of E18Q DJ-1;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;2rk4;1;b;1;372;100;99;372;100;99;0.25;0.25;99;0;1.35;1.15;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of E18Q DJ-1;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;4mnt;1;b;1;372;100;99;372;100;99;0.15;0.15;99;0;1.35;1.584;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion;Crystal Structure of E18Q DJ-1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;2rk3;1;b;1;372;100;99;372;100;99;0.21;0.21;99;0;1.35;1.05;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of E18Q DJ-1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;2rk6;1;b;1;370;99;99;370;99;99;0.12;0.12;98;0;1.35;1.15;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of E18Q DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;1pe0;1;b;1;371;100;99;372;100;99;0.37;0.38;99;0;1.35;1.7;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of E18Q DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;3b38;1;b;1;371;100;97;372;100;97;0.31;0.31;99;0;1.35;1.85;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;Crystal Structure of E18Q DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;4p36;1;b;1;372;100;99;372;100;99;0.24;0.24;99;0;1.35;1.182;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal Structure of E18Q DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;3cz9;1;b;1;371;100;99;372;100;99;0.28;0.28;99;0;1.35;1.15;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal Structure of E18Q DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;2r1t;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.35;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal Structure of E18Q DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;1soa;1;b;1;371;100;99;372;100;99;0.26;0.26;99;0;1.35;1.2;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal Structure of E18Q DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;1pdw;3;b;1;371;100;99;372;100;99;0.38;0.38;99;0;1.35;2.2;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine;Crystal Structure of E18Q DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;4n0m;1;b;1;372;100;99;372;100;99;0.20;0.20;99;0;1.35;1.95;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of E18Q DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;3b36;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.35;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of E18Q DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;1q2u;2;b;1;372;100;98;372;100;98;0.22;0.22;99;0;1.35;1.6;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of E18Q DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;3b3a;1;c;1;371;100;99;372;100;99;0.26;0.26;98;0;1.35;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of E18Q DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cy6;1;2r1v;1;b;1;372;100;99;372;100;99;0.18;0.18;99;0;1.35;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal Structure of E18Q DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;4p34;1;b;1;373;99;100;374;99;100;0.28;0.28;100;0;1.56;1.55;diffraction;diffraction;382;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;Structural insights into thiol stabilization of DJ-1;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;4oq4;1;b;1;373;99;100;374;99;100;0.38;0.38;99;0;1.56;1.49;diffraction;diffraction;382;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine| NA   sodium ion;Structural insights into thiol stabilization of DJ-1;Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;4p35;1;b;1;373;99;100;374;99;100;0.27;0.27;100;0;1.56;1.75;diffraction;diffraction;382;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Structural insights into thiol stabilization of DJ-1;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;2r1u;1;b;1;373;99;100;374;99;100;0.31;0.31;100;0;1.56;1.5;diffraction;diffraction;382;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;no/data;Structural insights into thiol stabilization of DJ-1;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;3cyf;1;b;1;371;98;100;372;99;100;0.30;0.30;99;0;1.56;1.6;diffraction;diffraction;382;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine;Structural insights into thiol stabilization of DJ-1;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;3bwe;3;b;1;373;99;100;374;99;100;0.37;0.37;100;0;1.56;2.4;diffraction;diffraction;382;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;MSE   selenomethionine| PO4   phosphate ion;Structural insights into thiol stabilization of DJ-1;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;4ogf;1;b;1;373;99;100;374;99;100;0.34;0.35;100;0;1.56;1.6;diffraction;diffraction;382;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Structural insights into thiol stabilization of DJ-1;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;3f71;1;b;1;373;99;100;374;99;100;0.31;0.31;99;0;1.56;1.2;diffraction;diffraction;382;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSO   s-hydroxycysteine;Structural insights into thiol stabilization of DJ-1;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;4n12;1;c;1;373;99;100;374;99;100;0.29;0.29;99;0;1.56;1.478;diffraction;diffraction;382;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Structural insights into thiol stabilization of DJ-1;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;3ezg;1;b;1;373;99;100;374;99;100;0.30;0.30;99;0;1.56;1.15;diffraction;diffraction;382;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine;Structural insights into thiol stabilization of DJ-1;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;2rk4;1;b;1;373;99;100;374;99;100;0.28;0.28;99;0;1.56;1.15;diffraction;diffraction;382;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;no/data;Structural insights into thiol stabilization of DJ-1;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;4mnt;1;b;1;373;99;100;374;99;100;0.29;0.29;100;0;1.56;1.584;diffraction;diffraction;382;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CU   copper (ii) ion;Structural insights into thiol stabilization of DJ-1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;2rk3;1;b;1;373;99;100;374;99;100;0.29;0.29;99;0;1.56;1.05;diffraction;diffraction;382;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;no/data;Structural insights into thiol stabilization of DJ-1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;2rk6;1;b;1;371;98;100;372;99;100;0.29;0.30;99;0;1.56;1.15;diffraction;diffraction;382;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine;Structural insights into thiol stabilization of DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;1pe0;1;b;1;373;99;100;374;99;100;0.27;0.27;99;0;1.56;1.7;diffraction;diffraction;382;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;no/data;Structural insights into thiol stabilization of DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;3b38;1;b;1;372;99;97;374;99;98;0.47;0.51;99;0;1.56;1.85;diffraction;diffraction;382;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;EDO   1,2-ethanediol;Structural insights into thiol stabilization of DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;4p36;1;b;1;373;99;100;374;99;100;0.28;0.28;100;0;1.56;1.182;diffraction;diffraction;382;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Structural insights into thiol stabilization of DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;3cz9;1;b;1;373;99;100;374;99;100;0.30;0.30;99;0;1.56;1.15;diffraction;diffraction;382;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;P4C   o-acetaldehydyl-hexaethylene glycol;Structural insights into thiol stabilization of DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;2r1t;1;b;1;373;99;100;374;99;100;0.29;0.29;99;0;1.56;1.7;diffraction;diffraction;382;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Structural insights into thiol stabilization of DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;1soa;1;b;1;373;99;100;374;99;100;0.31;0.31;100;0;1.56;1.2;diffraction;diffraction;382;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine;Structural insights into thiol stabilization of DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;1pdw;3;b;1;375;99;100;376;100;100;0.38;0.38;100;0;1.56;2.2;diffraction;diffraction;382;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;MSE   selenomethionine;Structural insights into thiol stabilization of DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;4n0m;1;b;1;373;99;100;374;99;100;0.33;0.33;99;0;1.56;1.95;diffraction;diffraction;382;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CU   copper (ii) ion| EDO   1,2-ethanediol;Structural insights into thiol stabilization of DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;3b36;1;b;1;373;99;100;374;99;100;0.31;0.31;99;0;1.56;1.5;diffraction;diffraction;382;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CL   chloride ion| EDO   1,2-ethanediol;Structural insights into thiol stabilization of DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;1q2u;2;b;1;374;99;99;375;99;99;0.35;0.35;100;0;1.56;1.6;diffraction;diffraction;382;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;no/data;Structural insights into thiol stabilization of DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;3b3a;1;b;1;373;99;100;374;99;100;0.34;0.34;99;0;1.56;1.5;diffraction;diffraction;382;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CL   chloride ion| EDO   1,2-ethanediol;Structural insights into thiol stabilization of DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3sf8;1;2r1v;1;b;1;373;99;100;374;99;100;0.29;0.29;99;0;1.56;1.7;diffraction;diffraction;382;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Structural insights into thiol stabilization of DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;4oq4;1;b;1;374;100;100;374;100;100;0.25;0.25;99;0;1.55;1.49;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CSD   3-sulfinoalanine| NA   sodium ion;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal Structure of E18A Human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;4p35;1;b;1;374;100;100;374;100;100;0.14;0.14;99;0;1.55;1.75;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;2r1u;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.55;1.5;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;no/data;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;3cyf;1;b;1;372;99;100;372;99;100;0.17;0.17;99;0;1.55;1.6;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;3bwe;3;b;1;372;99;99;373;100;100;0.40;0.41;99;0;1.55;2.4;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;MSE   selenomethionine| PO4   phosphate ion;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;4ogf;1;c;1;374;100;100;374;100;100;0.18;0.18;100;0;1.55;1.6;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;3f71;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.55;1.2;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CSO   s-hydroxycysteine;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;4n12;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.55;1.478;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;3ezg;1;b;1;374;100;100;374;100;100;0.11;0.11;99;0;1.55;1.15;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;2rk4;1;b;1;374;100;100;374;100;100;0.12;0.12;99;0;1.55;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;no/data;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;4mnt;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.55;1.584;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CU   copper (ii) ion;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;2rk3;1;b;1;374;100;100;374;100;100;0.13;0.13;99;0;1.55;1.05;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;no/data;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;2rk6;1;b;1;372;99;100;372;99;100;0.17;0.17;99;0;1.55;1.15;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;1pe0;1;b;1;373;100;100;374;100;100;0.32;0.32;99;0;1.55;1.7;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;no/data;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;3b38;1;b;1;373;100;98;374;100;98;0.43;0.45;99;0;1.55;1.85;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;EDO   1,2-ethanediol;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;4p36;1;b;1;374;100;100;374;100;100;0.14;0.14;100;0;1.55;1.182;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;3cz9;1;c;1;374;100;100;374;100;100;0.14;0.14;99;0;1.55;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;2r1t;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.55;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;1soa;1;b;1;374;100;100;374;100;100;0.15;0.15;100;0;1.55;1.2;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;1pdw;3;b;1;373;100;99;374;100;99;0.36;0.36;99;0;1.55;2.2;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;MSE   selenomethionine;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;4n0m;1;b;1;374;100;100;374;100;100;0.24;0.24;99;0;1.55;1.95;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;3b36;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.55;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;1q2u;2;b;1;374;100;99;374;100;99;0.17;0.17;99;0;1.55;1.6;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;no/data;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;3b3a;1;b;1;373;100;100;374;100;100;0.27;0.27;98;0;1.55;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p34;1;2r1v;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.55;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| 1PE   pentaethylene glycol;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of DJ-1 in sulfenic acid form (fresh crystal);Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;4p35;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.49;1.75;diffraction;diffraction;384;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;ZN   zinc ion| CL   chloride ion| GOL   glycerol;Crystal Structure of E18A Human DJ-1;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;2r1u;1;b;1;373;100;100;374;100;100;0.29;0.29;99;0;1.49;1.5;diffraction;diffraction;384;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;no/data;Crystal Structure of E18A Human DJ-1;DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;3cyf;1;b;1;372;99;100;372;99;100;0.14;0.14;99;0;1.49;1.6;diffraction;diffraction;384;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CSD   3-sulfinoalanine;Crystal Structure of E18A Human DJ-1;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;3bwe;3;b;1;371;99;99;373;100;100;0.48;0.48;99;0;1.49;2.4;diffraction;diffraction;384;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;MSE   selenomethionine| PO4   phosphate ion;Crystal Structure of E18A Human DJ-1;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;4ogf;1;b;1;373;100;100;374;100;100;0.30;0.30;99;0;1.49;1.6;diffraction;diffraction;384;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal Structure of E18A Human DJ-1;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;3f71;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.49;1.2;diffraction;diffraction;384;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CSO   s-hydroxycysteine;Crystal Structure of E18A Human DJ-1;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;4n12;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.49;1.478;diffraction;diffraction;384;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of E18A Human DJ-1;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;3ezg;1;b;1;373;100;100;374;100;100;0.30;0.30;99;0;1.49;1.15;diffraction;diffraction;384;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CSD   3-sulfinoalanine;Crystal Structure of E18A Human DJ-1;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;2rk4;1;b;1;373;100;100;374;100;100;0.27;0.27;98;0;1.49;1.15;diffraction;diffraction;384;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;no/data;Crystal Structure of E18A Human DJ-1;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;4mnt;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.49;1.584;diffraction;diffraction;384;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CU   copper (ii) ion;Crystal Structure of E18A Human DJ-1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;2rk3;1;b;1;374;100;100;374;100;100;0.22;0.22;98;0;1.49;1.05;diffraction;diffraction;384;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;no/data;Crystal Structure of E18A Human DJ-1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;2rk6;1;b;1;372;99;100;372;99;100;0.19;0.19;99;0;1.49;1.15;diffraction;diffraction;384;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CSD   3-sulfinoalanine;Crystal Structure of E18A Human DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;1pe0;1;b;1;373;100;100;374;100;100;0.42;0.42;98;0;1.49;1.7;diffraction;diffraction;384;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;no/data;Crystal Structure of E18A Human DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;3b38;1;b;1;372;100;97;374;100;98;0.46;0.49;98;0;1.49;1.85;diffraction;diffraction;384;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;EDO   1,2-ethanediol;Crystal Structure of E18A Human DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;4p36;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.49;1.182;diffraction;diffraction;384;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal Structure of E18A Human DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;3cz9;1;b;1;373;100;100;374;100;100;0.27;0.27;99;0;1.49;1.15;diffraction;diffraction;384;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal Structure of E18A Human DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;2r1t;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.49;1.7;diffraction;diffraction;384;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal Structure of E18A Human DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;1soa;1;b;1;373;100;100;374;100;100;0.29;0.29;99;0;1.49;1.2;diffraction;diffraction;384;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CSD   3-sulfinoalanine;Crystal Structure of E18A Human DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;1pdw;3;b;1;373;100;99;374;100;99;0.43;0.43;99;0;1.49;2.2;diffraction;diffraction;384;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;MSE   selenomethionine;Crystal Structure of E18A Human DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;4n0m;1;b;1;374;100;100;374;100;100;0.20;0.20;98;0;1.49;1.95;diffraction;diffraction;384;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of E18A Human DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;3b36;1;b;1;374;100;100;374;100;100;0.24;0.24;98;0;1.49;1.5;diffraction;diffraction;384;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of E18A Human DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;1q2u;2;b;1;374;100;99;374;100;99;0.25;0.25;99;0;1.49;1.6;diffraction;diffraction;384;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;no/data;Crystal Structure of E18A Human DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;3b3a;1;b;1;373;100;100;374;100;100;0.29;0.29;98;0;1.49;1.5;diffraction;diffraction;384;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of E18A Human DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4oq4;1;2r1v;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.49;1.7;diffraction;diffraction;384;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| NA   sodium ion;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal Structure of E18A Human DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;2r1u;1;b;1;374;100;100;374;100;100;0.20;0.20;100;0;1.75;1.5;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;no/data;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);DJ-1 activation by catechol quinone modification;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;3cyf;1;b;1;372;99;100;372;99;100;0.14;0.14;99;0;1.75;1.6;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;3bwe;3;b;1;372;99;99;373;100;100;0.38;0.39;100;0;1.75;2.4;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;MSE   selenomethionine| PO4   phosphate ion;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;4ogf;1;c;1;374;100;100;374;100;100;0.22;0.22;99;0;1.75;1.6;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;3f71;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.75;1.2;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CSO   s-hydroxycysteine;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;4n12;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.75;1.478;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;3ezg;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.75;1.15;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;2rk4;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.75;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;no/data;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;4mnt;1;b;1;374;100;100;374;100;100;0.14;0.14;100;0;1.75;1.584;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CU   copper (ii) ion;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;2rk3;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.75;1.05;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;no/data;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;2rk6;1;b;1;372;99;100;372;99;100;0.17;0.17;99;0;1.75;1.15;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;1pe0;1;b;1;373;100;100;374;100;100;0.32;0.32;99;0;1.75;1.7;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;no/data;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;3b38;1;b;1;373;100;98;374;100;98;0.43;0.46;99;0;1.75;1.85;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;EDO   1,2-ethanediol;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;4p36;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.75;1.182;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;3cz9;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.75;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;2r1t;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.75;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;1soa;1;b;1;374;100;100;374;100;100;0.24;0.24;99;0;1.75;1.2;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CSD   3-sulfinoalanine;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;1pdw;3;b;1;373;100;99;374;100;99;0.36;0.36;100;0;1.75;2.2;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;MSE   selenomethionine;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;4n0m;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.75;1.95;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;3b36;1;c;1;374;100;100;374;100;100;0.16;0.16;99;0;1.75;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;1q2u;2;b;1;374;100;99;374;100;99;0.22;0.22;100;0;1.75;1.6;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;no/data;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;3b3a;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.75;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p35;1;2r1v;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.75;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| CL   chloride ion| GOL   glycerol;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of DJ-1 with Zinc(II) bound (crystal I);Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;3cyf;1;b;1;372;99;100;372;99;100;0.22;0.22;99;0;1.5;1.6;diffraction;diffraction;374;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;DJ-1 activation by catechol quinone modification;Crystal Structure of E18N DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;3bwe;3;b;1;372;99;99;373;100;100;0.39;0.40;100;0;1.5;2.4;diffraction;diffraction;374;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine| PO4   phosphate ion;DJ-1 activation by catechol quinone modification;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;4ogf;1;b;1;373;100;100;374;100;100;0.29;0.29;99;0;1.5;1.6;diffraction;diffraction;374;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;DJ-1 activation by catechol quinone modification;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;3f71;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.5;1.2;diffraction;diffraction;374;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine;DJ-1 activation by catechol quinone modification;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;4n12;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.5;1.478;diffraction;diffraction;374;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;DJ-1 activation by catechol quinone modification;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;3ezg;1;b;1;374;100;100;374;100;100;0.24;0.24;99;0;1.5;1.15;diffraction;diffraction;374;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;DJ-1 activation by catechol quinone modification;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;2rk4;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.5;1.15;diffraction;diffraction;374;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;DJ-1 activation by catechol quinone modification;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;4mnt;1;b;1;374;100;100;374;100;100;0.20;0.20;100;0;1.5;1.584;diffraction;diffraction;374;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion;DJ-1 activation by catechol quinone modification;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;2rk3;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.5;1.05;diffraction;diffraction;374;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;DJ-1 activation by catechol quinone modification;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;2rk6;1;b;1;372;99;100;372;99;100;0.23;0.23;99;0;1.5;1.15;diffraction;diffraction;374;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;DJ-1 activation by catechol quinone modification;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;1pe0;1;b;1;373;100;100;374;100;100;0.34;0.34;99;0;1.5;1.7;diffraction;diffraction;374;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;DJ-1 activation by catechol quinone modification;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;3b38;1;c;1;372;100;97;374;100;98;0.45;0.49;99;0;1.5;1.85;diffraction;diffraction;374;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;DJ-1 activation by catechol quinone modification;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;4p36;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.5;1.182;diffraction;diffraction;374;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;DJ-1 activation by catechol quinone modification;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;3cz9;1;b;1;374;100;100;374;100;100;0.24;0.24;99;0;1.5;1.15;diffraction;diffraction;374;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;P4C   o-acetaldehydyl-hexaethylene glycol;DJ-1 activation by catechol quinone modification;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;2r1t;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.5;1.7;diffraction;diffraction;374;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;DJ-1 activation by catechol quinone modification;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;1soa;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.5;1.2;diffraction;diffraction;374;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;DJ-1 activation by catechol quinone modification;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;1pdw;3;b;1;373;100;99;374;100;99;0.36;0.36;100;0;1.5;2.2;diffraction;diffraction;374;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine;DJ-1 activation by catechol quinone modification;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;4n0m;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.5;1.95;diffraction;diffraction;374;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion| EDO   1,2-ethanediol;DJ-1 activation by catechol quinone modification;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;3b36;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.5;1.5;diffraction;diffraction;374;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;DJ-1 activation by catechol quinone modification;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;1q2u;2;b;1;374;100;99;374;100;99;0.22;0.22;100;0;1.5;1.6;diffraction;diffraction;374;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;DJ-1 activation by catechol quinone modification;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;3b3a;1;b;1;373;100;100;374;100;100;0.29;0.29;99;0;1.5;1.5;diffraction;diffraction;374;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;DJ-1 activation by catechol quinone modification;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1u;1;2r1v;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.5;1.7;diffraction;diffraction;374;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;DJ-1 activation by catechol quinone modification;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;3bwe;3;b;1;371;100;99;372;100;99;0.41;0.42;99;0;1.6;2.4;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;MSE   selenomethionine| PO4   phosphate ion;Crystal Structure of E18N DJ-1;Crystal structure of aggregated form of DJ1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;no/data;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;4ogf;1;b;1;372;100;99;372;100;99;0.19;0.19;99;0;1.6;1.6;diffraction;diffraction;394;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal Structure of E18N DJ-1;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;3f71;1;b;1;372;100;99;372;100;99;0.11;0.11;99;0;1.6;1.2;diffraction;diffraction;394;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSO   s-hydroxycysteine;Crystal Structure of E18N DJ-1;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;4n12;1;b;1;372;100;99;372;100;99;0.13;0.13;99;0;1.6;1.478;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of E18N DJ-1;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;3ezg;1;b;1;372;100;99;372;100;99;0.23;0.23;99;0;1.6;1.15;diffraction;diffraction;394;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSD   3-sulfinoalanine;Crystal Structure of E18N DJ-1;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;2rk4;1;b;1;372;100;99;372;100;99;0.20;0.20;98;0;1.6;1.15;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Crystal Structure of E18N DJ-1;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;4mnt;1;b;1;372;100;99;372;100;99;0.10;0.10;99;0;1.6;1.584;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CU   copper (ii) ion;Crystal Structure of E18N DJ-1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;2rk3;1;b;1;372;100;99;372;100;99;0.15;0.15;98;0;1.6;1.05;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Crystal Structure of E18N DJ-1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;2rk6;1;b;1;370;99;99;370;99;99;0.12;0.12;99;0;1.6;1.15;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSD   3-sulfinoalanine;Crystal Structure of E18N DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;1pe0;1;b;1;371;100;99;372;100;99;0.34;0.35;98;0;1.6;1.7;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Crystal Structure of E18N DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;3b38;1;b;1;371;100;97;372;100;97;0.28;0.28;98;0;1.6;1.85;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;EDO   1,2-ethanediol;Crystal Structure of E18N DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;4p36;1;b;1;372;100;99;372;100;99;0.21;0.21;99;0;1.6;1.182;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal Structure of E18N DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;3cz9;1;b;1;372;100;99;372;100;99;0.21;0.21;99;0;1.6;1.15;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal Structure of E18N DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;2r1t;1;b;1;372;100;99;372;100;99;0.14;0.14;99;0;1.6;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal Structure of E18N DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;1soa;1;b;1;372;100;99;372;100;99;0.23;0.23;99;0;1.6;1.2;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSD   3-sulfinoalanine;Crystal Structure of E18N DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;1pdw;3;b;1;371;100;99;372;100;99;0.37;0.37;99;0;1.6;2.2;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;MSE   selenomethionine;Crystal Structure of E18N DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;4n0m;1;b;1;372;100;99;372;100;99;0.16;0.16;98;0;1.6;1.95;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of E18N DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;3b36;1;b;1;372;100;99;372;100;99;0.16;0.16;98;0;1.6;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of E18N DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;1q2u;2;b;1;372;100;98;372;100;98;0.18;0.18;99;0;1.6;1.6;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Crystal Structure of E18N DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;3b3a;1;b;1;372;100;99;372;100;99;0.21;0.21;98;0;1.6;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of E18N DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cyf;1;2r1v;1;b;1;372;100;99;372;100;99;0.13;0.13;99;0;1.6;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal Structure of E18N DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;4ogf;1;b;1;372;99;99;373;100;100;0.43;0.44;99;0;2.4;1.6;diffraction;diffraction;378;374;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;Crystal structure of aggregated form of DJ1;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;no/data;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;3f71;1;b;1;372;99;99;373;100;100;0.42;0.43;99;0;2.4;1.2;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CSO   s-hydroxycysteine;Crystal structure of aggregated form of DJ1;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;4n12;1;b;1;372;99;99;373;100;100;0.40;0.40;99;0;2.4;1.478;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of aggregated form of DJ1;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;3ezg;1;b;1;372;99;99;373;100;100;0.42;0.42;99;0;2.4;1.15;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CSD   3-sulfinoalanine;Crystal structure of aggregated form of DJ1;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;2rk4;1;b;1;372;99;99;373;100;100;0.41;0.41;99;0;2.4;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;no/data;Crystal structure of aggregated form of DJ1;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;4mnt;1;b;1;372;99;99;373;100;100;0.40;0.40;100;0;2.4;1.584;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CU   copper (ii) ion;Crystal structure of aggregated form of DJ1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;2rk3;1;b;1;372;99;99;373;100;100;0.41;0.41;99;0;2.4;1.05;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;no/data;Crystal structure of aggregated form of DJ1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;2rk6;1;b;1;370;99;99;371;99;100;0.41;0.41;99;0;2.4;1.15;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CSD   3-sulfinoalanine;Crystal structure of aggregated form of DJ1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;1pe0;1;b;1;372;100;100;373;100;100;0.30;0.30;99;0;2.4;1.7;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;no/data;Crystal structure of aggregated form of DJ1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;3b38;1;b;1;371;99;97;373;100;98;0.46;0.49;99;0;2.4;1.85;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;EDO   1,2-ethanediol;Crystal structure of aggregated form of DJ1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;4p36;1;b;1;372;99;99;373;100;100;0.39;0.40;99;0;2.4;1.182;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of aggregated form of DJ1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;3cz9;1;b;1;372;99;99;373;100;100;0.42;0.42;99;0;2.4;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of aggregated form of DJ1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;2r1t;1;b;1;372;99;99;373;100;100;0.39;0.39;99;0;2.4;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of aggregated form of DJ1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;1soa;1;b;1;372;99;99;373;100;100;0.42;0.42;99;0;2.4;1.2;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CSD   3-sulfinoalanine;Crystal structure of aggregated form of DJ1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;1pdw;3;b;1;373;100;99;374;100;99;0.40;0.40;100;0;2.4;2.2;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;MSE   selenomethionine;Crystal structure of aggregated form of DJ1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;4n0m;1;b;1;372;99;99;373;100;100;0.43;0.43;99;0;2.4;1.95;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of aggregated form of DJ1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;3b36;1;b;1;372;99;99;373;100;100;0.42;0.42;99;0;2.4;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of aggregated form of DJ1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;1q2u;2;b;1;373;100;99;374;100;99;0.40;0.41;100;0;2.4;1.6;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;no/data;Crystal structure of aggregated form of DJ1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;3b3a;1;b;1;371;99;99;373;100;100;0.46;0.46;99;0;2.4;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of aggregated form of DJ1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3bwe;3;2r1v;1;b;1;372;99;99;373;100;100;0.39;0.39;99;0;2.4;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine| PO4   phosphate ion;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of aggregated form of DJ1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;no/data;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;3f71;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.6;1.2;diffraction;diffraction;374;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;CSO   s-hydroxycysteine;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Crystal structure of E18D DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;4n12;1;b;1;373;100;100;374;100;100;0.26;0.26;99;0;1.6;1.478;diffraction;diffraction;374;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;3ezg;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.6;1.15;diffraction;diffraction;374;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;2rk4;1;b;1;374;100;100;374;100;100;0.24;0.25;99;0;1.6;1.15;diffraction;diffraction;374;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;no/data;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;4mnt;1;b;1;374;100;100;374;100;100;0.24;0.25;99;0;1.6;1.584;diffraction;diffraction;374;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;CU   copper (ii) ion;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;2rk3;1;c;1;374;100;100;374;100;100;0.23;0.23;99;0;1.6;1.05;diffraction;diffraction;374;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;no/data;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;2rk6;1;c;1;372;99;100;372;99;100;0.23;0.23;99;0;1.6;1.15;diffraction;diffraction;374;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;1pe0;1;b;1;373;100;100;374;100;100;0.38;0.38;99;0;1.6;1.7;diffraction;diffraction;374;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;no/data;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;3b38;1;b;1;373;100;98;374;100;98;0.38;0.38;99;0;1.6;1.85;diffraction;diffraction;374;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;EDO   1,2-ethanediol;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;4p36;1;b;1;373;100;100;374;100;100;0.26;0.26;100;0;1.6;1.182;diffraction;diffraction;374;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;3cz9;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.6;1.15;diffraction;diffraction;374;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;2r1t;1;b;1;373;100;100;374;100;100;0.26;0.26;99;0;1.6;1.7;diffraction;diffraction;374;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;1soa;1;b;1;374;100;100;374;100;100;0.24;0.24;100;0;1.6;1.2;diffraction;diffraction;374;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;CSD   3-sulfinoalanine;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;1pdw;3;b;1;373;100;99;374;100;99;0.41;0.42;99;0;1.6;2.2;diffraction;diffraction;374;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;MSE   selenomethionine;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;4n0m;1;b;1;373;100;100;374;100;100;0.31;0.32;99;0;1.6;1.95;diffraction;diffraction;374;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;3b36;1;b;1;373;100;100;374;100;100;0.29;0.30;99;0;1.6;1.5;diffraction;diffraction;374;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;1q2u;2;b;1;373;100;99;374;100;99;0.27;0.27;99;0;1.6;1.6;diffraction;diffraction;374;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;no/data;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;3b3a;1;b;1;373;100;100;374;100;100;0.30;0.31;98;0;1.6;1.5;diffraction;diffraction;374;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4ogf;1;2r1v;1;b;1;374;100;100;374;100;100;0.24;0.24;99;0;1.6;1.7;diffraction;diffraction;374;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CGV   s-[(r)-carboxy(hydroxy)methyl]-l-cysteine;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal Structure of Human DJ-1 with glyoxylate as substrate analog;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;no/data;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;4n12;1;b;1;374;100;100;374;100;100;0.18;0.18;100;0;1.2;1.478;diffraction;diffraction;392;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of E18D DJ-1 with oxidized C106;Crystal structure of human E18D DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;3ezg;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.2;1.15;diffraction;diffraction;392;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine;Crystal structure of E18D DJ-1 with oxidized C106;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;2rk4;1;b;1;374;100;100;374;100;100;0.19;0.19;98;0;1.2;1.15;diffraction;diffraction;392;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;no/data;Crystal structure of E18D DJ-1 with oxidized C106;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;4mnt;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.2;1.584;diffraction;diffraction;392;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CU   copper (ii) ion;Crystal structure of E18D DJ-1 with oxidized C106;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;2rk3;1;b;1;374;100;100;374;100;100;0.16;0.16;98;0;1.2;1.05;diffraction;diffraction;392;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;no/data;Crystal structure of E18D DJ-1 with oxidized C106;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;2rk6;1;b;1;372;99;100;372;99;100;0.14;0.14;99;0;1.2;1.15;diffraction;diffraction;392;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine;Crystal structure of E18D DJ-1 with oxidized C106;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;1pe0;1;b;1;373;100;100;374;100;100;0.35;0.36;98;0;1.2;1.7;diffraction;diffraction;392;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;no/data;Crystal structure of E18D DJ-1 with oxidized C106;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;3b38;1;b;1;373;100;98;374;100;98;0.43;0.46;98;0;1.2;1.85;diffraction;diffraction;392;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;EDO   1,2-ethanediol;Crystal structure of E18D DJ-1 with oxidized C106;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;4p36;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.2;1.182;diffraction;diffraction;392;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of E18D DJ-1 with oxidized C106;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;3cz9;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.2;1.15;diffraction;diffraction;392;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of E18D DJ-1 with oxidized C106;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;2r1t;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.2;1.7;diffraction;diffraction;392;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of E18D DJ-1 with oxidized C106;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;1soa;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.2;1.2;diffraction;diffraction;392;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine;Crystal structure of E18D DJ-1 with oxidized C106;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;1pdw;3;b;1;373;100;99;374;100;99;0.40;0.40;99;0;1.2;2.2;diffraction;diffraction;392;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;MSE   selenomethionine;Crystal structure of E18D DJ-1 with oxidized C106;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;4n0m;1;b;1;374;100;100;374;100;100;0.19;0.19;98;0;1.2;1.95;diffraction;diffraction;392;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of E18D DJ-1 with oxidized C106;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;3b36;1;c;1;374;100;100;374;100;100;0.20;0.20;98;0;1.2;1.5;diffraction;diffraction;392;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of E18D DJ-1 with oxidized C106;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;1q2u;2;b;1;374;100;99;374;100;99;0.22;0.22;99;0;1.2;1.6;diffraction;diffraction;392;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;no/data;Crystal structure of E18D DJ-1 with oxidized C106;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;3b3a;1;b;1;374;100;100;374;100;100;0.26;0.26;98;0;1.2;1.5;diffraction;diffraction;392;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of E18D DJ-1 with oxidized C106;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3f71;1;2r1v;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.2;1.7;diffraction;diffraction;392;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of E18D DJ-1 with oxidized C106;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;3ezg;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.478;1.15;diffraction;diffraction;378;392;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of human E18D DJ-1 in complex with Cu;Crystal structure of E18Q DJ-1 with oxidized C106;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;2rk4;1;b;1;374;100;100;374;100;100;0.20;0.20;98;0;1.478;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;no/data;Crystal structure of human E18D DJ-1 in complex with Cu;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;4mnt;1;b;1;374;100;100;374;100;100;0.12;0.12;99;0;1.478;1.584;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;CU   copper (ii) ion;Crystal structure of human E18D DJ-1 in complex with Cu;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;2rk3;1;b;1;374;100;100;374;100;100;0.17;0.17;98;0;1.478;1.05;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;no/data;Crystal structure of human E18D DJ-1 in complex with Cu;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;2rk6;1;b;1;372;99;100;372;99;100;0.14;0.14;99;0;1.478;1.15;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of human E18D DJ-1 in complex with Cu;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;1pe0;1;b;1;373;100;100;374;100;100;0.32;0.32;98;0;1.478;1.7;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;no/data;Crystal structure of human E18D DJ-1 in complex with Cu;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;3b38;1;b;1;373;100;98;374;100;98;0.44;0.48;98;0;1.478;1.85;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;EDO   1,2-ethanediol;Crystal structure of human E18D DJ-1 in complex with Cu;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;4p36;1;c;1;374;100;100;374;100;100;0.15;0.15;99;0;1.478;1.182;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of human E18D DJ-1 in complex with Cu;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;3cz9;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.478;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of human E18D DJ-1 in complex with Cu;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;2r1t;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.478;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of human E18D DJ-1 in complex with Cu;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;1soa;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.478;1.2;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Crystal structure of human E18D DJ-1 in complex with Cu;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;1pdw;3;b;1;373;100;99;374;100;99;0.34;0.35;99;0;1.478;2.2;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;MSE   selenomethionine;Crystal structure of human E18D DJ-1 in complex with Cu;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;4n0m;1;b;1;374;100;100;374;100;100;0.19;0.19;98;0;1.478;1.95;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of human E18D DJ-1 in complex with Cu;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;3b36;1;b;1;374;100;100;374;100;100;0.19;0.19;98;0;1.478;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human E18D DJ-1 in complex with Cu;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;1q2u;2;b;1;374;100;99;374;100;99;0.15;0.15;99;0;1.478;1.6;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;no/data;Crystal structure of human E18D DJ-1 in complex with Cu;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;3b3a;1;b;1;374;100;100;374;100;100;0.25;0.25;98;0;1.478;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human E18D DJ-1 in complex with Cu;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n12;1;2r1v;1;b;1;374;100;100;374;100;100;0.14;0.14;99;0;1.478;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine| CU   copper (ii) ion| EDO   1,2-ethanediol;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of human E18D DJ-1 in complex with Cu;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;2rk4;1;b;1;374;100;100;374;100;100;0.13;0.13;98;0;1.15;1.15;diffraction;diffraction;392;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Crystal structure of E18Q DJ-1 with oxidized C106;Structure of M26I DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;4mnt;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.15;1.584;diffraction;diffraction;392;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CU   copper (ii) ion;Crystal structure of E18Q DJ-1 with oxidized C106;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;2rk3;1;c;1;374;100;100;374;100;100;0.15;0.15;98;0;1.15;1.05;diffraction;diffraction;392;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Crystal structure of E18Q DJ-1 with oxidized C106;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;2rk6;1;b;1;372;99;100;372;99;100;0.20;0.20;99;0;1.15;1.15;diffraction;diffraction;392;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSD   3-sulfinoalanine;Crystal structure of E18Q DJ-1 with oxidized C106;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;1pe0;1;b;1;373;100;100;374;100;100;0.33;0.34;98;0;1.15;1.7;diffraction;diffraction;392;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Crystal structure of E18Q DJ-1 with oxidized C106;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;3b38;1;b;1;373;100;98;374;100;98;0.44;0.47;98;0;1.15;1.85;diffraction;diffraction;392;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;EDO   1,2-ethanediol;Crystal structure of E18Q DJ-1 with oxidized C106;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;4p36;1;b;1;374;100;100;374;100;100;0.14;0.14;99;0;1.15;1.182;diffraction;diffraction;392;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of E18Q DJ-1 with oxidized C106;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;3cz9;1;b;1;374;100;100;374;100;100;0.14;0.14;99;0;1.15;1.15;diffraction;diffraction;392;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of E18Q DJ-1 with oxidized C106;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;2r1t;1;b;1;374;100;100;374;100;100;0.24;0.24;99;0;1.15;1.7;diffraction;diffraction;392;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of E18Q DJ-1 with oxidized C106;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;1soa;1;b;1;374;100;100;374;100;100;0.09;0.09;99;0;1.15;1.2;diffraction;diffraction;392;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSD   3-sulfinoalanine;Crystal structure of E18Q DJ-1 with oxidized C106;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;1pdw;3;b;1;373;100;99;374;100;99;0.37;0.37;99;0;1.15;2.2;diffraction;diffraction;392;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;MSE   selenomethionine;Crystal structure of E18Q DJ-1 with oxidized C106;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;4n0m;1;b;1;373;100;100;374;100;100;0.28;0.28;98;0;1.15;1.95;diffraction;diffraction;392;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of E18Q DJ-1 with oxidized C106;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;3b36;1;b;1;373;100;100;374;100;100;0.27;0.27;98;0;1.15;1.5;diffraction;diffraction;392;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of E18Q DJ-1 with oxidized C106;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;1q2u;2;c;1;374;100;99;374;100;99;0.17;0.17;99;0;1.15;1.6;diffraction;diffraction;392;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Crystal structure of E18Q DJ-1 with oxidized C106;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;3b3a;1;b;1;373;100;100;374;100;100;0.32;0.32;98;0;1.15;1.5;diffraction;diffraction;392;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of E18Q DJ-1 with oxidized C106;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3ezg;1;2r1v;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.15;1.7;diffraction;diffraction;392;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of E18Q DJ-1 with oxidized C106;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;4mnt;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.15;1.584;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion;Structure of M26I DJ-1;Crystal structure of human DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;2rk3;1;b;1;374;100;100;374;100;100;0.12;0.12;99;0;1.15;1.05;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Structure of M26I DJ-1;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;2rk6;1;b;1;372;99;100;372;99;100;0.19;0.19;98;0;1.15;1.15;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Structure of M26I DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;1pe0;1;b;1;373;100;100;374;100;100;0.31;0.32;99;0;1.15;1.7;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Structure of M26I DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;3b38;1;b;1;372;100;97;374;100;98;0.47;0.51;99;0;1.15;1.85;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;Structure of M26I DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;4p36;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.15;1.182;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Structure of M26I DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;3cz9;1;b;1;374;100;100;374;100;100;0.14;0.14;99;0;1.15;1.15;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;P4C   o-acetaldehydyl-hexaethylene glycol;Structure of M26I DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;2r1t;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.15;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Structure of M26I DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;1soa;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.15;1.2;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Structure of M26I DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;1pdw;3;b;1;373;100;99;374;100;99;0.36;0.36;99;0;1.15;2.2;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine;Structure of M26I DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;4n0m;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.15;1.95;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion| EDO   1,2-ethanediol;Structure of M26I DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;3b36;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.15;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Structure of M26I DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;1q2u;2;c;1;374;100;99;374;100;99;0.18;0.18;99;0;1.15;1.6;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Structure of M26I DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;3b3a;1;b;1;373;100;100;374;100;100;0.27;0.27;98;0;1.15;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Structure of M26I DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk4;1;2r1v;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.15;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Structure of M26I DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;2rk3;1;b;1;374;100;100;374;100;100;0.14;0.14;99;0;1.584;1.05;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;no/data;Crystal structure of human DJ-1 in complex with Cu;Structure of A104T DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;2rk6;1;b;1;372;99;100;372;99;100;0.12;0.12;99;0;1.584;1.15;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;CSD   3-sulfinoalanine;Crystal structure of human DJ-1 in complex with Cu;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;1pe0;1;b;1;373;100;100;374;100;100;0.33;0.33;99;0;1.584;1.7;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;no/data;Crystal structure of human DJ-1 in complex with Cu;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;3b38;1;b;1;373;100;98;374;100;98;0.43;0.47;99;0;1.584;1.85;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;EDO   1,2-ethanediol;Crystal structure of human DJ-1 in complex with Cu;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;4p36;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.584;1.182;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of human DJ-1 in complex with Cu;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;3cz9;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.584;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of human DJ-1 in complex with Cu;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;2r1t;1;b;1;374;100;100;374;100;100;0.12;0.12;99;0;1.584;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of human DJ-1 in complex with Cu;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;1soa;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.584;1.2;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;CSD   3-sulfinoalanine;Crystal structure of human DJ-1 in complex with Cu;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;1pdw;3;b;1;373;100;99;374;100;99;0.35;0.35;100;0;1.584;2.2;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;MSE   selenomethionine;Crystal structure of human DJ-1 in complex with Cu;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;4n0m;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.584;1.95;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of human DJ-1 in complex with Cu;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;3b36;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.584;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human DJ-1 in complex with Cu;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;1q2u;2;c;1;374;100;99;374;100;99;0.16;0.16;100;0;1.584;1.6;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;no/data;Crystal structure of human DJ-1 in complex with Cu;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;3b3a;1;b;1;374;100;100;374;100;100;0.23;0.23;99;0;1.584;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human DJ-1 in complex with Cu;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4mnt;1;2r1v;1;b;1;374;100;100;374;100;100;0.10;0.10;99;0;1.584;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of human DJ-1 in complex with Cu;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;2rk6;1;b;1;372;99;100;372;99;100;0.16;0.16;98;0;1.05;1.15;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Structure of A104T DJ-1;Structure of E163K DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;1pe0;1;b;1;373;100;100;374;100;100;0.32;0.32;99;0;1.05;1.7;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Structure of A104T DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;3b38;1;b;1;373;100;98;374;100;98;0.43;0.47;99;0;1.05;1.85;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;Structure of A104T DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;4p36;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.05;1.182;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Structure of A104T DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;3cz9;1;b;1;374;100;100;374;100;100;0.15;0.15;99;0;1.05;1.15;diffraction;diffraction;394;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;P4C   o-acetaldehydyl-hexaethylene glycol;Structure of A104T DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;2r1t;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.05;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Structure of A104T DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;1soa;1;b;1;374;100;100;374;100;100;0.16;0.16;99;0;1.05;1.2;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Structure of A104T DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;1pdw;3;b;1;373;100;99;374;100;99;0.37;0.37;99;0;1.05;2.2;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine;Structure of A104T DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;4n0m;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.05;1.95;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion| EDO   1,2-ethanediol;Structure of A104T DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;3b36;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.05;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Structure of A104T DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;1q2u;2;b;1;374;100;99;374;100;99;0.15;0.15;99;0;1.05;1.6;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Structure of A104T DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;3b3a;1;b;1;373;100;100;374;100;100;0.27;0.27;98;0;1.05;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Structure of A104T DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk3;1;2r1v;1;b;1;374;100;100;374;100;100;0.15;0.15;99;0;1.05;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Structure of A104T DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;1pe0;1;b;1;371;100;99;372;100;99;0.34;0.34;98;0;1.15;1.7;diffraction;diffraction;384;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Structure of E163K DJ-1;Crystal structure of the K130R mutant of human DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;3b38;1;b;1;371;100;97;372;100;97;0.44;0.48;98;0;1.15;1.85;diffraction;diffraction;384;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;EDO   1,2-ethanediol;Structure of E163K DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;4p36;1;b;1;372;100;99;372;100;99;0.17;0.17;99;0;1.15;1.182;diffraction;diffraction;384;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Structure of E163K DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;3cz9;1;b;1;372;100;99;372;100;99;0.22;0.22;98;0;1.15;1.15;diffraction;diffraction;384;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;P4C   o-acetaldehydyl-hexaethylene glycol;Structure of E163K DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;2r1t;1;b;1;372;100;99;372;100;99;0.16;0.16;99;0;1.15;1.7;diffraction;diffraction;384;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Structure of E163K DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;1soa;1;b;1;372;100;99;372;100;99;0.19;0.19;99;0;1.15;1.2;diffraction;diffraction;384;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CSD   3-sulfinoalanine;Structure of E163K DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;1pdw;3;b;1;371;100;99;372;100;99;0.35;0.35;99;0;1.15;2.2;diffraction;diffraction;384;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;MSE   selenomethionine;Structure of E163K DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;4n0m;1;b;1;372;100;99;372;100;99;0.21;0.21;98;0;1.15;1.95;diffraction;diffraction;384;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CU   copper (ii) ion| EDO   1,2-ethanediol;Structure of E163K DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;3b36;1;b;1;372;100;99;372;100;99;0.19;0.19;98;0;1.15;1.5;diffraction;diffraction;384;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CL   chloride ion| EDO   1,2-ethanediol;Structure of E163K DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;1q2u;2;b;1;372;100;98;372;100;98;0.16;0.16;99;0;1.15;1.6;diffraction;diffraction;384;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Structure of E163K DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;3b3a;1;b;1;372;100;99;372;100;99;0.21;0.22;99;0;1.15;1.5;diffraction;diffraction;384;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CL   chloride ion| EDO   1,2-ethanediol;Structure of E163K DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2rk6;1;2r1v;1;b;1;372;100;99;372;100;99;0.15;0.15;99;0;1.15;1.7;diffraction;diffraction;384;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Structure of E163K DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;3b38;1;b;1;372;100;97;374;100;98;0.49;0.53;99;0;1.7;1.85;diffraction;diffraction;394;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;EDO   1,2-ethanediol;Crystal structure of the K130R mutant of human DJ-1;Structure of A104V DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;4p36;1;b;1;373;100;100;374;100;100;0.31;0.32;99;0;1.7;1.182;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Crystal structure of the K130R mutant of human DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;3cz9;1;b;1;373;100;100;374;100;100;0.33;0.33;99;0;1.7;1.15;diffraction;diffraction;394;394;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of the K130R mutant of human DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;2r1t;1;b;1;373;100;100;374;100;100;0.34;0.34;99;0;1.7;1.7;diffraction;diffraction;394;374;DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of the K130R mutant of human DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;1soa;1;b;1;373;100;100;374;100;100;0.34;0.34;99;0;1.7;1.2;diffraction;diffraction;394;378;DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;no/data;CSD   3-sulfinoalanine;Crystal structure of the K130R mutant of human DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;1pdw;3;b;1;373;100;99;374;100;99;0.30;0.30;99;0;1.7;2.2;diffraction;diffraction;394;394;DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;MSE   selenomethionine;Crystal structure of the K130R mutant of human DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;4n0m;1;b;1;373;100;100;374;100;100;0.37;0.38;99;0;1.7;1.95;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of the K130R mutant of human DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;3b36;1;b;1;373;100;100;374;100;100;0.36;0.36;99;0;1.7;1.5;diffraction;diffraction;394;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of the K130R mutant of human DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;1q2u;2;b;1;373;100;99;374;100;99;0.33;0.34;99;0;1.7;1.6;diffraction;diffraction;394;378;DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal structure of the K130R mutant of human DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;3b3a;1;b;1;373;100;100;374;100;100;0.39;0.39;98;0;1.7;1.5;diffraction;diffraction;394;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of the K130R mutant of human DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pe0;1;2r1v;1;b;1;373;100;100;374;100;100;0.33;0.34;99;0;1.7;1.7;diffraction;diffraction;394;374;DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of the K130R mutant of human DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b38;1;4p36;1;b;1;372;98;100;374;98;100;0.45;0.48;99;0;1.85;1.182;diffraction;diffraction;384;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;Structure of A104V DJ-1;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b38;1;3cz9;1;b;1;373;98;100;374;98;100;0.44;0.47;99;0;1.85;1.15;diffraction;diffraction;384;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;P4C   o-acetaldehydyl-hexaethylene glycol;Structure of A104V DJ-1;Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b38;1;2r1t;1;b;1;373;98;100;374;98;100;0.43;0.47;99;0;1.85;1.7;diffraction;diffraction;384;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Structure of A104V DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b38;1;1soa;1;b;1;372;98;100;374;98;100;0.45;0.47;99;0;1.85;1.2;diffraction;diffraction;384;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CSD   3-sulfinoalanine;Structure of A104V DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b38;1;1pdw;3;b;1;371;97;99;373;98;99;0.46;0.47;99;0;1.85;2.2;diffraction;diffraction;384;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;MSE   selenomethionine;Structure of A104V DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b38;1;4n0m;1;b;1;372;97;100;374;98;100;0.47;0.52;99;0;1.85;1.95;diffraction;diffraction;384;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CU   copper (ii) ion| EDO   1,2-ethanediol;Structure of A104V DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b38;1;3b36;1;b;1;372;97;100;374;98;100;0.49;0.53;99;0;1.85;1.5;diffraction;diffraction;384;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Structure of A104V DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b38;1;1q2u;2;b;1;374;98;99;376;98;99;0.54;0.59;99;0;1.85;1.6;diffraction;diffraction;384;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;no/data;Structure of A104V DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b38;1;3b3a;1;b;1;372;97;99;374;98;100;0.52;0.56;98;0;1.85;1.5;diffraction;diffraction;384;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Structure of A104V DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b38;1;2r1v;1;b;1;373;98;100;374;98;100;0.43;0.46;99;0;1.85;1.7;diffraction;diffraction;384;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;EDO   1,2-ethanediol;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Structure of A104V DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p36;1;3cz9;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.182;1.15;diffraction;diffraction;378;394;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;P4C   o-acetaldehydyl-hexaethylene glycol;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Crystal Structure of E18L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p36;1;2r1t;1;b;1;374;100;100;374;100;100;0.19;0.19;99;0;1.182;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p36;1;1soa;1;b;1;374;100;100;374;100;100;0.11;0.11;100;0;1.182;1.2;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;CSD   3-sulfinoalanine;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p36;1;1pdw;3;b;1;373;100;99;374;100;99;0.33;0.34;99;0;1.182;2.2;diffraction;diffraction;378;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;MSE   selenomethionine;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p36;1;4n0m;1;b;1;373;100;100;374;100;100;0.26;0.26;99;0;1.182;1.95;diffraction;diffraction;378;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p36;1;3b36;1;b;1;374;100;100;374;100;100;0.25;0.25;99;0;1.182;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p36;1;1q2u;2;b;1;374;100;99;374;100;99;0.11;0.11;99;0;1.182;1.6;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;no/data;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p36;1;3b3a;1;b;1;373;100;100;374;100;100;0.33;0.33;98;0;1.182;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4p36;1;2r1v;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.182;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSO   s-hydroxycysteine| P15   2,5,8,11,14,17-hexaoxanonadecan-19-ol| ZN   zinc ion;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of DJ-1 With Zn(II) bound (crystal 2);Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cz9;1;2r1t;1;b;1;374;100;100;374;100;100;0.24;0.24;99;0;1.15;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;P4C   o-acetaldehydyl-hexaethylene glycol;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;Crystal Structure of E18L DJ-1;dopamine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cz9;1;1soa;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.15;1.2;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;P4C   o-acetaldehydyl-hexaethylene glycol;CSD   3-sulfinoalanine;Crystal Structure of E18L DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cz9;1;1pdw;3;b;1;373;100;99;374;100;99;0.39;0.39;99;0;1.15;2.2;diffraction;diffraction;394;394;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;P4C   o-acetaldehydyl-hexaethylene glycol;MSE   selenomethionine;Crystal Structure of E18L DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cz9;1;4n0m;1;b;1;374;100;100;374;100;100;0.25;0.25;99;0;1.15;1.95;diffraction;diffraction;394;378;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;P4C   o-acetaldehydyl-hexaethylene glycol;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal Structure of E18L DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cz9;1;3b36;1;b;1;373;100;100;374;100;100;0.26;0.26;99;0;1.15;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;P4C   o-acetaldehydyl-hexaethylene glycol;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of E18L DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cz9;1;1q2u;2;b;1;374;100;99;374;100;99;0.21;0.21;99;0;1.15;1.6;diffraction;diffraction;394;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;P4C   o-acetaldehydyl-hexaethylene glycol;no/data;Crystal Structure of E18L DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cz9;1;3b3a;1;b;1;373;100;100;374;100;100;0.30;0.30;98;0;1.15;1.5;diffraction;diffraction;394;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;P4C   o-acetaldehydyl-hexaethylene glycol;CL   chloride ion| EDO   1,2-ethanediol;Crystal Structure of E18L DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3cz9;1;2r1v;1;b;1;374;100;100;374;100;100;0.22;0.22;99;0;1.15;1.7;diffraction;diffraction;394;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;P4C   o-acetaldehydyl-hexaethylene glycol;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal Structure of E18L DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1t;1;1soa;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.7;1.2;diffraction;diffraction;374;378;DJ-1;RNA-binding protein regulatory subunit| oncogene DJ1;HOMO SAPIENS;HOMO SAPIENS;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;CSD   3-sulfinoalanine;dopamine quinone conjugation to DJ-1;Human DJ-1 with sulfinic acid;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1t;1;1pdw;3;b;1;373;100;99;374;100;99;0.34;0.34;99;0;1.7;2.2;diffraction;diffraction;374;394;DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;MSE   selenomethionine;dopamine quinone conjugation to DJ-1;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1t;1;4n0m;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.7;1.95;diffraction;diffraction;374;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;CU   copper (ii) ion| EDO   1,2-ethanediol;dopamine quinone conjugation to DJ-1;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1t;1;3b36;1;b;1;374;100;100;374;100;100;0.21;0.21;99;0;1.7;1.5;diffraction;diffraction;374;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;CL   chloride ion| EDO   1,2-ethanediol;dopamine quinone conjugation to DJ-1;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1t;1;1q2u;2;b;1;374;100;99;374;100;99;0.15;0.15;99;0;1.7;1.6;diffraction;diffraction;374;378;DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;no/data;dopamine quinone conjugation to DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1t;1;3b3a;1;b;1;373;100;100;374;100;100;0.27;0.28;98;0;1.7;1.5;diffraction;diffraction;374;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;CL   chloride ion| EDO   1,2-ethanediol;dopamine quinone conjugation to DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;2r1t;1;2r1v;1;b;1;374;100;100;374;100;100;0.07;0.07;99;0;1.7;1.7;diffraction;diffraction;374;374;DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;DYS   s-[5-(2-aminoethyl)-2,3-dihydroxyphenyl]-l-cysteine;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;dopamine quinone conjugation to DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;6.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1soa;1;1pdw;3;b;1;373;100;99;374;100;99;0.36;0.36;99;0;1.2;2.2;diffraction;diffraction;378;394;RNA-binding protein regulatory subunit| oncogene DJ1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;MSE   selenomethionine;Human DJ-1 with sulfinic acid;Crystal structure of human DJ-1, P 1 21 1 space group;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.0;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1soa;1;4n0m;1;b;1;373;100;100;374;100;100;0.27;0.28;99;0;1.2;1.95;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit| oncogene DJ1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CU   copper (ii) ion| EDO   1,2-ethanediol;Human DJ-1 with sulfinic acid;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1soa;1;3b36;1;b;1;373;100;100;374;100;100;0.28;0.28;99;0;1.2;1.5;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit| oncogene DJ1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CL   chloride ion| EDO   1,2-ethanediol;Human DJ-1 with sulfinic acid;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1soa;1;1q2u;2;c;1;374;100;99;374;100;99;0.13;0.13;99;0;1.2;1.6;diffraction;diffraction;378;378;RNA-binding protein regulatory subunit| oncogene DJ1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;no/data;Human DJ-1 with sulfinic acid;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1soa;1;3b3a;1;b;1;373;100;100;374;100;100;0.34;0.34;98;0;1.2;1.5;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit| oncogene DJ1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;CL   chloride ion| EDO   1,2-ethanediol;Human DJ-1 with sulfinic acid;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1soa;1;2r1v;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.2;1.7;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit| oncogene DJ1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CSD   3-sulfinoalanine;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Human DJ-1 with sulfinic acid;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdw;3;4n0m;1;b;1;373;99;100;374;99;100;0.39;0.39;99;0;2.2;1.95;diffraction;diffraction;394;378;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CU   copper (ii) ion| EDO   1,2-ethanediol;Crystal structure of human DJ-1, P 1 21 1 space group;Crystal structure of human C53A DJ-1 in complex with Cu;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdw;3;3b36;1;b;1;373;99;100;374;99;100;0.36;0.37;99;0;2.2;1.5;diffraction;diffraction;394;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human DJ-1, P 1 21 1 space group;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdw;3;1q2u;2;b;1;374;99;99;375;100;99;0.37;0.38;100;0;2.2;1.6;diffraction;diffraction;394;378;DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;no/data;Crystal structure of human DJ-1, P 1 21 1 space group;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdw;3;3b3a;1;b;1;373;99;100;374;99;100;0.41;0.42;99;0;2.2;1.5;diffraction;diffraction;394;384;DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human DJ-1, P 1 21 1 space group;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1pdw;3;2r1v;1;b;1;373;99;100;374;99;100;0.34;0.34;99;0;2.2;1.7;diffraction;diffraction;394;374;DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;MSE   selenomethionine;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of human DJ-1, P 1 21 1 space group;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.0;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n0m;1;3b36;1;b;1;374;100;100;374;100;100;0.18;0.18;99;0;1.95;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion| EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human C53A DJ-1 in complex with Cu;Structure of M26L DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.50;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n0m;1;1q2u;2;b;1;374;100;99;374;100;99;0.24;0.24;99;0;1.95;1.6;diffraction;diffraction;378;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion| EDO   1,2-ethanediol;no/data;Crystal structure of human C53A DJ-1 in complex with Cu;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n0m;1;3b3a;1;b;1;374;100;100;374;100;100;0.23;0.23;98;0;1.95;1.5;diffraction;diffraction;378;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion| EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of human C53A DJ-1 in complex with Cu;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;4n0m;1;2r1v;1;b;1;374;100;100;374;100;100;0.17;0.17;99;0;1.95;1.7;diffraction;diffraction;378;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CU   copper (ii) ion| EDO   1,2-ethanediol;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of human C53A DJ-1 in complex with Cu;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b36;1;1q2u;2;b;1;374;100;99;374;100;99;0.25;0.25;99;0;1.5;1.6;diffraction;diffraction;384;378;Protein DJ-1;RNA-binding protein regulatory subunit;HOMO SAPIENS;HOMO SAPIENS;CL   chloride ion| EDO   1,2-ethanediol;no/data;Structure of M26L DJ-1;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.50;110;8.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b36;1;3b3a;1;b;1;374;100;100;374;100;100;0.19;0.19;98;0;1.5;1.5;diffraction;diffraction;384;384;Protein DJ-1;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;CL   chloride ion| EDO   1,2-ethanediol;CL   chloride ion| EDO   1,2-ethanediol;Structure of M26L DJ-1;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.50;110;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b36;1;2r1v;1;b;1;374;100;100;374;100;100;0.20;0.20;99;0;1.5;1.7;diffraction;diffraction;384;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CL   chloride ion| EDO   1,2-ethanediol;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Structure of M26L DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.50;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;1q2u;2;3b3a;1;b;1;373;99;100;374;99;100;0.32;0.32;99;0;1.6;1.5;diffraction;diffraction;378;384;RNA-binding protein regulatory subunit;Protein DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;CL   chloride ion| EDO   1,2-ethanediol;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Structure of E163K/R145E DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;7.5;110;3bwe_A;3b38_A;0.68;0.59
2or3;2;1q2u;2;2r1v;1;b;1;374;99;100;374;99;100;0.14;0.14;99;0;1.6;1.7;diffraction;diffraction;378;374;RNA-binding protein regulatory subunit;DJ-1;HOMO SAPIENS;HOMO SAPIENS;no/data;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Crystal structure of DJ-1/RS and implication on familial Parkinson's disease;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;8.5;100;6.5;100;3bwe_A;3b38_A;0.68;0.59
2or3;2;3b3a;1;2r1v;1;b;1;373;100;100;374;100;100;0.27;0.27;98;0;1.5;1.7;diffraction;diffraction;384;374;Protein DJ-1;DJ-1;HOMO SAPIENS;HOMO SAPIENS;CL   chloride ion| EDO   1,2-ethanediol;NYS   s-{5-[(1r)-2-amino-1-hydroxyethyl]-2,3-dihydroxyphenyl}-l-cysteine;Structure of E163K/R145E DJ-1;Norepinephrine quinone conjugation to DJ-1;Q99497;PARK7;PF01965;Q99497;PARK7;PF01965;b;7.5;110;6.5;100;3bwe_A;3b38_A;0.68;0.59
1yak;4;1yak;1;1tyh;1;b;1;869;99;98;874;100;99;0.55;0.56;100;0;2.5;2.54;diffraction;diffraction;1052;992;Transcriptional activator tenA;Transcriptional activator tenA;BACILLUS SUBTILIS;BACILLUS SUBTILIS;HMH   4-amino-5-hydroxymethyl-2-methylpyrimidine;MSE   selenomethionine;Complex of Bacillus subtilis TenA with 4-amino-2-methyl-5-hydroxymethylpyrimidine;Crystal Structure of Transcriptional Activator tenA from Bacillus subtilis;P25052;tenA BSU11650;PF03070;P25052;tenA BSU11650;PF03070;b;4.4;no/data;5.2;100;1to9_A;1to9_B;0.93;0.69
1yak;4;1yak;1;1yaf;1;b;1;870;100;100;874;100;100;0.49;0.50;100;0;2.5;2.6;diffraction;diffraction;1052;1052;Transcriptional activator tenA;Transcriptional activator tenA;BACILLUS SUBTILIS;BACILLUS SUBTILIS;HMH   4-amino-5-hydroxymethyl-2-methylpyrimidine;no/data;Complex of Bacillus subtilis TenA with 4-amino-2-methyl-5-hydroxymethylpyrimidine;Structure of TenA from Bacillus subtilis;P25052;tenA BSU11650;PF03070;P25052;tenA BSU11650;PF03070;b;4.4;no/data;4.4;100;1to9_A;1to9_B;0.93;0.69
1yak;4;1yak;1;2qcx;1;b;1;872;100;97;874;100;97;0.37;0.38;100;0;2.5;2.2;diffraction;diffraction;1052;1052;Transcriptional activator tenA;Transcriptional activator tenA;BACILLUS SUBTILIS;BACILLUS SUBTILIS;HMH   4-amino-5-hydroxymethyl-2-methylpyrimidine;PF1   n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-(2-hydroxyethyl)formamide;Complex of Bacillus subtilis TenA with 4-amino-2-methyl-5-hydroxymethylpyrimidine;Crystal structure of Bacillus subtilis TenA Y112F mutant complexed with formyl aminomethyl pyrimidine;P25052;tenA BSU11650;PF03070;P25052;tenA BSU11650;PF03070;b;4.4;no/data;4.1;100;1to9_A;1to9_B;0.93;0.69
1yak;4;1yak;1;1to9;2;b;1;868;99;97;874;100;98;0.57;0.57;100;0;2.5;2.4;diffraction;diffraction;1052;1040;Transcriptional activator tenA;THI-4 protein;BACILLUS SUBTILIS;BACILLUS SUBTILIS;HMH   4-amino-5-hydroxymethyl-2-methylpyrimidine;MSE   selenomethionine| HMH   4-amino-5-hydroxymethyl-2-methylpyrimidine| CSD   3-sulfinoalanine;Complex of Bacillus subtilis TenA with 4-amino-2-methyl-5-hydroxymethylpyrimidine;Crystal structure of THI-4 protein from Bacillus subtilis;P25052;tenA BSU11650;PF03070;P25052;tenA BSU11650;PF03070;b;4.4;no/data;4.6;77;1to9_A;1to9_B;0.93;0.69
1yak;4;1tyh;1;1yaf;1;b;1;870;98;100;874;99;100;0.47;0.47;100;0;2.54;2.6;diffraction;diffraction;992;1052;Transcriptional activator tenA;Transcriptional activator tenA;BACILLUS SUBTILIS;BACILLUS SUBTILIS;MSE   selenomethionine;no/data;Crystal Structure of Transcriptional Activator tenA from Bacillus subtilis;Structure of TenA from Bacillus subtilis;P25052;tenA BSU11650;PF03070;P25052;tenA BSU11650;PF03070;b;5.2;100;4.4;100;1to9_A;1to9_B;0.93;0.69
1yak;4;1tyh;1;2qcx;1;b;1;877;99;98;882;100;98;0.53;0.54;99;0;2.54;2.2;diffraction;diffraction;992;1052;Transcriptional activator tenA;Transcriptional activator tenA;BACILLUS SUBTILIS;BACILLUS SUBTILIS;MSE   selenomethionine;PF1   n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-(2-hydroxyethyl)formamide;Crystal Structure of Transcriptional Activator tenA from Bacillus subtilis;Crystal structure of Bacillus subtilis TenA Y112F mutant complexed with formyl aminomethyl pyrimidine;P25052;tenA BSU11650;PF03070;P25052;tenA BSU11650;PF03070;b;5.2;100;4.1;100;1to9_A;1to9_B;0.93;0.69
1yak;4;1tyh;1;1to9;2;b;1;875;99;98;882;100;98;0.61;0.62;100;0;2.54;2.4;diffraction;diffraction;992;1040;Transcriptional activator tenA;THI-4 protein;BACILLUS SUBTILIS;BACILLUS SUBTILIS;MSE   selenomethionine;MSE   selenomethionine| HMH   4-amino-5-hydroxymethyl-2-methylpyrimidine| CSD   3-sulfinoalanine;Crystal Structure of Transcriptional Activator tenA from Bacillus subtilis;Crystal structure of THI-4 protein from Bacillus subtilis;P25052;tenA BSU11650;PF03070;P25052;tenA BSU11650;PF03070;b;5.2;100;4.6;77;1to9_A;1to9_B;0.93;0.69
1yak;4;1yaf;1;2qcx;1;b;1;871;100;97;874;100;97;0.40;0.40;100;0;2.6;2.2;diffraction;diffraction;1052;1052;Transcriptional activator tenA;Transcriptional activator tenA;BACILLUS SUBTILIS;BACILLUS SUBTILIS;no/data;PF1   n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-(2-hydroxyethyl)formamide;Structure of TenA from Bacillus subtilis;Crystal structure of Bacillus subtilis TenA Y112F mutant complexed with formyl aminomethyl pyrimidine;P25052;tenA BSU11650;PF03070;P25052;tenA BSU11650;PF03070;b;4.4;100;4.1;100;1to9_A;1to9_B;0.93;0.69
1yak;4;1yaf;1;1to9;2;b;1;867;99;97;874;100;98;0.61;0.62;100;0;2.6;2.4;diffraction;diffraction;1052;1040;Transcriptional activator tenA;THI-4 protein;BACILLUS SUBTILIS;BACILLUS SUBTILIS;no/data;MSE   selenomethionine| HMH   4-amino-5-hydroxymethyl-2-methylpyrimidine| CSD   3-sulfinoalanine;Structure of TenA from Bacillus subtilis;Crystal structure of THI-4 protein from Bacillus subtilis;P25052;tenA BSU11650;PF03070;P25052;tenA BSU11650;PF03070;b;4.4;100;4.6;77;1to9_A;1to9_B;0.93;0.69
1yak;4;2qcx;1;1to9;2;b;1;886;99;99;894;100;100;0.67;0.69;99;0;2.2;2.4;diffraction;diffraction;1052;1040;Transcriptional activator tenA;THI-4 protein;BACILLUS SUBTILIS;BACILLUS SUBTILIS;PF1   n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-(2-hydroxyethyl)formamide;MSE   selenomethionine| HMH   4-amino-5-hydroxymethyl-2-methylpyrimidine| CSD   3-sulfinoalanine;Crystal structure of Bacillus subtilis TenA Y112F mutant complexed with formyl aminomethyl pyrimidine;Crystal structure of THI-4 protein from Bacillus subtilis;P25052;tenA BSU11650;PF03070;P25052;tenA BSU11650;PF03070;b;4.1;100;4.6;77;1to9_A;1to9_B;0.93;0.69
3kbf;2;3kbf;1;3kbe;1;b;1;247;79;88;256;82;91;1.35;1.44;100;0;1.3;1.1;diffraction;diffraction;314;314;Superoxide dismutase [Cu-Zn];Superoxide dismutase [Cu-Zn];CAENORHABDITIS ELEGANS;CAENORHABDITIS ELEGANS;CU   copper (ii) ion| ZN   zinc ion| SO4   sulfate ion;no/data;C. elegans Cu,Zn Superoxide Dismutase;Metal-free C. elegans Cu,Zn Superoxide Dismutase;P34697;sod-1 C15F1.7;PF00080;P34697;sod-1 C15F1.7;PF00080;no/data;6.9;100;9.0;100;no/data;no/data;no/data;1.44
3ggu;2;3ggu;1;4nju;2;b;1;196;99;99;198;100;100;0.77;0.78;86;0;1.8;1.8;diffraction;diffraction;198;198;Protease;Protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;HIV PR drug resistant patient's variant in complex with darunavir;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q9J006;pol;PF00077;c;5.0;100;7.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;2b60;1;b;1;197;99;99;198;100;100;0.52;0.52;82;0;1.8;2.2;diffraction;diffraction;198;198;Protease;Gag-Pol polyprotein;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;RIT   ritonavir| GOL   glycerol;HIV PR drug resistant patient's variant in complex with darunavir;Structure of HIV-1 protease mutant bound to Ritonavir;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q7SMT3;pol;PF00077,PF00078;c;5.0;100;5.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;1rq9;1;b;1;183;92;92;195;98;98;1.80;1.92;83;0;1.8;2.6;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;HIV PR drug resistant patient's variant in complex with darunavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q5RTL1;pol;PF00077;c;5.0;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;3r0w;1;b;1;182;92;92;191;96;96;1.57;1.61;84;0;1.8;1.7;diffraction;diffraction;198;198;Protease;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;HIV PR drug resistant patient's variant in complex with darunavir;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;5.0;100;7.2;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;3r0y;1;b;1;182;92;92;192;97;97;1.59;1.64;85;0;1.8;1.65;diffraction;diffraction;198;198;Protease;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;HIV PR drug resistant patient's variant in complex with darunavir;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;5.0;100;7.2;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;3spk;1;b;1;197;99;99;198;100;100;0.58;0.58;87;0;1.8;1.24;diffraction;diffraction;198;198;Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;HIV PR drug resistant patient's variant in complex with darunavir;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;5.0;100;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;3so9;1;b;1;195;98;98;198;100;100;0.92;0.93;87;0;1.8;2.87;diffraction;diffraction;198;198;Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;HIV PR drug resistant patient's variant in complex with darunavir;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;5.0;100;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;1rpi;1;b;1;178;90;90;194;98;98;2.03;2.14;76;0;1.8;1.86;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;GLC   alpha-d-glucose;HIV PR drug resistant patient's variant in complex with darunavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q9QM22;pol;PF00077;c;5.0;100;6.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;1z8c;1;b;1;196;99;99;198;100;100;0.75;0.75;83;0;1.8;2.2;diffraction;diffraction;198;198;Protease;PROTEASE RETROPEPSIN;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;HIV PR drug resistant patient's variant in complex with darunavir;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;5.0;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;1sgu;1;b;1;197;100;100;198;100;100;0.49;0.50;84;0;1.8;1.9;diffraction;diffraction;198;198;Protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;HIV PR drug resistant patient's variant in complex with darunavir;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;5.0;100;4.50;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;4njs;2;b;1;196;99;99;198;100;100;0.72;0.73;86;0;1.8;1.8;diffraction;diffraction;198;198;Protease;Protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;HIV PR drug resistant patient's variant in complex with darunavir;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q9J006;pol;PF00077;c;5.0;100;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;4eyr;1;b;1;181;91;91;191;96;96;1.63;1.68;84;0;1.8;1.8;diffraction;diffraction;198;198;Protease;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;RIT   ritonavir;HIV PR drug resistant patient's variant in complex with darunavir;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;5.0;100;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;1tw7;1;c;1;182;92;92;198;100;100;2.03;2.27;87;0;1.8;1.3;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;NA   sodium ion;HIV PR drug resistant patient's variant in complex with darunavir;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q5RTL1;pol;PF00077;c;5.0;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;1rv7;1;b;1;179;90;90;191;96;96;1.77;1.81;83;0;1.8;2.7;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;HIV PR drug resistant patient's variant in complex with darunavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q9QM22;pol;PF00077;c;5.0;100;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;2p3a;1;b;1;196;99;99;198;100;100;0.68;0.68;82;0;1.8;1.75;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;HIV PR drug resistant patient's variant in complex with darunavir;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q6BB74;pol;PF00077,PF00078;c;5.0;100;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;1sh9;1;b;1;197;99;99;198;100;100;0.53;0.54;84;0;1.8;2.5;diffraction;diffraction;198;198;Protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;RIT   ritonavir;HIV PR drug resistant patient's variant in complex with darunavir;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;5.0;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3ggu;1;4nkk;1;c;1;180;91;91;198;100;100;2.17;2.39;86;0;1.8;1.8;diffraction;diffraction;198;198;Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU ISOLATE);HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;no/data;HIV PR drug resistant patient's variant in complex with darunavir;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;5.0;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;2b60;1;b;1;196;99;99;198;100;100;0.68;0.68;88;0;1.8;2.2;diffraction;diffraction;198;198;Protease;Gag-Pol polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;RIT   ritonavir| GOL   glycerol;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Structure of HIV-1 protease mutant bound to Ritonavir;Q9J006;pol;PF00077;Q7SMT3;pol;PF00077,PF00078;c;7.0;100;5.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;1rq9;1;b;1;181;91;91;190;96;96;1.57;1.61;86;0;1.8;2.6;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q9J006;pol;PF00077;Q5RTL1;pol;PF00077;c;7.0;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;3r0w;1;b;1;180;91;91;190;96;96;1.59;1.63;89;0;1.8;1.7;diffraction;diffraction;198;198;Protease;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Q9J006;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;7.0;100;7.2;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;3r0y;1;b;1;181;91;91;195;98;98;1.91;2.05;83;0;1.8;1.65;diffraction;diffraction;198;198;Protease;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Q9J006;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;7.0;100;7.2;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;3spk;1;b;1;196;99;99;198;100;100;0.69;0.70;89;0;1.8;1.24;diffraction;diffraction;198;198;Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q9J006;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;7.0;100;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;3so9;1;b;1;195;99;99;198;100;100;0.84;0.85;89;0;1.8;2.87;diffraction;diffraction;198;198;Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q9J006;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;7.0;100;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;1rpi;1;c;1;179;90;90;198;100;100;2.22;2.49;89;0;1.8;1.86;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;GLC   alpha-d-glucose;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q9J006;pol;PF00077;Q9QM22;pol;PF00077;c;7.0;100;6.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;1z8c;1;b;1;196;99;99;198;100;100;0.65;0.66;90;0;1.8;2.2;diffraction;diffraction;198;198;Protease;PROTEASE RETROPEPSIN;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Q9J006;pol;PF00077;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;7.0;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;1sgu;1;b;1;196;99;99;198;100;100;0.66;0.67;88;0;1.8;1.9;diffraction;diffraction;198;198;Protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q9J006;pol;PF00077;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;7.0;100;4.50;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;4njs;2;b;1;197;100;100;198;100;100;0.44;0.44;100;0;1.8;1.8;diffraction;diffraction;198;198;Protease;Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Q9J006;pol;PF00077;Q9J006;pol;PF00077;c;7.0;100;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;4eyr;1;b;1;179;91;91;190;96;96;1.69;1.74;89;0;1.8;1.8;diffraction;diffraction;198;198;Protease;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;RIT   ritonavir;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Q9J006;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;7.0;100;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;1tw7;1;b;1;179;90;90;191;96;96;1.77;1.84;81;0;1.8;1.3;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;NA   sodium ion;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q9J006;pol;PF00077;Q5RTL1;pol;PF00077;c;7.0;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;1rv7;1;b;1;179;91;91;192;97;97;1.84;1.90;84;0;1.8;2.7;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q9J006;pol;PF00077;Q9QM22;pol;PF00077;c;7.0;100;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;2p3a;1;b;1;196;99;99;198;100;100;0.71;0.71;91;0;1.8;1.75;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q9J006;pol;PF00077;Q6BB74;pol;PF00077,PF00078;c;7.0;100;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;1sh9;1;b;1;196;99;99;198;100;100;0.70;0.70;88;0;1.8;2.5;diffraction;diffraction;198;198;Protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;RIT   ritonavir;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q9J006;pol;PF00077;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;7.0;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4nju;2;4nkk;1;c;1;179;90;90;197;99;99;2.16;2.40;88;0;1.8;1.8;diffraction;diffraction;198;198;Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;no/data;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with tipranavir;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q9J006;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;7.0;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;1rq9;1;b;1;183;92;92;194;98;98;1.68;1.81;89;0;2.2;2.6;diffraction;diffraction;198;198;Gag-Pol polyprotein;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;Structure of HIV-1 protease mutant bound to Ritonavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q7SMT3;pol;PF00077,PF00078;Q5RTL1;pol;PF00077;c;5.5;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;3r0w;1;b;1;184;93;93;195;98;98;1.68;1.82;86;0;2.2;1.7;diffraction;diffraction;198;198;Gag-Pol polyprotein;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;Structure of HIV-1 protease mutant bound to Ritonavir;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Q7SMT3;pol;PF00077,PF00078;Q000H7;pol;PF00077,PF00078,PF06817;c;5.5;100;7.2;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;3r0y;1;b;1;184;93;93;194;98;98;1.62;1.74;88;0;2.2;1.65;diffraction;diffraction;198;198;Gag-Pol polyprotein;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;Structure of HIV-1 protease mutant bound to Ritonavir;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Q7SMT3;pol;PF00077,PF00078;Q000H7;pol;PF00077,PF00078,PF06817;c;5.5;100;7.2;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;3spk;1;b;1;197;100;100;198;100;100;0.42;0.42;87;0;2.2;1.24;diffraction;diffraction;198;198;Gag-Pol polyprotein;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;RIT   ritonavir| GOL   glycerol;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;Structure of HIV-1 protease mutant bound to Ritonavir;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q7SMT3;pol;PF00077,PF00078;Q000H7;pol;PF00077,PF00078,PF06817;c;5.5;100;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;3so9;1;b;1;196;99;99;198;100;100;0.76;0.76;87;0;2.2;2.87;diffraction;diffraction;198;198;Gag-Pol polyprotein;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;Structure of HIV-1 protease mutant bound to Ritonavir;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q7SMT3;pol;PF00077,PF00078;Q000H7;pol;PF00077,PF00078,PF06817;c;5.5;100;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;1rpi;1;c;1;181;91;91;198;100;100;2.10;2.33;89;0;2.2;1.86;diffraction;diffraction;198;198;Gag-Pol polyprotein;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;GLC   alpha-d-glucose;Structure of HIV-1 protease mutant bound to Ritonavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q7SMT3;pol;PF00077,PF00078;Q9QM22;pol;PF00077;c;5.5;100;6.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;1z8c;1;b;1;197;99;99;198;100;100;0.57;0.57;92;0;2.2;2.2;diffraction;diffraction;198;198;Gag-Pol polyprotein;PROTEASE RETROPEPSIN;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;Structure of HIV-1 protease mutant bound to Ritonavir;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Q7SMT3;pol;PF00077,PF00078;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;5.5;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;1sgu;1;b;1;198;100;100;198;100;100;0.26;0.26;98;0;2.2;1.9;diffraction;diffraction;198;198;Gag-Pol polyprotein;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;Structure of HIV-1 protease mutant bound to Ritonavir;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q7SMT3;pol;PF00077,PF00078;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;5.5;100;4.50;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;4njs;2;b;1;196;99;99;198;100;100;0.72;0.72;88;0;2.2;1.8;diffraction;diffraction;198;198;Gag-Pol polyprotein;Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;Structure of HIV-1 protease mutant bound to Ritonavir;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Q7SMT3;pol;PF00077,PF00078;Q9J006;pol;PF00077;c;5.5;100;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;4eyr;1;b;1;182;92;92;191;96;96;1.53;1.58;85;0;2.2;1.8;diffraction;diffraction;198;198;Gag-Pol polyprotein;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;RIT   ritonavir;Structure of HIV-1 protease mutant bound to Ritonavir;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Q7SMT3;pol;PF00077,PF00078;Q000H7;pol;PF00077,PF00078,PF06817;c;5.5;100;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;1tw7;1;c;1;183;92;92;198;100;100;1.98;2.23;89;0;2.2;1.3;diffraction;diffraction;198;198;Gag-Pol polyprotein;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;NA   sodium ion;Structure of HIV-1 protease mutant bound to Ritonavir;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q7SMT3;pol;PF00077,PF00078;Q5RTL1;pol;PF00077;c;5.5;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;1rv7;1;b;1;181;91;91;192;97;97;1.73;1.77;84;0;2.2;2.7;diffraction;diffraction;198;198;Gag-Pol polyprotein;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Structure of HIV-1 protease mutant bound to Ritonavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q7SMT3;pol;PF00077,PF00078;Q9QM22;pol;PF00077;c;5.5;100;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;2p3a;1;b;1;197;100;100;198;100;100;0.48;0.49;90;0;2.2;1.75;diffraction;diffraction;198;198;Gag-Pol polyprotein;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Structure of HIV-1 protease mutant bound to Ritonavir;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q7SMT3;pol;PF00077,PF00078;Q6BB74;pol;PF00077,PF00078;c;5.5;100;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;1sh9;1;b;1;198;100;100;198;100;100;0.29;0.29;98;0;2.2;2.5;diffraction;diffraction;198;198;Gag-Pol polyprotein;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;RIT   ritonavir;Structure of HIV-1 protease mutant bound to Ritonavir;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q7SMT3;pol;PF00077,PF00078;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;5.5;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2b60;1;4nkk;1;c;1;181;91;91;198;100;100;2.09;2.32;89;0;2.2;1.8;diffraction;diffraction;198;198;Gag-Pol polyprotein;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir| GOL   glycerol;no/data;Structure of HIV-1 protease mutant bound to Ritonavir;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q7SMT3;pol;PF00077,PF00078;Q000H7;pol;PF00077,PF00078,PF06817;c;5.5;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;3r0w;1;b;1;197;100;100;198;100;100;0.45;0.45;99;0;2.6;1.7;diffraction;diffraction;198;198;protease;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Q5RTL1;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;6.5;100;7.2;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;3r0y;1;b;1;197;100;100;198;100;100;0.46;0.46;99;0;2.6;1.65;diffraction;diffraction;198;198;protease;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Q5RTL1;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;6.5;100;7.2;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;3spk;1;b;1;181;91;91;195;98;98;1.90;2.03;90;0;2.6;1.24;diffraction;diffraction;198;198;protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q5RTL1;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;6.5;100;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;3so9;1;b;1;179;91;91;189;95;95;1.60;1.64;94;0;2.6;2.87;diffraction;diffraction;198;198;protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q5RTL1;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;6.5;100;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;1rpi;1;b;1;197;99;99;198;100;100;0.53;0.53;100;0;2.6;1.86;diffraction;diffraction;198;198;protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;GLC   alpha-d-glucose;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q5RTL1;pol;PF00077;Q9QM22;pol;PF00077;c;6.5;100;6.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;1z8c;1;b;1;183;92;92;190;96;96;1.39;1.42;89;0;2.6;2.2;diffraction;diffraction;198;198;protease;PROTEASE RETROPEPSIN;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Q5RTL1;pol;PF00077;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.5;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;1sgu;1;b;1;181;91;91;190;96;96;1.58;1.61;91;0;2.6;1.9;diffraction;diffraction;198;198;protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q5RTL1;pol;PF00077;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.5;100;4.50;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;4njs;2;b;1;180;91;91;195;98;98;1.97;2.09;82;0;2.6;1.8;diffraction;diffraction;198;198;protease;Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Q5RTL1;pol;PF00077;Q9J006;pol;PF00077;c;6.5;100;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;4eyr;1;b;1;197;100;100;198;100;100;0.49;0.49;99;0;2.6;1.8;diffraction;diffraction;198;198;protease;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;RIT   ritonavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Q5RTL1;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;6.5;100;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;1tw7;1;b;1;197;99;99;198;100;100;0.54;0.55;100;0;2.6;1.3;diffraction;diffraction;198;198;protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;NA   sodium ion;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q5RTL1;pol;PF00077;Q5RTL1;pol;PF00077;c;6.5;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;1rv7;1;b;1;197;99;99;198;100;100;0.56;0.57;100;0;2.6;2.7;diffraction;diffraction;198;198;protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q5RTL1;pol;PF00077;Q9QM22;pol;PF00077;c;6.5;100;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;2p3a;1;c;1;185;93;93;198;100;100;1.82;2.02;89;0;2.6;1.75;diffraction;diffraction;198;198;protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q5RTL1;pol;PF00077;Q6BB74;pol;PF00077,PF00078;c;6.5;100;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;1sh9;1;b;1;182;92;92;195;98;98;1.86;1.96;83;0;2.6;2.5;diffraction;diffraction;198;198;protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;RIT   ritonavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q5RTL1;pol;PF00077;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.5;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rq9;1;4nkk;1;b;1;197;99;99;198;100;100;0.54;0.54;99;0;2.6;1.8;diffraction;diffraction;198;198;protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;DMQ   [4-r-(-4-alpha,5-alpha,6-beta,7-beta)]-hexahydro-5,6-bis(hydroxy)-1,3-bis([(3-amino)phenyl]methyl)-4,7-bis(phenylmethyl)-2h-1,3-diazepinone;no/data;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q5RTL1;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;6.5;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;3r0y;1;b;1;198;100;100;198;100;100;0.13;0.13;100;0;1.7;1.65;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;7.2;298;7.2;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;3spk;1;b;1;181;92;92;190;96;96;1.50;1.54;99;0;1.7;1.24;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;7.2;298;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;3so9;1;b;1;184;93;93;196;99;99;1.76;1.88;89;0;1.7;2.87;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;7.2;298;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;1rpi;1;b;1;196;99;99;198;100;100;0.62;0.63;99;0;1.7;1.86;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;GLC   alpha-d-glucose;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q000H7;pol;PF00077,PF00078,PF06817;Q9QM22;pol;PF00077;c;7.2;298;6.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;1z8c;1;b;1;183;92;92;190;96;96;1.35;1.38;91;0;1.7;2.2;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;PROTEASE RETROPEPSIN;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Q000H7;pol;PF00077,PF00078,PF06817;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;7.2;298;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;1sgu;1;b;1;182;92;92;191;96;96;1.55;1.60;85;0;1.7;1.9;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q000H7;pol;PF00077,PF00078,PF06817;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;7.2;298;4.50;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;4njs;2;b;1;180;91;91;190;96;96;1.64;1.67;89;0;1.7;1.8;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Q000H7;pol;PF00077,PF00078,PF06817;Q9J006;pol;PF00077;c;7.2;298;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;4eyr;1;b;1;198;100;100;198;100;100;0.32;0.32;100;0;1.7;1.8;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;RIT   ritonavir;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;7.2;298;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;1tw7;1;b;1;197;100;100;198;100;100;0.46;0.46;99;0;1.7;1.3;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;NA   sodium ion;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q000H7;pol;PF00077,PF00078,PF06817;Q5RTL1;pol;PF00077;c;7.2;298;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;1rv7;1;b;1;196;99;99;198;100;100;0.65;0.66;99;0;1.7;2.7;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q000H7;pol;PF00077,PF00078,PF06817;Q9QM22;pol;PF00077;c;7.2;298;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;2p3a;1;b;1;183;92;92;190;96;96;1.37;1.40;87;0;1.7;1.75;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q000H7;pol;PF00077,PF00078,PF06817;Q6BB74;pol;PF00077,PF00078;c;7.2;298;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;1sh9;1;c;1;183;92;92;197;99;99;1.93;2.13;88;0;1.7;2.5;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;RIT   ritonavir;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q000H7;pol;PF00077,PF00078,PF06817;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;7.2;298;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0w;1;4nkk;1;b;1;196;99;99;198;100;100;0.62;0.63;98;0;1.7;1.8;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSY   n-[(2r)-1-{[(2s,3s)-5-{[(2r)-1-{[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]amino}-3-chloro-1-oxopropan-2-yl]amino}-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;no/data;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors.;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;7.2;298;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;3spk;1;c;1;184;93;93;198;100;100;1.90;2.11;99;0;1.65;1.24;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;7.2;298;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;3so9;1;b;1;183;93;93;195;98;98;1.73;1.85;90;0;1.65;2.87;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;7.2;298;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;1rpi;1;b;1;196;99;99;198;100;100;0.63;0.63;99;0;1.65;1.86;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;GLC   alpha-d-glucose;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q000H7;pol;PF00077,PF00078,PF06817;Q9QM22;pol;PF00077;c;7.2;298;6.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;1z8c;1;b;1;184;93;93;192;97;97;1.48;1.53;86;0;1.65;2.2;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;PROTEASE RETROPEPSIN;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Q000H7;pol;PF00077,PF00078,PF06817;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;7.2;298;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;1sgu;1;b;1;182;92;92;191;96;96;1.53;1.58;81;0;1.65;1.9;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q000H7;pol;PF00077,PF00078,PF06817;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;7.2;298;4.50;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;4njs;2;b;1;180;91;91;190;96;96;1.65;1.68;89;0;1.65;1.8;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Q000H7;pol;PF00077,PF00078,PF06817;Q9J006;pol;PF00077;c;7.2;298;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;4eyr;1;b;1;198;100;100;198;100;100;0.31;0.31;100;0;1.65;1.8;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;RIT   ritonavir;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;7.2;298;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;1tw7;1;b;1;197;100;100;198;100;100;0.43;0.43;99;0;1.65;1.3;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;NA   sodium ion;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q000H7;pol;PF00077,PF00078,PF06817;Q5RTL1;pol;PF00077;c;7.2;298;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;1rv7;1;b;1;196;99;99;198;100;100;0.66;0.66;99;0;1.65;2.7;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q000H7;pol;PF00077,PF00078,PF06817;Q9QM22;pol;PF00077;c;7.2;298;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;2p3a;1;b;1;183;92;92;190;96;96;1.38;1.41;87;0;1.65;1.75;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q000H7;pol;PF00077,PF00078,PF06817;Q6BB74;pol;PF00077,PF00078;c;7.2;298;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;1sh9;1;b;1;183;92;92;192;97;97;1.54;1.59;82;0;1.65;2.5;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;RIT   ritonavir;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q000H7;pol;PF00077,PF00078,PF06817;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;7.2;298;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3r0y;1;4nkk;1;b;1;196;99;99;198;100;100;0.62;0.62;98;0;1.65;1.8;diffraction;diffraction;198;198;Multidrug-resistant clinical isolate 769 HIV-1 Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RSZ   n-[(2s)-1-{[(2s,3s)-3-hydroxy-5-oxo-5-{[(2r)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}-1-phenylpentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide;no/data;Crystal Structures of Multidrug-resistant HIV-1 Protease in Complex with Mechanism-Based Aspartyl Protease Inhibitors;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;7.2;298;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;3so9;1;b;1;196;99;99;198;100;100;0.73;0.74;100;0;1.24;2.87;diffraction;diffraction;198;198;HIV-1 protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;6.0;no/data;6.0;no/data;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;1rpi;1;b;1;177;89;89;190;96;96;1.85;1.90;98;0;1.24;1.86;diffraction;diffraction;198;198;HIV-1 protease;protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;GLC   alpha-d-glucose;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q000H7;pol;PF00077,PF00078,PF06817;Q9QM22;pol;PF00077;c;6.0;no/data;6.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;1z8c;1;b;1;196;99;99;198;100;100;0.66;0.67;90;0;1.24;2.2;diffraction;diffraction;198;198;HIV-1 protease;PROTEASE RETROPEPSIN;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Q000H7;pol;PF00077,PF00078,PF06817;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.0;no/data;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;1sgu;1;b;1;198;100;100;198;100;100;0.34;0.34;89;0;1.24;1.9;diffraction;diffraction;198;198;HIV-1 protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q000H7;pol;PF00077,PF00078,PF06817;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.0;no/data;4.50;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;4njs;2;b;1;196;99;99;198;100;100;0.76;0.78;89;0;1.24;1.8;diffraction;diffraction;198;198;HIV-1 protease;Protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Q000H7;pol;PF00077,PF00078,PF06817;Q9J006;pol;PF00077;c;6.0;no/data;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;4eyr;1;c;1;183;92;92;198;100;100;1.99;2.26;99;0;1.24;1.8;diffraction;diffraction;198;198;HIV-1 protease;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;RIT   ritonavir;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;6.0;no/data;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;1tw7;1;b;1;179;91;91;190;96;96;1.68;1.72;98;0;1.24;1.3;diffraction;diffraction;198;198;HIV-1 protease;protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;NA   sodium ion;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q000H7;pol;PF00077,PF00078,PF06817;Q5RTL1;pol;PF00077;c;6.0;no/data;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;1rv7;1;b;1;179;90;90;192;97;97;1.88;1.94;92;0;1.24;2.7;diffraction;diffraction;198;198;HIV-1 protease;protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q000H7;pol;PF00077,PF00078,PF06817;Q9QM22;pol;PF00077;c;6.0;no/data;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;2p3a;1;b;1;196;99;99;198;100;100;0.63;0.64;89;0;1.24;1.75;diffraction;diffraction;198;198;HIV-1 protease;protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q000H7;pol;PF00077,PF00078,PF06817;Q6BB74;pol;PF00077,PF00078;c;6.0;no/data;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;1sh9;1;b;1;197;100;100;198;100;100;0.47;0.47;89;0;1.24;2.5;diffraction;diffraction;198;198;HIV-1 protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;RIT   ritonavir;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q000H7;pol;PF00077,PF00078,PF06817;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.0;no/data;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3spk;1;4nkk;1;b;1;179;90;90;191;96;96;1.82;1.88;88;0;1.24;1.8;diffraction;diffraction;198;198;HIV-1 protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;HUMAN IMMUNODEFICIENCY VIRUS 1;TPV   n-(3-{(1r)-1-[(6r)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2h-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)-2-pyridinesulfonamide;no/data;Tipranavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;6.0;no/data;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3so9;1;1rpi;1;b;1;179;91;91;195;98;98;2.03;2.16;87;0;2.87;1.86;diffraction;diffraction;198;198;HIV-1 protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;GLC   alpha-d-glucose;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q000H7;pol;PF00077,PF00078,PF06817;Q9QM22;pol;PF00077;c;6.0;no/data;6.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3so9;1;1z8c;1;b;1;196;99;99;198;100;100;0.77;0.78;90;0;2.87;2.2;diffraction;diffraction;198;198;HIV-1 protease;PROTEASE RETROPEPSIN;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Q000H7;pol;PF00077,PF00078,PF06817;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.0;no/data;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3so9;1;1sgu;1;b;1;196;99;99;198;100;100;0.78;0.79;89;0;2.87;1.9;diffraction;diffraction;198;198;HIV-1 protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q000H7;pol;PF00077,PF00078,PF06817;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.0;no/data;4.50;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3so9;1;4njs;2;b;1;195;98;98;198;100;100;0.92;0.93;89;0;2.87;1.8;diffraction;diffraction;198;198;HIV-1 protease;Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Q000H7;pol;PF00077,PF00078,PF06817;Q9J006;pol;PF00077;c;6.0;no/data;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3so9;1;4eyr;1;c;1;182;92;92;198;100;100;2.00;2.22;99;0;2.87;1.8;diffraction;diffraction;198;198;HIV-1 protease;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;RIT   ritonavir;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;6.0;no/data;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3so9;1;1tw7;1;b;1;179;90;90;190;96;96;1.74;1.79;98;0;2.87;1.3;diffraction;diffraction;198;198;HIV-1 protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;NA   sodium ion;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q000H7;pol;PF00077,PF00078,PF06817;Q5RTL1;pol;PF00077;c;6.0;no/data;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3so9;1;1rv7;1;b;1;179;91;91;192;97;97;1.83;1.90;92;0;2.87;2.7;diffraction;diffraction;198;198;HIV-1 protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q000H7;pol;PF00077,PF00078,PF06817;Q9QM22;pol;PF00077;c;6.0;no/data;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3so9;1;2p3a;1;b;1;195;99;99;198;100;100;0.82;0.83;89;0;2.87;1.75;diffraction;diffraction;198;198;HIV-1 protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q000H7;pol;PF00077,PF00078,PF06817;Q6BB74;pol;PF00077,PF00078;c;6.0;no/data;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3so9;1;1sh9;1;b;1;196;99;99;198;100;100;0.77;0.78;89;0;2.87;2.5;diffraction;diffraction;198;198;HIV-1 protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;RIT   ritonavir;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q000H7;pol;PF00077,PF00078,PF06817;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.0;no/data;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;3so9;1;4nkk;1;b;1;176;89;89;193;97;97;2.10;2.22;80;0;2.87;1.8;diffraction;diffraction;198;198;HIV-1 protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;017   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;no/data;Darunavir in Complex with a Human Immunodeficiency Virus Type 1 Protease Variant;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;6.0;no/data;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rpi;1;1z8c;1;c;1;182;92;92;198;100;100;2.02;2.29;90;0;1.86;2.2;diffraction;diffraction;198;198;protease;PROTEASE RETROPEPSIN;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;GLC   alpha-d-glucose;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Q9QM22;pol;PF00077;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.3;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rpi;1;1sgu;1;c;1;180;91;91;198;100;100;2.19;2.44;91;0;1.86;1.9;diffraction;diffraction;198;198;protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;GLC   alpha-d-glucose;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q9QM22;pol;PF00077;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.3;100;4.50;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rpi;1;4njs;2;b;1;177;90;90;191;96;96;1.91;1.98;81;0;1.86;1.8;diffraction;diffraction;198;198;protease;Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;GLC   alpha-d-glucose;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Q9QM22;pol;PF00077;Q9J006;pol;PF00077;c;6.3;100;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rpi;1;4eyr;1;b;1;197;99;99;198;100;100;0.51;0.52;99;0;1.86;1.8;diffraction;diffraction;198;198;protease;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;GLC   alpha-d-glucose;RIT   ritonavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Q9QM22;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;6.3;100;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rpi;1;1tw7;1;b;1;197;100;100;198;100;100;0.49;0.50;100;0;1.86;1.3;diffraction;diffraction;198;198;protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;GLC   alpha-d-glucose;NA   sodium ion;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q9QM22;pol;PF00077;Q5RTL1;pol;PF00077;c;6.3;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rpi;1;1rv7;1;b;1;197;100;100;198;100;100;0.48;0.49;100;0;1.86;2.7;diffraction;diffraction;198;198;protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;GLC   alpha-d-glucose;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q9QM22;pol;PF00077;Q9QM22;pol;PF00077;c;6.3;100;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rpi;1;2p3a;1;b;1;179;91;91;190;96;96;1.68;1.72;88;0;1.86;1.75;diffraction;diffraction;198;198;protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;GLC   alpha-d-glucose;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q9QM22;pol;PF00077;Q6BB74;pol;PF00077,PF00078;c;6.3;100;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rpi;1;1sh9;1;b;1;179;91;91;191;96;96;1.75;1.79;83;0;1.86;2.5;diffraction;diffraction;198;198;protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;GLC   alpha-d-glucose;RIT   ritonavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q9QM22;pol;PF00077;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.3;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rpi;1;4nkk;1;b;1;198;100;100;198;100;100;0.23;0.23;99;0;1.86;1.8;diffraction;diffraction;198;198;protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;GLC   alpha-d-glucose;no/data;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q9QM22;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;6.3;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1z8c;1;1sgu;1;b;1;196;99;99;198;100;100;0.63;0.63;92;0;2.2;1.9;diffraction;diffraction;198;198;PROTEASE RETROPEPSIN;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.5;100;4.50;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1z8c;1;4njs;2;b;1;195;99;99;198;100;100;0.80;0.81;90;0;2.2;1.8;diffraction;diffraction;198;198;PROTEASE RETROPEPSIN;Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q9J006;pol;PF00077;c;6.5;100;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1z8c;1;4eyr;1;b;1;182;92;92;191;96;96;1.52;1.57;87;0;2.2;1.8;diffraction;diffraction;198;198;PROTEASE RETROPEPSIN;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;RIT   ritonavir;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;6.5;100;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1z8c;1;1tw7;1;b;1;181;91;91;190;96;96;1.55;1.59;89;0;2.2;1.3;diffraction;diffraction;198;198;PROTEASE RETROPEPSIN;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;NA   sodium ion;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q5RTL1;pol;PF00077;c;6.5;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1z8c;1;1rv7;1;b;1;182;92;92;192;97;97;1.63;1.68;85;0;2.2;2.7;diffraction;diffraction;198;198;PROTEASE RETROPEPSIN;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q9QM22;pol;PF00077;c;6.5;100;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1z8c;1;2p3a;1;b;1;197;99;99;198;100;100;0.55;0.56;92;0;2.2;1.75;diffraction;diffraction;198;198;PROTEASE RETROPEPSIN;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q6BB74;pol;PF00077,PF00078;c;6.5;100;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1z8c;1;1sh9;1;b;1;197;99;99;198;100;100;0.61;0.61;92;0;2.2;2.5;diffraction;diffraction;198;198;PROTEASE RETROPEPSIN;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;RIT   ritonavir;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.5;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1z8c;1;4nkk;1;b;1;180;91;91;191;96;96;1.68;1.74;85;0;2.2;1.8;diffraction;diffraction;198;198;PROTEASE RETROPEPSIN;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;CME   s,s-(2-hydroxyethyl)thiocysteine| 0ZS   n-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl}-l-phenylalanyl-l-alpha-glutamyl-l-phenylalaninamide| SO4   sulfate ion;no/data;Crystal structure of the complex of mutant HIV-1 protease (l63P, A71V, V82T, I84V) with a hydroxyethylamine peptidomimetic inhibitor BOC-PHE-PSI[R-CH(OH)CH2NH]-PHE-GLU-PHE-NH2;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q9JAU9,P03367;no/data,gag-pol;PF00077,PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;6.5;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1sgu;1;4njs;2;b;1;196;99;99;198;100;100;0.71;0.71;88;0;1.9;1.8;diffraction;diffraction;198;198;POL polyprotein;Protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q9J006;pol;PF00077;c;4.50;100;5.0;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1sgu;1;4eyr;1;c;1;181;91;91;194;98;98;1.84;2.02;90;0;1.9;1.8;diffraction;diffraction;198;198;POL polyprotein;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;RIT   ritonavir;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;4.50;100;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1sgu;1;1tw7;1;c;1;181;91;91;195;98;98;1.92;2.10;91;0;1.9;1.3;diffraction;diffraction;198;198;POL polyprotein;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;NA   sodium ion;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q5RTL1;pol;PF00077;c;4.50;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1sgu;1;1rv7;1;b;1;180;91;91;192;97;97;1.81;1.87;86;0;1.9;2.7;diffraction;diffraction;198;198;POL polyprotein;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q9QM22;pol;PF00077;c;4.50;100;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1sgu;1;2p3a;1;b;1;197;99;99;198;100;100;0.54;0.55;90;0;1.9;1.75;diffraction;diffraction;198;198;POL polyprotein;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q6BB74;pol;PF00077,PF00078;c;4.50;100;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1sgu;1;1sh9;1;b;1;198;100;100;198;100;100;0.33;0.33;100;0;1.9;2.5;diffraction;diffraction;198;198;POL polyprotein;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;RIT   ritonavir;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;4.50;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1sgu;1;4nkk;1;c;1;180;91;91;198;100;100;2.18;2.43;91;0;1.9;1.8;diffraction;diffraction;198;198;POL polyprotein;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;MK1   n-[2(r)-hydroxy-1(s)-indanyl]-5-[(2(s)-tertiary butylaminocarbonyl)-4(3-pyridylmethyl)piperazino]-4(s)-hydroxy-2(r)-phenylmethylpentanamide;no/data;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;4.50;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4njs;2;4eyr;1;b;1;179;90;90;190;96;96;1.73;1.77;89;0;1.8;1.8;diffraction;diffraction;198;198;Protease;HIV-1 PROTEASE;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;RIT   ritonavir;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Q9J006;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;5.0;100;5.8;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4njs;2;1tw7;1;b;1;178;90;90;190;96;96;1.79;1.83;88;0;1.8;1.3;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;NA   sodium ion;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q9J006;pol;PF00077;Q5RTL1;pol;PF00077;c;5.0;100;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4njs;2;1rv7;1;b;1;179;91;91;193;97;97;1.90;1.95;85;0;1.8;2.7;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q9J006;pol;PF00077;Q9QM22;pol;PF00077;c;5.0;100;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4njs;2;2p3a;1;b;1;196;99;99;198;100;100;0.78;0.78;91;0;1.8;1.75;diffraction;diffraction;198;198;Protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q9J006;pol;PF00077;Q6BB74;pol;PF00077,PF00078;c;5.0;100;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4njs;2;1sh9;1;b;1;196;99;99;198;100;100;0.72;0.73;88;0;1.8;2.5;diffraction;diffraction;198;198;Protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;RIT   ritonavir;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q9J006;pol;PF00077;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;5.0;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4njs;2;4nkk;1;b;1;177;90;90;191;96;96;1.90;1.96;83;0;1.8;1.8;diffraction;diffraction;198;198;Protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;G08   (3r,3as,6ar)-hexahydrofuro[2,3-b]furan-3-yl [(2s,3r)-4-{[(4-carbamoylphenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate;no/data;Crystal structure of multidrug-resistant clinical isolate A02 HIV-1 protease in complex with non-peptidic inhibitor, GRL008;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q9J006;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;5.0;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4eyr;1;1tw7;1;b;1;198;100;100;198;100;100;0.22;0.22;99;0;1.8;1.3;diffraction;diffraction;198;198;HIV-1 PROTEASE;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir;NA   sodium ion;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Q000H7;pol;PF00077,PF00078,PF06817;Q5RTL1;pol;PF00077;c;5.8;298;6.5;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4eyr;1;1rv7;1;b;1;196;99;99;198;100;100;0.61;0.62;99;0;1.8;2.7;diffraction;diffraction;198;198;HIV-1 PROTEASE;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q000H7;pol;PF00077,PF00078,PF06817;Q9QM22;pol;PF00077;c;5.8;298;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4eyr;1;2p3a;1;c;1;184;93;93;198;100;100;1.90;2.14;88;0;1.8;1.75;diffraction;diffraction;198;198;HIV-1 PROTEASE;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q000H7;pol;PF00077,PF00078,PF06817;Q6BB74;pol;PF00077,PF00078;c;5.8;298;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4eyr;1;1sh9;1;b;1;181;92;92;191;96;96;1.59;1.63;85;0;1.8;2.5;diffraction;diffraction;198;198;HIV-1 PROTEASE;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir;RIT   ritonavir;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q000H7;pol;PF00077,PF00078,PF06817;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;5.8;298;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;4eyr;1;4nkk;1;b;1;197;99;99;198;100;100;0.52;0.53;98;0;1.8;1.8;diffraction;diffraction;198;198;HIV-1 PROTEASE;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir;no/data;Crystal structure of multidrug-resistant clinical isolate 769 HIV-1 protease in complex with ritonavir;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q000H7;pol;PF00077,PF00078,PF06817;Q000H7;pol;PF00077,PF00078,PF06817;c;5.8;298;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1tw7;1;1rv7;1;b;1;197;99;99;198;100;100;0.61;0.62;100;0;1.3;2.7;diffraction;diffraction;198;198;protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;NA   sodium ion;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Q5RTL1;pol;PF00077;Q9QM22;pol;PF00077;c;6.5;100;6.7;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1tw7;1;2p3a;1;c;1;183;92;92;198;100;100;1.97;2.22;89;0;1.3;1.75;diffraction;diffraction;198;198;protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;NA   sodium ion;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q5RTL1;pol;PF00077;Q6BB74;pol;PF00077,PF00078;c;6.5;100;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1tw7;1;1sh9;1;c;1;182;92;92;198;100;100;2.00;2.24;91;0;1.3;2.5;diffraction;diffraction;198;198;protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;NA   sodium ion;RIT   ritonavir;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q5RTL1;pol;PF00077;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.5;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1tw7;1;4nkk;1;b;1;197;99;99;198;100;100;0.52;0.52;99;0;1.3;1.8;diffraction;diffraction;198;198;protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;NA   sodium ion;no/data;Wide Open 1.3A Structure of a Multi-drug Resistant HIV-1 Protease Represents a Novel Drug Target;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q5RTL1;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;6.5;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rv7;1;2p3a;1;b;1;181;91;91;191;96;96;1.64;1.68;88;0;2.7;1.75;diffraction;diffraction;198;198;protease;protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Q9QM22;pol;PF00077;Q6BB74;pol;PF00077,PF00078;c;6.7;100;6.2;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rv7;1;1sh9;1;b;1;180;91;91;191;96;96;1.72;1.76;87;0;2.7;2.5;diffraction;diffraction;198;198;protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;RIT   ritonavir;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q9QM22;pol;PF00077;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.7;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1rv7;1;4nkk;1;b;1;197;100;100;198;100;100;0.49;0.49;99;0;2.7;1.8;diffraction;diffraction;198;198;protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;AB1   n-{1-benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-3-methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyramide;no/data;Crystal structures of a Multidrug-Resistant HIV-1 Protease Reveal an Expanded Active Site Cavity;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q9QM22;pol;PF00077;Q000H7;pol;PF00077,PF00078,PF06817;c;6.7;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2p3a;1;1sh9;1;b;1;197;99;99;198;100;100;0.56;0.56;90;0;1.75;2.5;diffraction;diffraction;198;198;protease;POL polyprotein;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;RIT   ritonavir;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Q6BB74;pol;PF00077,PF00078;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;c;6.2;100;6.00;298;4nju_A;1tw7_A;1.52;2.49
3ggu;2;2p3a;1;4nkk;1;b;1;181;91;91;194;98;98;1.88;2.02;89;0;1.75;1.8;diffraction;diffraction;198;198;protease;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;CME   s,s-(2-hydroxyethyl)thiocysteine| 3TL   benzyl [(1s,4s,7s,8r,9r,10s,13s,16s)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate;no/data;Crystal Structure of the multi-drug resistant mutant subtype B HIV protease complexed with TL-3 inhibitor;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;Q6BB74;pol;PF00077,PF00078;Q000H7;pol;PF00077,PF00078,PF06817;c;6.2;100;7.3;100;4nju_A;1tw7_A;1.52;2.49
3ggu;2;1sh9;1;4nkk;1;b;1;179;90;90;191;96;96;1.79;1.83;86;0;2.5;1.8;diffraction;diffraction;198;198;POL polyprotein;HIV-1 protease;HUMAN IMMUNODEFICIENCY VIRUS 1;HUMAN IMMUNODEFICIENCY VIRUS 1;RIT   ritonavir;no/data;Comparing the Accumulation of Active Site and Non-active Site Mutations in the HIV-1 Protease;Crystal structure of a multi-drug resistant clinical isolate-769 HIV-1 protease variant that is resistant to the dimerization inhibitory activity of TLF-PafF;P03367;gag-pol;PF00540,PF00607,PF00552,PF02022,PF00075,PF00665,PF00077,PF00078,PF06815,PF06817,PF00098;Q000H7;pol;PF00077,PF00078,PF06817;c;6.00;298;7.3;100;4nju_A;1tw7_A;1.52;2.49
1qy2;2;1qy2;2;1qy1;2;b;1;314;100;100;314;100;100;0.08;0.08;100;0;1.75;1.7;diffraction;diffraction;348;348;Major Urinary Protein;Major Urinary Protein;MUS MUSCULUS;MUS MUSCULUS;CD   cadmium ion| NA   sodium ion| IPZ   2-isopropyl-3-methoxypyrazine;CD   cadmium ion| NA   sodium ion| PRZ   2-isobutyl-3-methoxypyrazine;Thermodynamics of Binding of 2-methoxy-3-isopropylpyrazine and 2-methoxy-3-isobutylpyrazine to the Major Urinary Protein;Thermodynamics of Binding of 2-methoxy-3-isopropylpyrazine and 2-methoxy-3-isobutylpyrazine to the Major Urinary Protein;P11588;Mup1;PF00061;P11588;Mup1;PF00061;b;4.9;100;4.9;100;1qy2_A;1qy1_A;0.07;0.08
1dlj;2;1dlj;1;1dli;1;b;1;803;100;100;804;100;100;0.20;0.20;100;0;1.8;2.31;diffraction;diffraction;804;804;UDP-GLUCOSE DEHYDROGENASE;UDP-GLUCOSE DEHYDROGENASE;STREPTOCOCCUS PYOGENES;STREPTOCOCCUS PYOGENES;SO4   sulfate ion| NAI   1,4-dihydronicotinamide adenine dinucleotide| UGA   uridine-5'-diphosphate-glucuronic acid| GOL   glycerol;SO4   sulfate ion| NAD   nicotinamide-adenine-dinucleotide| UDX   uridine-5'-diphosphate-xylopyranose| GOL   glycerol;THE FIRST STRUCTURE OF UDP-GLUCOSE DEHYDROGENASE (UDPGDH) REVEALS THE CATALYTIC RESIDUES NECESSARY FOR THE TWO-FOLD OXIDATION;THE FIRST STRUCTURE OF UDP-GLUCOSE DEHYDROGENASE (UDPGDH) REVEALS THE CATALYTIC RESIDUES NECESSARY FOR THE TWO-FOLD OXIDATION;P0C0F4;hasB;PF00984,PF03720,PF03721;P0C0F4;hasB;PF00984,PF03720,PF03721;b;7.8;100;7.8;100;1dlj_A;1dli_A;0.19;0.20
3e6g;4;3e6g;1;4iyo;1;b;1;1377;98;90;1406;100;92;1.02;1.05;100;0;2.8;1.8;diffraction;diffraction;1600;1588;Cystathionine gamma-lyase-like protein;Cystathionine gamma-lyase-like protein, LYS201A modified;XANTHOMONAS ORYZAE PV. ORYZAE;XANTHOMONAS ORYZAE PV. ORYZAE;no/data;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SER   serine| NAK   amino-acrylate| PYR   pyruvic acid| GOL   glycerol| SO4   sulfate ion| 0JO   2-{[(e)-{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene]amino}prop-2-enoic acid;Crystal structure of XometC, a cystathionine c-lyase-like protein from Xanthomonas oryzae pv.oryzae;Crystal structure of cystathionine gamma lyase from Xanthomonas oryzae pv. oryzae (XometC) in complex with E-site serine, A-site serine, A-site external aldimine structure with aminoacrylate and A-site iminopropionate intermediates;Q5H4T8;metB XOO0778;PF01053;Q5H4T8;metB XOO0778;PF01053;b;5.5;100;9.0;100;3e6g_D;4ixs_A;1.12;1.08
3e6g;4;3e6g;1;4iy7;1;b;1;1375;98;90;1406;100;92;1.05;1.08;100;0;2.8;1.7;diffraction;diffraction;1600;1588;Cystathionine gamma-lyase-like protein;Cystathionine gamma-lyase-like protein;XANTHOMONAS ORYZAE PV. ORYZAE;XANTHOMONAS ORYZAE PV. ORYZAE;no/data;SER   serine| PYR   pyruvic acid| KOU   (e)-n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)-l-serine| GOL   glycerol| SO4   sulfate ion| 0JO   2-{[(e)-{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene]amino}prop-2-enoic acid;Crystal structure of XometC, a cystathionine c-lyase-like protein from Xanthomonas oryzae pv.oryzae;crystal structure of cystathionine gamma lyase (XometC) from Xanthomonas oryzae pv. oryzae in complex with E-site serine, A-site external aldimine structure with serine and A-site external aldimine structure with aminoacrylate intermediates;Q5H4T8;metB XOO0778;PF01053;Q5H4T8;metB XOO0778;PF01053;b;5.5;100;9.0;100;3e6g_D;4ixs_A;1.12;1.08
3e6g;4;3e6g;1;4ixz;1;b;1;1385;98;91;1404;100;92;0.81;0.83;100;0;2.8;2.07;diffraction;diffraction;1600;1588;Cystathionine gamma-lyase-like protein;Cystathionine gamma-lyase-like protein;XANTHOMONAS ORYZAE PV. ORYZAE;XANTHOMONAS ORYZAE PV. ORYZAE;no/data;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| BCT   bicarbonate ion| BME   beta-mercaptoethanol| GOL   glycerol;Crystal structure of XometC, a cystathionine c-lyase-like protein from Xanthomonas oryzae pv.oryzae;Native structure of cystathionine gamma lyase (XometC) from xanthomonas oryzae pv. oryzae at pH 9.0;Q5H4T8;metB XOO0778;PF01053;Q5H4T8;metB XOO0778;PF01053;b;5.5;100;9.0;100;3e6g_D;4ixs_A;1.12;1.08
3e6g;4;3e6g;1;4ixs;1;b;1;1370;97;93;1390;99;95;0.85;0.87;100;0;2.8;2.29;diffraction;diffraction;1600;1588;Cystathionine gamma-lyase-like protein;Cystathionine gamma-lyase-like protein;XANTHOMONAS ORYZAE PV. ORYZAE;XANTHOMONAS ORYZAE PV. ORYZAE;no/data;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| CO3   carbonate ion| GOL   glycerol;Crystal structure of XometC, a cystathionine c-lyase-like protein from Xanthomonas oryzae pv.oryzae;Native structure of xometc at ph 5.2;Q5H4T8;metB XOO0778;PF01053;Q5H4T8;metB XOO0778;PF01053;b;5.5;100;5.2;100;3e6g_D;4ixs_A;1.12;1.08
3e6g;4;4iyo;1;4iy7;1;b;1;1526;100;100;1526;100;100;0.09;0.09;100;0;1.8;1.7;diffraction;diffraction;1588;1588;Cystathionine gamma-lyase-like protein, LYS201A modified;Cystathionine gamma-lyase-like protein;XANTHOMONAS ORYZAE PV. ORYZAE;XANTHOMONAS ORYZAE PV. ORYZAE;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SER   serine| NAK   amino-acrylate| PYR   pyruvic acid| GOL   glycerol| SO4   sulfate ion| 0JO   2-{[(e)-{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene]amino}prop-2-enoic acid;SER   serine| PYR   pyruvic acid| KOU   (e)-n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)-l-serine| GOL   glycerol| SO4   sulfate ion| 0JO   2-{[(e)-{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene]amino}prop-2-enoic acid;Crystal structure of cystathionine gamma lyase from Xanthomonas oryzae pv. oryzae (XometC) in complex with E-site serine, A-site serine, A-site external aldimine structure with aminoacrylate and A-site iminopropionate intermediates;crystal structure of cystathionine gamma lyase (XometC) from Xanthomonas oryzae pv. oryzae in complex with E-site serine, A-site external aldimine structure with serine and A-site external aldimine structure with aminoacrylate intermediates;Q5H4T8;metB XOO0778;PF01053;Q5H4T8;metB XOO0778;PF01053;b;9.0;100;9.0;100;3e6g_D;4ixs_A;1.12;1.08
3e6g;4;4iyo;1;4ixz;1;b;1;1509;99;99;1518;99;100;0.52;0.53;100;0;1.8;2.07;diffraction;diffraction;1588;1588;Cystathionine gamma-lyase-like protein, LYS201A modified;Cystathionine gamma-lyase-like protein;XANTHOMONAS ORYZAE PV. ORYZAE;XANTHOMONAS ORYZAE PV. ORYZAE;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SER   serine| NAK   amino-acrylate| PYR   pyruvic acid| GOL   glycerol| SO4   sulfate ion| 0JO   2-{[(e)-{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene]amino}prop-2-enoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| BCT   bicarbonate ion| BME   beta-mercaptoethanol| GOL   glycerol;Crystal structure of cystathionine gamma lyase from Xanthomonas oryzae pv. oryzae (XometC) in complex with E-site serine, A-site serine, A-site external aldimine structure with aminoacrylate and A-site iminopropionate intermediates;Native structure of cystathionine gamma lyase (XometC) from xanthomonas oryzae pv. oryzae at pH 9.0;Q5H4T8;metB XOO0778;PF01053;Q5H4T8;metB XOO0778;PF01053;b;9.0;100;9.0;100;3e6g_D;4ixs_A;1.12;1.08
3e6g;4;4iyo;1;4ixs;1;b;1;1449;95;99;1464;96;100;0.70;0.71;100;0;1.8;2.29;diffraction;diffraction;1588;1588;Cystathionine gamma-lyase-like protein, LYS201A modified;Cystathionine gamma-lyase-like protein;XANTHOMONAS ORYZAE PV. ORYZAE;XANTHOMONAS ORYZAE PV. ORYZAE;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SER   serine| NAK   amino-acrylate| PYR   pyruvic acid| GOL   glycerol| SO4   sulfate ion| 0JO   2-{[(e)-{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene]amino}prop-2-enoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| CO3   carbonate ion| GOL   glycerol;Crystal structure of cystathionine gamma lyase from Xanthomonas oryzae pv. oryzae (XometC) in complex with E-site serine, A-site serine, A-site external aldimine structure with aminoacrylate and A-site iminopropionate intermediates;Native structure of xometc at ph 5.2;Q5H4T8;metB XOO0778;PF01053;Q5H4T8;metB XOO0778;PF01053;b;9.0;100;5.2;100;3e6g_D;4ixs_A;1.12;1.08
3e6g;4;4iy7;1;4ixz;1;b;1;1508;99;99;1518;99;100;0.56;0.57;100;0;1.7;2.07;diffraction;diffraction;1588;1588;Cystathionine gamma-lyase-like protein;Cystathionine gamma-lyase-like protein;XANTHOMONAS ORYZAE PV. ORYZAE;XANTHOMONAS ORYZAE PV. ORYZAE;SER   serine| PYR   pyruvic acid| KOU   (e)-n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)-l-serine| GOL   glycerol| SO4   sulfate ion| 0JO   2-{[(e)-{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene]amino}prop-2-enoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| BCT   bicarbonate ion| BME   beta-mercaptoethanol| GOL   glycerol;crystal structure of cystathionine gamma lyase (XometC) from Xanthomonas oryzae pv. oryzae in complex with E-site serine, A-site external aldimine structure with serine and A-site external aldimine structure with aminoacrylate intermediates;Native structure of cystathionine gamma lyase (XometC) from xanthomonas oryzae pv. oryzae at pH 9.0;Q5H4T8;metB XOO0778;PF01053;Q5H4T8;metB XOO0778;PF01053;b;9.0;100;9.0;100;3e6g_D;4ixs_A;1.12;1.08
3e6g;4;4iy7;1;4ixs;1;b;1;1448;95;99;1465;96;100;0.76;0.77;100;0;1.7;2.29;diffraction;diffraction;1588;1588;Cystathionine gamma-lyase-like protein;Cystathionine gamma-lyase-like protein;XANTHOMONAS ORYZAE PV. ORYZAE;XANTHOMONAS ORYZAE PV. ORYZAE;SER   serine| PYR   pyruvic acid| KOU   (e)-n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)-l-serine| GOL   glycerol| SO4   sulfate ion| 0JO   2-{[(e)-{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene]amino}prop-2-enoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| CO3   carbonate ion| GOL   glycerol;crystal structure of cystathionine gamma lyase (XometC) from Xanthomonas oryzae pv. oryzae in complex with E-site serine, A-site external aldimine structure with serine and A-site external aldimine structure with aminoacrylate intermediates;Native structure of xometc at ph 5.2;Q5H4T8;metB XOO0778;PF01053;Q5H4T8;metB XOO0778;PF01053;b;9.0;100;5.2;100;3e6g_D;4ixs_A;1.12;1.08
3e6g;4;4ixz;1;4ixs;1;b;1;1449;95;99;1463;96;100;0.68;0.69;100;0;2.07;2.29;diffraction;diffraction;1588;1588;Cystathionine gamma-lyase-like protein;Cystathionine gamma-lyase-like protein;XANTHOMONAS ORYZAE PV. ORYZAE;XANTHOMONAS ORYZAE PV. ORYZAE;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| BCT   bicarbonate ion| BME   beta-mercaptoethanol| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| CO3   carbonate ion| GOL   glycerol;Native structure of cystathionine gamma lyase (XometC) from xanthomonas oryzae pv. oryzae at pH 9.0;Native structure of xometc at ph 5.2;Q5H4T8;metB XOO0778;PF01053;Q5H4T8;metB XOO0778;PF01053;b;9.0;100;5.2;100;3e6g_D;4ixs_A;1.12;1.08
1b62;2;1b62;1;1b63;1;b;1;657;99;99;662;100;99;0.62;0.63;100;0;2.1;1.9;diffraction;diffraction;710;666;PROTEIN (MUTL);MUTL;ESCHERICHIA COLI K12;ESCHERICHIA COLI K12;MG   magnesium ion| ADP   adenosine-5'-diphosphate;MG   magnesium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;MUTL COMPLEXED WITH ADP;MUTL COMPLEXED WITH ADPNP;P23367;mutL b4170 JW4128;PF01119,PF08676;P23367;mutL b4170 JW4128;PF01119,PF08676;b;8.5;98;8.5;98;1b62_A;1nhh_A;0.56;0.78
1b62;2;1b62;1;1nhh;1;b;1;644;97;98;652;98;99;0.76;0.78;99;0;2.1;2.4;diffraction;diffraction;710;666;PROTEIN (MUTL);DNA mismatch repair protein mutL;ESCHERICHIA COLI K12;ESCHERICHIA COLI K12;MG   magnesium ion| ADP   adenosine-5'-diphosphate;MG   magnesium ion| RB   rubidium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;MUTL COMPLEXED WITH ADP;Crystal structure of N-terminal 40KD MutL protein (LN40) complex with ADPnP and one Rubidium;P23367;mutL b4170 JW4128;PF01119,PF08676;P23367;mutL b4170 JW4128;PF01119,PF08676;b;8.5;98;8.4;98;1b62_A;1nhh_A;0.56;0.78
1b62;2;1b62;1;1nhj;1;b;1;655;99;98;662;100;99;0.70;0.70;99;0;2.1;2.3;diffraction;diffraction;710;666;PROTEIN (MUTL);DNA mismatch repair protein mutL;ESCHERICHIA COLI K12;ESCHERICHIA COLI K12;MG   magnesium ion| ADP   adenosine-5'-diphosphate;NA   sodium ion| MG   magnesium ion| ANP   phosphoaminophosphonic acid-adenylate ester;MUTL COMPLEXED WITH ADP;Crystal structure of N-terminal 40KD MutL/A100P mutant protein complex with ADPnP and one sodium;P23367;mutL b4170 JW4128;PF01119,PF08676;P23367;mutL b4170 JW4128;PF01119,PF08676;b;8.5;98;8.2;98;1b62_A;1nhh_A;0.56;0.78
1b62;2;1b62;1;1nhi;1;b;1;657;99;99;662;100;99;0.62;0.64;100;0;2.1;2.0;diffraction;diffraction;710;666;PROTEIN (MUTL);DNA mismatch repair protein mutL;ESCHERICHIA COLI K12;ESCHERICHIA COLI K12;MG   magnesium ion| ADP   adenosine-5'-diphosphate;MG   magnesium ion| K   potassium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;MUTL COMPLEXED WITH ADP;Crystal structure of N-terminal 40KD MutL (LN40) complex with ADPnP and one potassium;P23367;mutL b4170 JW4128;PF01119,PF08676;P23367;mutL b4170 JW4128;PF01119,PF08676;b;8.5;98;8.2;98;1b62_A;1nhh_A;0.56;0.78
1b62;2;1b63;1;1nhh;1;b;1;653;98;100;656;98;100;0.45;0.45;100;0;1.9;2.4;diffraction;diffraction;666;666;MUTL;DNA mismatch repair protein mutL;ESCHERICHIA COLI K12;ESCHERICHIA COLI K12;MG   magnesium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;MG   magnesium ion| RB   rubidium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;MUTL COMPLEXED WITH ADPNP;Crystal structure of N-terminal 40KD MutL protein (LN40) complex with ADPnP and one Rubidium;P23367;mutL b4170 JW4128;PF01119,PF08676;P23367;mutL b4170 JW4128;PF01119,PF08676;b;8.5;98;8.4;98;1b62_A;1nhh_A;0.56;0.78
1b62;2;1b63;1;1nhj;1;b;1;665;100;100;666;100;100;0.28;0.28;100;0;1.9;2.3;diffraction;diffraction;666;666;MUTL;DNA mismatch repair protein mutL;ESCHERICHIA COLI K12;ESCHERICHIA COLI K12;MG   magnesium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;NA   sodium ion| MG   magnesium ion| ANP   phosphoaminophosphonic acid-adenylate ester;MUTL COMPLEXED WITH ADPNP;Crystal structure of N-terminal 40KD MutL/A100P mutant protein complex with ADPnP and one sodium;P23367;mutL b4170 JW4128;PF01119,PF08676;P23367;mutL b4170 JW4128;PF01119,PF08676;b;8.5;98;8.2;98;1b62_A;1nhh_A;0.56;0.78
1b62;2;1b63;1;1nhi;1;b;1;665;100;100;666;100;100;0.23;0.23;100;0;1.9;2.0;diffraction;diffraction;666;666;MUTL;DNA mismatch repair protein mutL;ESCHERICHIA COLI K12;ESCHERICHIA COLI K12;MG   magnesium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;MG   magnesium ion| K   potassium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;MUTL COMPLEXED WITH ADPNP;Crystal structure of N-terminal 40KD MutL (LN40) complex with ADPnP and one potassium;P23367;mutL b4170 JW4128;PF01119,PF08676;P23367;mutL b4170 JW4128;PF01119,PF08676;b;8.5;98;8.2;98;1b62_A;1nhh_A;0.56;0.78
1b62;2;1nhh;1;1nhj;1;b;1;654;100;98;656;100;98;0.38;0.38;100;0;2.4;2.3;diffraction;diffraction;666;666;DNA mismatch repair protein mutL;DNA mismatch repair protein mutL;ESCHERICHIA COLI K12;ESCHERICHIA COLI K12;MG   magnesium ion| RB   rubidium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;NA   sodium ion| MG   magnesium ion| ANP   phosphoaminophosphonic acid-adenylate ester;Crystal structure of N-terminal 40KD MutL protein (LN40) complex with ADPnP and one Rubidium;Crystal structure of N-terminal 40KD MutL/A100P mutant protein complex with ADPnP and one sodium;P23367;mutL b4170 JW4128;PF01119,PF08676;P23367;mutL b4170 JW4128;PF01119,PF08676;b;8.4;98;8.2;98;1b62_A;1nhh_A;0.56;0.78
1b62;2;1nhh;1;1nhi;1;b;1;654;100;98;656;100;98;0.37;0.38;100;0;2.4;2.0;diffraction;diffraction;666;666;DNA mismatch repair protein mutL;DNA mismatch repair protein mutL;ESCHERICHIA COLI K12;ESCHERICHIA COLI K12;MG   magnesium ion| RB   rubidium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;MG   magnesium ion| K   potassium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;Crystal structure of N-terminal 40KD MutL protein (LN40) complex with ADPnP and one Rubidium;Crystal structure of N-terminal 40KD MutL (LN40) complex with ADPnP and one potassium;P23367;mutL b4170 JW4128;PF01119,PF08676;P23367;mutL b4170 JW4128;PF01119,PF08676;b;8.4;98;8.2;98;1b62_A;1nhh_A;0.56;0.78
1b62;2;1nhj;1;1nhi;1;b;1;665;100;100;666;100;100;0.26;0.26;100;0;2.3;2.0;diffraction;diffraction;666;666;DNA mismatch repair protein mutL;DNA mismatch repair protein mutL;ESCHERICHIA COLI K12;ESCHERICHIA COLI K12;NA   sodium ion| MG   magnesium ion| ANP   phosphoaminophosphonic acid-adenylate ester;MG   magnesium ion| K   potassium ion| EDO   1,2-ethanediol| ANP   phosphoaminophosphonic acid-adenylate ester;Crystal structure of N-terminal 40KD MutL/A100P mutant protein complex with ADPnP and one sodium;Crystal structure of N-terminal 40KD MutL (LN40) complex with ADPnP and one potassium;P23367;mutL b4170 JW4128;PF01119,PF08676;P23367;mutL b4170 JW4128;PF01119,PF08676;b;8.2;98;8.2;98;1b62_A;1nhh_A;0.56;0.78
4ur3;2;4ur3;2;4ur2;1;b;1;848;98;98;851;98;98;0.38;0.39;100;0;2.235;2.096;diffraction;diffraction;928;928;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;SULFUROSPIRILLUM MULTIVORANS;SULFUROSPIRILLUM MULTIVORANS;SF4   iron/sulfur cluster| BVQ   norpseudo-b12;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| GOL   glycerol| IOD   iodide ion;Crystal structure of the PCE reductive dehalogenase from S. multivorans P2(1) crystal form;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with iodide;W6EQP0;pceA SMUL_1531;PF13486;W6EQP0;pceA SMUL_1531;PF13486;b;8;100;8;100;4ur3_A;4ur3_F;0.59;0.53
4ur3;2;4ur3;2;4uqu;1;b;1;859;99;98;864;100;98;0.51;0.53;100;0;2.235;1.595;diffraction;diffraction;928;928;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;SULFUROSPIRILLUM MULTIVORANS;SULFUROSPIRILLUM MULTIVORANS;SF4   iron/sulfur cluster| BVQ   norpseudo-b12;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| BEN   benzamidine| GOL   glycerol;Crystal structure of the PCE reductive dehalogenase from S. multivorans P2(1) crystal form;Crystal structure of the tetrachloroethene reductive dehalogenase from Sulfurospirillum multivorans;W6EQP0;pceA SMUL_1531;PF13486;W6EQP0;pceA SMUL_1531;PF13486;b;8;100;8;100;4ur3_A;4ur3_F;0.59;0.53
4ur3;2;4ur3;2;4ur0;1;b;1;860;100;97;864;100;97;0.46;0.47;100;0;2.235;1.798;diffraction;diffraction;928;928;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;SULFUROSPIRILLUM MULTIVORANS;SULFUROSPIRILLUM MULTIVORANS;SF4   iron/sulfur cluster| BVQ   norpseudo-b12;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| TCV   1,1,2-trichloroethene| GOL   glycerol| BEN   benzamidine;Crystal structure of the PCE reductive dehalogenase from S. multivorans P2(1) crystal form;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with trichloroethene;W6EQP0;pceA SMUL_1531;PF13486;W6EQP0;pceA SMUL_1531;PF13486;b;8;100;8;100;4ur3_A;4ur3_F;0.59;0.53
4ur3;2;4ur3;2;4ur1;1;b;1;860;100;97;864;100;97;0.47;0.48;100;0;2.235;1.649;diffraction;diffraction;928;928;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;SULFUROSPIRILLUM MULTIVORANS;SULFUROSPIRILLUM MULTIVORANS;SF4   iron/sulfur cluster| BVQ   norpseudo-b12;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| CB0   cis-dibromoethene| BEN   benzamidine| GOL   glycerol;Crystal structure of the PCE reductive dehalogenase from S. multivorans P2(1) crystal form;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with dibromoethene;W6EQP0;pceA SMUL_1531;PF13486;W6EQP0;pceA SMUL_1531;PF13486;b;8;100;8;100;4ur3_A;4ur3_F;0.59;0.53
4ur3;2;4ur2;1;4uqu;1;b;1;862;100;98;862;100;98;0.16;0.16;100;0;2.096;1.595;diffraction;diffraction;928;928;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;SULFUROSPIRILLUM MULTIVORANS;SULFUROSPIRILLUM MULTIVORANS;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| GOL   glycerol| IOD   iodide ion;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| BEN   benzamidine| GOL   glycerol;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with iodide;Crystal structure of the tetrachloroethene reductive dehalogenase from Sulfurospirillum multivorans;W6EQP0;pceA SMUL_1531;PF13486;W6EQP0;pceA SMUL_1531;PF13486;b;8;100;8;100;4ur3_A;4ur3_F;0.59;0.53
4ur3;2;4ur2;1;4ur0;1;b;1;864;100;97;864;100;97;0.16;0.16;100;0;2.096;1.798;diffraction;diffraction;928;928;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;SULFUROSPIRILLUM MULTIVORANS;SULFUROSPIRILLUM MULTIVORANS;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| GOL   glycerol| IOD   iodide ion;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| TCV   1,1,2-trichloroethene| GOL   glycerol| BEN   benzamidine;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with iodide;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with trichloroethene;W6EQP0;pceA SMUL_1531;PF13486;W6EQP0;pceA SMUL_1531;PF13486;b;8;100;8;100;4ur3_A;4ur3_F;0.59;0.53
4ur3;2;4ur2;1;4ur1;1;b;1;864;100;97;864;100;97;0.14;0.14;100;0;2.096;1.649;diffraction;diffraction;928;928;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;SULFUROSPIRILLUM MULTIVORANS;SULFUROSPIRILLUM MULTIVORANS;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| GOL   glycerol| IOD   iodide ion;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| CB0   cis-dibromoethene| BEN   benzamidine| GOL   glycerol;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with iodide;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with dibromoethene;W6EQP0;pceA SMUL_1531;PF13486;W6EQP0;pceA SMUL_1531;PF13486;b;8;100;8;100;4ur3_A;4ur3_F;0.59;0.53
4ur3;2;4uqu;1;4ur0;1;b;1;877;100;99;878;100;99;0.23;0.23;100;0;1.595;1.798;diffraction;diffraction;928;928;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;SULFUROSPIRILLUM MULTIVORANS;SULFUROSPIRILLUM MULTIVORANS;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| BEN   benzamidine| GOL   glycerol;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| TCV   1,1,2-trichloroethene| GOL   glycerol| BEN   benzamidine;Crystal structure of the tetrachloroethene reductive dehalogenase from Sulfurospirillum multivorans;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with trichloroethene;W6EQP0;pceA SMUL_1531;PF13486;W6EQP0;pceA SMUL_1531;PF13486;b;8;100;8;100;4ur3_A;4ur3_F;0.59;0.53
4ur3;2;4uqu;1;4ur1;1;b;1;877;100;99;878;100;99;0.22;0.22;100;0;1.595;1.649;diffraction;diffraction;928;928;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;SULFUROSPIRILLUM MULTIVORANS;SULFUROSPIRILLUM MULTIVORANS;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| BEN   benzamidine| GOL   glycerol;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| CB0   cis-dibromoethene| BEN   benzamidine| GOL   glycerol;Crystal structure of the tetrachloroethene reductive dehalogenase from Sulfurospirillum multivorans;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with dibromoethene;W6EQP0;pceA SMUL_1531;PF13486;W6EQP0;pceA SMUL_1531;PF13486;b;8;100;8;100;4ur3_A;4ur3_F;0.59;0.53
4ur3;2;4ur0;1;4ur1;1;b;1;887;100;100;887;100;100;0.09;0.09;100;0;1.798;1.649;diffraction;diffraction;928;928;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;TETRACHLOROETHENE REDUCTIVE DEHALOGENASE CATALYTIC SUBUNIT PCEA;SULFUROSPIRILLUM MULTIVORANS;SULFUROSPIRILLUM MULTIVORANS;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| TCV   1,1,2-trichloroethene| GOL   glycerol| BEN   benzamidine;SF4   iron/sulfur cluster| BVQ   norpseudo-b12| CB0   cis-dibromoethene| BEN   benzamidine| GOL   glycerol;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with trichloroethene;Crystal structure of the PCE reductive dehalogenase from S. multivorans in complex with dibromoethene;W6EQP0;pceA SMUL_1531;PF13486;W6EQP0;pceA SMUL_1531;PF13486;b;8;100;8;100;4ur3_A;4ur3_F;0.59;0.53
1rpt;2;1rpt;1;1rpa;1;b;1;681;100;100;684;100;100;0.45;0.45;100;0;3.0;3.0;diffraction;diffraction;684;684;PROSTATIC ACID PHOSPHATASE;PROSTATIC ACID PHOSPHATASE;RATTUS NORVEGICUS;RATTUS NORVEGICUS;NAG   n-acetyl-d-glucosamine| BMA   beta-d-mannose| VO4   vanadate ion;NAG   n-acetyl-d-glucosamine| BMA   beta-d-mannose| TAR   d(-)-tartaric acid;CRYSTAL STRUCTURES OF RAT ACID PHOSPHATASE COMPLEXED WITH THE TRANSITIONS STATE ANALOGS VANADATE AND MOLYBDATE: IMPLICATIONS FOR THE REACTION MECHANISM;THREE-DIMENSIONAL STRUCTURE OF RAT ACID PHOSPHATASE IN COMPLEX WITH L(+) TARTRATE;P20646;Acpp;PF00328;P20646;Acpp;PF00328;b;no/data;no/data;no/data;no/data;1rpt_A;1rpa_A;0.44;0.45
4a65;2;4a65;1;4a5l;1;b;1;585;94;94;618;99;99;1.63;1.73;84;0;1.7;1.66;diffraction;diffraction;628;628;THIOREDOXIN REDUCTASE;THIOREDOXIN REDUCTASE;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| AU   gold ion| FAD   flavin-adenine dinucleotide;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| FAD   flavin-adenine dinucleotide;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with AuCN;Crystal structure of the thioredoxin reductase from Entamoeba histolytica;C4LW95;CL6EHI_155440 EHI_155440;PF07992;C4LW95;CL6EHI_155440 EHI_155440;PF07992;c;9.0;110;9.0;110;4ccr_A;4ccr_C;0.68;1.73
4a65;2;4a65;1;4cbq;1;b;1;619;99;99;623;100;100;0.56;0.56;100;0;1.7;1.94;diffraction;diffraction;628;628;THIOREDOXIN REDUCTASE;THIOREDOXIN REDUCTASE;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| AU   gold ion| FAD   flavin-adenine dinucleotide;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| AU   gold ion| FAD   flavin-adenine dinucleotide| CL   chloride ion;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with AuCN;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with auranofin Au(I) bound to Cys286;C4LW95;CL6EHI_155440 EHI_155440;PF07992;C4LW95;CL6EHI_155440 EHI_155440;PF07992;c;9.0;110;8.5;110;4ccr_A;4ccr_C;0.68;1.73
4a65;2;4a65;1;4ccq;1;b;1;619;99;99;623;100;100;0.55;0.55;100;0;1.7;1.5;diffraction;diffraction;628;628;THIOREDOXIN REDUCTASE;THIOREDOXIN REDUCTASE;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| AU   gold ion| FAD   flavin-adenine dinucleotide;NAP   nadp nicotinamide-adenine-dinucleotide phosphate| EDO   1,2-ethanediol| FAD   flavin-adenine dinucleotide| ACT   acetate ion;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with AuCN;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with NADP;C4LW95;CL6EHI_155440 EHI_155440;PF07992;C4LW95;CL6EHI_155440 EHI_155440;PF07992;c;9.0;110;7;110;4ccr_A;4ccr_C;0.68;1.73
4a65;2;4a65;1;4ccr;1;b;1;385;62;62;392;63;63;0.94;1.01;97;0;1.7;2.28;diffraction;diffraction;628;628;THIOREDOXIN REDUCTASE;THIOREDOXIN REDUCTASE;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| AU   gold ion| FAD   flavin-adenine dinucleotide;AU   gold ion| FAD   flavin-adenine dinucleotide;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with AuCN;Crystal structure of the thioredoxin reductase apoenzyme from Entamoeba histolytica in the absence of the NADP cofactor;C4LW95;CL6EHI_155440 EHI_155440;PF07992;C4LW95;CL6EHI_155440 EHI_155440;PF07992;c;9.0;110;7.0;110;4ccr_A;4ccr_C;0.68;1.73
4a65;2;4a5l;1;4cbq;1;b;1;624;100;100;624;100;100;0.18;0.18;100;0;1.66;1.94;diffraction;diffraction;628;628;THIOREDOXIN REDUCTASE;THIOREDOXIN REDUCTASE;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| FAD   flavin-adenine dinucleotide;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| AU   gold ion| FAD   flavin-adenine dinucleotide| CL   chloride ion;Crystal structure of the thioredoxin reductase from Entamoeba histolytica;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with auranofin Au(I) bound to Cys286;C4LW95;CL6EHI_155440 EHI_155440;PF07992;C4LW95;CL6EHI_155440 EHI_155440;PF07992;c;9.0;110;8.5;110;4ccr_A;4ccr_C;0.68;1.73
4a65;2;4a5l;1;4ccq;1;b;1;624;100;100;625;100;100;0.20;0.20;100;0;1.66;1.5;diffraction;diffraction;628;628;THIOREDOXIN REDUCTASE;THIOREDOXIN REDUCTASE;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| FAD   flavin-adenine dinucleotide;NAP   nadp nicotinamide-adenine-dinucleotide phosphate| EDO   1,2-ethanediol| FAD   flavin-adenine dinucleotide| ACT   acetate ion;Crystal structure of the thioredoxin reductase from Entamoeba histolytica;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with NADP;C4LW95;CL6EHI_155440 EHI_155440;PF07992;C4LW95;CL6EHI_155440 EHI_155440;PF07992;c;9.0;110;7;110;4ccr_A;4ccr_C;0.68;1.73
4a65;2;4a5l;1;4ccr;1;b;1;387;62;62;394;63;63;0.94;1.01;97;0;1.66;2.28;diffraction;diffraction;628;628;THIOREDOXIN REDUCTASE;THIOREDOXIN REDUCTASE;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| FAD   flavin-adenine dinucleotide;AU   gold ion| FAD   flavin-adenine dinucleotide;Crystal structure of the thioredoxin reductase from Entamoeba histolytica;Crystal structure of the thioredoxin reductase apoenzyme from Entamoeba histolytica in the absence of the NADP cofactor;C4LW95;CL6EHI_155440 EHI_155440;PF07992;C4LW95;CL6EHI_155440 EHI_155440;PF07992;c;9.0;110;7.0;110;4ccr_A;4ccr_C;0.68;1.73
4a65;2;4cbq;1;4ccq;1;b;1;623;100;100;624;100;100;0.23;0.23;100;0;1.94;1.5;diffraction;diffraction;628;628;THIOREDOXIN REDUCTASE;THIOREDOXIN REDUCTASE;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| AU   gold ion| FAD   flavin-adenine dinucleotide| CL   chloride ion;NAP   nadp nicotinamide-adenine-dinucleotide phosphate| EDO   1,2-ethanediol| FAD   flavin-adenine dinucleotide| ACT   acetate ion;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with auranofin Au(I) bound to Cys286;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with NADP;C4LW95;CL6EHI_155440 EHI_155440;PF07992;C4LW95;CL6EHI_155440 EHI_155440;PF07992;c;8.5;110;7;110;4ccr_A;4ccr_C;0.68;1.73
4a65;2;4cbq;1;4ccr;1;b;1;386;62;62;393;63;63;0.93;0.99;97;0;1.94;2.28;diffraction;diffraction;628;628;THIOREDOXIN REDUCTASE;THIOREDOXIN REDUCTASE;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;NDP   nadph dihydro-nicotinamide-adenine-dinucleotide phosphate| SO4   sulfate ion| AU   gold ion| FAD   flavin-adenine dinucleotide| CL   chloride ion;AU   gold ion| FAD   flavin-adenine dinucleotide;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with auranofin Au(I) bound to Cys286;Crystal structure of the thioredoxin reductase apoenzyme from Entamoeba histolytica in the absence of the NADP cofactor;C4LW95;CL6EHI_155440 EHI_155440;PF07992;C4LW95;CL6EHI_155440 EHI_155440;PF07992;c;8.5;110;7.0;110;4ccr_A;4ccr_C;0.68;1.73
4a65;2;4ccq;1;4ccr;1;b;1;387;62;62;394;63;63;0.93;1.00;97;0;1.5;2.28;diffraction;diffraction;628;628;THIOREDOXIN REDUCTASE;THIOREDOXIN REDUCTASE;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;NAP   nadp nicotinamide-adenine-dinucleotide phosphate| EDO   1,2-ethanediol| FAD   flavin-adenine dinucleotide| ACT   acetate ion;AU   gold ion| FAD   flavin-adenine dinucleotide;Crystal structure of the thioredoxin reductase from Entamoeba histolytica with NADP;Crystal structure of the thioredoxin reductase apoenzyme from Entamoeba histolytica in the absence of the NADP cofactor;C4LW95;CL6EHI_155440 EHI_155440;PF07992;C4LW95;CL6EHI_155440 EHI_155440;PF07992;c;7;110;7.0;110;4ccr_A;4ccr_C;0.68;1.73
3uie;2;3uie;1;4fxp;2;b;1;379;99;97;381;100;98;0.57;0.62;100;0;1.794;1.954;diffraction;diffraction;400;400;Adenylyl-sulfate kinase 1, chloroplastic;Adenylyl-sulfate kinase 1, chloroplastic;ARABIDOPSIS THALIANA;ARABIDOPSIS THALIANA;ADX   adenosine-5'-phosphosulfate| ANP   phosphoaminophosphonic acid-adenylate ester| MG   magnesium ion;ADX   adenosine-5'-phosphosulfate| SO4   sulfate ion;Crystal structure of adenosine 5'-phosphosulfate kinase from Arabidopsis Thaliana in Complex with AMPPNP and APS;Crystal structure of adenosine 5'-phosphosulfate kinase from Arabidopsis thaliana in Complex with Sulfate and APS;Q43295;APK1 AKN1 At2g14750 F26C24.11 T6B13.1;no/data;Q43295;APK1 AKN1 At2g14750 F26C24.11 T6B13.1;no/data;b;7.5;100;7.25;100;3uie_B;4fxp_C;0.97;0.62
2pnh;2;2pnh;1;1woc;3;b;1;184;97;93;188;99;94;1.01;1.02;99;0;2.25;2.0;diffraction;diffraction;214;206;Primosomal replication protein n;Primosomal replication protein n;ESCHERICHIA COLI;ESCHERICHIA COLI;no/data;MSE   selenomethionine;Escherichia coli PriB E39A variant;Crystal structure of PriB;P07013;priB b4201 JW4159;PF00436;P07013;priB b4201 JW4159;PF00436;b;8.5;100;8.0;100;2pnh_B;1woc_C;1.18;1.02
2pnh;2;2pnh;1;1txy;1;b;1;176;92;100;176;93;100;0.36;0.36;99;0;2.25;2.0;diffraction;diffraction;214;208;Primosomal replication protein n;Primosomal replication protein n;ESCHERICHIA COLI;ESCHERICHIA COLI;no/data;MSE   selenomethionine;Escherichia coli PriB E39A variant;E. coli PriB;P07013;priB b4201 JW4159;PF00436;P07013;priB b4201 JW4159;PF00436;b;8.5;100;8.5;110;2pnh_B;1woc_C;1.18;1.02
2pnh;2;1woc;3;1txy;1;b;1;171;86;97;174;87;99;0.90;0.93;99;0;2.0;2.0;diffraction;diffraction;206;208;Primosomal replication protein n;Primosomal replication protein n;ESCHERICHIA COLI;ESCHERICHIA COLI;MSE   selenomethionine;MSE   selenomethionine;Crystal structure of PriB;E. coli PriB;P07013;priB b4201 JW4159;PF00436;P07013;priB b4201 JW4159;PF00436;b;8.0;100;8.5;110;2pnh_B;1woc_C;1.18;1.02
3dwi;2;3dwi;1;3dki;1;b;1;581;96;96;596;98;98;1.11;1.17;97;0;2.81;2.1;diffraction;diffraction;646;652;Cysteine synthase B;Cysteine synthase B;MYCOBACTERIUM TUBERCULOSIS;MYCOBACTERIUM TUBERCULOSIS;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| NA   sodium ion;Crystal structure of Mycobacterium tuberculosis CysM, the cysteine synthase B;2.1 A X-ray structure of CysM (Rv1336) from Mycobacterium tuberculosis an O-phosphoserine dependent cysteine synthase;P9WP53;cysM Rv1336 MTCY130.21;PF00291;P9WP53;cysM Rv1336 MTCY130.21;PF00291;b;7.1;100;7.5;110;3dwi_B;3fgp_B;1.23;1.17
3dwi;2;3dwi;1;3fgp;1;b;1;587;97;92;602;99;95;1.10;1.13;99;0;2.81;2.05;diffraction;diffraction;646;652;Cysteine synthase B;Cysteine synthase B;MYCOBACTERIUM TUBERCULOSIS;MYCOBACTERIUM TUBERCULOSIS;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Crystal structure of Mycobacterium tuberculosis CysM, the cysteine synthase B;2.05 a Crystal Structure of CysM from Mycobacterium Tuberculosis - Open and Closed Conformations;P9WP53;cysM Rv1336 MTCY130.21;PF00291;P9WP53;cysM Rv1336 MTCY130.21;PF00291;b;7.1;100;7.4;110;3dwi_B;3fgp_B;1.23;1.17
3dwi;2;3dki;1;3fgp;1;b;1;600;99;94;606;100;95;0.70;0.71;100;0;2.1;2.05;diffraction;diffraction;652;652;Cysteine synthase B;Cysteine synthase B;MYCOBACTERIUM TUBERCULOSIS;MYCOBACTERIUM TUBERCULOSIS;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| NA   sodium ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;2.1 A X-ray structure of CysM (Rv1336) from Mycobacterium tuberculosis an O-phosphoserine dependent cysteine synthase;2.05 a Crystal Structure of CysM from Mycobacterium Tuberculosis - Open and Closed Conformations;P9WP53;cysM Rv1336 MTCY130.21;PF00291;P9WP53;cysM Rv1336 MTCY130.21;PF00291;b;7.5;110;7.4;110;3dwi_B;3fgp_B;1.23;1.17
2q8o;2;2q8o;1;3b9i;1;b;1;246;98;100;246;98;100;0.22;0.22;99;0;1.75;2.49;diffraction;diffraction;272;264;GITR ligand;GITR ligand;MUS MUSCULUS;MUS MUSCULUS;no/data;no/data;crystal structure of mouse GITR ligand dimer;Crystal Structure of mouse GITRL at 2.5 A.;Q7TS55;Tnfsf18 Gitrl;PF00229;Q7TS55;Tnfsf18 Gitrl;PF00229;b;7.5;100;6.5;100;2q8o_A;3b9i_B;0.82;0.34
2q8o;2;2q8o;1;3fc0;1;b;1;242;97;100;242;97;100;0.29;0.29;99;0;1.75;1.76;diffraction;diffraction;272;278;GITR ligand;GITR ligand;MUS MUSCULUS;MUS MUSCULUS;no/data;ACT   acetate ion;crystal structure of mouse GITR ligand dimer;1.8 A crystal structure of murine GITR ligand dimer expressed in Drosophila melanogaster S2 cells;Q7TS55;Tnfsf18 Gitrl;PF00229;Q7TS55;Tnfsf18 Gitrl;PF00229;b;7.5;100;7.0;100;2q8o_A;3b9i_B;0.82;0.34
2q8o;2;2q8o;1;2qdn;1;b;1;246;98;100;246;98;100;0.16;0.16;99;0;1.75;2.09;diffraction;diffraction;272;264;GITR ligand;GITR ligand;MUS MUSCULUS;MUS MUSCULUS;no/data;no/data;crystal structure of mouse GITR ligand dimer;Crystal Structure of mouse GITRL;Q7TS55;Tnfsf18 Gitrl;PF00229;Q7TS55;Tnfsf18 Gitrl;PF00229;b;7.5;100;7.0;100;2q8o_A;3b9i_B;0.82;0.34
2q8o;2;3b9i;1;3fc0;1;b;1;241;98;100;242;98;100;0.34;0.34;100;0;2.49;1.76;diffraction;diffraction;264;278;GITR ligand;GITR ligand;MUS MUSCULUS;MUS MUSCULUS;no/data;ACT   acetate ion;Crystal Structure of mouse GITRL at 2.5 A.;1.8 A crystal structure of murine GITR ligand dimer expressed in Drosophila melanogaster S2 cells;Q7TS55;Tnfsf18 Gitrl;PF00229;Q7TS55;Tnfsf18 Gitrl;PF00229;b;6.5;100;7.0;100;2q8o_A;3b9i_B;0.82;0.34
2q8o;2;3b9i;1;2qdn;1;b;1;246;100;100;246;100;100;0.18;0.18;100;0;2.49;2.09;diffraction;diffraction;264;264;GITR ligand;GITR ligand;MUS MUSCULUS;MUS MUSCULUS;no/data;no/data;Crystal Structure of mouse GITRL at 2.5 A.;Crystal Structure of mouse GITRL;Q7TS55;Tnfsf18 Gitrl;PF00229;Q7TS55;Tnfsf18 Gitrl;PF00229;b;6.5;100;7.0;100;2q8o_A;3b9i_B;0.82;0.34
2q8o;2;3fc0;1;2qdn;1;b;1;241;100;98;242;100;98;0.33;0.34;100;0;1.76;2.09;diffraction;diffraction;278;264;GITR ligand;GITR ligand;MUS MUSCULUS;MUS MUSCULUS;ACT   acetate ion;no/data;1.8 A crystal structure of murine GITR ligand dimer expressed in Drosophila melanogaster S2 cells;Crystal Structure of mouse GITRL;Q7TS55;Tnfsf18 Gitrl;PF00229;Q7TS55;Tnfsf18 Gitrl;PF00229;b;7.0;100;7.0;100;2q8o_A;3b9i_B;0.82;0.34
3epn;2;3epn;1;3epo;1;b;1;1041;100;99;1042;100;99;0.26;0.26;100;0;2.11;2.1;diffraction;diffraction;1224;1224;Thiamine biosynthesis protein thiC;Thiamine biosynthesis protein thiC;CAULOBACTER CRESCENTUS;CAULOBACTER CRESCENTUS;IRN   1-(5-o-phosphono-beta-d-ribofuranosyl)-1h-imidazole;MP5   (4-amino-2-methylpyrimidin-5-yl)methyl dihydrogen phosphate;Crystal structure of Caulobacter crescentus ThiC complexed with imidazole ribonucleotide;Crystal structure of Caulobacter crescentus ThiC complexed with HMP-P;Q9A6Q5;thiC CC_2029;PF13667,PF01964;Q9A6Q5;thiC CC_2029;PF13667,PF01964;b;7.5;100;7.5;100;3epn_A;3epo_B;0.59;0.62
3epn;2;3epn;1;3epm;1;b;1;1013;97;99;1021;98;99;0.61;0.62;100;0;2.11;2.793;diffraction;diffraction;1224;1224;Thiamine biosynthesis protein thiC;Thiamine biosynthesis protein thiC;CAULOBACTER CRESCENTUS;CAULOBACTER CRESCENTUS;IRN   1-(5-o-phosphono-beta-d-ribofuranosyl)-1h-imidazole;MSE   selenomethionine| ZN   zinc ion| HMH   4-amino-5-hydroxymethyl-2-methylpyrimidine| SO4   sulfate ion;Crystal structure of Caulobacter crescentus ThiC complexed with imidazole ribonucleotide;Crystal structure of Caulobacter crescentus ThiC;Q9A6Q5;thiC CC_2029;PF13667,PF01964;Q9A6Q5;thiC CC_2029;PF13667,PF01964;b;7.5;100;8.2;100;3epn_A;3epo_B;0.59;0.62
3epn;2;3epo;1;3epm;1;b;1;1015;97;99;1021;97;99;0.52;0.54;100;0;2.1;2.793;diffraction;diffraction;1224;1224;Thiamine biosynthesis protein thiC;Thiamine biosynthesis protein thiC;CAULOBACTER CRESCENTUS;CAULOBACTER CRESCENTUS;MP5   (4-amino-2-methylpyrimidin-5-yl)methyl dihydrogen phosphate;MSE   selenomethionine| ZN   zinc ion| HMH   4-amino-5-hydroxymethyl-2-methylpyrimidine| SO4   sulfate ion;Crystal structure of Caulobacter crescentus ThiC complexed with HMP-P;Crystal structure of Caulobacter crescentus ThiC;Q9A6Q5;thiC CC_2029;PF13667,PF01964;Q9A6Q5;thiC CC_2029;PF13667,PF01964;b;7.5;100;8.2;100;3epn_A;3epo_B;0.59;0.62
1x3e;4;1x3e;1;1x3f;1;b;1;430;94;97;438;96;99;0.96;1.01;99;0;2.15;2.7;diffraction;diffraction;660;660;Single-strand binding protein;Single-strand binding protein;MYCOBACTERIUM SMEGMATIS;MYCOBACTERIUM SMEGMATIS;CD   cadmium ion;CD   cadmium ion;Crystal structure of the single-stranded DNA-binding protein from Mycobacterium smegmatis;Crystal structure of the single-stranded DNA-binding protein from Mycobacterium SMEGMATIS;Q9AFI5;ssb MSMEG_6896 MSMEI_6712;PF00436;Q9AFI5;ssb MSMEG_6896 MSMEI_6712;PF00436;b;7.4;100;7.4;100;1x3e_A;1x3g_B;1.47;1.13
1x3e;4;1x3e;1;1x3g;1;b;1;444;97;97;450;98;98;0.84;0.86;99;0;2.15;3.0;diffraction;diffraction;660;660;Single-strand binding protein;Single-strand binding protein;MYCOBACTERIUM SMEGMATIS;MYCOBACTERIUM SMEGMATIS;CD   cadmium ion;CD   cadmium ion;Crystal structure of the single-stranded DNA-binding protein from Mycobacterium smegmatis;Crystal structure of the single-stranded DNA-binding protein from Mycobacterium SMEGMATIS;Q9AFI5;ssb MSMEG_6896 MSMEI_6712;PF00436;Q9AFI5;ssb MSMEG_6896 MSMEI_6712;PF00436;b;7.4;100;7.4;298;1x3e_A;1x3g_B;1.47;1.13
1x3e;4;1x3f;1;1x3g;1;b;1;429;97;94;440;99;96;1.10;1.13;99;0;2.7;3.0;diffraction;diffraction;660;660;Single-strand binding protein;Single-strand binding protein;MYCOBACTERIUM SMEGMATIS;MYCOBACTERIUM SMEGMATIS;CD   cadmium ion;CD   cadmium ion;Crystal structure of the single-stranded DNA-binding protein from Mycobacterium SMEGMATIS;Crystal structure of the single-stranded DNA-binding protein from Mycobacterium SMEGMATIS;Q9AFI5;ssb MSMEG_6896 MSMEI_6712;PF00436;Q9AFI5;ssb MSMEG_6896 MSMEI_6712;PF00436;b;7.4;100;7.4;298;1x3e_A;1x3g_B;1.47;1.13
4dx3;8;4dx3;1;4dxk;1;b;1;2878;100;99;2880;100;99;0.19;0.19;100;0;1.65;1.25;diffraction;diffraction;3200;3200;Mandelate racemase / muconate lactonizing enzyme family protein;Mandelate racemase / muconate lactonizing enzyme family protein;AGROBACTERIUM TUMEFACIENS;AGROBACTERIUM TUMEFACIENS;SNN   l-3-aminosuccinimide| GOL   glycerol| CL   chloride ion;SNN   l-3-aminosuccinimide| PO4   phosphate ion| NA   sodium ion;Crystal structure of an enolase (mandelate racemase subgroup, target EFI-502086) from Agrobacterium tumefaciens, with a succinimide residue;Crystal structure of an enolase (mandelate racemase subgroup, target EFI-502086) from Agrobacterium tumefaciens, with a succinimide residue, na and phosphate;Q7D1T6;Atu0270;PF13378,PF02746;Q7D1T6;Atu0270;PF13378,PF02746;b;4.0;100;4.0;100;4dx3_A;4dxk_A;0.18;0.19
3lhd;4;3lhd;1;3mb5;1;b;1;1002;99;98;1012;100;99;0.70;0.71;100;0;2.59;1.6;diffraction;diffraction;1012;1020;SAM-dependent methyltransferase, putative;SAM-dependent methyltransferase;PYROCOCCUS ABYSSI;PYROCOCCUS ABYSSI;SAH   s-adenosyl-l-homocysteine;SAM   s-adenosylmethionine| SO4   sulfate ion| EDO   1,2-ethanediol| ACT   acetate ion;Crystal structure of P. abyssi tRNA m1A58 methyltransferase in complex with S-adenosyl-L-homocysteine;Crystal structure of P. abyssi tRNA m1A58 methyltransferase in complex with S-adenosyl-L-methionine;Q9V1J7;trmI pimT-like PYRAB04300 PAB0283;PF08704;Q9V1J7;trmI pimT-like PYRAB04300 PAB0283;PF08704;b;4.6;100;no/data;100;3lhd_A;3lhd_B;0.66;0.71
3lhd;4;3lhd;1;3lga;1;b;1;1003;99;99;1012;100;100;0.66;0.66;100;0;2.59;2.05;diffraction;diffraction;1012;1012;SAM-dependent methyltransferase, putative;SAM-dependent methyltransferase;PYROCOCCUS ABYSSI;PYROCOCCUS ABYSSI;SAH   s-adenosyl-l-homocysteine;SAH   s-adenosyl-l-homocysteine| SO4   sulfate ion;Crystal structure of P. abyssi tRNA m1A58 methyltransferase in complex with S-adenosyl-L-homocysteine;Crystal structure of P. abyssi tRNA m1A58 methyltransferase in complex with S-adenosyl-L-homocysteine;Q9V1J7;trmI pimT-like PYRAB04300 PAB0283;PF08704;Q9V1J7;trmI pimT-like PYRAB04300 PAB0283;PF08704;b;4.6;100;no/data;100;3lhd_A;3lhd_B;0.66;0.71
3lhd;4;3mb5;1;3lga;1;b;1;1003;98;99;1012;99;100;0.65;0.67;100;0;1.6;2.05;diffraction;diffraction;1020;1012;SAM-dependent methyltransferase;SAM-dependent methyltransferase;PYROCOCCUS ABYSSI;PYROCOCCUS ABYSSI;SAM   s-adenosylmethionine| SO4   sulfate ion| EDO   1,2-ethanediol| ACT   acetate ion;SAH   s-adenosyl-l-homocysteine| SO4   sulfate ion;Crystal structure of P. abyssi tRNA m1A58 methyltransferase in complex with S-adenosyl-L-methionine;Crystal structure of P. abyssi tRNA m1A58 methyltransferase in complex with S-adenosyl-L-homocysteine;Q9V1J7;trmI pimT-like PYRAB04300 PAB0283;PF08704;Q9V1J7;trmI pimT-like PYRAB04300 PAB0283;PF08704;b;no/data;100;no/data;100;3lhd_A;3lhd_B;0.66;0.71
1pv2;2;1pv2;3;1n57;1;b;1;529;100;95;531;100;95;0.46;0.46;100;0;2.71;1.6;diffraction;diffraction;566;582;Chaperone protein hchA;Chaperone Hsp31;ESCHERICHIA COLI;ESCHERICHIA COLI;no/data;MSE   selenomethionine| MG   magnesium ion;Native Form 2 E.coli Chaperone Hsp31;Crystal Structure of Chaperone Hsp31;P31658;hchA yedU yzzC b1967 JW1950;no/data;P31658;hchA yedU yzzC b1967 JW1950;no/data;a;7.5;100;6.5;200;1pv2_A;1pv2_C;2.11;0.46
1geu;2;1geu;1;1get;1;b;1;895;100;100;897;100;100;0.32;0.32;98;0;2.2;2.0;diffraction;diffraction;900;900;GLUTATHIONE REDUCTASE;GLUTATHIONE REDUCTASE;ESCHERICHIA COLI;ESCHERICHIA COLI;FAD   flavin-adenine dinucleotide| NAD   nicotinamide-adenine-dinucleotide;FAD   flavin-adenine dinucleotide| NAP   nadp nicotinamide-adenine-dinucleotide phosphate;ANATOMY OF AN ENGINEERED NAD-BINDING SITE;ANATOMY OF AN ENGINEERED NAD-BINDING SITE;P06715;gor b3500 JW3467;PF07992,PF02852;P06715;gor b3500 JW3467;PF07992,PF02852;b;no/data;no/data;no/data;no/data;1geu_B;1ger_A;0.42;0.33
1geu;2;1geu;1;1ges;1;b;1;896;100;100;897;100;100;0.27;0.27;100;0;2.2;1.74;diffraction;diffraction;900;900;GLUTATHIONE REDUCTASE;GLUTATHIONE REDUCTASE;ESCHERICHIA COLI;ESCHERICHIA COLI;FAD   flavin-adenine dinucleotide| NAD   nicotinamide-adenine-dinucleotide;FAD   flavin-adenine dinucleotide;ANATOMY OF AN ENGINEERED NAD-BINDING SITE;ANATOMY OF AN ENGINEERED NAD-BINDING SITE;P06715;gor b3500 JW3467;PF07992,PF02852;P06715;gor b3500 JW3467;PF07992,PF02852;b;no/data;no/data;no/data;no/data;1geu_B;1ger_A;0.42;0.33
1geu;2;1geu;1;1ger;1;b;1;895;100;100;897;100;100;0.32;0.33;98;0;2.2;1.86;diffraction;diffraction;900;900;GLUTATHIONE REDUCTASE;GLUTATHIONE REDUCTASE;ESCHERICHIA COLI;ESCHERICHIA COLI;FAD   flavin-adenine dinucleotide| NAD   nicotinamide-adenine-dinucleotide;FAD   flavin-adenine dinucleotide;ANATOMY OF AN ENGINEERED NAD-BINDING SITE;THE STRUCTURE OF GLUTATHIONE REDUCTASE FROM ESCHERICHIA COLI AT 1.86 ANGSTROMS RESOLUTION: COMPARISON WITH THE ENZYME FROM HUMAN ERYTHROCYTES;P06715;gor b3500 JW3467;PF07992,PF02852;P06715;gor b3500 JW3467;PF07992,PF02852;b;no/data;no/data;no/data;no/data;1geu_B;1ger_A;0.42;0.33
1geu;2;1get;1;1ges;1;b;1;895;100;100;897;100;100;0.31;0.31;98;0;2.0;1.74;diffraction;diffraction;900;900;GLUTATHIONE REDUCTASE;GLUTATHIONE REDUCTASE;ESCHERICHIA COLI;ESCHERICHIA COLI;FAD   flavin-adenine dinucleotide| NAP   nadp nicotinamide-adenine-dinucleotide phosphate;FAD   flavin-adenine dinucleotide;ANATOMY OF AN ENGINEERED NAD-BINDING SITE;ANATOMY OF AN ENGINEERED NAD-BINDING SITE;P06715;gor b3500 JW3467;PF07992,PF02852;P06715;gor b3500 JW3467;PF07992,PF02852;b;no/data;no/data;no/data;no/data;1geu_B;1ger_A;0.42;0.33
1geu;2;1get;1;1ger;1;b;1;896;100;100;897;100;100;0.22;0.22;100;0;2.0;1.86;diffraction;diffraction;900;900;GLUTATHIONE REDUCTASE;GLUTATHIONE REDUCTASE;ESCHERICHIA COLI;ESCHERICHIA COLI;FAD   flavin-adenine dinucleotide| NAP   nadp nicotinamide-adenine-dinucleotide phosphate;FAD   flavin-adenine dinucleotide;ANATOMY OF AN ENGINEERED NAD-BINDING SITE;THE STRUCTURE OF GLUTATHIONE REDUCTASE FROM ESCHERICHIA COLI AT 1.86 ANGSTROMS RESOLUTION: COMPARISON WITH THE ENZYME FROM HUMAN ERYTHROCYTES;P06715;gor b3500 JW3467;PF07992,PF02852;P06715;gor b3500 JW3467;PF07992,PF02852;b;no/data;no/data;no/data;no/data;1geu_B;1ger_A;0.42;0.33
1geu;2;1ges;1;1ger;1;b;1;895;100;100;897;100;100;0.29;0.29;98;0;1.74;1.86;diffraction;diffraction;900;900;GLUTATHIONE REDUCTASE;GLUTATHIONE REDUCTASE;ESCHERICHIA COLI;ESCHERICHIA COLI;FAD   flavin-adenine dinucleotide;FAD   flavin-adenine dinucleotide;ANATOMY OF AN ENGINEERED NAD-BINDING SITE;THE STRUCTURE OF GLUTATHIONE REDUCTASE FROM ESCHERICHIA COLI AT 1.86 ANGSTROMS RESOLUTION: COMPARISON WITH THE ENZYME FROM HUMAN ERYTHROCYTES;P06715;gor b3500 JW3467;PF07992,PF02852;P06715;gor b3500 JW3467;PF07992,PF02852;b;no/data;no/data;no/data;no/data;1geu_B;1ger_A;0.42;0.33
4hmr;2;4hmr;3;4hls;3;b;1;201;99;100;202;100;100;0.41;0.44;99;0;1.6;1.45;diffraction;diffraction;264;264;Major prion protein;Major prion protein;ORYCTOLAGUS CUNICULUS;ORYCTOLAGUS CUNICULUS;CL   chloride ion| NA   sodium ion| GOL   glycerol;CL   chloride ion| NA   sodium ion| GOL   glycerol;Crystal structure of mutant rabbit PRP 121-230 (S170N/S174N);Crystal structure of mutant rabbit PRP 121-230 (S170N);Q95211;PRNP PRP;PF00377,PF11587,PF03991;Q95211;PRNP PRP;PF00377,PF11587,PF03991;b;6.5;100;6.5;100;4hls_A;4hls_B;0.56;0.44
1us6;2;1us6;1;1rfy;2;b;1;174;92;99;176;93;100;0.73;0.78;99;0;1.65;1.6;diffraction;diffraction;204;204;TRANSCRIPTIONAL REPRESSOR TRAM;Transcriptional repressor traM;AGROBACTERIUM TUMEFACIENS;AGROBACTERIUM TUMEFACIENS;no/data;no/data;Crystal structure of the quorum-sensing protein TraM from Agrobacterium tumefaciens at 1.65 Ang. resolution;Crystal Structure of Quorum-Sensing Antiactivator TraM;Q57471;traM;PF09228;Q57471;traM;PF09228;b;8.50;100;5.6;100;1rfy_A;1rfy_B;1.04;0.78
3nfz;2;3nfz;1;3nh8;1;b;1;608;100;99;610;100;100;0.36;0.36;100;0;2.147;2.802;diffraction;diffraction;654;654;Aspartoacylase-2;Aspartoacylase-2;MUS MUSCULUS;MUS MUSCULUS;ZN   zinc ion| CL   chloride ion| 3NF   n-acetyl-l-tyrosine;ZN   zinc ion| CL   chloride ion| DC2   n-acetyl-s-[(1s)-1,2-dichloroethyl]-l-cysteine;Crystal structure of murine aminoacylase 3 in complex with N-acetyl-L-tyrosine;Crystal structure of murine aminoacylase 3 in complex with N-acetyl-S-1,2-dichlorovinyl-L-cysteine;Q91XE4;Acy3 Aspa2;PF04952;Q91XE4;Acy3 Aspa2;PF04952;b;5.0;100;5.0;100;3nfz_A;3nh8_A;0.35;0.44
3nfz;2;3nfz;1;3nh5;1;b;1;609;100;100;610;100;100;0.28;0.29;100;0;2.147;2.094;diffraction;diffraction;654;654;Aspartoacylase-2;Aspartoacylase-2;MUS MUSCULUS;MUS MUSCULUS;ZN   zinc ion| CL   chloride ion| 3NF   n-acetyl-l-tyrosine;ZN   zinc ion| CL   chloride ion| ACT   acetate ion| FMT   formic acid;Crystal structure of murine aminoacylase 3 in complex with N-acetyl-L-tyrosine;Crystal structure of E177A-mutant murine aminoacylase 3;Q91XE4;Acy3 Aspa2;PF04952;Q91XE4;Acy3 Aspa2;PF04952;b;5.0;100;5.0;100;3nfz_A;3nh8_A;0.35;0.44
3nfz;2;3nfz;1;3nh4;1;b;1;604;99;100;606;99;100;0.40;0.40;100;0;2.147;2.0;diffraction;diffraction;654;654;Aspartoacylase-2;Aspartoacylase-2;MUS MUSCULUS;MUS MUSCULUS;ZN   zinc ion| CL   chloride ion| 3NF   n-acetyl-l-tyrosine;ZN   zinc ion| CS   cesium ion| CL   chloride ion| ACT   acetate ion| FMT   formic acid;Crystal structure of murine aminoacylase 3 in complex with N-acetyl-L-tyrosine;Crystal structure of murine aminoacylase 3;Q91XE4;Acy3 Aspa2;PF04952;Q91XE4;Acy3 Aspa2;PF04952;b;5.0;100;5.0;100;3nfz_A;3nh8_A;0.35;0.44
3nfz;2;3nh8;1;3nh5;1;b;1;611;100;100;612;100;100;0.28;0.28;100;0;2.802;2.094;diffraction;diffraction;654;654;Aspartoacylase-2;Aspartoacylase-2;MUS MUSCULUS;MUS MUSCULUS;ZN   zinc ion| CL   chloride ion| DC2   n-acetyl-s-[(1s)-1,2-dichloroethyl]-l-cysteine;ZN   zinc ion| CL   chloride ion| ACT   acetate ion| FMT   formic acid;Crystal structure of murine aminoacylase 3 in complex with N-acetyl-S-1,2-dichlorovinyl-L-cysteine;Crystal structure of E177A-mutant murine aminoacylase 3;Q91XE4;Acy3 Aspa2;PF04952;Q91XE4;Acy3 Aspa2;PF04952;b;5.0;100;5.0;100;3nfz_A;3nh8_A;0.35;0.44
3nfz;2;3nh8;1;3nh4;1;b;1;604;99;100;606;99;100;0.44;0.44;100;0;2.802;2.0;diffraction;diffraction;654;654;Aspartoacylase-2;Aspartoacylase-2;MUS MUSCULUS;MUS MUSCULUS;ZN   zinc ion| CL   chloride ion| DC2   n-acetyl-s-[(1s)-1,2-dichloroethyl]-l-cysteine;ZN   zinc ion| CS   cesium ion| CL   chloride ion| ACT   acetate ion| FMT   formic acid;Crystal structure of murine aminoacylase 3 in complex with N-acetyl-S-1,2-dichlorovinyl-L-cysteine;Crystal structure of murine aminoacylase 3;Q91XE4;Acy3 Aspa2;PF04952;Q91XE4;Acy3 Aspa2;PF04952;b;5.0;100;5.0;100;3nfz_A;3nh8_A;0.35;0.44
3nfz;2;3nh5;1;3nh4;1;b;1;604;99;100;606;99;100;0.39;0.39;100;0;2.094;2.0;diffraction;diffraction;654;654;Aspartoacylase-2;Aspartoacylase-2;MUS MUSCULUS;MUS MUSCULUS;ZN   zinc ion| CL   chloride ion| ACT   acetate ion| FMT   formic acid;ZN   zinc ion| CS   cesium ion| CL   chloride ion| ACT   acetate ion| FMT   formic acid;Crystal structure of E177A-mutant murine aminoacylase 3;Crystal structure of murine aminoacylase 3;Q91XE4;Acy3 Aspa2;PF04952;Q91XE4;Acy3 Aspa2;PF04952;b;5.0;100;5.0;100;3nfz_A;3nh8_A;0.35;0.44
2zuu;2;2zuu;2;3wfz;1;b;1;1474;99;100;1478;100;100;0.38;0.38;100;0;2.3;2.6;diffraction;diffraction;1518;1518;Lacto-N-biose phosphorylase;Lacto-N-biose phosphorylase;BIFIDOBACTERIUM LONGUM;BIFIDOBACTERIUM LONGUM;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose| GOL   glycerol| MG   magnesium ion;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc;Crystal structure of Galacto-N-Biose/Lacto-N-Biose I Phosphorylase C236Y Mutant;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;b;6.5;95;6.5;95;2zus_C;2zuw_D;1.24;0.87
2zuu;2;2zuu;2;2zus;2;b;1;1472;99;99;1479;100;99;0.49;0.49;100;0;2.3;2.11;diffraction;diffraction;1518;1518;Lacto-N-biose phosphorylase;Lacto-N-biose phosphorylase;BIFIDOBACTERIUM LONGUM;BIFIDOBACTERIUM LONGUM;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose| GOL   glycerol| MG   magnesium ion;MG   magnesium ion;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;b;6.5;95;6.5;95;2zus_C;2zuw_D;1.24;0.87
2zuu;2;2zuu;2;2zuw;2;b;1;1443;97;99;1453;98;99;0.59;0.64;100;0;2.3;2.11;diffraction;diffraction;1518;1518;Lacto-N-biose phosphorylase;Lacto-N-biose phosphorylase;BIFIDOBACTERIUM LONGUM;BIFIDOBACTERIUM LONGUM;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose| GOL   glycerol| MG   magnesium ion;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose| GOL   glycerol| NO3   nitrate ion| MG   magnesium ion| SO4   sulfate ion;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc and sulfate;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;b;6.5;95;6.5;95;2zus_C;2zuw_D;1.24;0.87
2zuu;2;2zuu;2;2zut;2;b;1;1482;100;100;1483;100;100;0.18;0.18;100;0;2.3;1.9;diffraction;diffraction;1518;1518;Lacto-N-biose phosphorylase;Lacto-N-biose phosphorylase;BIFIDOBACTERIUM LONGUM;BIFIDOBACTERIUM LONGUM;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose| GOL   glycerol| MG   magnesium ion;A2G   n-acetyl-2-deoxy-2-amino-galactose| GOL   glycerol| NO3   nitrate ion| MG   magnesium ion;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GalNAc;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;b;6.5;95;6.5;95;2zus_C;2zuw_D;1.24;0.87
2zuu;2;3wfz;1;2zus;2;b;1;1470;99;99;1476;100;99;0.46;0.47;100;0;2.6;2.11;diffraction;diffraction;1518;1518;Lacto-N-biose phosphorylase;Lacto-N-biose phosphorylase;BIFIDOBACTERIUM LONGUM;BIFIDOBACTERIUM LONGUM;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose;MG   magnesium ion;Crystal structure of Galacto-N-Biose/Lacto-N-Biose I Phosphorylase C236Y Mutant;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;b;6.5;95;6.5;95;2zus_C;2zuw_D;1.24;0.87
2zuu;2;3wfz;1;2zuw;2;b;1;1438;97;98;1454;98;100;0.75;0.80;100;0;2.6;2.11;diffraction;diffraction;1518;1518;Lacto-N-biose phosphorylase;Lacto-N-biose phosphorylase;BIFIDOBACTERIUM LONGUM;BIFIDOBACTERIUM LONGUM;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose| GOL   glycerol| NO3   nitrate ion| MG   magnesium ion| SO4   sulfate ion;Crystal structure of Galacto-N-Biose/Lacto-N-Biose I Phosphorylase C236Y Mutant;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc and sulfate;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;b;6.5;95;6.5;95;2zus_C;2zuw_D;1.24;0.87
2zuu;2;3wfz;1;2zut;2;c;1;1474;100;99;1478;100;100;0.36;0.36;100;0;2.6;1.9;diffraction;diffraction;1518;1518;Lacto-N-biose phosphorylase;Lacto-N-biose phosphorylase;BIFIDOBACTERIUM LONGUM;BIFIDOBACTERIUM LONGUM;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose;A2G   n-acetyl-2-deoxy-2-amino-galactose| GOL   glycerol| NO3   nitrate ion| MG   magnesium ion;Crystal structure of Galacto-N-Biose/Lacto-N-Biose I Phosphorylase C236Y Mutant;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GalNAc;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;b;6.5;95;6.5;95;2zus_C;2zuw_D;1.24;0.87
2zuu;2;2zus;2;2zuw;2;b;1;1433;96;98;1453;98;99;0.82;0.87;100;0;2.11;2.11;diffraction;diffraction;1518;1518;Lacto-N-biose phosphorylase;Lacto-N-biose phosphorylase;BIFIDOBACTERIUM LONGUM;BIFIDOBACTERIUM LONGUM;MG   magnesium ion;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose| GOL   glycerol| NO3   nitrate ion| MG   magnesium ion| SO4   sulfate ion;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc and sulfate;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;b;6.5;95;6.5;95;2zus_C;2zuw_D;1.24;0.87
2zuu;2;2zus;2;2zut;2;b;1;1473;99;99;1479;99;100;0.45;0.45;100;0;2.11;1.9;diffraction;diffraction;1518;1518;Lacto-N-biose phosphorylase;Lacto-N-biose phosphorylase;BIFIDOBACTERIUM LONGUM;BIFIDOBACTERIUM LONGUM;MG   magnesium ion;A2G   n-acetyl-2-deoxy-2-amino-galactose| GOL   glycerol| NO3   nitrate ion| MG   magnesium ion;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GalNAc;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;b;6.5;95;6.5;95;2zus_C;2zuw_D;1.24;0.87
2zuu;2;2zuw;2;2zut;2;b;1;1442;99;97;1453;99;98;0.62;0.67;100;0;2.11;1.9;diffraction;diffraction;1518;1518;Lacto-N-biose phosphorylase;Lacto-N-biose phosphorylase;BIFIDOBACTERIUM LONGUM;BIFIDOBACTERIUM LONGUM;NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose| GOL   glycerol| NO3   nitrate ion| MG   magnesium ion| SO4   sulfate ion;A2G   n-acetyl-2-deoxy-2-amino-galactose| GOL   glycerol| NO3   nitrate ion| MG   magnesium ion;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GlcNAc and sulfate;Crystal structure of Galacto-N-biose/Lacto-N-biose I phosphorylase in complex with GalNAc;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;E8MF13;lnpA lnbp BLLJ_1623;PF09508,PF17386,PF17385;b;6.5;95;6.5;95;2zus_C;2zuw_D;1.24;0.87
3u8m;5;3u8m;3;3u8k;4;b;1;988;98;99;995;99;99;0.57;0.61;99;0;2.7;2.47;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;4qac;1;b;1;978;97;94;994;99;95;0.88;0.90;100;0;2.7;2.1;diffraction;diffraction;1050;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;4alx;2;b;1;989;98;97;1000;100;98;0.73;0.74;100;0;2.7;2.3;diffraction;diffraction;1050;1145;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;7.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;4qab;2;b;1;964;96;92;993;99;95;1.21;1.25;97;0;2.7;2.984;diffraction;diffraction;1050;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;2zju;1;b;1;989;98;95;1003;100;96;0.84;0.86;99;0;2.7;2.58;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;2zjv;1;b;1;993;99;96;1004;100;97;0.73;0.74;99;0;2.7;2.7;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;4qaa;1;b;1;955;95;92;976;97;94;1.03;1.06;100;0;2.7;2.7;diffraction;diffraction;1050;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;3u8l;1;b;1;994;99;98;999;99;99;0.50;0.52;100;0;2.7;2.32;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;3u8n;3;b;1;994;99;99;997;99;99;0.38;0.39;100;0;2.7;2.35;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;1uv6;1;b;1;996;99;97;1000;100;98;0.44;0.45;100;0;2.7;2.5;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;1ux2;2;b;1;995;99;96;1000;100;97;0.49;0.49;100;0;2.7;2.2;diffraction;diffraction;1050;1060;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;1uw6;2;b;1;998;99;97;1002;100;97;0.46;0.46;100;0;2.7;2.2;diffraction;diffraction;1050;1055;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;3wti;1;b;1;991;99;95;1004;100;97;0.80;0.81;99;0;2.7;2.68;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;3zdg;1;b;1;981;98;99;992;99;100;0.73;0.81;98;0;2.7;2.48;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;3wth;1;b;1;988;98;95;1003;100;96;0.85;0.87;99;0;2.7;2.54;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;3wtl;1;b;1;992;99;95;1004;100;97;0.78;0.82;99;0;2.7;2.3;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;3wtm;1;b;1;990;98;95;1003;100;97;0.81;0.83;99;0;2.7;2.48;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;3wto;1;b;1;995;99;97;1001;100;97;0.54;0.54;99;0;2.7;2.25;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;3wtj;1;b;1;991;99;95;1003;100;96;0.76;0.77;99;0;2.7;2.24;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8m;3;3wtk;1;b;1;991;99;95;1003;100;96;0.78;0.79;99;0;2.7;2.69;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09R   1-(6-bromopyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3920 (1-(6-bromopyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;4qac;1;b;1;979;98;94;993;99;95;0.82;0.84;100;0;2.47;2.1;diffraction;diffraction;1050;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;4alx;2;b;1;988;99;97;997;100;98;0.67;0.70;100;0;2.47;2.3;diffraction;diffraction;1050;1145;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;7.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;4qab;2;b;1;952;95;91;992;99;95;1.42;1.49;92;0;2.47;2.984;diffraction;diffraction;1050;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;2zju;1;b;1;988;99;95;1000;100;96;0.78;0.80;99;0;2.47;2.58;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;2zjv;1;b;1;990;99;95;1000;100;96;0.70;0.71;99;0;2.47;2.7;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;4qaa;1;b;1;953;95;92;974;97;94;1.03;1.06;99;0;2.47;2.7;diffraction;diffraction;1050;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;3u8l;1;b;1;991;99;98;996;100;98;0.49;0.51;100;0;2.47;2.32;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;3u8n;3;b;1;993;99;99;996;100;99;0.40;0.42;100;0;2.47;2.35;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;1uv6;1;b;1;994;99;97;998;100;97;0.47;0.47;100;0;2.47;2.5;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;1ux2;2;b;1;993;99;96;998;100;97;0.49;0.50;99;0;2.47;2.2;diffraction;diffraction;1050;1060;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;1uw6;2;b;1;994;99;96;1000;100;97;0.55;0.56;100;0;2.47;2.2;diffraction;diffraction;1050;1055;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;3wti;1;b;1;989;99;95;1000;100;96;0.75;0.76;98;0;2.47;2.68;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;3zdg;1;b;1;977;98;98;989;99;99;0.78;0.86;99;0;2.47;2.48;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;3wth;1;b;1;987;99;95;1000;100;96;0.79;0.80;98;0;2.47;2.54;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;3wtl;1;b;1;989;99;95;1000;100;96;0.73;0.75;99;0;2.47;2.3;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;3wtm;1;b;1;987;99;95;998;100;96;0.73;0.74;98;0;2.47;2.48;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;3wto;1;b;1;994;99;96;999;100;97;0.52;0.53;98;0;2.47;2.25;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;3wtj;1;b;1;988;99;95;1000;100;96;0.75;0.77;99;0;2.47;2.24;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8k;4;3wtk;1;b;1;988;99;95;1000;100;96;0.76;0.77;98;0;2.47;2.69;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09P   1-(5-ethoxypyridin-3-yl)-1,4-diazepane| SO4   sulfate ion| NAG   n-acetyl-d-glucosamine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3573 (1-(5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;4alx;2;b;1;986;94;97;1004;96;99;0.95;1.00;100;0;2.1;2.3;diffraction;diffraction;1085;1145;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;7.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;4qab;2;b;1;1030;98;99;1037;99;99;0.57;0.57;100;0;2.1;2.984;diffraction;diffraction;1085;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;2zju;1;b;1;993;95;96;1008;96;97;0.85;0.91;99;0;2.1;2.58;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;2zjv;1;b;1;994;95;96;1010;97;97;0.88;0.95;99;0;2.1;2.7;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;4qaa;1;b;1;1013;97;97;1021;98;98;0.62;0.65;100;0;2.1;2.7;diffraction;diffraction;1085;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;3u8l;1;b;1;984;94;97;1000;96;99;0.89;0.92;100;0;2.1;2.32;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;3u8n;3;b;1;981;94;98;997;95;99;0.90;0.92;100;0;2.1;2.35;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;1uv6;1;b;1;988;94;96;1004;96;98;0.90;0.92;100;0;2.1;2.5;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;1ux2;2;b;1;981;94;95;1005;96;97;1.09;1.14;97;0;2.1;2.2;diffraction;diffraction;1085;1060;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;1uw6;2;b;1;984;94;95;1005;96;97;1.02;1.05;99;0;2.1;2.2;diffraction;diffraction;1085;1055;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;3wti;1;b;1;995;95;96;1010;97;97;0.85;0.89;98;0;2.1;2.68;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;3zdg;1;b;1;973;93;98;989;95;99;0.90;0.91;100;0;2.1;2.48;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;3wth;1;b;1;994;95;95;1010;97;97;0.88;0.95;98;0;2.1;2.54;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;3wtl;1;b;1;995;95;96;1010;97;97;0.86;0.90;99;0;2.1;2.3;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;3wtm;1;b;1;995;95;96;1011;97;97;0.90;0.93;98;0;2.1;2.48;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;3wto;1;b;1;991;95;96;1006;96;98;0.85;0.90;98;0;2.1;2.25;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;3wtj;1;b;1;993;95;95;1009;96;97;0.88;0.94;98;0;2.1;2.24;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qac;1;3wtk;1;b;1;992;95;95;1008;96;97;0.90;0.95;98;0;2.1;2.69;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| KK3   4-(4-methylpiperidin-1-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| PO4   phosphate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(4-methylpiperidin-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrimidin-2-amine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;4qab;2;b;1;970;95;93;997;98;96;1.16;1.20;97;0;2.3;2.984;diffraction;diffraction;1145;1085;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;2zju;1;b;1;998;98;96;1013;100;97;0.86;0.89;99;0;2.3;2.58;diffraction;diffraction;1145;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;2zjv;1;b;1;1002;99;96;1013;100;97;0.73;0.75;99;0;2.3;2.7;diffraction;diffraction;1145;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;4qaa;1;b;1;964;95;93;984;97;95;1.00;1.04;100;0;2.3;2.7;diffraction;diffraction;1145;1085;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;3u8l;1;b;1;997;98;98;1008;99;100;0.75;0.77;100;0;2.3;2.32;diffraction;diffraction;1145;1050;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;3u8n;3;b;1;992;98;99;1000;98;100;0.64;0.66;100;0;2.3;2.35;diffraction;diffraction;1145;1050;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;1uv6;1;b;1;1000;98;98;1010;99;99;0.68;0.70;100;0;2.3;2.5;diffraction;diffraction;1145;1050;ACETYLCHOLINE BINDING PROTEIN;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;1ux2;2;b;1;999;98;97;1010;99;98;0.72;0.74;100;0;2.3;2.2;diffraction;diffraction;1145;1060;ACETYLCHOLINE BINDING PROTEIN;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;1uw6;2;b;1;1001;99;97;1010;99;98;0.66;0.68;100;0;2.3;2.2;diffraction;diffraction;1145;1055;ACETYLCHOLINE BINDING PROTEIN;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;3wti;1;b;1;999;98;96;1013;100;98;0.84;0.86;99;0;2.3;2.68;diffraction;diffraction;1145;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;3zdg;1;b;1;985;97;99;994;98;100;0.67;0.69;100;0;2.3;2.48;diffraction;diffraction;1145;1050;ACETYLCHOLINE BINDING PROTEIN;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;3wth;1;b;1;998;98;96;1013;100;97;0.85;0.87;99;0;2.3;2.54;diffraction;diffraction;1145;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;3wtl;1;b;1;1001;99;96;1012;100;97;0.73;0.74;99;0;2.3;2.3;diffraction;diffraction;1145;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;3wtm;1;b;1;1001;98;96;1013;100;98;0.78;0.80;99;0;2.3;2.48;diffraction;diffraction;1145;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;3wto;1;b;1;996;98;97;1010;99;98;0.84;0.86;99;0;2.3;2.25;diffraction;diffraction;1145;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;3wtj;1;b;1;997;98;96;1012;100;97;0.86;0.88;99;0;2.3;2.24;diffraction;diffraction;1145;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4alx;2;3wtk;1;b;1;999;98;96;1013;100;97;0.82;0.83;99;0;2.3;2.69;diffraction;diffraction;1145;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IZN   (4bs,6s)-6-methoxy-1,4,6,7,9,10,12,13-octahydro-3h,5h-pyrano[4',3':3,4]pyrido[2,1-i]indol-3-one| 1PE   pentaethylene glycol| MG   magnesium ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Ls-AChBP complexed with the potent nAChR antagonist DHbE;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;7.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;2zju;1;b;1;988;95;95;1003;96;96;0.86;0.88;99;0;2.984;2.58;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;2zjv;1;b;1;987;95;95;1004;96;97;0.91;0.94;99;0;2.984;2.7;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;4qaa;1;b;1;1014;97;97;1023;98;98;0.64;0.67;100;0;2.984;2.7;diffraction;diffraction;1085;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;3u8l;1;b;1;973;93;96;997;96;98;1.10;1.15;99;0;2.984;2.32;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;3u8n;3;b;1;960;92;96;993;95;99;1.28;1.33;96;0;2.984;2.35;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;1uv6;1;b;1;977;94;95;1000;96;98;1.06;1.08;100;0;2.984;2.5;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;1ux2;2;b;1;977;94;95;1001;96;97;1.08;1.11;100;0;2.984;2.2;diffraction;diffraction;1085;1060;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;1uw6;2;b;1;975;93;94;1001;96;97;1.13;1.16;100;0;2.984;2.2;diffraction;diffraction;1085;1055;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;3wti;1;b;1;986;95;95;1003;96;97;0.91;0.93;99;0;2.984;2.68;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;3zdg;1;b;1;965;93;97;989;95;99;1.09;1.11;100;0;2.984;2.48;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;3wth;1;b;1;987;95;95;1003;96;96;0.90;0.92;99;0;2.984;2.54;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;3wtl;1;b;1;986;95;95;1004;96;97;0.95;0.98;99;0;2.984;2.3;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;3wtm;1;b;1;987;95;95;1004;96;97;0.92;0.95;99;0;2.984;2.48;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;3wto;1;b;1;985;94;96;1003;96;97;0.95;0.97;99;0;2.984;2.25;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;3wtj;1;b;1;986;95;95;1004;96;97;0.94;0.97;99;0;2.984;2.24;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qab;2;3wtk;1;b;1;987;95;95;1003;96;96;0.90;0.92;99;0;2.984;2.69;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK2   4-(morpholin-4-yl)-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-RAY STRUCTURE of ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 4-(MORPHOLIN-4-YL)-6-[4-(TRIFLUOROMETHYL)PHENYL]PYRIMIDIN-2-AMINE;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;2zjv;1;b;1;1031;99;99;1038;100;100;0.58;0.60;100;0;2.58;2.7;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;4qaa;1;b;1;984;95;94;1001;96;96;0.92;0.98;99;0;2.58;2.7;diffraction;diffraction;1070;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;3u8l;1;b;1;998;96;99;1013;97;100;0.85;0.88;99;0;2.58;2.32;diffraction;diffraction;1070;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;3u8n;3;b;1;991;95;99;1004;97;100;0.81;0.82;99;0;2.58;2.35;diffraction;diffraction;1070;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;1uv6;1;b;1;1009;97;98;1025;99;100;0.87;0.89;99;0;2.58;2.5;diffraction;diffraction;1070;1050;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;1ux2;2;b;1;1014;98;98;1030;99;100;0.87;0.90;99;0;2.58;2.2;diffraction;diffraction;1070;1060;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;1uw6;2;b;1;1013;97;98;1032;99;100;0.94;0.97;98;0;2.58;2.2;diffraction;diffraction;1070;1055;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;3wti;1;b;1;1032;99;99;1037;100;100;0.48;0.49;100;0;2.58;2.68;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;3zdg;1;b;1;980;94;99;994;96;100;0.83;0.85;99;0;2.58;2.48;diffraction;diffraction;1070;1050;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;3wth;1;b;1;1036;100;100;1039;100;100;0.35;0.35;100;0;2.58;2.54;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;3wtl;1;b;1;1027;99;99;1039;100;100;0.76;0.80;98;0;2.58;2.3;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;3wtm;1;b;1;1028;99;99;1035;100;100;0.56;0.59;100;0;2.58;2.48;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;3wto;1;b;1;1018;98;99;1031;99;100;0.78;0.80;100;0;2.58;2.25;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;3wtj;1;b;1;1028;99;99;1039;100;100;0.72;0.75;98;0;2.58;2.24;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zju;1;3wtk;1;b;1;1036;100;100;1040;100;100;0.42;0.42;99;0;2.58;2.69;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;4qaa;1;b;1;982;94;94;1000;96;96;0.96;1.01;99;0;2.7;2.7;diffraction;diffraction;1070;1085;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;3u8l;1;b;1;1000;96;99;1013;97;100;0.78;0.80;99;0;2.7;2.32;diffraction;diffraction;1070;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;3u8n;3;b;1;995;96;99;1005;97;100;0.68;0.70;99;0;2.7;2.35;diffraction;diffraction;1070;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;1uv6;1;b;1;1013;97;99;1025;99;100;0.77;0.78;99;0;2.7;2.5;diffraction;diffraction;1070;1050;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;1ux2;2;b;1;1015;98;98;1028;99;100;0.78;0.80;99;0;2.7;2.2;diffraction;diffraction;1070;1060;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;1uw6;2;b;1;1019;98;99;1030;99;100;0.74;0.75;99;0;2.7;2.2;diffraction;diffraction;1070;1055;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;3wti;1;b;1;1030;99;99;1037;100;100;0.58;0.61;100;0;2.7;2.68;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;3zdg;1;b;1;985;95;99;994;96;100;0.66;0.67;99;0;2.7;2.48;diffraction;diffraction;1070;1050;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;3wth;1;b;1;1030;99;99;1038;100;100;0.60;0.63;100;0;2.7;2.54;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;3wtl;1;b;1;1034;99;99;1037;100;100;0.40;0.40;100;0;2.7;2.3;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;3wtm;1;b;1;1030;99;99;1035;100;100;0.47;0.49;100;0;2.7;2.48;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;3wto;1;b;1;1019;98;99;1029;99;100;0.68;0.69;100;0;2.7;2.25;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;3wtj;1;b;1;1026;99;99;1037;100;100;0.72;0.75;100;0;2.7;2.24;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;2zjv;1;3wtk;1;b;1;1034;99;99;1039;100;100;0.51;0.52;100;0;2.7;2.69;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein (Ls-AChBP) Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;3u8l;1;b;1;962;92;95;984;95;97;1.05;1.08;100;0;2.7;2.32;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;3u8n;3;b;1;956;92;95;978;94;97;1.05;1.07;100;0;2.7;2.35;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;1uv6;1;b;1;971;93;95;996;96;97;1.12;1.17;100;0;2.7;2.5;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;1ux2;2;b;1;970;93;94;995;96;96;1.12;1.17;100;0;2.7;2.2;diffraction;diffraction;1085;1060;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;1uw6;2;b;1;969;93;94;995;96;96;1.13;1.17;100;0;2.7;2.2;diffraction;diffraction;1085;1055;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;3wti;1;b;1;983;94;95;1002;96;97;0.97;1.02;99;0;2.7;2.68;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;3zdg;1;b;1;949;91;95;970;93;98;1.03;1.05;100;0;2.7;2.48;diffraction;diffraction;1085;1050;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;3wth;1;b;1;982;94;94;1000;96;96;0.94;0.99;99;0;2.7;2.54;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;3wtl;1;b;1;981;94;94;1000;96;96;0.97;1.02;99;0;2.7;2.3;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;3wtm;1;b;1;980;94;94;999;96;96;0.97;1.02;98;0;2.7;2.48;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;3wto;1;b;1;976;94;95;997;96;97;1.03;1.07;99;0;2.7;2.25;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;3wtj;1;b;1;982;94;94;999;96;96;0.92;0.98;99;0;2.7;2.24;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;4qaa;1;3wtk;1;b;1;981;94;94;998;96;96;0.92;0.97;99;0;2.7;2.69;diffraction;diffraction;1085;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;KK1   6-(4-methoxyphenyl)-n~4~-octylpyrimidine-2,4-diamine| NAG   n-acetyl-d-glucosamine| PO4   phosphate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-RAY STRUCTURE OF ACETYLCHOLINE BINDING PROTEIN (ACHBP) IN COMPLEX WITH 6-(4-Methoxyphenyl)-N4-octylpyrimidine-2,4-diamine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;3u8n;3;b;1;998;98;99;1002;99;100;0.45;0.47;100;0;2.32;2.35;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.0;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;1uv6;1;b;1;1006;99;98;1012;100;99;0.53;0.55;100;0;2.32;2.5;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;1ux2;2;b;1;1006;99;97;1012;100;98;0.55;0.56;100;0;2.32;2.2;diffraction;diffraction;1050;1060;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;1uw6;2;b;1;1005;99;97;1012;100;98;0.59;0.60;100;0;2.32;2.2;diffraction;diffraction;1050;1055;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;3wti;1;b;1;1000;99;96;1013;100;98;0.79;0.81;99;0;2.32;2.68;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;3zdg;1;b;1;989;98;99;993;98;100;0.46;0.46;100;0;2.32;2.48;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;3wth;1;b;1;998;99;96;1013;100;97;0.85;0.88;99;0;2.32;2.54;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;3wtl;1;b;1;999;99;96;1013;100;97;0.82;0.84;99;0;2.32;2.3;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;3wtm;1;b;1;999;99;96;1013;100;98;0.83;0.85;99;0;2.32;2.48;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;3wto;1;b;1;1004;99;97;1012;100;98;0.64;0.65;99;0;2.32;2.25;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;3wtj;1;b;1;999;99;96;1013;100;97;0.81;0.84;99;0;2.32;2.24;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8l;1;3wtk;1;b;1;1000;99;96;1013;100;97;0.81;0.83;99;0;2.32;2.69;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09Q   1-(5-phenylpyridin-3-yl)-1,4-diazepane| SO4   sulfate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3570 (1-(5-phenylpyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;1uv6;1;b;1;998;99;97;1002;100;98;0.44;0.44;100;0;2.35;2.5;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;1ux2;2;b;1;998;99;97;1002;100;97;0.46;0.46;100;0;2.35;2.2;diffraction;diffraction;1050;1060;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;1uw6;2;b;1;1000;100;97;1004;100;97;0.42;0.42;100;0;2.35;2.2;diffraction;diffraction;1050;1055;Acetylcholine-binding protein;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;3wti;1;b;1;993;99;96;1004;100;97;0.73;0.74;99;0;2.35;2.68;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;3zdg;1;b;1;991;99;100;994;99;100;0.42;0.46;100;0;2.35;2.48;diffraction;diffraction;1050;1050;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;3wth;1;b;1;991;99;95;1004;100;96;0.80;0.83;99;0;2.35;2.54;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;3wtl;1;b;1;994;99;96;1005;100;97;0.73;0.75;99;0;2.35;2.3;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;3wtm;1;b;1;992;99;96;1004;100;97;0.77;0.80;99;0;2.35;2.48;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;3wto;1;b;1;997;99;97;1003;100;97;0.52;0.53;99;0;2.35;2.25;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;3wtj;1;b;1;994;99;96;1005;100;97;0.74;0.75;99;0;2.35;2.24;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3u8n;3;3wtk;1;b;1;993;99;95;1005;100;97;0.76;0.78;99;0;2.35;2.69;diffraction;diffraction;1050;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;09S   1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane| NAG   n-acetyl-d-glucosamine| SO4   sulfate ion;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis in complex with NS3950 (1-(6-bromo-5-ethoxypyridin-3-yl)-1,4-diazepane);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.0;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uv6;1;1ux2;2;b;1;1021;100;99;1025;100;99;0.45;0.46;100;0;2.5;2.2;diffraction;diffraction;1050;1060;ACETYLCHOLINE-BINDING PROTEIN;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;X-ray structure of acetylcholine binding protein (AChBP);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uv6;1;1uw6;2;b;1;1018;99;99;1025;100;99;0.59;0.61;100;0;2.5;2.2;diffraction;diffraction;1050;1055;ACETYLCHOLINE-BINDING PROTEIN;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uv6;1;3wti;1;b;1;1012;99;97;1025;100;99;0.80;0.82;99;0;2.5;2.68;diffraction;diffraction;1050;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uv6;1;3zdg;1;b;1;991;97;100;994;97;100;0.40;0.41;100;0;2.5;2.48;diffraction;diffraction;1050;1050;ACETYLCHOLINE-BINDING PROTEIN;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uv6;1;3wth;1;b;1;1010;99;97;1025;100;98;0.85;0.87;99;0;2.5;2.54;diffraction;diffraction;1050;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uv6;1;3wtl;1;b;1;1011;99;97;1025;100;99;0.81;0.83;99;0;2.5;2.3;diffraction;diffraction;1050;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uv6;1;3wtm;1;b;1;1010;99;97;1025;100;99;0.84;0.85;99;0;2.5;2.48;diffraction;diffraction;1050;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uv6;1;3wto;1;b;1;1017;99;99;1025;100;99;0.63;0.64;99;0;2.5;2.25;diffraction;diffraction;1050;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uv6;1;3wtj;1;b;1;1012;99;97;1025;100;99;0.78;0.79;99;0;2.5;2.24;diffraction;diffraction;1050;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uv6;1;3wtk;1;b;1;1012;99;97;1025;100;98;0.80;0.82;99;0;2.5;2.69;diffraction;diffraction;1050;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CCE   2-[(aminocarbonyl)oxy]-n,n,n-trimethylethanaminium;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-ray structure of acetylcholine binding protein (AChBP) in complex with carbamylcholine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1ux2;2;1uw6;2;b;1;1023;99;99;1030;100;100;0.59;0.61;100;0;2.2;2.2;diffraction;diffraction;1060;1055;ACETYLCHOLINE BINDING PROTEIN;ACETYLCHOLINE-BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;X-ray structure of acetylcholine binding protein (AChBP);X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;8.00;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1ux2;2;3wti;1;b;1;1013;98;98;1026;99;99;0.78;0.79;98;0;2.2;2.68;diffraction;diffraction;1060;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;X-ray structure of acetylcholine binding protein (AChBP);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1ux2;2;3zdg;1;b;1;990;96;100;994;96;100;0.44;0.45;99;0;2.2;2.48;diffraction;diffraction;1060;1050;ACETYLCHOLINE BINDING PROTEIN;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;X-ray structure of acetylcholine binding protein (AChBP);Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1ux2;2;3wth;1;b;1;1014;98;97;1029;100;99;0.84;0.87;98;0;2.2;2.54;diffraction;diffraction;1060;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;X-ray structure of acetylcholine binding protein (AChBP);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1ux2;2;3wtl;1;b;1;1016;98;98;1030;100;99;0.83;0.85;99;0;2.2;2.3;diffraction;diffraction;1060;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-ray structure of acetylcholine binding protein (AChBP);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1ux2;2;3wtm;1;b;1;1011;98;97;1026;99;99;0.86;0.87;98;0;2.2;2.48;diffraction;diffraction;1060;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-ray structure of acetylcholine binding protein (AChBP);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1ux2;2;3wto;1;b;1;1021;99;99;1030;100;100;0.65;0.66;98;0;2.2;2.25;diffraction;diffraction;1060;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;X-ray structure of acetylcholine binding protein (AChBP);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1ux2;2;3wtj;1;b;1;1017;99;98;1030;100;99;0.78;0.80;99;0;2.2;2.24;diffraction;diffraction;1060;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-ray structure of acetylcholine binding protein (AChBP);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1ux2;2;3wtk;1;b;1;1017;99;98;1030;100;99;0.80;0.82;98;0;2.2;2.69;diffraction;diffraction;1060;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NAG   n-acetyl-d-glucosamine| SO4   sulfate ion| NH4   ammonium ion| EPE   4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-ray structure of acetylcholine binding protein (AChBP);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uw6;2;3wti;1;b;1;1014;98;98;1029;100;99;0.85;0.87;98;0;2.2;2.68;diffraction;diffraction;1055;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uw6;2;3zdg;1;b;1;991;96;100;994;96;100;0.36;0.37;99;0;2.2;2.48;diffraction;diffraction;1055;1050;ACETYLCHOLINE-BINDING PROTEIN;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uw6;2;3wth;1;b;1;1014;98;97;1032;100;99;0.93;0.97;98;0;2.2;2.54;diffraction;diffraction;1055;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uw6;2;3wtl;1;b;1;1018;99;98;1031;100;99;0.78;0.79;99;0;2.2;2.3;diffraction;diffraction;1055;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uw6;2;3wtm;1;b;1;1012;98;97;1027;100;99;0.85;0.87;98;0;2.2;2.48;diffraction;diffraction;1055;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uw6;2;3wto;1;b;1;1020;99;99;1031;100;100;0.71;0.73;98;0;2.2;2.25;diffraction;diffraction;1055;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uw6;2;3wtj;1;b;1;1019;99;98;1032;100;99;0.80;0.81;99;0;2.2;2.24;diffraction;diffraction;1055;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;1uw6;2;3wtk;1;b;1;1017;99;98;1032;100;99;0.84;0.86;98;0;2.2;2.69;diffraction;diffraction;1055;1070;ACETYLCHOLINE-BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;NCT   (s)-3-(1-methylpyrrolidin-2-yl)pyridine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;X-ray structure of acetylcholine binding protein (AChBP) in complex with nicotine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.00;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wti;1;3zdg;1;b;1;984;95;99;994;96;100;0.72;0.73;98;0;2.68;2.48;diffraction;diffraction;1070;1050;Acetylcholine-binding protein;ACETYLCHOLINE BINDING PROTEIN;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wti;1;3wth;1;b;1;1033;100;99;1037;100;100;0.43;0.44;100;0;2.68;2.54;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wti;1;3wtl;1;b;1;1021;98;98;1035;100;100;0.80;0.82;100;0;2.68;2.3;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wti;1;3wtm;1;b;1;1028;99;99;1035;100;100;0.58;0.61;100;0;2.68;2.48;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wti;1;3wto;1;b;1;1016;98;99;1028;99;100;0.76;0.77;100;0;2.68;2.25;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wti;1;3wtj;1;b;1;1024;99;98;1036;100;100;0.77;0.80;100;0;2.68;2.24;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wti;1;3wtk;1;b;1;1034;100;99;1038;100;100;0.45;0.47;100;0;2.68;2.69;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;CT4   1-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-methyl-2-nitroguanidine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Clothianidin;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3zdg;1;3wth;1;b;1;981;99;94;994;100;95;0.81;0.83;98;0;2.48;2.54;diffraction;diffraction;1050;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3zdg;1;3wtl;1;b;1;984;99;95;994;100;96;0.70;0.71;99;0;2.48;2.3;diffraction;diffraction;1050;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3zdg;1;3wtm;1;b;1;982;99;95;994;100;96;0.77;0.79;98;0;2.48;2.48;diffraction;diffraction;1050;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3zdg;1;3wto;1;b;1;988;99;96;994;100;96;0.53;0.53;98;0;2.48;2.25;diffraction;diffraction;1050;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.5;100;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3zdg;1;3wtj;1;b;1;984;99;95;994;100;96;0.69;0.70;99;0;2.48;2.24;diffraction;diffraction;1050;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.5;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3zdg;1;3wtk;1;b;1;983;99;94;994;100;95;0.74;0.75;98;0;2.48;2.69;diffraction;diffraction;1050;1070;ACETYLCHOLINE BINDING PROTEIN;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;XRX   3-(dimethylamino)butyl dimethylcarbamate| NAG   n-acetyl-d-glucosamine| PEG   di(hydroxyethyl)ether| SO4   sulfate ion| 1PE   pentaethylene glycol;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Ls-AChBP complexed with carbamoylcholine analogue 3-(dimethylamino)butyl dimethylcarbamate (DMABC);Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wth;1;3wtl;1;b;1;1033;99;99;1040;100;100;0.58;0.60;100;0;2.54;2.3;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wth;1;3wtm;1;b;1;1025;98;99;1036;100;100;0.73;0.77;100;0;2.54;2.48;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wth;1;3wto;1;b;1;1018;98;99;1031;99;100;0.77;0.79;100;0;2.54;2.25;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wth;1;3wtj;1;b;1;1031;99;99;1038;100;100;0.58;0.60;99;0;2.54;2.24;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wth;1;3wtk;1;b;1;1037;100;100;1041;100;100;0.44;0.46;100;0;2.54;2.69;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;IM4   (2e)-1-[(6-chloropyridin-3-yl)methyl]-n-nitroimidazolidin-2-imine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wtl;1;3wtm;1;b;1;1023;98;99;1034;99;100;0.71;0.74;100;0;2.3;2.48;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wtl;1;3wto;1;b;1;1020;98;99;1031;99;100;0.72;0.73;100;0;2.3;2.25;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wtl;1;3wtj;1;b;1;1033;99;99;1039;100;100;0.54;0.55;100;0;2.3;2.24;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wtl;1;3wtk;1;b;1;1034;99;99;1040;100;100;0.53;0.56;100;0;2.3;2.69;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Nitromethylene Analogue of Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wtm;1;3wto;1;b;1;1016;98;99;1027;99;100;0.73;0.75;100;0;2.48;2.25;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;8.5;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wtm;1;3wtj;1;b;1;1027;99;99;1034;100;99;0.60;0.61;100;0;2.48;2.24;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wtm;1;3wtk;1;b;1;1027;99;99;1036;100;100;0.64;0.68;99;0;2.48;2.69;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;N1Y   2-chloro-5-{[(2e)-2-(nitromethylidene)imidazolidin-1-yl]methyl}pyridine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Nitromethylene Analogue of Imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;90;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wto;1;3wtj;1;b;1;1021;99;98;1031;100;99;0.69;0.70;100;0;2.25;2.24;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.5;100;5.7;100;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wto;1;3wtk;1;b;1;1020;99;98;1031;100;99;0.73;0.74;100;0;2.25;2.69;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;N2Y   (2z)-1-[(6-chloropyridin-3-yl)methyl]imidazolidin-2-imine;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Desnitro-imidacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;8.5;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
3u8m;5;3wtj;1;3wtk;1;b;1;1034;99;99;1040;100;100;0.53;0.54;100;0;2.24;2.69;diffraction;diffraction;1070;1070;Acetylcholine-binding protein;Acetylcholine-binding protein;LYMNAEA STAGNALIS;LYMNAEA STAGNALIS;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;TH4   {(2z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide;Crystal Structure of Lymnaea stagnalis Acetylcholine Binding Protein Complexed with Thiacloprid;Crystal Structure of Lymnaea stagnalis Acetylcholine-Binding Protein Q55R Mutant Complexed with Thiacloprid;P58154;no/data;PF02931;P58154;no/data;PF02931;a;5.7;100;5.7;90;3u8m_F;4qab_G;2.06;1.49
4l4y;2;4l4y;1;4l51;1;b;1;472;99;96;474;99;96;0.40;0.40;100;0;1.9;1.9;diffraction;diffraction;532;532;Transcriptional regulator LsrR;Transcriptional regulator LsrR;ESCHERICHIA COLI;ESCHERICHIA COLI;no/data;HSX   5-o-phosphono-alpha-d-ribofuranose;Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition;Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition;P76141;lsrR ydeW b1512 JW1505;PF04198;P76141;lsrR ydeW b1512 JW1505;PF04198;b;6.5;100;6.5;100;4l4y_B;4l50_B;0.54;0.53
4l4y;2;4l4y;1;4l50;1;b;1;472;99;95;475;100;96;0.52;0.53;100;0;1.9;2.1;diffraction;diffraction;532;532;Transcriptional regulator LsrR;Transcriptional regulator LsrR;ESCHERICHIA COLI;ESCHERICHIA COLI;no/data;D8X   (2s)-2,3,3-trihydroxy-6-methyl-4-oxoheptyl dihydrogen phosphate;Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition;Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition;P76141;lsrR ydeW b1512 JW1505;PF04198;P76141;lsrR ydeW b1512 JW1505;PF04198;b;6.5;100;6.5;100;4l4y_B;4l50_B;0.54;0.53
4l4y;2;4l51;1;4l50;1;b;1;491;99;99;494;100;100;0.53;0.53;100;0;1.9;2.1;diffraction;diffraction;532;532;Transcriptional regulator LsrR;Transcriptional regulator LsrR;ESCHERICHIA COLI;ESCHERICHIA COLI;HSX   5-o-phosphono-alpha-d-ribofuranose;D8X   (2s)-2,3,3-trihydroxy-6-methyl-4-oxoheptyl dihydrogen phosphate;Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition;Crystal structures of the LsrR proteins complexed with phospho-AI-2 and its two different analogs reveal distinct mechanisms for ligand recognition;P76141;lsrR ydeW b1512 JW1505;PF04198;P76141;lsrR ydeW b1512 JW1505;PF04198;b;6.5;100;6.5;100;4l4y_B;4l50_B;0.54;0.53
1wb8;4;1wb8;1;1wb7;1;b;1;818;100;100;820;100;100;0.31;0.31;100;0;2.3;2.24;diffraction;diffraction;840;840;SUPEROXIDE DISMUTASE [FE];SUPEROXIDE DISMUTASE [FE];SULFOLOBUS SOLFATARICUS;SULFOLOBUS SOLFATARICUS;FE   fe (iii) ion| PMS   phenylmethanesulfonic acid;FE   fe (iii) ion;IRON SUPEROXIDE DISMUTASE (FE-SOD) FROM THE HYPERTHERMOPHILE SULFOLOBUS SOLFATARICUS. 2.3 A RESOLUTION STRUCTURE OF RECOMBINANT PROTEIN WITH A COVALENTLY MODIFIED TYROSIN IN THE ACTIVE SITE.;Iron Superoxide Dismutase (Fe-SOD) From The Hyperthermophile Sulfolobus Solfataricus. Crystal Structure of the Y41F mutant.;P80857;sod SSO0316;PF02777,PF00081;P80857;sod SSO0316;PF02777,PF00081;b;8.50;294;8.50;100;1wb8_A;1wb7_A;0.24;0.31
3ta0;3;3ta0;1;3ta2;2;b;1;283;97;87;285;97;87;0.54;0.55;100;0;2.3;1.9;diffraction;diffraction;354;354;Nitrogen regulatory protein P-II (GlnB-3);Nitrogen regulatory protein P-II (GlnB-3);ARCHAEOGLOBUS FULGIDUS;ARCHAEOGLOBUS FULGIDUS;ATP   adenosine-5'-triphosphate;MG   magnesium ion| AKG   2-oxoglutaric acid| ATP   adenosine-5'-triphosphate| NI   nickel (ii) ion;A. fulgidus GlnK3, MgATP complex;A. fulgidus GlnK3, MgATP/2-OG complex;O28524;AF_1750;PF00543;O28524;AF_1750;PF00543;b;3.5;100;4.6;100;3ta2_B;3ta1_D;1.81;1.45
3ta0;3;3ta0;1;3o8w;1;b;1;288;98;92;290;99;93;0.60;0.62;99;0;2.3;2.28;diffraction;diffraction;354;354;Nitrogen regulatory protein P-II (GlnB-3);Nitrogen regulatory protein P-II (GlnB-1);ARCHAEOGLOBUS FULGIDUS;ARCHAEOGLOBUS FULGIDUS;ATP   adenosine-5'-triphosphate;ACT   acetate ion;A. fulgidus GlnK3, MgATP complex;Archaeoglobus fulgidus GlnK1;O28524;AF_1750;PF00543;O29284;AF_0978;PF00543;b;3.5;100;5.5;100;3ta2_B;3ta1_D;1.81;1.45
3ta0;3;3ta0;1;3ta1;2;b;1;291;99;88;292;100;88;0.49;0.49;100;0;2.3;1.9;diffraction;diffraction;354;354;Nitrogen regulatory protein P-II (GlnB-3);Nitrogen regulatory protein P-II (GlnB-3);ARCHAEOGLOBUS FULGIDUS;ARCHAEOGLOBUS FULGIDUS;ATP   adenosine-5'-triphosphate;ADP   adenosine-5'-diphosphate;A. fulgidus GlnK3, MgATP complex;A. fulgidus GlnK3, MgADP complex;O28524;AF_1750;PF00543;O28524;AF_1750;PF00543;b;3.5;100;3.5;100;3ta2_B;3ta1_D;1.81;1.45
3ta0;3;3ta0;1;3t9z;2;b;1;281;96;100;282;96;100;0.49;0.51;100;0;2.3;1.82;diffraction;diffraction;354;354;Nitrogen regulatory protein P-II (GlnB-3);Nitrogen regulatory protein P-II (GlnB-3);ARCHAEOGLOBUS FULGIDUS;ARCHAEOGLOBUS FULGIDUS;ATP   adenosine-5'-triphosphate;FLC   citrate anion;A. fulgidus GlnK3, MgATP complex;A. fulgidus GlnK3, ligand-free;O28524;AF_1750;PF00543;O28524;AF_1750;PF00543;b;3.5;100;3.5;100;3ta2_B;3ta1_D;1.81;1.45
3ta0;3;3ta2;2;3o8w;1;b;1;286;87;92;288;88;92;0.63;0.66;99;0;1.9;2.28;diffraction;diffraction;354;354;Nitrogen regulatory protein P-II (GlnB-3);Nitrogen regulatory protein P-II (GlnB-1);ARCHAEOGLOBUS FULGIDUS;ARCHAEOGLOBUS FULGIDUS;MG   magnesium ion| AKG   2-oxoglutaric acid| ATP   adenosine-5'-triphosphate| NI   nickel (ii) ion;ACT   acetate ion;A. fulgidus GlnK3, MgATP/2-OG complex;Archaeoglobus fulgidus GlnK1;O28524;AF_1750;PF00543;O29284;AF_0978;PF00543;b;4.6;100;5.5;100;3ta2_B;3ta1_D;1.81;1.45
3ta0;3;3ta2;2;3ta1;2;b;1;292;89;89;302;92;92;1.28;1.45;100;0;1.9;1.9;diffraction;diffraction;354;354;Nitrogen regulatory protein P-II (GlnB-3);Nitrogen regulatory protein P-II (GlnB-3);ARCHAEOGLOBUS FULGIDUS;ARCHAEOGLOBUS FULGIDUS;MG   magnesium ion| AKG   2-oxoglutaric acid| ATP   adenosine-5'-triphosphate| NI   nickel (ii) ion;ADP   adenosine-5'-diphosphate;A. fulgidus GlnK3, MgATP/2-OG complex;A. fulgidus GlnK3, MgADP complex;O28524;AF_1750;PF00543;O28524;AF_1750;PF00543;b;4.6;100;3.5;100;3ta2_B;3ta1_D;1.81;1.45
3ta0;3;3ta2;2;3t9z;2;b;1;276;84;98;277;85;98;0.43;0.43;100;0;1.9;1.82;diffraction;diffraction;354;354;Nitrogen regulatory protein P-II (GlnB-3);Nitrogen regulatory protein P-II (GlnB-3);ARCHAEOGLOBUS FULGIDUS;ARCHAEOGLOBUS FULGIDUS;MG   magnesium ion| AKG   2-oxoglutaric acid| ATP   adenosine-5'-triphosphate| NI   nickel (ii) ion;FLC   citrate anion;A. fulgidus GlnK3, MgATP/2-OG complex;A. fulgidus GlnK3, ligand-free;O28524;AF_1750;PF00543;O28524;AF_1750;PF00543;b;4.6;100;3.5;100;3ta2_B;3ta1_D;1.81;1.45
3ta0;3;3o8w;1;3ta1;2;b;1;290;93;88;294;94;89;0.78;0.83;99;0;2.28;1.9;diffraction;diffraction;354;354;Nitrogen regulatory protein P-II (GlnB-1);Nitrogen regulatory protein P-II (GlnB-3);ARCHAEOGLOBUS FULGIDUS;ARCHAEOGLOBUS FULGIDUS;ACT   acetate ion;ADP   adenosine-5'-diphosphate;Archaeoglobus fulgidus GlnK1;A. fulgidus GlnK3, MgADP complex;O29284;AF_0978;PF00543;O28524;AF_1750;PF00543;b;5.5;100;3.5;100;3ta2_B;3ta1_D;1.81;1.45
3ta0;3;3o8w;1;3t9z;2;b;1;281;90;100;282;90;100;0.33;0.33;99;0;2.28;1.82;diffraction;diffraction;354;354;Nitrogen regulatory protein P-II (GlnB-1);Nitrogen regulatory protein P-II (GlnB-3);ARCHAEOGLOBUS FULGIDUS;ARCHAEOGLOBUS FULGIDUS;ACT   acetate ion;FLC   citrate anion;Archaeoglobus fulgidus GlnK1;A. fulgidus GlnK3, ligand-free;O29284;AF_0978;PF00543;O28524;AF_1750;PF00543;b;5.5;100;3.5;100;3ta2_B;3ta1_D;1.81;1.45
3ta0;3;3ta1;2;3t9z;2;b;1;282;85;100;282;85;100;0.26;0.26;100;0;1.9;1.82;diffraction;diffraction;354;354;Nitrogen regulatory protein P-II (GlnB-3);Nitrogen regulatory protein P-II (GlnB-3);ARCHAEOGLOBUS FULGIDUS;ARCHAEOGLOBUS FULGIDUS;ADP   adenosine-5'-diphosphate;FLC   citrate anion;A. fulgidus GlnK3, MgADP complex;A. fulgidus GlnK3, ligand-free;O28524;AF_1750;PF00543;O28524;AF_1750;PF00543;b;3.5;100;3.5;100;3ta2_B;3ta1_D;1.81;1.45
3lia;2;3lia;3;3li8;2;b;1;523;100;99;525;100;100;0.41;0.41;100;0;1.99;1.75;diffraction;diffraction;582;582;Hypothetical sensory transduction histidine kinase;Hypothetical sensory transduction histidine kinase;METHANOSARCINA MAZEI;METHANOSARCINA MAZEI;BTB   2-[bis-(2-hydroxy-ethyl)-amino]-2-hydroxymethyl-propane-1,3-diol| SO4   sulfate ion;MSE   selenomethionine| EDO   1,2-ethanediol| SO4   sulfate ion;Crystal Structure of the extracellular domain of the putative histidine kinase mmHK1S-Z2;Crystal Structure of the extracellular domain of the putative histidine kinase mmHK1S-Z2;Q8PSW8;MM_2955;PF02743,PF00672,PF02518,PF07568,PF08447;Q8PSW8;MM_2955;PF02743,PF00672,PF02518,PF07568,PF08447;b;5.6;100;5.6;100;3lia_A;3lia_B;0.50;0.41
3lia;2;3lia;3;3li9;2;b;1;522;100;100;524;100;100;0.39;0.39;100;0;1.99;1.7;diffraction;diffraction;582;582;Hypothetical sensory transduction histidine kinase;Hypothetical sensory transduction histidine kinase;METHANOSARCINA MAZEI;METHANOSARCINA MAZEI;BTB   2-[bis-(2-hydroxy-ethyl)-amino]-2-hydroxymethyl-propane-1,3-diol| SO4   sulfate ion;MSE   selenomethionine| BTB   2-[bis-(2-hydroxy-ethyl)-amino]-2-hydroxymethyl-propane-1,3-diol;Crystal Structure of the extracellular domain of the putative histidine kinase mmHK1S-Z2;Crystal Structure of the extracellular domain of the putative histidine kinase mmHK1S-Z2;Q8PSW8;MM_2955;PF02743,PF00672,PF02518,PF07568,PF08447;Q8PSW8;MM_2955;PF02743,PF00672,PF02518,PF07568,PF08447;b;5.6;100;5.6;100;3lia_A;3lia_B;0.50;0.41
3lia;2;3li8;2;3li9;2;b;1;523;99;100;524;100;100;0.25;0.25;100;0;1.75;1.7;diffraction;diffraction;582;582;Hypothetical sensory transduction histidine kinase;Hypothetical sensory transduction histidine kinase;METHANOSARCINA MAZEI;METHANOSARCINA MAZEI;MSE   selenomethionine| EDO   1,2-ethanediol| SO4   sulfate ion;MSE   selenomethionine| BTB   2-[bis-(2-hydroxy-ethyl)-amino]-2-hydroxymethyl-propane-1,3-diol;Crystal Structure of the extracellular domain of the putative histidine kinase mmHK1S-Z2;Crystal Structure of the extracellular domain of the putative histidine kinase mmHK1S-Z2;Q8PSW8;MM_2955;PF02743,PF00672,PF02518,PF07568,PF08447;Q8PSW8;MM_2955;PF02743,PF00672,PF02518,PF07568,PF08447;b;5.6;100;5.6;100;3lia_A;3lia_B;0.50;0.41
3atf;4;3atf;1;3agw;1;b;1;771;100;98;772;100;98;0.22;0.22;100;0;2.95;2.2;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;CS   cesium ion| MG   magnesium ion| EOH   ethanol;MG   magnesium ion| EOH   ethanol;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 200 mM Cesium chloride);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 in the absence of Na+;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atf;1;3at8;1;b;1;771;100;98;772;100;98;0.22;0.22;100;0;2.95;3.3;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;CS   cesium ion| MG   magnesium ion| EOH   ethanol;BA   barium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 200 mM Cesium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atf;1;3at9;1;b;1;771;100;98;772;100;98;0.22;0.22;100;0;2.95;3.3;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;CS   cesium ion| MG   magnesium ion| EOH   ethanol;MG   magnesium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 200 mM Cesium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atf;1;3ata;1;b;1;771;100;98;772;100;98;0.24;0.24;100;0;2.95;3.49;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;CS   cesium ion| MG   magnesium ion| EOH   ethanol;BA   barium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 200 mM Cesium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM Spermine);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atf;1;2e4f;1;b;1;708;92;93;728;94;95;1.16;1.22;99;0;2.95;2.302;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;CS   cesium ion| MG   magnesium ion| EOH   ethanol;no/data;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 200 mM Cesium chloride);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.0;90;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atf;1;3atb;1;b;1;771;100;98;772;100;98;0.26;0.26;100;0;2.95;3.51;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;CS   cesium ion| MG   magnesium ion| EOH   ethanol;GD   gadolinium atom;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 200 mM Cesium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atf;1;3ate;1;b;1;770;100;98;772;100;98;0.31;0.31;100;0;2.95;3.2;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;CS   cesium ion| MG   magnesium ion| EOH   ethanol;PR   praseodymium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 200 mM Cesium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM praseodymium (III) acetate);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atf;1;3atd;1;b;1;771;100;98;772;100;98;0.22;0.22;100;0;2.95;3.01;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;CS   cesium ion| MG   magnesium ion| EOH   ethanol;GD   gadolinium atom;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 200 mM Cesium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atf;1;3vsq;1;b;1;739;96;94;748;97;95;0.78;0.80;99;0;2.95;2.0;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;CS   cesium ion| MG   magnesium ion| EOH   ethanol;BME   beta-mercaptoethanol| MG   magnesium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 200 mM Cesium chloride);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 E236R Mutant in the presence of ethanol;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.5;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3agw;1;3at8;1;b;1;783;100;100;784;100;100;0.26;0.26;100;0;2.2;3.3;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion| EOH   ethanol;BA   barium ion;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 in the absence of Na+;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3agw;1;3at9;1;b;1;783;100;100;784;100;100;0.24;0.24;100;0;2.2;3.3;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion| EOH   ethanol;MG   magnesium ion;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 in the absence of Na+;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3agw;1;3ata;1;b;1;783;100;100;784;100;100;0.23;0.23;100;0;2.2;3.49;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion| EOH   ethanol;BA   barium ion;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 in the absence of Na+;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM Spermine);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3agw;1;2e4f;1;b;1;709;90;93;728;93;95;1.13;1.16;99;0;2.2;2.302;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion| EOH   ethanol;no/data;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 in the absence of Na+;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.0;90;3agw_A;2e4f_A;1.18;1.22
3atf;4;3agw;1;3atb;1;b;1;783;100;100;784;100;100;0.27;0.27;100;0;2.2;3.51;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion| EOH   ethanol;GD   gadolinium atom;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 in the absence of Na+;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3agw;1;3ate;1;b;1;782;100;100;784;100;100;0.36;0.36;100;0;2.2;3.2;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion| EOH   ethanol;PR   praseodymium ion;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 in the absence of Na+;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM praseodymium (III) acetate);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3agw;1;3atd;1;b;1;783;100;100;784;100;100;0.23;0.23;100;0;2.2;3.01;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion| EOH   ethanol;GD   gadolinium atom;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 in the absence of Na+;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3agw;1;3vsq;1;b;1;738;94;94;748;95;95;0.81;0.85;99;0;2.2;2.0;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion| EOH   ethanol;BME   beta-mercaptoethanol| MG   magnesium ion;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 in the absence of Na+;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 E236R Mutant in the presence of ethanol;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.5;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at8;1;3at9;1;b;1;784;100;100;784;100;100;0.17;0.17;100;0;3.3;3.3;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;MG   magnesium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at8;1;3ata;1;b;1;783;100;100;784;100;100;0.18;0.18;100;0;3.3;3.49;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;BA   barium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM Spermine);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at8;1;2e4f;1;b;1;714;91;93;732;93;96;1.10;1.15;99;0;3.3;2.302;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;no/data;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.0;90;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at8;1;3atb;1;b;1;783;100;100;784;100;100;0.20;0.20;100;0;3.3;3.51;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;GD   gadolinium atom;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at8;1;3ate;1;b;1;783;100;100;784;100;100;0.28;0.28;100;0;3.3;3.2;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;PR   praseodymium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM praseodymium (III) acetate);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at8;1;3atd;1;b;1;783;100;100;784;100;100;0.21;0.21;100;0;3.3;3.01;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;GD   gadolinium atom;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at8;1;3vsq;1;b;1;739;94;94;748;95;95;0.78;0.81;99;0;3.3;2.0;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;BME   beta-mercaptoethanol| MG   magnesium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 E236R Mutant in the presence of ethanol;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.5;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at9;1;3ata;1;b;1;783;100;100;784;100;100;0.19;0.19;100;0;3.3;3.49;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion;BA   barium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM magnesium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM Spermine);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at9;1;2e4f;1;b;1;712;91;93;732;93;96;1.16;1.21;99;0;3.3;2.302;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion;no/data;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM magnesium chloride);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.0;90;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at9;1;3atb;1;b;1;783;100;100;784;100;100;0.22;0.22;100;0;3.3;3.51;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion;GD   gadolinium atom;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM magnesium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at9;1;3ate;1;b;1;783;100;100;784;100;100;0.29;0.29;100;0;3.3;3.2;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion;PR   praseodymium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM magnesium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM praseodymium (III) acetate);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at9;1;3atd;1;b;1;783;100;100;784;100;100;0.22;0.22;100;0;3.3;3.01;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion;GD   gadolinium atom;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM magnesium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3at9;1;3vsq;1;b;1;739;94;94;749;96;95;0.83;0.87;99;0;3.3;2.0;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;MG   magnesium ion;BME   beta-mercaptoethanol| MG   magnesium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM magnesium chloride);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 E236R Mutant in the presence of ethanol;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.5;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3ata;1;2e4f;1;b;1;713;91;93;732;93;96;1.14;1.19;99;0;3.49;2.302;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;no/data;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM Spermine);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.0;90;3agw_A;2e4f_A;1.18;1.22
3atf;4;3ata;1;3atb;1;b;1;783;100;100;784;100;100;0.21;0.21;100;0;3.49;3.51;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;GD   gadolinium atom;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM Spermine);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3ata;1;3ate;1;b;1;783;100;100;784;100;100;0.31;0.31;100;0;3.49;3.2;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;PR   praseodymium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM Spermine);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM praseodymium (III) acetate);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3ata;1;3atd;1;b;1;783;100;100;784;100;100;0.23;0.23;100;0;3.49;3.01;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;GD   gadolinium atom;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM Spermine);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3ata;1;3vsq;1;b;1;738;94;94;748;95;95;0.81;0.84;99;0;3.49;2.0;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;BA   barium ion;BME   beta-mercaptoethanol| MG   magnesium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM barium chloride and 10 mM Spermine);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 E236R Mutant in the presence of ethanol;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.5;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;2e4f;1;3atb;1;b;1;711;93;91;728;95;93;1.08;1.11;99;0;2.302;3.51;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;no/data;GD   gadolinium atom;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;7.0;90;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;2e4f;1;3ate;1;b;1;713;93;91;732;96;93;1.13;1.18;99;0;2.302;3.2;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;no/data;PR   praseodymium ion;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM praseodymium (III) acetate);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;7.0;90;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;2e4f;1;3atd;1;b;1;712;93;91;732;96;93;1.15;1.20;99;0;2.302;3.01;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;no/data;GD   gadolinium atom;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;7.0;90;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;2e4f;1;3vsq;1;b;1;733;96;93;752;98;95;1.13;1.18;99;0;2.302;2.0;diffraction;diffraction;832;832;G protein-activated inward rectifier potassium channel 2;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;no/data;BME   beta-mercaptoethanol| MG   magnesium ion;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2;Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 E236R Mutant in the presence of ethanol;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;7.0;90;7.5;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atb;1;3ate;1;b;1;783;100;100;784;100;100;0.24;0.24;100;0;3.51;3.2;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;GD   gadolinium atom;PR   praseodymium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM praseodymium (III) acetate);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atb;1;3atd;1;b;1;783;100;100;784;100;100;0.21;0.21;100;0;3.51;3.01;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;GD   gadolinium atom;GD   gadolinium atom;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atb;1;3vsq;1;b;1;741;94;94;753;96;96;0.90;0.97;99;0;3.51;2.0;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;GD   gadolinium atom;BME   beta-mercaptoethanol| MG   magnesium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 E236R Mutant in the presence of ethanol;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.5;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3ate;1;3atd;1;b;1;783;100;100;784;100;100;0.27;0.27;100;0;3.2;3.01;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;Potassium inwardly-rectifying channel, subfamily J, member 6;MUS MUSCULUS;MUS MUSCULUS;PR   praseodymium ion;GD   gadolinium atom;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM praseodymium (III) acetate);Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride and 10 mM magnesium chloride);P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;8.0;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3ate;1;3vsq;1;b;1;739;94;94;748;95;95;0.76;0.79;99;0;3.2;2.0;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;PR   praseodymium ion;BME   beta-mercaptoethanol| MG   magnesium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM praseodymium (III) acetate);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 E236R Mutant in the presence of ethanol;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.5;100;3agw_A;2e4f_A;1.18;1.22
3atf;4;3atd;1;3vsq;1;b;1;738;94;94;748;95;95;0.81;0.83;99;0;3.01;2.0;diffraction;diffraction;832;832;Potassium inwardly-rectifying channel, subfamily J, member 6;G protein-activated inward rectifier potassium channel 2;MUS MUSCULUS;MUS MUSCULUS;GD   gadolinium atom;BME   beta-mercaptoethanol| MG   magnesium ion;Crystal Structure of the Kir3.2 Cytoplasmic Domain (Na+-free crystal soaked in 10 mM Gadolinium chloride and 10 mM magnesium chloride);Crystal Structure of the Cytoplasmic Domain of G-Protein-Gated Inward Rectifier Potassium Channel Kir3.2 E236R Mutant in the presence of ethanol;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;P48542;Kcnj6 Girk2 Kcnj7 W;PF01007,PF17655;b;8.0;100;7.5;100;3agw_A;2e4f_A;1.18;1.22
1vpn;10;1vpn;2;1vps;2;b;1;2856;100;100;2858;100;100;0.19;0.19;100;0;2.0;1.9;diffraction;diffraction;2890;2890;POLYOMAVIRUS VP1 PENTAMER;POLYOMAVIRUS VP1 PENTAMER;MURINE POLYOMAVIRUS;MURINE POLYOMAVIRUS;no/data;SIA   o-sialic acid| GAL   beta-d-galactose| NAG   n-acetyl-d-glucosamine;UNASSEMBLED POLYOMAVIRUS VP1 PENTAMER;POLYOMAVIRUS VP1 PENTAMER COMPLEXED WITH A DISIALYLATED HEXASACCHARIDE;P49302;no/data;PF00718;P49302;no/data;PF00718;b;8.0;120;8.0;120;1vpn_B;1vps_C;0.47;0.19
1e12;3;1e12;1;2jaf;1;b;1;707;99;97;711;99;98;0.53;0.53;100;0;1.8;1.7;diffraction;diffraction;759;822;HALORHODOPSIN;Halorhodopsin;HALOBACTERIUM SALINARUM;HALOBACTERIUM SALINARUM (STRAIN ATCC 29341 / DSM 671 / R1);CL   chloride ion| K   potassium ion| RET   retinal| PLM   palmitic acid| OLC   (2r)-2,3-dihydroxypropyl (9z)-octadec-9-enoate;BOG   b-octylglucoside| CL   chloride ion| PLM   palmitic acid| RET   retinal;Halorhodopsin, a light-driven chloride pump;Ground state of halorhodopsin T203V;B0R2U4;hop OE_1299R;PF01036;B0R2U4;hop OE_1299R;PF01036;b;7.00;100;no/data;100;1e12_A;2jaf_A;0.44;0.53
3ux3;2;3ux3;1;3ux2;1;b;1;118;45;47;120;46;48;0.99;1.02;100;0;1.8;1.8;diffraction;diffraction;260;260;MIP18 family protein FAM96A;MIP18 family protein FAM96A;HOMO SAPIENS;HOMO SAPIENS;ZN   zinc ion| ACT   acetate ion;MSE   selenomethionine;Crystal Structure of Domain-Swapped Fam96a minor dimer;Crystal Structure of Domain-Swapped Fam96a Major dimer;Q9H5X1;CIAO2A CIA2A FAM96A;PF01883;Q9H5X1;CIAO2A CIA2A FAM96A;PF01883;c;4.7;100;7.5;100;3ux3_A;3ux3_B;0.38;1.02
3fb3;2;3fb3;1;3i3g;1;b;1;280;96;98;285;98;100;0.95;0.96;100;0;2.35;1.86;diffraction;diffraction;322;322;N-acetyltransferase;N-acetyltransferase;TRYPANOSOMA BRUCEI;TRYPANOSOMA BRUCEI;no/data;no/data;Crystal Structure of Trypanosoma Brucei Acetyltransferase, Tb11.01.2886;Crystal Structure of Trypanosoma brucei N-acetyltransferase (Tb11.01.2886) at 1.86A;Q383G8;Tb11.01.2886;PF00583;Q383G8;Tb11.01.2886;PF00583;b;7.5;100;no/data;100;3fb3_A;3i3g_A;0.97;0.96
2y3g;2;2y3g;1;2y3d;1;b;1;187;86;85;213;98;96;2.51;2.55;96;0;1.91;2.3;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;CUPRIAVIDUS METALLIDURANS;CUPRIAVIDUS METALLIDURANS;MSE   selenomethionine| ZN   zinc ion| CL   chloride ion| GOL   glycerol;ZN   zinc ion| CL   chloride ion;Se-Met form of Cupriavidus metallidurans CH34 CnrXs;Zn-bound form of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3g;1;2y39;1;b;1;199;91;90;214;98;97;1.92;1.95;100;0;1.91;1.41;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;CUPRIAVIDUS METALLIDURANS;CUPRIAVIDUS METALLIDURANS;MSE   selenomethionine| ZN   zinc ion| CL   chloride ion| GOL   glycerol;NI   nickel (ii) ion| ACT   acetate ion;Se-Met form of Cupriavidus metallidurans CH34 CnrXs;Ni-bound form of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3g;1;2y3b;1;b;1;193;89;87;214;98;96;2.24;2.27;100;0;1.91;1.554;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;CUPRIAVIDUS METALLIDURANS;CUPRIAVIDUS METALLIDURANS;MSE   selenomethionine| ZN   zinc ion| CL   chloride ion| GOL   glycerol;CO   cobalt (ii) ion| GOL   glycerol;Se-Met form of Cupriavidus metallidurans CH34 CnrXs;Co-bound form of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;8;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3g;1;3epv;1;b;1;216;99;99;218;100;100;0.73;0.75;100;0;1.91;1.742;diffraction;diffraction;236;218;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein cnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;MSE   selenomethionine| ZN   zinc ion| CL   chloride ion| GOL   glycerol;MSE   selenomethionine| CU   copper (ii) ion;Se-Met form of Cupriavidus metallidurans CH34 CnrXs;X-ray Structure of the Metal-sensor CnrX in both the Apo- and Copper-bound Forms;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3g;1;4wwf;2;b;1;208;95;98;212;97;100;0.99;0.99;99;0;1.91;1.1;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;MSE   selenomethionine| ZN   zinc ion| CL   chloride ion| GOL   glycerol;NI   nickel (ii) ion| NA   sodium ion;Se-Met form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of two Ni-bound forms of the M123C mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3g;1;2y3h;2;b;1;213;97;98;215;99;99;0.76;0.79;99;0;1.91;1.892;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;CUPRIAVIDUS METALLIDURANS;CUPRIAVIDUS METALLIDURANS;MSE   selenomethionine| ZN   zinc ion| CL   chloride ion| GOL   glycerol;GOL   glycerol;Se-Met form of Cupriavidus metallidurans CH34 CnrXs;E63Q mutant of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;8;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3g;1;4wwb;1;b;1;197;90;88;214;98;96;2.01;2.04;99;0;1.91;1.11;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;MSE   selenomethionine| ZN   zinc ion| CL   chloride ion| GOL   glycerol;NI   nickel (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;Se-Met form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of the Ni-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3g;1;4wwd;1;b;1;197;90;88;214;98;96;2.00;2.03;99;0;1.91;1.3;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;MSE   selenomethionine| ZN   zinc ion| CL   chloride ion| GOL   glycerol;CO   cobalt (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;Se-Met form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of the Co-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3d;1;2y39;1;b;1;203;92;92;216;98;98;1.73;1.80;95;0;2.3;1.41;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;CUPRIAVIDUS METALLIDURANS;CUPRIAVIDUS METALLIDURANS;ZN   zinc ion| CL   chloride ion;NI   nickel (ii) ion| ACT   acetate ion;Zn-bound form of Cupriavidus metallidurans CH34 CnrXs;Ni-bound form of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3d;1;2y3b;1;b;1;205;93;92;216;98;97;1.62;1.72;94;0;2.3;1.554;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;CUPRIAVIDUS METALLIDURANS;CUPRIAVIDUS METALLIDURANS;ZN   zinc ion| CL   chloride ion;CO   cobalt (ii) ion| GOL   glycerol;Zn-bound form of Cupriavidus metallidurans CH34 CnrXs;Co-bound form of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;8;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3d;1;3epv;1;c;1;184;83;84;211;95;97;2.60;2.65;96;0;2.3;1.742;diffraction;diffraction;236;218;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein cnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;ZN   zinc ion| CL   chloride ion;MSE   selenomethionine| CU   copper (ii) ion;Zn-bound form of Cupriavidus metallidurans CH34 CnrXs;X-ray Structure of the Metal-sensor CnrX in both the Apo- and Copper-bound Forms;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3d;1;4wwf;2;b;1;189;86;89;211;95;100;2.31;2.36;95;0;2.3;1.1;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;ZN   zinc ion| CL   chloride ion;NI   nickel (ii) ion| NA   sodium ion;Zn-bound form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of two Ni-bound forms of the M123C mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3d;1;2y3h;2;b;1;188;85;87;214;97;99;2.50;2.55;94;0;2.3;1.892;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;CUPRIAVIDUS METALLIDURANS;CUPRIAVIDUS METALLIDURANS;ZN   zinc ion| CL   chloride ion;GOL   glycerol;Zn-bound form of Cupriavidus metallidurans CH34 CnrXs;E63Q mutant of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;8;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3d;1;4wwb;1;b;1;203;92;91;216;98;96;1.76;1.84;94;0;2.3;1.11;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;ZN   zinc ion| CL   chloride ion;NI   nickel (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;Zn-bound form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of the Ni-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3d;1;4wwd;1;b;1;203;92;91;216;98;96;1.76;1.85;94;0;2.3;1.3;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;ZN   zinc ion| CL   chloride ion;CO   cobalt (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;Zn-bound form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of the Co-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y39;1;2y3b;1;b;1;216;98;97;220;100;99;0.96;0.96;100;0;1.41;1.554;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;CUPRIAVIDUS METALLIDURANS;CUPRIAVIDUS METALLIDURANS;NI   nickel (ii) ion| ACT   acetate ion;CO   cobalt (ii) ion| GOL   glycerol;Ni-bound form of Cupriavidus metallidurans CH34 CnrXs;Co-bound form of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;8;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y39;1;3epv;1;b;1;198;90;91;214;97;98;1.93;1.96;100;0;1.41;1.742;diffraction;diffraction;236;218;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein cnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;NI   nickel (ii) ion| ACT   acetate ion;MSE   selenomethionine| CU   copper (ii) ion;Ni-bound form of Cupriavidus metallidurans CH34 CnrXs;X-ray Structure of the Metal-sensor CnrX in both the Apo- and Copper-bound Forms;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y39;1;4wwf;2;b;1;200;91;94;212;96;100;1.69;1.71;99;0;1.41;1.1;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;NI   nickel (ii) ion| ACT   acetate ion;NI   nickel (ii) ion| NA   sodium ion;Ni-bound form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of two Ni-bound forms of the M123C mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y39;1;2y3h;2;b;1;201;91;93;214;97;99;1.76;1.78;99;0;1.41;1.892;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;CUPRIAVIDUS METALLIDURANS;CUPRIAVIDUS METALLIDURANS;NI   nickel (ii) ion| ACT   acetate ion;GOL   glycerol;Ni-bound form of Cupriavidus metallidurans CH34 CnrXs;E63Q mutant of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;8;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y39;1;4wwb;1;b;1;220;100;98;220;100;98;0.20;0.20;99;0;1.41;1.11;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;NI   nickel (ii) ion| ACT   acetate ion;NI   nickel (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;Ni-bound form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of the Ni-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y39;1;4wwd;1;b;1;220;100;98;220;100;98;0.17;0.17;99;0;1.41;1.3;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;NI   nickel (ii) ion| ACT   acetate ion;CO   cobalt (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;Ni-bound form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of the Co-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3b;1;3epv;1;b;1;189;85;87;211;95;97;2.31;2.35;96;0;1.554;1.742;diffraction;diffraction;236;218;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein cnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;CO   cobalt (ii) ion| GOL   glycerol;MSE   selenomethionine| CU   copper (ii) ion;Co-bound form of Cupriavidus metallidurans CH34 CnrXs;X-ray Structure of the Metal-sensor CnrX in both the Apo- and Copper-bound Forms;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;8;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3b;1;4wwf;2;b;1;195;88;92;212;95;100;2.04;2.06;99;0;1.554;1.1;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;CO   cobalt (ii) ion| GOL   glycerol;NI   nickel (ii) ion| NA   sodium ion;Co-bound form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of two Ni-bound forms of the M123C mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;8;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3b;1;2y3h;2;b;1;196;88;90;214;96;99;2.08;2.11;99;0;1.554;1.892;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;CUPRIAVIDUS METALLIDURANS;CUPRIAVIDUS METALLIDURANS;CO   cobalt (ii) ion| GOL   glycerol;GOL   glycerol;Co-bound form of Cupriavidus metallidurans CH34 CnrXs;E63Q mutant of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;8;100;8;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3b;1;4wwb;1;b;1;218;98;97;222;100;99;0.96;0.97;99;0;1.554;1.11;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;CO   cobalt (ii) ion| GOL   glycerol;NI   nickel (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;Co-bound form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of the Ni-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;8;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3b;1;4wwd;1;b;1;218;98;97;222;100;99;0.98;0.99;99;0;1.554;1.3;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;CO   cobalt (ii) ion| GOL   glycerol;CO   cobalt (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;Co-bound form of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of the Co-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;8;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;3epv;1;4wwf;2;b;1;206;95;97;212;97;100;1.17;1.19;99;0;1.742;1.1;diffraction;diffraction;218;236;Nickel and cobalt resistance protein cnrR;Nickel and cobalt resistance protein CnrR;RALSTONIA METALLIDURANS;RALSTONIA METALLIDURANS;MSE   selenomethionine| CU   copper (ii) ion;NI   nickel (ii) ion| NA   sodium ion;X-ray Structure of the Metal-sensor CnrX in both the Apo- and Copper-bound Forms;High-resolution structure of two Ni-bound forms of the M123C mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;3epv;1;2y3h;2;b;1;214;98;98;215;99;99;0.58;0.60;99;0;1.742;1.892;diffraction;diffraction;218;236;Nickel and cobalt resistance protein cnrR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;RALSTONIA METALLIDURANS;CUPRIAVIDUS METALLIDURANS;MSE   selenomethionine| CU   copper (ii) ion;GOL   glycerol;X-ray Structure of the Metal-sensor CnrX in both the Apo- and Copper-bound Forms;E63Q mutant of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;8;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;3epv;1;4wwb;1;b;1;197;90;88;214;98;96;2.02;2.05;99;0;1.742;1.11;diffraction;diffraction;218;236;Nickel and cobalt resistance protein cnrR;Nickel and cobalt resistance protein CnrR;RALSTONIA METALLIDURANS;RALSTONIA METALLIDURANS;MSE   selenomethionine| CU   copper (ii) ion;NI   nickel (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;X-ray Structure of the Metal-sensor CnrX in both the Apo- and Copper-bound Forms;High-resolution structure of the Ni-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;3epv;1;4wwd;1;b;1;197;90;88;214;98;96;2.01;2.04;99;0;1.742;1.3;diffraction;diffraction;218;236;Nickel and cobalt resistance protein cnrR;Nickel and cobalt resistance protein CnrR;RALSTONIA METALLIDURANS;RALSTONIA METALLIDURANS;MSE   selenomethionine| CU   copper (ii) ion;CO   cobalt (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;X-ray Structure of the Metal-sensor CnrX in both the Apo- and Copper-bound Forms;High-resolution structure of the Co-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;4wwf;2;2y3h;2;b;1;207;98;95;212;100;98;1.08;1.10;98;0;1.1;1.892;diffraction;diffraction;236;236;Nickel and cobalt resistance protein CnrR;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;RALSTONIA METALLIDURANS;CUPRIAVIDUS METALLIDURANS;NI   nickel (ii) ion| NA   sodium ion;GOL   glycerol;High-resolution structure of two Ni-bound forms of the M123C mutant of C. metallidurans CnrXs;E63Q mutant of Cupriavidus metallidurans CH34 CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;8;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;4wwf;2;4wwb;1;b;1;199;94;89;212;100;95;1.77;1.79;98;0;1.1;1.11;diffraction;diffraction;236;236;Nickel and cobalt resistance protein CnrR;Nickel and cobalt resistance protein CnrR;RALSTONIA METALLIDURANS;RALSTONIA METALLIDURANS;NI   nickel (ii) ion| NA   sodium ion;NI   nickel (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;High-resolution structure of two Ni-bound forms of the M123C mutant of C. metallidurans CnrXs;High-resolution structure of the Ni-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;4wwf;2;4wwd;1;b;1;199;94;89;212;100;95;1.77;1.78;98;0;1.1;1.3;diffraction;diffraction;236;236;Nickel and cobalt resistance protein CnrR;Nickel and cobalt resistance protein CnrR;RALSTONIA METALLIDURANS;RALSTONIA METALLIDURANS;NI   nickel (ii) ion| NA   sodium ion;CO   cobalt (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;High-resolution structure of two Ni-bound forms of the M123C mutant of C. metallidurans CnrXs;High-resolution structure of the Co-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3h;2;4wwb;1;b;1;200;92;89;214;99;96;1.84;1.86;98;0;1.892;1.11;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;GOL   glycerol;NI   nickel (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;E63Q mutant of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of the Ni-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;8;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;2y3h;2;4wwd;1;b;1;200;92;89;214;99;96;1.83;1.85;98;0;1.892;1.3;diffraction;diffraction;236;236;NICKEL AND COBALT RESISTANCE PROTEIN CNRR;Nickel and cobalt resistance protein CnrR;CUPRIAVIDUS METALLIDURANS;RALSTONIA METALLIDURANS;GOL   glycerol;CO   cobalt (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;E63Q mutant of Cupriavidus metallidurans CH34 CnrXs;High-resolution structure of the Co-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;8;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
2y3g;2;4wwb;1;4wwd;1;b;1;224;100;100;224;100;100;0.08;0.08;100;0;1.11;1.3;diffraction;diffraction;236;236;Nickel and cobalt resistance protein CnrR;Nickel and cobalt resistance protein CnrR;RALSTONIA METALLIDURANS;RALSTONIA METALLIDURANS;NI   nickel (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;CO   cobalt (ii) ion| CL   chloride ion| CO2   carbon dioxide| K   potassium ion| FMT   formic acid;High-resolution structure of the Ni-bound form of the Y135F mutant of C. metallidurans CnrXs;High-resolution structure of the Co-bound form of the Y135F mutant of C. metallidurans CnrXs;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;P37975;cnrR cnrX Rmet_6206 RMe0087;PF13801;b;7.5;100;7.5;100;3epv_C;4wwf_A;2.17;2.65
3v4t;4;3v4t;2;1ryw;1;b;1;1659;99;99;1676;100;100;0.70;0.71;100;0;2.5;2.3;diffraction;diffraction;1676;1676;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;ENTEROBACTER CLOACAE;ENTEROBACTER CLOACAE;IAS   beta-l-aspartic acid| UD1   uridine-diphosphate-n-acetylglucosamine| ACT   acetate ion| EDO   1,2-ethanediol;IAS   beta-l-aspartic acid| PO4   phosphate ion| EPU   uridine-diphosphate-2(n-acetylglucosaminyl) butyric acid| GOL   glycerol;E. cloacae C115D MURA liganded with UNAG;C115S MurA liganded with reaction products;P33038;murA murZ ECL_04571;PF00275;P33038;murA murZ ECL_04571;PF00275;a;7.5;93;6.5;85;3v4t_D;1dlg_B;1.99;1.44
3v4t;4;3v4t;2;1q3g;3;b;1;1658;99;99;1676;100;100;0.73;0.73;100;0;2.5;2.65;diffraction;diffraction;1676;1676;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;ENTEROBACTER CLOACAE;ENTEROBACTER CLOACAE;IAS   beta-l-aspartic acid| UD1   uridine-diphosphate-n-acetylglucosamine| ACT   acetate ion| EDO   1,2-ethanediol;IAS   beta-l-aspartic acid| UDA   3'-1-carboxy-1-phosphonooxy-ethoxy-uridine-diphosphate-n-acetylglucosamine| EDO   1,2-ethanediol;E. cloacae C115D MURA liganded with UNAG;MurA (Asp305Ala) liganded with tetrahedral reaction intermediate;P33038;murA murZ ECL_04571;PF00275;P33038;murA murZ ECL_04571;PF00275;a;7.5;93;6.4;90;3v4t_D;1dlg_B;1.99;1.44
3v4t;4;3v4t;2;1dlg;3;b;1;397;24;24;413;25;25;1.37;1.40;100;0;2.5;1.9;diffraction;diffraction;1676;1676;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;UDP-N-ACETYLGLUCOSAMINE ENOLPYRUVYL TRANSFERASE MURA;ENTEROBACTER CLOACAE;ENTEROBACTER CLOACAE;IAS   beta-l-aspartic acid| UD1   uridine-diphosphate-n-acetylglucosamine| ACT   acetate ion| EDO   1,2-ethanediol;IAS   beta-l-aspartic acid| PO4   phosphate ion| HAI   cyclohexylammonium ion;E. cloacae C115D MURA liganded with UNAG;CRYSTAL STRUCTURE OF THE C115S ENTEROBACTER CLOACAE MURA IN THE UN-LIGANDED STATE;P33038;murA murZ ECL_04571;PF00275;P33038;murA murZ ECL_04571;PF00275;a;7.5;93;6.5;120;3v4t_D;1dlg_B;1.99;1.44
3v4t;4;3v4t;2;1ejd;3;b;1;397;24;24;412;25;25;1.36;1.39;100;0;2.5;1.55;diffraction;diffraction;1676;1676;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;UDP-N-ACETYLGLUCOSAMINE ENOLPYRUVYLTRANSFERASE;ENTEROBACTER CLOACAE;ENTEROBACTER CLOACAE;IAS   beta-l-aspartic acid| UD1   uridine-diphosphate-n-acetylglucosamine| ACT   acetate ion| EDO   1,2-ethanediol;IAS   beta-l-aspartic acid| PO4   phosphate ion| HAI   cyclohexylammonium ion;E. cloacae C115D MURA liganded with UNAG;Crystal structure of unliganded mura (type1);P33038;murA murZ ECL_04571;PF00275;P33038;murA murZ ECL_04571;PF00275;a;7.5;93;6.5;120;3v4t_D;1dlg_B;1.99;1.44
3v4t;4;1ryw;1;1q3g;3;b;1;1667;99;99;1676;100;100;0.50;0.51;100;0;2.3;2.65;diffraction;diffraction;1676;1676;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;ENTEROBACTER CLOACAE;ENTEROBACTER CLOACAE;IAS   beta-l-aspartic acid| PO4   phosphate ion| EPU   uridine-diphosphate-2(n-acetylglucosaminyl) butyric acid| GOL   glycerol;IAS   beta-l-aspartic acid| UDA   3'-1-carboxy-1-phosphonooxy-ethoxy-uridine-diphosphate-n-acetylglucosamine| EDO   1,2-ethanediol;C115S MurA liganded with reaction products;MurA (Asp305Ala) liganded with tetrahedral reaction intermediate;P33038;murA murZ ECL_04571;PF00275;P33038;murA murZ ECL_04571;PF00275;a;6.5;85;6.4;90;3v4t_D;1dlg_B;1.99;1.44
3v4t;4;1ryw;1;1dlg;3;b;1;397;24;24;412;25;25;1.34;1.37;100;0;2.3;1.9;diffraction;diffraction;1676;1676;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;UDP-N-ACETYLGLUCOSAMINE ENOLPYRUVYL TRANSFERASE MURA;ENTEROBACTER CLOACAE;ENTEROBACTER CLOACAE;IAS   beta-l-aspartic acid| PO4   phosphate ion| EPU   uridine-diphosphate-2(n-acetylglucosaminyl) butyric acid| GOL   glycerol;IAS   beta-l-aspartic acid| PO4   phosphate ion| HAI   cyclohexylammonium ion;C115S MurA liganded with reaction products;CRYSTAL STRUCTURE OF THE C115S ENTEROBACTER CLOACAE MURA IN THE UN-LIGANDED STATE;P33038;murA murZ ECL_04571;PF00275;P33038;murA murZ ECL_04571;PF00275;a;6.5;85;6.5;120;3v4t_D;1dlg_B;1.99;1.44
3v4t;4;1ryw;1;1ejd;3;b;1;397;24;24;412;25;25;1.35;1.38;100;0;2.3;1.55;diffraction;diffraction;1676;1676;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;UDP-N-ACETYLGLUCOSAMINE ENOLPYRUVYLTRANSFERASE;ENTEROBACTER CLOACAE;ENTEROBACTER CLOACAE;IAS   beta-l-aspartic acid| PO4   phosphate ion| EPU   uridine-diphosphate-2(n-acetylglucosaminyl) butyric acid| GOL   glycerol;IAS   beta-l-aspartic acid| PO4   phosphate ion| HAI   cyclohexylammonium ion;C115S MurA liganded with reaction products;Crystal structure of unliganded mura (type1);P33038;murA murZ ECL_04571;PF00275;P33038;murA murZ ECL_04571;PF00275;a;6.5;85;6.5;120;3v4t_D;1dlg_B;1.99;1.44
3v4t;4;1q3g;3;1dlg;3;b;1;396;24;24;412;25;25;1.40;1.43;100;0;2.65;1.9;diffraction;diffraction;1676;1676;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;UDP-N-ACETYLGLUCOSAMINE ENOLPYRUVYL TRANSFERASE MURA;ENTEROBACTER CLOACAE;ENTEROBACTER CLOACAE;IAS   beta-l-aspartic acid| UDA   3'-1-carboxy-1-phosphonooxy-ethoxy-uridine-diphosphate-n-acetylglucosamine| EDO   1,2-ethanediol;IAS   beta-l-aspartic acid| PO4   phosphate ion| HAI   cyclohexylammonium ion;MurA (Asp305Ala) liganded with tetrahedral reaction intermediate;CRYSTAL STRUCTURE OF THE C115S ENTEROBACTER CLOACAE MURA IN THE UN-LIGANDED STATE;P33038;murA murZ ECL_04571;PF00275;P33038;murA murZ ECL_04571;PF00275;a;6.4;90;6.5;120;3v4t_D;1dlg_B;1.99;1.44
3v4t;4;1q3g;3;1ejd;3;b;1;396;24;24;412;25;25;1.41;1.44;100;0;2.65;1.55;diffraction;diffraction;1676;1676;UDP-N-acetylglucosamine 1-carboxyvinyltransferase;UDP-N-ACETYLGLUCOSAMINE ENOLPYRUVYLTRANSFERASE;ENTEROBACTER CLOACAE;ENTEROBACTER CLOACAE;IAS   beta-l-aspartic acid| UDA   3'-1-carboxy-1-phosphonooxy-ethoxy-uridine-diphosphate-n-acetylglucosamine| EDO   1,2-ethanediol;IAS   beta-l-aspartic acid| PO4   phosphate ion| HAI   cyclohexylammonium ion;MurA (Asp305Ala) liganded with tetrahedral reaction intermediate;Crystal structure of unliganded mura (type1);P33038;murA murZ ECL_04571;PF00275;P33038;murA murZ ECL_04571;PF00275;a;6.4;90;6.5;120;3v4t_D;1dlg_B;1.99;1.44
3v4t;4;1dlg;3;1ejd;3;b;1;1674;100;100;1676;100;100;0.22;0.22;100;0;1.9;1.55;diffraction;diffraction;1676;1676;UDP-N-ACETYLGLUCOSAMINE ENOLPYRUVYL TRANSFERASE MURA;UDP-N-ACETYLGLUCOSAMINE ENOLPYRUVYLTRANSFERASE;ENTEROBACTER CLOACAE;ENTEROBACTER CLOACAE;IAS   beta-l-aspartic acid| PO4   phosphate ion| HAI   cyclohexylammonium ion;IAS   beta-l-aspartic acid| PO4   phosphate ion| HAI   cyclohexylammonium ion;CRYSTAL STRUCTURE OF THE C115S ENTEROBACTER CLOACAE MURA IN THE UN-LIGANDED STATE;Crystal structure of unliganded mura (type1);P33038;murA murZ ECL_04571;PF00275;P33038;murA murZ ECL_04571;PF00275;a;6.5;120;6.5;120;3v4t_D;1dlg_B;1.99;1.44
4hcd;8;4hcd;2;4mmw;3;b;1;3046;99;100;3048;99;100;0.18;0.18;100;0;1.7;1.647;diffraction;diffraction;3216;3240;Isomerase/lactonizing enzyme;Isomerase/lactonizing enzyme;AGROBACTERIUM TUMEFACIENS;AGROBACTERIUM FABRUM;MSE   selenomethionine| CL   chloride ion| MG   magnesium ion| NA   sodium ion;MG   magnesium ion| XYH   xylarohydroxamate| LLH   (2r,3s,4r)-2,3,4-trihydroxy-5-(hydroxyamino)-5-oxopentanoic acid| CL   chloride ion| PGE   triethylene glycol;Crystal structure of D-glucarate dehydratase from agrobacterium tumefaciens complexed with magnesium;Crystal structure of D-glucarate dehydratase from Agrobacterium tumefaciens complexed with magnesium, L-Xylarohydroxamate and L-Lyxarohydroxamate;Q7CSI0;Atu3453;PF13378,PF02746;Q7CSI0;Atu3453;PF13378,PF02746;b;7.5;100;7.5;100;4hcd_A;4hch_A;0.27;0.32
4hcd;8;4hcd;2;4hch;2;b;1;3066;100;100;3072;100;100;0.31;0.32;100;0;1.7;1.699;diffraction;diffraction;3216;3216;Isomerase/lactonizing enzyme;Isomerase/lactonizing enzyme;AGROBACTERIUM TUMEFACIENS;AGROBACTERIUM TUMEFACIENS;MSE   selenomethionine| CL   chloride ion| MG   magnesium ion| NA   sodium ion;TLA   l(+)-tartaric acid| GOL   glycerol| MG   magnesium ion| NA   sodium ion| PGE   triethylene glycol| EDO   1,2-ethanediol;Crystal structure of D-glucarate dehydratase from agrobacterium tumefaciens complexed with magnesium;CRYSTAL STRUCTURE OF D-GLUCARATE DEHYDRATASE FROM AGROBACTERIUM TUMEFACIENS complexed with magnesium and L-tartrate;Q7CSI0;Atu3453;PF13378,PF02746;Q7CSI0;Atu3453;PF13378,PF02746;b;7.5;100;7.0;100;4hcd_A;4hch_A;0.27;0.32
4hcd;8;4hcd;2;1rvk;2;b;1;3048;99;100;3048;99;100;0.06;0.06;100;0;1.7;1.7;diffraction;diffraction;3216;3056;Isomerase/lactonizing enzyme;isomerase/lactonizing enzyme;AGROBACTERIUM TUMEFACIENS;AGROBACTERIUM TUMEFACIENS;MSE   selenomethionine| CL   chloride ion| MG   magnesium ion| NA   sodium ion;MSE   selenomethionine| MG   magnesium ion;Crystal structure of D-glucarate dehydratase from agrobacterium tumefaciens complexed with magnesium;Crystal structure of enolase AGR_L_2751 from Agrobacterium Tumefaciens;Q7CSI0;Atu3453;PF13378,PF02746;Q7CSI0;Atu3453;PF13378,PF02746;b;7.5;100;7.5;110;4hcd_A;4hch_A;0.27;0.32
4hcd;8;4hcd;2;4hcl;2;b;1;3066;100;100;3072;100;100;0.30;0.31;100;0;1.7;1.8;diffraction;diffraction;3216;3216;Isomerase/lactonizing enzyme;Isomerase/lactonizing enzyme;AGROBACTERIUM TUMEFACIENS;AGROBACTERIUM TUMEFACIENS;MSE   selenomethionine| CL   chloride ion| MG   magnesium ion| NA   sodium ion;MG   magnesium ion| LLH   (2r,3s,4r)-2,3,4-trihydroxy-5-(hydroxyamino)-5-oxopentanoic acid| PG4   tetraethylene glycol;Crystal structure of D-glucarate dehydratase from agrobacterium tumefaciens complexed with magnesium;CRYSTAL STRUCTURE OF D-GLUCARATE DEHYDRATASE FROM AGROBACTERIUM TUMEFACIENS complexed with magnesium and L-Lyxarohydroxamate;Q7CSI0;Atu3453;PF13378,PF02746;Q7CSI0;Atu3453;PF13378,PF02746;b;7.5;100;7.5;100;4hcd_A;4hch_A;0.27;0.32
4hcd;8;4mmw;3;4hch;2;b;1;3046;100;99;3048;100;99;0.17;0.17;100;0;1.647;1.699;diffraction;diffraction;3240;3216;Isomerase/lactonizing enzyme;Isomerase/lactonizing enzyme;AGROBACTERIUM FABRUM;AGROBACTERIUM TUMEFACIENS;MG   magnesium ion| XYH   xylarohydroxamate| LLH   (2r,3s,4r)-2,3,4-trihydroxy-5-(hydroxyamino)-5-oxopentanoic acid| CL   chloride ion| PGE   triethylene glycol;TLA   l(+)-tartaric acid| GOL   glycerol| MG   magnesium ion| NA   sodium ion| PGE   triethylene glycol| EDO   1,2-ethanediol;Crystal structure of D-glucarate dehydratase from Agrobacterium tumefaciens complexed with magnesium, L-Xylarohydroxamate and L-Lyxarohydroxamate;CRYSTAL STRUCTURE OF D-GLUCARATE DEHYDRATASE FROM AGROBACTERIUM TUMEFACIENS complexed with magnesium and L-tartrate;Q7CSI0;Atu3453;PF13378,PF02746;Q7CSI0;Atu3453;PF13378,PF02746;b;7.5;100;7.0;100;4hcd_A;4hch_A;0.27;0.32
4hcd;8;4mmw;3;1rvk;2;b;1;3046;100;100;3048;100;100;0.19;0.19;100;0;1.647;1.7;diffraction;diffraction;3240;3056;Isomerase/lactonizing enzyme;isomerase/lactonizing enzyme;AGROBACTERIUM FABRUM;AGROBACTERIUM TUMEFACIENS;MG   magnesium ion| XYH   xylarohydroxamate| LLH   (2r,3s,4r)-2,3,4-trihydroxy-5-(hydroxyamino)-5-oxopentanoic acid| CL   chloride ion| PGE   triethylene glycol;MSE   selenomethionine| MG   magnesium ion;Crystal structure of D-glucarate dehydratase from Agrobacterium tumefaciens complexed with magnesium, L-Xylarohydroxamate and L-Lyxarohydroxamate;Crystal structure of enolase AGR_L_2751 from Agrobacterium Tumefaciens;Q7CSI0;Atu3453;PF13378,PF02746;Q7CSI0;Atu3453;PF13378,PF02746;b;7.5;100;7.5;110;4hcd_A;4hch_A;0.27;0.32
4hcd;8;4mmw;3;4hcl;2;b;1;3047;100;99;3048;100;99;0.14;0.14;100;0;1.647;1.8;diffraction;diffraction;3240;3216;Isomerase/lactonizing enzyme;Isomerase/lactonizing enzyme;AGROBACTERIUM FABRUM;AGROBACTERIUM TUMEFACIENS;MG   magnesium ion| XYH   xylarohydroxamate| LLH   (2r,3s,4r)-2,3,4-trihydroxy-5-(hydroxyamino)-5-oxopentanoic acid| CL   chloride ion| PGE   triethylene glycol;MG   magnesium ion| LLH   (2r,3s,4r)-2,3,4-trihydroxy-5-(hydroxyamino)-5-oxopentanoic acid| PG4   tetraethylene glycol;Crystal structure of D-glucarate dehydratase from Agrobacterium tumefaciens complexed with magnesium, L-Xylarohydroxamate and L-Lyxarohydroxamate;CRYSTAL STRUCTURE OF D-GLUCARATE DEHYDRATASE FROM AGROBACTERIUM TUMEFACIENS complexed with magnesium and L-Lyxarohydroxamate;Q7CSI0;Atu3453;PF13378,PF02746;Q7CSI0;Atu3453;PF13378,PF02746;b;7.5;100;7.5;100;4hcd_A;4hch_A;0.27;0.32
4hcd;8;4hch;2;1rvk;2;b;1;3044;99;100;3048;99;100;0.24;0.24;100;0;1.699;1.7;diffraction;diffraction;3216;3056;Isomerase/lactonizing enzyme;isomerase/lactonizing enzyme;AGROBACTERIUM TUMEFACIENS;AGROBACTERIUM TUMEFACIENS;TLA   l(+)-tartaric acid| GOL   glycerol| MG   magnesium ion| NA   sodium ion| PGE   triethylene glycol| EDO   1,2-ethanediol;MSE   selenomethionine| MG   magnesium ion;CRYSTAL STRUCTURE OF D-GLUCARATE DEHYDRATASE FROM AGROBACTERIUM TUMEFACIENS complexed with magnesium and L-tartrate;Crystal structure of enolase AGR_L_2751 from Agrobacterium Tumefaciens;Q7CSI0;Atu3453;PF13378,PF02746;Q7CSI0;Atu3453;PF13378,PF02746;b;7.0;100;7.5;110;4hcd_A;4hch_A;0.27;0.32
4hcd;8;4hch;2;4hcl;2;b;1;3070;100;100;3072;100;100;0.19;0.19;100;0;1.699;1.8;diffraction;diffraction;3216;3216;Isomerase/lactonizing enzyme;Isomerase/lactonizing enzyme;AGROBACTERIUM TUMEFACIENS;AGROBACTERIUM TUMEFACIENS;TLA   l(+)-tartaric acid| GOL   glycerol| MG   magnesium ion| NA   sodium ion| PGE   triethylene glycol| EDO   1,2-ethanediol;MG   magnesium ion| LLH   (2r,3s,4r)-2,3,4-trihydroxy-5-(hydroxyamino)-5-oxopentanoic acid| PG4   tetraethylene glycol;CRYSTAL STRUCTURE OF D-GLUCARATE DEHYDRATASE FROM AGROBACTERIUM TUMEFACIENS complexed with magnesium and L-tartrate;CRYSTAL STRUCTURE OF D-GLUCARATE DEHYDRATASE FROM AGROBACTERIUM TUMEFACIENS complexed with magnesium and L-Lyxarohydroxamate;Q7CSI0;Atu3453;PF13378,PF02746;Q7CSI0;Atu3453;PF13378,PF02746;b;7.0;100;7.5;100;4hcd_A;4hch_A;0.27;0.32
4hcd;8;1rvk;2;4hcl;2;b;1;3045;100;99;3048;100;99;0.23;0.23;100;0;1.7;1.8;diffraction;diffraction;3056;3216;isomerase/lactonizing enzyme;Isomerase/lactonizing enzyme;AGROBACTERIUM TUMEFACIENS;AGROBACTERIUM TUMEFACIENS;MSE   selenomethionine| MG   magnesium ion;MG   magnesium ion| LLH   (2r,3s,4r)-2,3,4-trihydroxy-5-(hydroxyamino)-5-oxopentanoic acid| PG4   tetraethylene glycol;Crystal structure of enolase AGR_L_2751 from Agrobacterium Tumefaciens;CRYSTAL STRUCTURE OF D-GLUCARATE DEHYDRATASE FROM AGROBACTERIUM TUMEFACIENS complexed with magnesium and L-Lyxarohydroxamate;Q7CSI0;Atu3453;PF13378,PF02746;Q7CSI0;Atu3453;PF13378,PF02746;b;7.5;110;7.5;100;4hcd_A;4hch_A;0.27;0.32
4o7w;2;4o7w;1;3u55;1;b;1;453;98;100;454;98;100;0.38;0.38;100;0;2.2;1.9;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| ATP   adenosine-5'-triphosphate| PO4   phosphate ion| ACT   acetate ion;SO4   sulfate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ATP and TDP;Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7w;1;4o7z;1;b;1;450;97;100;452;97;100;0.48;0.51;100;0;2.2;2.3;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| ATP   adenosine-5'-triphosphate| PO4   phosphate ion| ACT   acetate ion;5GP   guanosine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ATP and TDP;SAICAR synthetase (Type-2) in complex with GMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7w;1;4o7r;1;b;1;455;98;100;456;98;100;0.36;0.36;100;0;2.2;2.35;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| ATP   adenosine-5'-triphosphate| PO4   phosphate ion| ACT   acetate ion;U5P   uridine-5'-monophosphate| UDP   uridine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ATP and TDP;SAICAR synthetase (Type-2) in complex with UMP/UDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7w;1;4o7v;1;b;1;456;98;100;456;98;100;0.19;0.19;100;0;2.2;2.3;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| ATP   adenosine-5'-triphosphate| PO4   phosphate ion| ACT   acetate ion;UDP   uridine-5'-diphosphate| ADP   adenosine-5'-diphosphate| U5P   uridine-5'-monophosphate| ACT   acetate ion| PO4   phosphate ion;SAICAR synthetase (Type-2) in complex with ATP and TDP;SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7w;1;4o7t;1;b;1;450;97;100;450;97;100;0.23;0.23;100;0;2.2;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| ATP   adenosine-5'-triphosphate| PO4   phosphate ion| ACT   acetate ion;TMP   thymidine-5'-phosphate| ADP   adenosine-5'-diphosphate| ASP   aspartic acid| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ATP and TDP;SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7w;1;4o7s;1;b;1;448;96;100;448;97;100;0.18;0.18;100;0;2.2;2.24;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| ATP   adenosine-5'-triphosphate| PO4   phosphate ion| ACT   acetate ion;TYD   thymidine-5'-diphosphate| TMP   thymidine-5'-phosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ATP and TDP;SAICAR synthetase (Type-2) in complex with TMP/TDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7w;1;4o7y;1;b;1;456;98;100;456;98;100;0.22;0.22;100;0;2.2;2.0;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| ATP   adenosine-5'-triphosphate| PO4   phosphate ion| ACT   acetate ion;C5P   cytidine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ATP and TDP;SAICAR synthetase (Type-2) in complex with CMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7w;1;4o86;1;b;1;454;98;100;454;98;100;0.19;0.19;100;0;2.2;2.2;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| ATP   adenosine-5'-triphosphate| PO4   phosphate ion| ACT   acetate ion;PO4   phosphate ion| CDP   cytidine-5'-diphosphate| C5P   cytidine-5'-monophosphate| ACT   acetate ion| MG   magnesium ion| ADP   adenosine-5'-diphosphate;SAICAR synthetase (Type-2) in complex with ATP and TDP;SAICAR synthetase (Type-2) in complex with ADP and CDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7w;1;4o7l;1;b;1;464;100;100;464;100;100;0.19;0.19;100;0;2.2;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| ATP   adenosine-5'-triphosphate| PO4   phosphate ion| ACT   acetate ion;ADP   adenosine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with ATP and TDP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7w;1;4o7n;1;b;1;464;100;99;464;100;100;0.21;0.21;100;0;2.2;2.16;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| ATP   adenosine-5'-triphosphate| PO4   phosphate ion| ACT   acetate ion;PO4   phosphate ion| ACT   acetate ion| ADP   adenosine-5'-diphosphate| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with ATP and TDP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;3u55;1;4o7z;1;b;1;450;99;100;452;100;100;0.45;0.45;100;0;1.9;2.3;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;SO4   sulfate ion| ACT   acetate ion;5GP   guanosine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3;SAICAR synthetase (Type-2) in complex with GMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;3u55;1;4o7r;1;b;1;451;99;99;454;100;100;0.57;0.58;100;0;1.9;2.35;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;SO4   sulfate ion| ACT   acetate ion;U5P   uridine-5'-monophosphate| UDP   uridine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion;Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3;SAICAR synthetase (Type-2) in complex with UMP/UDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;3u55;1;4o7v;1;b;1;453;100;99;454;100;100;0.29;0.29;100;0;1.9;2.3;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;SO4   sulfate ion| ACT   acetate ion;UDP   uridine-5'-diphosphate| ADP   adenosine-5'-diphosphate| U5P   uridine-5'-monophosphate| ACT   acetate ion| PO4   phosphate ion;Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3;SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;3u55;1;4o7t;1;b;1;448;99;100;450;99;100;0.46;0.46;100;0;1.9;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;SO4   sulfate ion| ACT   acetate ion;TMP   thymidine-5'-phosphate| ADP   adenosine-5'-diphosphate| ASP   aspartic acid| ACT   acetate ion;Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3;SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;3u55;1;4o7s;1;b;1;447;98;100;448;99;100;0.35;0.35;100;0;1.9;2.24;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;SO4   sulfate ion| ACT   acetate ion;TYD   thymidine-5'-diphosphate| TMP   thymidine-5'-phosphate| PO4   phosphate ion| ACT   acetate ion;Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3;SAICAR synthetase (Type-2) in complex with TMP/TDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;3u55;1;4o7y;1;b;1;453;100;99;454;100;100;0.31;0.31;100;0;1.9;2.0;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;SO4   sulfate ion| ACT   acetate ion;C5P   cytidine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3;SAICAR synthetase (Type-2) in complex with CMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;3u55;1;4o86;1;b;1;453;100;100;454;100;100;0.38;0.38;100;0;1.9;2.2;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;SO4   sulfate ion| ACT   acetate ion;PO4   phosphate ion| CDP   cytidine-5'-diphosphate| C5P   cytidine-5'-monophosphate| ACT   acetate ion| MG   magnesium ion| ADP   adenosine-5'-diphosphate;Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3;SAICAR synthetase (Type-2) in complex with ADP and CDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;3u55;1;4o7l;1;b;1;452;100;97;454;100;98;0.47;0.47;100;0;1.9;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;SO4   sulfate ion| ACT   acetate ion;ADP   adenosine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion| MG   magnesium ion;Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;3u55;1;4o7n;1;b;1;453;100;97;454;100;97;0.33;0.33;100;0;1.9;2.16;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;SO4   sulfate ion| ACT   acetate ion;PO4   phosphate ion| ACT   acetate ion| ADP   adenosine-5'-diphosphate| MG   magnesium ion;Crystal structure (Type-2) of SAICAR synthetase from Pyrococcus horikoshii OT3;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7z;1;4o7r;1;b;1;450;100;99;452;100;99;0.49;0.52;99;0;2.3;2.35;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;5GP   guanosine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;U5P   uridine-5'-monophosphate| UDP   uridine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with GMP;SAICAR synthetase (Type-2) in complex with UMP/UDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7z;1;4o7v;1;b;1;450;100;99;452;100;99;0.43;0.46;99;0;2.3;2.3;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;5GP   guanosine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;UDP   uridine-5'-diphosphate| ADP   adenosine-5'-diphosphate| U5P   uridine-5'-monophosphate| ACT   acetate ion| PO4   phosphate ion;SAICAR synthetase (Type-2) in complex with GMP;SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7z;1;4o7t;1;b;1;446;99;99;448;99;100;0.44;0.46;100;0;2.3;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;5GP   guanosine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;TMP   thymidine-5'-phosphate| ADP   adenosine-5'-diphosphate| ASP   aspartic acid| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with GMP;SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7z;1;4o7s;1;b;1;448;99;100;448;99;100;0.20;0.20;100;0;2.3;2.24;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;5GP   guanosine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;TYD   thymidine-5'-diphosphate| TMP   thymidine-5'-phosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with GMP;SAICAR synthetase (Type-2) in complex with TMP/TDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7z;1;4o7y;1;b;1;450;100;99;452;100;99;0.41;0.43;99;0;2.3;2.0;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;5GP   guanosine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;C5P   cytidine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with GMP;SAICAR synthetase (Type-2) in complex with CMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7z;1;4o86;1;b;1;450;100;99;452;100;100;0.45;0.47;100;0;2.3;2.2;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;5GP   guanosine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;PO4   phosphate ion| CDP   cytidine-5'-diphosphate| C5P   cytidine-5'-monophosphate| ACT   acetate ion| MG   magnesium ion| ADP   adenosine-5'-diphosphate;SAICAR synthetase (Type-2) in complex with GMP;SAICAR synthetase (Type-2) in complex with ADP and CDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7z;1;4o7l;1;b;1;450;99;97;452;100;97;0.50;0.53;100;0;2.3;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;5GP   guanosine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;ADP   adenosine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with GMP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7z;1;4o7n;1;b;1;450;99;96;452;100;97;0.52;0.55;100;0;2.3;2.16;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;5GP   guanosine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;PO4   phosphate ion| ACT   acetate ion| ADP   adenosine-5'-diphosphate| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with GMP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7r;1;4o7v;1;b;1;455;100;100;456;100;100;0.38;0.38;100;0;2.35;2.3;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;U5P   uridine-5'-monophosphate| UDP   uridine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion;UDP   uridine-5'-diphosphate| ADP   adenosine-5'-diphosphate| U5P   uridine-5'-monophosphate| ACT   acetate ion| PO4   phosphate ion;SAICAR synthetase (Type-2) in complex with UMP/UDP;SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7r;1;4o7t;1;b;1;449;99;100;450;99;100;0.29;0.29;100;0;2.35;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;U5P   uridine-5'-monophosphate| UDP   uridine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion;TMP   thymidine-5'-phosphate| ADP   adenosine-5'-diphosphate| ASP   aspartic acid| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with UMP/UDP;SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7r;1;4o7s;1;b;1;447;98;100;448;98;100;0.31;0.31;100;0;2.35;2.24;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;U5P   uridine-5'-monophosphate| UDP   uridine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion;TYD   thymidine-5'-diphosphate| TMP   thymidine-5'-phosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with UMP/UDP;SAICAR synthetase (Type-2) in complex with TMP/TDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7r;1;4o7y;1;b;1;455;100;100;456;100;100;0.35;0.35;100;0;2.35;2.0;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;U5P   uridine-5'-monophosphate| UDP   uridine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion;C5P   cytidine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with UMP/UDP;SAICAR synthetase (Type-2) in complex with CMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7r;1;4o86;1;b;1;453;99;100;454;100;100;0.37;0.37;100;0;2.35;2.2;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;U5P   uridine-5'-monophosphate| UDP   uridine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion;PO4   phosphate ion| CDP   cytidine-5'-diphosphate| C5P   cytidine-5'-monophosphate| ACT   acetate ion| MG   magnesium ion| ADP   adenosine-5'-diphosphate;SAICAR synthetase (Type-2) in complex with UMP/UDP;SAICAR synthetase (Type-2) in complex with ADP and CDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7r;1;4o7l;1;b;1;455;100;98;456;100;98;0.28;0.28;100;0;2.35;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;U5P   uridine-5'-monophosphate| UDP   uridine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion;ADP   adenosine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with UMP/UDP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7r;1;4o7n;1;b;1;454;100;97;456;100;98;0.43;0.43;100;0;2.35;2.16;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;U5P   uridine-5'-monophosphate| UDP   uridine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion;PO4   phosphate ion| ACT   acetate ion| ADP   adenosine-5'-diphosphate| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with UMP/UDP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7v;1;4o7t;1;b;1;450;99;100;450;99;100;0.23;0.23;100;0;2.3;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;UDP   uridine-5'-diphosphate| ADP   adenosine-5'-diphosphate| U5P   uridine-5'-monophosphate| ACT   acetate ion| PO4   phosphate ion;TMP   thymidine-5'-phosphate| ADP   adenosine-5'-diphosphate| ASP   aspartic acid| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP;SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7v;1;4o7s;1;b;1;448;98;100;448;98;100;0.20;0.20;100;0;2.3;2.24;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;UDP   uridine-5'-diphosphate| ADP   adenosine-5'-diphosphate| U5P   uridine-5'-monophosphate| ACT   acetate ion| PO4   phosphate ion;TYD   thymidine-5'-diphosphate| TMP   thymidine-5'-phosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP;SAICAR synthetase (Type-2) in complex with TMP/TDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7v;1;4o7y;1;b;1;456;100;100;456;100;100;0.16;0.16;100;0;2.3;2.0;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;UDP   uridine-5'-diphosphate| ADP   adenosine-5'-diphosphate| U5P   uridine-5'-monophosphate| ACT   acetate ion| PO4   phosphate ion;C5P   cytidine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP;SAICAR synthetase (Type-2) in complex with CMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7v;1;4o86;1;b;1;454;100;100;454;100;100;0.16;0.16;100;0;2.3;2.2;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;UDP   uridine-5'-diphosphate| ADP   adenosine-5'-diphosphate| U5P   uridine-5'-monophosphate| ACT   acetate ion| PO4   phosphate ion;PO4   phosphate ion| CDP   cytidine-5'-diphosphate| C5P   cytidine-5'-monophosphate| ACT   acetate ion| MG   magnesium ion| ADP   adenosine-5'-diphosphate;SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP;SAICAR synthetase (Type-2) in complex with ADP and CDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7v;1;4o7l;1;b;1;455;100;98;456;100;98;0.26;0.26;100;0;2.3;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;UDP   uridine-5'-diphosphate| ADP   adenosine-5'-diphosphate| U5P   uridine-5'-monophosphate| ACT   acetate ion| PO4   phosphate ion;ADP   adenosine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7v;1;4o7n;1;b;1;456;100;98;456;100;98;0.22;0.22;100;0;2.3;2.16;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;UDP   uridine-5'-diphosphate| ADP   adenosine-5'-diphosphate| U5P   uridine-5'-monophosphate| ACT   acetate ion| PO4   phosphate ion;PO4   phosphate ion| ACT   acetate ion| ADP   adenosine-5'-diphosphate| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with ADP and UDP/UMP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7t;1;4o7s;1;b;1;444;99;99;444;99;99;0.22;0.22;100;0;2.1;2.24;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TMP   thymidine-5'-phosphate| ADP   adenosine-5'-diphosphate| ASP   aspartic acid| ACT   acetate ion;TYD   thymidine-5'-diphosphate| TMP   thymidine-5'-phosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP;SAICAR synthetase (Type-2) in complex with TMP/TDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7t;1;4o7y;1;b;1;450;100;99;450;100;99;0.21;0.21;100;0;2.1;2.0;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TMP   thymidine-5'-phosphate| ADP   adenosine-5'-diphosphate| ASP   aspartic acid| ACT   acetate ion;C5P   cytidine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP;SAICAR synthetase (Type-2) in complex with CMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7t;1;4o86;1;b;1;450;100;99;450;100;99;0.18;0.18;100;0;2.1;2.2;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TMP   thymidine-5'-phosphate| ADP   adenosine-5'-diphosphate| ASP   aspartic acid| ACT   acetate ion;PO4   phosphate ion| CDP   cytidine-5'-diphosphate| C5P   cytidine-5'-monophosphate| ACT   acetate ion| MG   magnesium ion| ADP   adenosine-5'-diphosphate;SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP;SAICAR synthetase (Type-2) in complex with ADP and CDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7t;1;4o7l;1;b;1;450;100;97;450;100;97;0.23;0.23;100;0;2.1;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TMP   thymidine-5'-phosphate| ADP   adenosine-5'-diphosphate| ASP   aspartic acid| ACT   acetate ion;ADP   adenosine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7t;1;4o7n;1;b;1;449;100;96;450;100;97;0.33;0.33;100;0;2.1;2.16;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TMP   thymidine-5'-phosphate| ADP   adenosine-5'-diphosphate| ASP   aspartic acid| ACT   acetate ion;PO4   phosphate ion| ACT   acetate ion| ADP   adenosine-5'-diphosphate| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with ADP, ASP and TMP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7s;1;4o7y;1;b;1;448;100;98;448;100;98;0.18;0.18;100;0;2.24;2.0;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| TMP   thymidine-5'-phosphate| PO4   phosphate ion| ACT   acetate ion;C5P   cytidine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;SAICAR synthetase (Type-2) in complex with TMP/TDP;SAICAR synthetase (Type-2) in complex with CMP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7s;1;4o86;1;b;1;448;100;99;448;100;99;0.21;0.21;100;0;2.24;2.2;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| TMP   thymidine-5'-phosphate| PO4   phosphate ion| ACT   acetate ion;PO4   phosphate ion| CDP   cytidine-5'-diphosphate| C5P   cytidine-5'-monophosphate| ACT   acetate ion| MG   magnesium ion| ADP   adenosine-5'-diphosphate;SAICAR synthetase (Type-2) in complex with TMP/TDP;SAICAR synthetase (Type-2) in complex with ADP and CDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7s;1;4o7l;1;b;1;447;100;96;448;100;97;0.23;0.23;100;0;2.24;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| TMP   thymidine-5'-phosphate| PO4   phosphate ion| ACT   acetate ion;ADP   adenosine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with TMP/TDP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7s;1;4o7n;1;b;1;447;100;96;448;100;96;0.28;0.29;100;0;2.24;2.16;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;TYD   thymidine-5'-diphosphate| TMP   thymidine-5'-phosphate| PO4   phosphate ion| ACT   acetate ion;PO4   phosphate ion| ACT   acetate ion| ADP   adenosine-5'-diphosphate| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with TMP/TDP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7y;1;4o86;1;b;1;454;99;100;454;100;100;0.19;0.19;100;0;2.0;2.2;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;C5P   cytidine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;PO4   phosphate ion| CDP   cytidine-5'-diphosphate| C5P   cytidine-5'-monophosphate| ACT   acetate ion| MG   magnesium ion| ADP   adenosine-5'-diphosphate;SAICAR synthetase (Type-2) in complex with CMP;SAICAR synthetase (Type-2) in complex with ADP and CDP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7y;1;4o7l;1;b;1;455;100;98;456;100;98;0.27;0.27;100;0;2.0;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;C5P   cytidine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;ADP   adenosine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with CMP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7y;1;4o7n;1;b;1;455;100;98;456;100;98;0.25;0.25;100;0;2.0;2.16;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;C5P   cytidine-5'-monophosphate| PO4   phosphate ion| ACT   acetate ion;PO4   phosphate ion| ACT   acetate ion| ADP   adenosine-5'-diphosphate| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with CMP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o86;1;4o7l;1;b;1;453;100;98;454;100;98;0.26;0.26;100;0;2.2;2.1;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;PO4   phosphate ion| CDP   cytidine-5'-diphosphate| C5P   cytidine-5'-monophosphate| ACT   acetate ion| MG   magnesium ion| ADP   adenosine-5'-diphosphate;ADP   adenosine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with ADP and CDP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o86;1;4o7n;1;b;1;453;100;97;454;100;97;0.27;0.27;100;0;2.2;2.16;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;PO4   phosphate ion| CDP   cytidine-5'-diphosphate| C5P   cytidine-5'-monophosphate| ACT   acetate ion| MG   magnesium ion| ADP   adenosine-5'-diphosphate;PO4   phosphate ion| ACT   acetate ion| ADP   adenosine-5'-diphosphate| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with ADP and CDP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
4o7w;2;4o7l;1;4o7n;1;b;1;463;100;99;464;100;100;0.26;0.26;100;0;2.1;2.16;diffraction;diffraction;476;476;Phosphoribosylaminoimidazole-succinocarboxamide synthase;Phosphoribosylaminoimidazole-succinocarboxamide synthase;PYROCOCCUS HORIKOSHII;PYROCOCCUS HORIKOSHII;ADP   adenosine-5'-diphosphate| PO4   phosphate ion| ACT   acetate ion| MG   magnesium ion;PO4   phosphate ion| ACT   acetate ion| ADP   adenosine-5'-diphosphate| MG   magnesium ion;SAICAR synthetase (Type-2) in complex with ADP;SAICAR synthetase (Type-2) in complex with ADP;O57978;purC PH0239;PF01259;O57978;purC PH0239;PF01259;b;4.6;100;4.6;100;4o7z_A;4o7n_A;0.52;0.58
1wq3;2;1wq3;1;1x8x;1;b;1;643;100;100;644;100;100;0.28;0.28;99;0;2.0;2.0;diffraction;diffraction;644;644;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI STR. K12 SUBSTR.;ESCHERICHIA COLI;IYR   3-iodo-tyrosine;SO4   sulfate ion| TYR   tyrosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with 3-iodo-L-tyrosine;Tyrosyl t-RNA Synthetase from E.coli Complexed with Tyrosine;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.50;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1wq3;1;2yxn;1;b;1;643;100;100;644;100;100;0.27;0.27;100;0;2.0;1.8;diffraction;diffraction;644;644;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI STR. K12 SUBSTR.;ESCHERICHIA COLI;IYR   3-iodo-tyrosine;AZY   3-azido-l-tyrosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with 3-iodo-L-tyrosine;Structual basis of azido-tyrosine recognition by engineered bacterial Tyrosyl-tRNA synthetase;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.50;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1wq3;1;1wq4;1;b;1;635;99;99;636;99;99;0.26;0.26;100;0;2.0;2.0;diffraction;diffraction;644;642;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI STR. K12 SUBSTR.;ESCHERICHIA COLI STR. K12 SUBSTR.;IYR   3-iodo-tyrosine;TYR   tyrosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with 3-iodo-L-tyrosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with L-tyrosine;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.50;100;7.50;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1wq3;1;1vbm;1;b;1;625;97;98;636;99;100;0.91;0.91;99;0;2.0;2.7;diffraction;diffraction;644;636;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI STR. K12 SUBSTR.;ESCHERICHIA COLI;IYR   3-iodo-tyrosine;SO4   sulfate ion| YSA   5'-o-[n-(l-tyrosyl)sulfamoyl]adenosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with 3-iodo-L-tyrosine;Crystal structure of the Escherichia coli tyrosyl-tRNA synthetase complexed with Tyr-AMS;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.50;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1wq3;1;1vbn;1;b;1;627;97;99;636;99;100;0.83;0.83;100;0;2.0;2.7;diffraction;diffraction;644;636;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI STR. K12 SUBSTR.;ESCHERICHIA COLI;IYR   3-iodo-tyrosine;YSA   5'-o-[n-(l-tyrosyl)sulfamoyl]adenosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with 3-iodo-L-tyrosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with Tyr-AMS;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.50;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1x8x;1;2yxn;1;b;1;643;100;100;644;100;100;0.25;0.25;99;0;2.0;1.8;diffraction;diffraction;644;644;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| TYR   tyrosine;AZY   3-azido-l-tyrosine;Tyrosyl t-RNA Synthetase from E.coli Complexed with Tyrosine;Structual basis of azido-tyrosine recognition by engineered bacterial Tyrosyl-tRNA synthetase;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.5;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1x8x;1;1wq4;1;b;1;635;99;99;636;99;99;0.27;0.28;99;0;2.0;2.0;diffraction;diffraction;644;642;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI;ESCHERICHIA COLI STR. K12 SUBSTR.;SO4   sulfate ion| TYR   tyrosine;TYR   tyrosine;Tyrosyl t-RNA Synthetase from E.coli Complexed with Tyrosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with L-tyrosine;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.5;100;7.50;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1x8x;1;1vbm;1;b;1;626;97;98;636;99;100;0.88;0.88;100;0;2.0;2.7;diffraction;diffraction;644;636;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| TYR   tyrosine;SO4   sulfate ion| YSA   5'-o-[n-(l-tyrosyl)sulfamoyl]adenosine;Tyrosyl t-RNA Synthetase from E.coli Complexed with Tyrosine;Crystal structure of the Escherichia coli tyrosyl-tRNA synthetase complexed with Tyr-AMS;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.5;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1x8x;1;1vbn;1;b;1;627;97;99;636;99;100;0.83;0.83;99;0;2.0;2.7;diffraction;diffraction;644;636;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| TYR   tyrosine;YSA   5'-o-[n-(l-tyrosyl)sulfamoyl]adenosine;Tyrosyl t-RNA Synthetase from E.coli Complexed with Tyrosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with Tyr-AMS;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.5;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;2yxn;1;1wq4;1;b;1;635;99;99;636;99;99;0.33;0.33;100;0;1.8;2.0;diffraction;diffraction;644;642;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI;ESCHERICHIA COLI STR. K12 SUBSTR.;AZY   3-azido-l-tyrosine;TYR   tyrosine;Structual basis of azido-tyrosine recognition by engineered bacterial Tyrosyl-tRNA synthetase;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with L-tyrosine;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.5;100;7.50;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;2yxn;1;1vbm;1;b;1;627;97;99;636;99;100;0.84;0.84;99;0;1.8;2.7;diffraction;diffraction;644;636;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI;ESCHERICHIA COLI;AZY   3-azido-l-tyrosine;SO4   sulfate ion| YSA   5'-o-[n-(l-tyrosyl)sulfamoyl]adenosine;Structual basis of azido-tyrosine recognition by engineered bacterial Tyrosyl-tRNA synthetase;Crystal structure of the Escherichia coli tyrosyl-tRNA synthetase complexed with Tyr-AMS;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.5;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;2yxn;1;1vbn;1;b;1;628;98;99;636;99;100;0.77;0.78;100;0;1.8;2.7;diffraction;diffraction;644;636;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI;ESCHERICHIA COLI;AZY   3-azido-l-tyrosine;YSA   5'-o-[n-(l-tyrosyl)sulfamoyl]adenosine;Structual basis of azido-tyrosine recognition by engineered bacterial Tyrosyl-tRNA synthetase;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with Tyr-AMS;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.5;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1wq4;1;1vbm;1;b;1;625;97;98;636;99;100;0.91;0.91;99;0;2.0;2.7;diffraction;diffraction;642;636;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI STR. K12 SUBSTR.;ESCHERICHIA COLI;TYR   tyrosine;SO4   sulfate ion| YSA   5'-o-[n-(l-tyrosyl)sulfamoyl]adenosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with L-tyrosine;Crystal structure of the Escherichia coli tyrosyl-tRNA synthetase complexed with Tyr-AMS;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.50;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1wq4;1;1vbn;1;b;1;627;98;99;636;99;100;0.84;0.84;100;0;2.0;2.7;diffraction;diffraction;642;636;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI STR. K12 SUBSTR.;ESCHERICHIA COLI;TYR   tyrosine;YSA   5'-o-[n-(l-tyrosyl)sulfamoyl]adenosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with L-tyrosine;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with Tyr-AMS;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.50;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
1wq3;2;1vbm;1;1vbn;1;b;1;634;100;100;636;100;100;0.42;0.43;99;0;2.7;2.7;diffraction;diffraction;636;636;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| YSA   5'-o-[n-(l-tyrosyl)sulfamoyl]adenosine;YSA   5'-o-[n-(l-tyrosyl)sulfamoyl]adenosine;Crystal structure of the Escherichia coli tyrosyl-tRNA synthetase complexed with Tyr-AMS;Escherichia coli tyrosyl-tRNA synthetase mutant complexed with Tyr-AMS;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;P0AGJ9;tyrS b1637 JW1629;PF01479,PF00579;b;7.5;100;7.5;100;2yxn_A;1vbn_A;0.63;0.91
3mhu;2;3mhu;1;4ef8;1;b;1;610;99;97;614;100;98;0.53;0.54;100;0;1.85;1.56;diffraction;diffraction;692;708;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| EJZ   5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;0FI   n-phenylthioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Nitroorotic acid;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with Phenyl isothiocyanate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3mhu;1;3gz3;1;b;1;598;97;100;598;97;100;0.14;0.14;100;0;1.85;1.9;diffraction;diffraction;692;708;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase, putative;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| EJZ   5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;FMN   flavin mononucleotide| ORO   orotic acid| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Nitroorotic acid;Leishmania major Dihydroorotate Dehydrogenase in complex with orotate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3mhu;1;4ef9;1;b;1;610;99;97;613;100;98;0.47;0.48;100;0;1.85;1.6;diffraction;diffraction;692;708;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| EJZ   5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;4NF   n-(4-nitrophenyl)thioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Nitroorotic acid;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 4-Nitrophenyl isothiocyanate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3mhu;1;3gye;1;b;1;596;97;100;598;97;100;0.44;0.46;100;0;1.85;2.0;diffraction;diffraction;692;708;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase, putative;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| EJZ   5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;FMN   flavin mononucleotide| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Nitroorotic acid;Didydroorotate dehydrogenase from Leishmania major;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3mhu;1;3mjy;1;b;1;612;99;100;612;100;100;0.18;0.19;100;0;1.85;1.96;diffraction;diffraction;692;692;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| EJZ   5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;FMN   flavin mononucleotide| IJZ   5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Nitroorotic acid;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Aminoorotic acid;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3mhu;1;3c61;1;b;1;610;99;97;613;100;98;0.50;0.50;95;0;1.85;1.8;diffraction;diffraction;692;628;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA DONOVANI;FMN   flavin mononucleotide| EJZ   5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;CL   chloride ion| AZI   azide ion| FMN   flavin mononucleotide| ORO   orotic acid| DTU   (2r,3s)-1,4-dimercaptobutane-2,3-diol| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Nitroorotic acid;Crystal structure of dihydroorotate dehydrogenase from Leishmania donovani;Q4QEW7;DHODH LMJF_16_0530;PF01180;D0VWT2;no/data;PF01180;b;5.6;100;5.0;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3mhu;1;3tq0;1;b;1;611;99;98;613;100;98;0.38;0.38;100;0;1.85;1.9;diffraction;diffraction;692;692;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| EJZ   5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;FMN   flavin mononucleotide| FUM   fumaric acid| GOL   glycerol| NI   nickel (ii) ion| SO4   sulfate ion;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Nitroorotic acid;Crystal structure of Leishmania major dihydroorotate dehydrogenase in complex with fumarate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;4ef8;1;3gz3;1;b;1;596;95;100;598;95;100;0.37;0.37;100;0;1.56;1.9;diffraction;diffraction;708;708;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase, putative;LEISHMANIA MAJOR;LEISHMANIA MAJOR;0FI   n-phenylthioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;FMN   flavin mononucleotide| ORO   orotic acid| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with Phenyl isothiocyanate;Leishmania major Dihydroorotate Dehydrogenase in complex with orotate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;4ef8;1;4ef9;1;b;1;614;98;98;618;99;99;0.55;0.63;100;0;1.56;1.6;diffraction;diffraction;708;708;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;0FI   n-phenylthioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;4NF   n-(4-nitrophenyl)thioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with Phenyl isothiocyanate;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 4-Nitrophenyl isothiocyanate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;4ef8;1;3gye;1;b;1;598;95;100;598;95;100;0.20;0.20;100;0;1.56;2.0;diffraction;diffraction;708;708;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase, putative;LEISHMANIA MAJOR;LEISHMANIA MAJOR;0FI   n-phenylthioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;FMN   flavin mononucleotide| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with Phenyl isothiocyanate;Didydroorotate dehydrogenase from Leishmania major;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;4ef8;1;3mjy;1;b;1;608;97;99;611;97;100;0.51;0.51;100;0;1.56;1.96;diffraction;diffraction;708;692;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;0FI   n-phenylthioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;FMN   flavin mononucleotide| IJZ   5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with Phenyl isothiocyanate;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Aminoorotic acid;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;4ef8;1;3c61;1;b;1;611;98;97;614;98;98;0.46;0.47;95;0;1.56;1.8;diffraction;diffraction;708;628;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA DONOVANI;0FI   n-phenylthioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;CL   chloride ion| AZI   azide ion| FMN   flavin mononucleotide| ORO   orotic acid| DTU   (2r,3s)-1,4-dimercaptobutane-2,3-diol| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with Phenyl isothiocyanate;Crystal structure of dihydroorotate dehydrogenase from Leishmania donovani;Q4QEW7;DHODH LMJF_16_0530;PF01180;D0VWT2;no/data;PF01180;b;5.6;100;5.0;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;4ef8;1;3tq0;1;b;1;608;97;97;614;98;98;0.70;0.70;100;0;1.56;1.9;diffraction;diffraction;708;692;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;0FI   n-phenylthioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;FMN   flavin mononucleotide| FUM   fumaric acid| GOL   glycerol| NI   nickel (ii) ion| SO4   sulfate ion;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with Phenyl isothiocyanate;Crystal structure of Leishmania major dihydroorotate dehydrogenase in complex with fumarate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3gz3;1;4ef9;1;b;1;596;100;95;598;100;96;0.38;0.38;100;0;1.9;1.6;diffraction;diffraction;708;708;Dihydroorotate dehydrogenase, putative;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| ORO   orotic acid| GOL   glycerol;4NF   n-(4-nitrophenyl)thioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;Leishmania major Dihydroorotate Dehydrogenase in complex with orotate;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 4-Nitrophenyl isothiocyanate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3gz3;1;3gye;1;b;1;597;100;100;598;100;100;0.27;0.27;100;0;1.9;2.0;diffraction;diffraction;708;708;Dihydroorotate dehydrogenase, putative;Dihydroorotate dehydrogenase, putative;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| ORO   orotic acid| GOL   glycerol;FMN   flavin mononucleotide| GOL   glycerol;Leishmania major Dihydroorotate Dehydrogenase in complex with orotate;Didydroorotate dehydrogenase from Leishmania major;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3gz3;1;3mjy;1;b;1;598;100;98;598;100;98;0.16;0.16;100;0;1.9;1.96;diffraction;diffraction;708;692;Dihydroorotate dehydrogenase, putative;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| ORO   orotic acid| GOL   glycerol;FMN   flavin mononucleotide| IJZ   5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;Leishmania major Dihydroorotate Dehydrogenase in complex with orotate;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Aminoorotic acid;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3gz3;1;3c61;1;b;1;596;100;95;598;100;95;0.44;0.44;96;0;1.9;1.8;diffraction;diffraction;708;628;Dihydroorotate dehydrogenase, putative;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA DONOVANI;FMN   flavin mononucleotide| ORO   orotic acid| GOL   glycerol;CL   chloride ion| AZI   azide ion| FMN   flavin mononucleotide| ORO   orotic acid| DTU   (2r,3s)-1,4-dimercaptobutane-2,3-diol| GOL   glycerol;Leishmania major Dihydroorotate Dehydrogenase in complex with orotate;Crystal structure of dihydroorotate dehydrogenase from Leishmania donovani;Q4QEW7;DHODH LMJF_16_0530;PF01180;D0VWT2;no/data;PF01180;b;5.6;100;5.0;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3gz3;1;3tq0;1;b;1;596;100;95;598;100;96;0.43;0.43;100;0;1.9;1.9;diffraction;diffraction;708;692;Dihydroorotate dehydrogenase, putative;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| ORO   orotic acid| GOL   glycerol;FMN   flavin mononucleotide| FUM   fumaric acid| GOL   glycerol| NI   nickel (ii) ion| SO4   sulfate ion;Leishmania major Dihydroorotate Dehydrogenase in complex with orotate;Crystal structure of Leishmania major dihydroorotate dehydrogenase in complex with fumarate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;4ef9;1;3gye;1;b;1;597;95;100;598;96;100;0.27;0.27;100;0;1.6;2.0;diffraction;diffraction;708;708;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase, putative;LEISHMANIA MAJOR;LEISHMANIA MAJOR;4NF   n-(4-nitrophenyl)thioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;FMN   flavin mononucleotide| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 4-Nitrophenyl isothiocyanate;Didydroorotate dehydrogenase from Leishmania major;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;4ef9;1;3mjy;1;b;1;607;97;99;610;97;100;0.47;0.47;100;0;1.6;1.96;diffraction;diffraction;708;692;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;4NF   n-(4-nitrophenyl)thioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;FMN   flavin mononucleotide| IJZ   5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 4-Nitrophenyl isothiocyanate;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Aminoorotic acid;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;4ef9;1;3c61;1;b;1;624;100;99;626;100;100;0.35;0.35;96;0;1.6;1.8;diffraction;diffraction;708;628;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA DONOVANI;4NF   n-(4-nitrophenyl)thioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;CL   chloride ion| AZI   azide ion| FMN   flavin mononucleotide| ORO   orotic acid| DTU   (2r,3s)-1,4-dimercaptobutane-2,3-diol| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 4-Nitrophenyl isothiocyanate;Crystal structure of dihydroorotate dehydrogenase from Leishmania donovani;Q4QEW7;DHODH LMJF_16_0530;PF01180;D0VWT2;no/data;PF01180;b;5.6;100;5.0;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;4ef9;1;3tq0;1;b;1;622;99;99;626;100;100;0.55;0.55;100;0;1.6;1.9;diffraction;diffraction;708;692;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;4NF   n-(4-nitrophenyl)thioformamide| FMN   flavin mononucleotide| SO4   sulfate ion| GOL   glycerol;FMN   flavin mononucleotide| FUM   fumaric acid| GOL   glycerol| NI   nickel (ii) ion| SO4   sulfate ion;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 4-Nitrophenyl isothiocyanate;Crystal structure of Leishmania major dihydroorotate dehydrogenase in complex with fumarate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3gye;1;3mjy;1;b;1;595;100;97;598;100;98;0.46;0.48;100;0;2.0;1.96;diffraction;diffraction;708;692;Dihydroorotate dehydrogenase, putative;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| GOL   glycerol;FMN   flavin mononucleotide| IJZ   5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;Didydroorotate dehydrogenase from Leishmania major;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Aminoorotic acid;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3gye;1;3c61;1;b;1;596;100;95;598;100;95;0.41;0.41;96;0;2.0;1.8;diffraction;diffraction;708;628;Dihydroorotate dehydrogenase, putative;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA DONOVANI;FMN   flavin mononucleotide| GOL   glycerol;CL   chloride ion| AZI   azide ion| FMN   flavin mononucleotide| ORO   orotic acid| DTU   (2r,3s)-1,4-dimercaptobutane-2,3-diol| GOL   glycerol;Didydroorotate dehydrogenase from Leishmania major;Crystal structure of dihydroorotate dehydrogenase from Leishmania donovani;Q4QEW7;DHODH LMJF_16_0530;PF01180;D0VWT2;no/data;PF01180;b;5.6;100;5.0;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3gye;1;3tq0;1;b;1;593;99;95;598;100;96;0.63;0.63;100;0;2.0;1.9;diffraction;diffraction;708;692;Dihydroorotate dehydrogenase, putative;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| GOL   glycerol;FMN   flavin mononucleotide| FUM   fumaric acid| GOL   glycerol| NI   nickel (ii) ion| SO4   sulfate ion;Didydroorotate dehydrogenase from Leishmania major;Crystal structure of Leishmania major dihydroorotate dehydrogenase in complex with fumarate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3mjy;1;3c61;1;b;1;607;99;97;610;100;97;0.50;0.50;95;0;1.96;1.8;diffraction;diffraction;692;628;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA DONOVANI;FMN   flavin mononucleotide| IJZ   5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;CL   chloride ion| AZI   azide ion| FMN   flavin mononucleotide| ORO   orotic acid| DTU   (2r,3s)-1,4-dimercaptobutane-2,3-diol| GOL   glycerol;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Aminoorotic acid;Crystal structure of dihydroorotate dehydrogenase from Leishmania donovani;Q4QEW7;DHODH LMJF_16_0530;PF01180;D0VWT2;no/data;PF01180;b;5.6;100;5.0;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3mjy;1;3tq0;1;b;1;609;99;97;610;100;97;0.34;0.34;100;0;1.96;1.9;diffraction;diffraction;692;692;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA MAJOR;LEISHMANIA MAJOR;FMN   flavin mononucleotide| IJZ   5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid| GOL   glycerol| SO4   sulfate ion;FMN   flavin mononucleotide| FUM   fumaric acid| GOL   glycerol| NI   nickel (ii) ion| SO4   sulfate ion;Crystal structure of dihydroorotate dehydrogenase from Leishmania major in complex with 5-Aminoorotic acid;Crystal structure of Leishmania major dihydroorotate dehydrogenase in complex with fumarate;Q4QEW7;DHODH LMJF_16_0530;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.6;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
3mhu;2;3c61;1;3tq0;1;b;1;622;99;99;626;100;100;0.55;0.55;96;0;1.8;1.9;diffraction;diffraction;628;692;Dihydroorotate dehydrogenase;Dihydroorotate dehydrogenase;LEISHMANIA DONOVANI;LEISHMANIA MAJOR;CL   chloride ion| AZI   azide ion| FMN   flavin mononucleotide| ORO   orotic acid| DTU   (2r,3s)-1,4-dimercaptobutane-2,3-diol| GOL   glycerol;FMN   flavin mononucleotide| FUM   fumaric acid| GOL   glycerol| NI   nickel (ii) ion| SO4   sulfate ion;Crystal structure of dihydroorotate dehydrogenase from Leishmania donovani;Crystal structure of Leishmania major dihydroorotate dehydrogenase in complex with fumarate;D0VWT2;no/data;PF01180;Q4QEW7;DHODH LMJF_16_0530;PF01180;b;5.0;100;5.6;100;4ef8_B;3tq0_B;0.84;0.70
4pbs;2;4pbs;1;4hpw;1;b;1;557;90;90;605;98;98;2.00;2.06;94;0;2.011;1.998;diffraction;diffraction;628;620;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;3YM   3-methoxy-l-tyrosine;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;1u7d;1;b;1;513;83;89;574;93;100;2.34;2.39;98;0;2.011;2.65;diffraction;diffraction;628;612;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;no/data;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;5.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;4pbr;1;b;1;619;100;100;620;100;100;0.31;0.31;98;0;2.011;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;1u7x;1;b;1;563;91;92;608;98;99;1.94;1.99;97;0;2.011;3.0;diffraction;diffraction;628;624;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;K   potassium ion;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;5.0;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;4nda;1;c;1;614;99;100;616;99;100;0.35;0.35;98;0;2.011;1.7;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;2ag6;2;b;1;606;98;99;614;99;100;0.78;0.83;98;0;2.011;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;4BF   4-bromo-l-phenylalanine;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;3d6u;2;b;1;605;98;99;612;99;100;0.77;0.83;97;0;2.011;2.2;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;2pxh;2;c;1;610;98;100;612;99;100;0.37;0.37;98;0;2.011;1.97;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of a bipyridylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;4nd7;1;b;1;618;100;100;620;100;100;0.37;0.37;98;0;2.011;2.0;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;NA   sodium ion| BME   beta-mercaptoethanol;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;3d6v;2;b;1;608;98;99;616;99;100;0.82;0.88;97;0;2.011;2.2;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;2zp1;1;b;1;615;99;100;616;99;100;0.33;0.33;98;0;2.011;1.7;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;IYR   3-iodo-tyrosine;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;1zh6;2;b;1;608;98;99;614;99;100;0.70;0.71;99;0;2.011;2.5;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;1zh0;2;b;1;599;97;98;614;99;100;1.10;1.15;98;0;2.011;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;4pbt;1;b;1;618;100;100;620;100;100;0.38;0.38;98;0;2.011;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;2hgz;1;c;1;610;98;100;612;99;100;0.36;0.36;98;0;2.011;2.5;diffraction;diffraction;628;612;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;PBF   para-(benzoyl)-phenylalanine;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;4hjx;1;b;1;608;98;99;612;99;100;0.58;0.60;97;0;2.011;2.91;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;4hk4;1;c;1;557;90;90;609;98;99;2.10;2.22;92;0;2.011;2.298;diffraction;diffraction;628;624;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;PEG   di(hydroxyethyl)ether;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;4hjr;1;b;1;575;93;94;615;99;100;1.81;1.83;97;0;2.011;2.5;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;no/data;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbs;1;4nd6;1;b;1;568;92;94;601;97;99;1.67;1.72;97;0;2.011;2.0;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine;GOL   glycerol;Crystal structure of the M. jannaschii F9 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;1u7d;1;b;1;541;87;94;570;92;99;1.61;1.68;97;0;1.998;2.65;diffraction;diffraction;620;612;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;no/data;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;5.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;4pbr;1;c;1;548;88;88;603;97;97;2.16;2.26;92;0;1.998;1.9;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;1u7x;1;b;1;573;92;94;605;98;99;1.63;1.71;97;0;1.998;3.0;diffraction;diffraction;620;624;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;K   potassium ion;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;5.0;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;4nda;1;c;1;554;89;90;605;98;98;2.07;2.16;91;0;1.998;1.7;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;2ag6;2;c;1;551;89;90;608;98;99;2.20;2.27;92;0;1.998;1.9;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;4BF   4-bromo-l-phenylalanine;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;3d6u;2;c;1;550;89;90;608;98;99;2.21;2.29;92;0;1.998;2.2;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;2pxh;2;c;1;563;91;92;609;98;100;1.96;2.00;97;0;1.998;1.97;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of a bipyridylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;4nd7;1;c;1;549;89;89;599;97;97;2.06;2.14;92;0;1.998;2.0;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;NA   sodium ion| BME   beta-mercaptoethanol;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;3d6v;2;c;1;550;89;89;600;97;97;2.07;2.17;93;0;1.998;2.2;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;2zp1;1;b;1;551;89;89;599;97;97;2.03;2.09;93;0;1.998;1.7;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;IYR   3-iodo-tyrosine;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;1zh6;2;c;1;542;87;88;595;96;97;2.13;2.22;92;0;1.998;2.5;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;1zh0;2;b;1;563;91;92;611;99;100;2.01;2.09;94;0;1.998;1.9;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;4pbt;1;c;1;546;88;88;613;99;99;2.38;2.52;92;0;1.998;1.9;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;2hgz;1;c;1;558;90;91;608;98;99;2.05;2.09;96;0;1.998;2.5;diffraction;diffraction;620;612;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;PBF   para-(benzoyl)-phenylalanine;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;4hjx;1;c;1;555;90;91;610;98;100;2.14;2.20;98;0;1.998;2.91;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;3YM   3-methoxy-l-tyrosine;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;4hk4;1;b;1;616;99;100;618;100;100;0.37;0.38;100;0;1.998;2.298;diffraction;diffraction;620;624;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;PEG   di(hydroxyethyl)ether;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;4hjr;1;b;1;604;97;98;615;99;100;0.93;0.95;98;0;1.998;2.5;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;3YM   3-methoxy-l-tyrosine;no/data;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hpw;1;4nd6;1;c;1;545;88;90;605;98;100;2.27;2.43;96;0;1.998;2.0;diffraction;diffraction;620;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;3YM   3-methoxy-l-tyrosine;GOL   glycerol;Crystal structure of Tyrosine-tRNA ligase mutant complexed with unnatural amino acid 3-o-methyl-Tyrosine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;4pbr;1;b;1;506;88;82;575;100;93;2.49;2.55;98;0;2.65;1.9;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;1u7x;1;b;1;565;98;92;576;100;94;0.99;1.00;99;0;2.65;3.0;diffraction;diffraction;612;624;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;K   potassium ion;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;5.0;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;4nda;1;b;1;505;88;82;573;99;93;2.48;2.55;97;0;2.65;1.7;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;2ag6;2;c;1;487;84;79;561;97;91;2.64;2.74;91;0;2.65;1.9;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;4BF   4-bromo-l-phenylalanine;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;3d6u;2;c;1;494;86;81;565;98;92;2.56;2.64;92;0;2.65;2.2;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;2pxh;2;c;1;503;87;82;566;98;92;2.41;2.46;96;0;2.65;1.97;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of a bipyridylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;4nd7;1;b;1;505;88;81;566;98;91;2.36;2.42;97;0;2.65;2.0;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;NA   sodium ion| BME   beta-mercaptoethanol;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;3d6v;2;b;1;490;85;79;559;97;91;2.55;2.63;90;0;2.65;2.2;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;2zp1;1;c;1;510;88;83;575;100;93;2.43;2.49;98;0;2.65;1.7;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;IYR   3-iodo-tyrosine;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;1zh6;2;c;1;495;86;81;570;99;93;2.63;2.71;97;0;2.65;2.5;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;1zh0;2;c;1;515;89;84;574;100;93;2.31;2.38;98;0;2.65;1.9;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;4pbt;1;b;1;507;88;82;574;100;93;2.47;2.53;98;0;2.65;1.9;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;2hgz;1;c;1;502;87;82;567;98;93;2.45;2.51;92;0;2.65;2.5;diffraction;diffraction;612;612;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;PBF   para-(benzoyl)-phenylalanine;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;4hjx;1;c;1;499;87;82;571;99;93;2.57;2.63;97;0;2.65;2.91;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;no/data;F2Y   3,5-difluoro-l-tyrosine;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;4hk4;1;b;1;539;94;87;569;99;92;1.62;1.69;97;0;2.65;2.298;diffraction;diffraction;612;624;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;PEG   di(hydroxyethyl)ether;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;4hjr;1;b;1;532;92;86;569;99;93;1.82;1.91;98;0;2.65;2.5;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;no/data;no/data;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7d;1;4nd6;1;b;1;545;95;90;576;100;95;1.64;1.66;98;0;2.65;2.0;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;no/data;GOL   glycerol;crystal structure of apo M. jannashii tyrosyl-tRNA synthetase;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;1u7x;1;b;1;558;90;91;609;98;100;2.07;2.12;97;0;1.9;3.0;diffraction;diffraction;628;624;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;K   potassium ion;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;5.0;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;4nda;1;b;1;614;99;100;616;99;100;0.40;0.40;98;0;1.9;1.7;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;2ag6;2;b;1;606;98;99;614;99;100;0.79;0.84;97;0;1.9;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;4BF   4-bromo-l-phenylalanine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;3d6u;2;b;1;604;97;99;612;99;100;0.80;0.86;97;0;1.9;2.2;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;2pxh;2;b;1;609;98;99;612;99;100;0.52;0.52;97;0;1.9;1.97;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of a bipyridylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;4nd7;1;b;1;618;100;100;620;100;100;0.38;0.38;98;0;1.9;2.0;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;NA   sodium ion| BME   beta-mercaptoethanol;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;3d6v;2;b;1;606;98;98;616;99;100;0.89;0.95;97;0;1.9;2.2;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;2zp1;1;b;1;615;99;100;616;99;100;0.34;0.34;97;0;1.9;1.7;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;IYR   3-iodo-tyrosine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;1zh6;2;b;1;608;98;99;614;99;100;0.66;0.67;98;0;1.9;2.5;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;1zh0;2;b;1;595;96;97;614;99;100;1.23;1.27;97;0;1.9;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;4pbt;1;b;1;619;100;100;620;100;100;0.27;0.27;100;0;1.9;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;2hgz;1;b;1;609;98;100;612;99;100;0.46;0.46;97;0;1.9;2.5;diffraction;diffraction;628;612;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;PBF   para-(benzoyl)-phenylalanine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;4hjx;1;b;1;607;98;99;612;99;100;0.63;0.65;98;0;1.9;2.91;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;4hk4;1;b;1;549;89;89;601;97;97;2.10;2.18;93;0;1.9;2.298;diffraction;diffraction;628;624;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;PEG   di(hydroxyethyl)ether;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;4hjr;1;b;1;573;92;93;615;99;100;1.87;1.89;98;0;1.9;2.5;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;no/data;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbr;1;4nd6;1;b;1;561;91;93;602;97;99;1.86;1.92;98;0;1.9;2.0;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;2L7   4-[(2-bromo-2-methylpropanoyl)amino]-l-phenylalanine| PEG   di(hydroxyethyl)ether| GOL   glycerol;GOL   glycerol;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-(2-bromoisobutyramido)-phenylalanine (BibaF);Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;4nda;1;b;1;558;91;91;607;99;99;2.03;2.08;97;0;3.0;1.7;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;2ag6;2;b;1;547;89;89;603;99;98;2.18;2.27;97;0;3.0;1.9;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;4BF   4-bromo-l-phenylalanine;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;3d6u;2;b;1;550;90;90;603;99;99;2.12;2.19;97;0;3.0;2.2;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;2pxh;2;b;1;561;92;92;608;99;99;1.99;2.04;97;0;3.0;1.97;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of a bipyridylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;4nd7;1;b;1;563;92;91;609;100;98;1.97;2.03;97;0;3.0;2.0;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;NA   sodium ion| BME   beta-mercaptoethanol;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;3d6v;2;b;1;554;91;90;605;99;98;2.08;2.15;97;0;3.0;2.2;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;2zp1;1;b;1;560;91;91;610;100;99;2.05;2.11;98;0;3.0;1.7;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;IYR   3-iodo-tyrosine;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;1zh6;2;b;1;552;90;90;609;100;99;2.20;2.26;97;0;3.0;2.5;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;1zh0;2;b;1;562;92;92;607;99;99;1.93;2.02;95;0;3.0;1.9;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;4pbt;1;c;1;559;91;90;612;100;99;2.10;2.16;98;0;3.0;1.9;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;2hgz;1;b;1;558;91;91;607;99;99;2.04;2.09;97;0;3.0;2.5;diffraction;diffraction;624;612;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;PBF   para-(benzoyl)-phenylalanine;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;4hjx;1;b;1;559;91;91;609;100;100;2.06;2.11;97;0;3.0;2.91;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;K   potassium ion;F2Y   3,5-difluoro-l-tyrosine;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;4hk4;1;b;1;571;93;92;604;99;98;1.66;1.74;97;0;3.0;2.298;diffraction;diffraction;624;624;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;PEG   di(hydroxyethyl)ether;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;4hjr;1;b;1;571;93;93;607;99;99;1.74;1.81;96;0;3.0;2.5;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;K   potassium ion;no/data;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1u7x;1;4nd6;1;b;1;590;96;97;606;99;100;1.13;1.14;98;0;3.0;2.0;diffraction;diffraction;624;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;K   potassium ion;GOL   glycerol;crystal structure of a mutant M. jannashii tyrosyl-tRNA synthetase specific for O-methyl-tyrosine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;5.0;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;2ag6;2;b;1;607;99;99;614;100;100;0.74;0.80;98;0;1.7;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;4BF   4-bromo-l-phenylalanine;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;3d6u;2;b;1;605;98;99;612;99;100;0.76;0.82;98;0;1.7;2.2;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;2pxh;2;b;1;608;99;99;612;99;100;0.55;0.55;98;0;1.7;1.97;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of a bipyridylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;4nd7;1;c;1;614;100;99;616;100;99;0.35;0.35;100;0;1.7;2.0;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;NA   sodium ion| BME   beta-mercaptoethanol;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;3d6v;2;b;1;606;98;98;614;100;100;0.79;0.84;98;0;1.7;2.2;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;2zp1;1;b;1;615;100;100;616;100;100;0.26;0.26;98;0;1.7;1.7;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;IYR   3-iodo-tyrosine;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;1zh6;2;b;1;609;99;99;614;100;100;0.61;0.62;99;0;1.7;2.5;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;1zh0;2;b;1;595;97;97;614;100;100;1.24;1.28;98;0;1.7;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;4pbt;1;b;1;614;100;99;616;100;99;0.37;0.37;98;0;1.7;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;2hgz;1;c;1;610;99;100;612;99;100;0.43;0.43;97;0;1.7;2.5;diffraction;diffraction;628;612;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;PBF   para-(benzoyl)-phenylalanine;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;4hjx;1;b;1;606;98;99;612;99;100;0.67;0.70;97;0;1.7;2.91;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;4hk4;1;b;1;552;90;89;601;98;97;2.03;2.09;94;0;1.7;2.298;diffraction;diffraction;628;624;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;PEG   di(hydroxyethyl)ether;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;4hjr;1;c;1;573;93;93;614;100;100;1.84;1.86;97;0;1.7;2.5;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;no/data;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nda;1;4nd6;1;b;1;560;91;92;599;97;99;1.81;1.86;99;0;1.7;2.0;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NIY   meta-nitro-tyrosine| GOL   glycerol| NA   sodium ion;GOL   glycerol;Crystal structure of 3-nitro-tyrosine tRNA synthetase (5B) bound to 3-nitro-tyrosine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;3d6u;2;b;1;611;100;100;612;100;100;0.21;0.21;99;0;1.9;2.2;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;2pxh;2;b;1;603;98;99;612;100;100;0.83;0.88;97;0;1.9;1.97;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal structure of a bipyridylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;4nd7;1;c;1;605;99;98;614;100;99;0.83;0.89;98;0;1.9;2.0;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;NA   sodium ion| BME   beta-mercaptoethanol;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;3d6v;2;b;1;610;99;99;612;100;99;0.40;0.40;99;0;1.9;2.2;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;2zp1;1;b;1;607;99;99;614;100;100;0.75;0.81;98;0;1.9;1.7;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;IYR   3-iodo-tyrosine;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;1zh6;2;b;1;608;99;99;614;100;100;0.67;0.74;99;0;1.9;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;1zh0;2;b;1;602;98;98;614;100;100;1.00;1.01;99;0;1.9;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;4pbt;1;b;1;605;99;98;614;100;99;0.85;0.90;97;0;1.9;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;2hgz;1;b;1;605;98;99;612;100;100;0.78;0.83;98;0;1.9;2.5;diffraction;diffraction;628;612;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;PBF   para-(benzoyl)-phenylalanine;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;4hjx;1;b;1;600;98;98;612;100;100;0.97;1.02;97;0;1.9;2.91;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;4BF   4-bromo-l-phenylalanine;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;4hk4;1;b;1;558;91;90;608;99;98;2.06;2.12;97;0;1.9;2.298;diffraction;diffraction;628;624;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;PEG   di(hydroxyethyl)ether;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;4hjr;1;c;1;570;93;93;613;100;100;1.88;1.93;97;0;1.9;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;4BF   4-bromo-l-phenylalanine;no/data;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2ag6;2;4nd6;1;b;1;552;90;91;596;97;98;1.94;2.01;98;0;1.9;2.0;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4BF   4-bromo-l-phenylalanine;GOL   glycerol;Crystal structure of p-bromo-l-phenylalanine-tRNA sythetase in complex with p-bromo-l-phenylalanine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;2pxh;2;b;1;604;99;99;612;100;100;0.81;0.86;97;0;2.2;1.97;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of a bipyridylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;4nd7;1;b;1;603;99;97;612;100;99;0.83;0.88;98;0;2.2;2.0;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;NA   sodium ion| BME   beta-mercaptoethanol;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;3d6v;2;b;1;611;100;99;612;100;99;0.32;0.32;100;0;2.2;2.2;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;2zp1;1;c;1;605;99;98;612;100;99;0.77;0.83;97;0;2.2;1.7;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;IYR   3-iodo-tyrosine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;1zh6;2;b;1;605;99;99;610;100;99;0.63;0.66;98;0;2.2;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;1zh0;2;b;1;601;98;98;612;100;100;0.92;0.93;98;0;2.2;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;4pbt;1;b;1;603;99;97;612;100;99;0.85;0.90;97;0;2.2;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;2hgz;1;c;1;605;99;99;612;100;100;0.75;0.81;97;0;2.2;2.5;diffraction;diffraction;628;612;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;PBF   para-(benzoyl)-phenylalanine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;4hjx;1;b;1;599;98;98;610;100;100;0.94;0.99;97;0;2.2;2.91;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;4hk4;1;c;1;552;90;89;605;99;98;2.11;2.20;96;0;2.2;2.298;diffraction;diffraction;628;624;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;PEG   di(hydroxyethyl)ether;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;4hjr;1;b;1;568;93;92;609;100;99;1.84;1.88;97;0;2.2;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;no/data;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6u;2;4nd6;1;b;1;554;91;91;598;98;99;1.93;2.01;97;0;2.2;2.0;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;T11   4-[3-(trifluoromethyl)diaziridin-3-yl]-l-phenylalanine| BME   beta-mercaptoethanol;GOL   glycerol;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;4nd7;1;b;1;608;99;98;612;100;99;0.59;0.60;98;0;1.97;2.0;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;NA   sodium ion| BME   beta-mercaptoethanol;Crystal structure of a bipyridylalanyl-tRNA synthetase;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;3d6v;2;b;1;603;99;98;612;100;99;0.83;0.88;97;0;1.97;2.2;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of a bipyridylalanyl-tRNA synthetase;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;2zp1;1;c;1;608;99;99;612;100;99;0.55;0.55;98;0;1.97;1.7;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;IYR   3-iodo-tyrosine;Crystal structure of a bipyridylalanyl-tRNA synthetase;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;1zh6;2;b;1;604;99;98;612;100;100;0.79;0.80;98;0;1.97;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of a bipyridylalanyl-tRNA synthetase;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;1zh0;2;b;1;599;98;98;612;100;100;1.02;1.06;97;0;1.97;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal structure of a bipyridylalanyl-tRNA synthetase;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;4pbt;1;b;1;607;99;98;612;100;99;0.62;0.62;97;0;1.97;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal structure of a bipyridylalanyl-tRNA synthetase;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;2hgz;1;c;1;610;100;100;612;100;100;0.36;0.36;97;0;1.97;2.5;diffraction;diffraction;628;612;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;PBF   para-(benzoyl)-phenylalanine;Crystal structure of a bipyridylalanyl-tRNA synthetase;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;4hjx;1;b;1;605;99;99;610;100;100;0.63;0.65;98;0;1.97;2.91;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of a bipyridylalanyl-tRNA synthetase;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;4hk4;1;c;1;560;92;91;608;99;98;2.01;2.07;97;0;1.97;2.298;diffraction;diffraction;628;624;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;PEG   di(hydroxyethyl)ether;Crystal structure of a bipyridylalanyl-tRNA synthetase;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;4hjr;1;b;1;569;93;93;611;100;99;1.86;1.89;98;0;1.97;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;no/data;Crystal structure of a bipyridylalanyl-tRNA synthetase;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2pxh;2;4nd6;1;b;1;567;93;94;602;98;99;1.72;1.78;98;0;1.97;2.0;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;BP5   3-(2,2'-bipyridin-5-yl)-l-alanine;GOL   glycerol;Crystal structure of a bipyridylalanyl-tRNA synthetase;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nd7;1;3d6v;2;b;1;606;98;98;616;99;100;0.88;0.93;98;0;2.0;2.2;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NA   sodium ion| BME   beta-mercaptoethanol;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;7.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nd7;1;2zp1;1;c;1;614;99;100;616;99;100;0.36;0.36;98;0;2.0;1.7;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NA   sodium ion| BME   beta-mercaptoethanol;IYR   3-iodo-tyrosine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nd7;1;1zh6;2;b;1;608;98;99;614;99;100;0.69;0.70;99;0;2.0;2.5;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NA   sodium ion| BME   beta-mercaptoethanol;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nd7;1;1zh0;2;b;1;597;96;97;614;99;100;1.18;1.22;98;0;2.0;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NA   sodium ion| BME   beta-mercaptoethanol;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nd7;1;4pbt;1;b;1;619;100;100;620;100;100;0.30;0.31;98;0;2.0;1.9;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NA   sodium ion| BME   beta-mercaptoethanol;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nd7;1;2hgz;1;b;1;609;98;100;612;99;100;0.48;0.48;97;0;2.0;2.5;diffraction;diffraction;628;612;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NA   sodium ion| BME   beta-mercaptoethanol;PBF   para-(benzoyl)-phenylalanine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nd7;1;4hjx;1;b;1;607;98;99;612;99;100;0.62;0.64;97;0;2.0;2.91;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;NA   sodium ion| BME   beta-mercaptoethanol;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nd7;1;4hk4;1;b;1;562;91;91;616;99;100;2.12;2.18;97;0;2.0;2.298;diffraction;diffraction;628;624;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NA   sodium ion| BME   beta-mercaptoethanol;PEG   di(hydroxyethyl)ether;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nd7;1;4hjr;1;b;1;572;92;93;615;99;100;1.88;1.91;97;0;2.0;2.5;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;NA   sodium ion| BME   beta-mercaptoethanol;no/data;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4nd7;1;4nd6;1;b;1;566;91;93;599;97;99;1.65;1.70;99;0;2.0;2.0;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NA   sodium ion| BME   beta-mercaptoethanol;GOL   glycerol;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the closed form;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.1;77;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6v;2;2zp1;1;c;1;606;98;98;614;100;100;0.81;0.87;97;0;2.2;1.7;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;IYR   3-iodo-tyrosine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.50;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6v;2;1zh6;2;b;1;604;98;98;610;99;99;0.70;0.73;98;0;2.2;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6v;2;1zh0;2;b;1;602;98;98;612;99;100;0.91;0.92;98;0;2.2;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6v;2;4pbt;1;b;1;606;98;98;616;100;99;0.90;0.95;97;0;2.2;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6v;2;2hgz;1;c;1;605;98;99;612;99;100;0.77;0.82;97;0;2.2;2.5;diffraction;diffraction;628;612;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;PBF   para-(benzoyl)-phenylalanine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6v;2;4hjx;1;b;1;599;97;98;610;99;100;0.94;1.00;97;0;2.2;2.91;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6v;2;4hk4;1;b;1;558;91;90;606;98;98;2.00;2.06;97;0;2.2;2.298;diffraction;diffraction;628;624;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;PEG   di(hydroxyethyl)ether;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6v;2;4hjr;1;c;1;568;92;92;611;99;99;1.89;1.93;97;0;2.2;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;no/data;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;3d6v;2;4nd6;1;b;1;557;90;92;597;97;99;1.85;1.92;97;0;2.2;2.0;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;TFQ   4-(2,2,2-trifluoroethyl)-l-phenylalanine| BME   beta-mercaptoethanol;GOL   glycerol;Crystal structure of 4-(trifluoromethyldiazirinyl)phenylalanyl-tRNA synthetase;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2zp1;1;1zh6;2;b;1;610;99;99;614;100;100;0.60;0.60;98;0;1.7;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;IYR   3-iodo-tyrosine;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.50;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2zp1;1;1zh0;2;b;1;595;97;97;614;100;100;1.23;1.27;97;0;1.7;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;IYR   3-iodo-tyrosine;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.50;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2zp1;1;4pbt;1;b;1;614;100;99;616;100;99;0.36;0.36;97;0;1.7;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;IYR   3-iodo-tyrosine;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.50;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2zp1;1;2hgz;1;c;1;609;99;100;612;99;100;0.45;0.45;98;0;1.7;2.5;diffraction;diffraction;628;612;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;IYR   3-iodo-tyrosine;PBF   para-(benzoyl)-phenylalanine;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.50;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2zp1;1;4hjx;1;b;1;606;98;99;612;99;100;0.67;0.69;97;0;1.7;2.91;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;IYR   3-iodo-tyrosine;F2Y   3,5-difluoro-l-tyrosine;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.50;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2zp1;1;4hk4;1;b;1;561;91;91;611;99;99;2.06;2.12;95;0;1.7;2.298;diffraction;diffraction;628;624;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;IYR   3-iodo-tyrosine;PEG   di(hydroxyethyl)ether;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.50;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2zp1;1;4hjr;1;b;1;573;93;93;614;100;100;1.83;1.86;97;0;1.7;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;IYR   3-iodo-tyrosine;no/data;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.50;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2zp1;1;4nd6;1;b;1;563;91;93;604;98;100;1.85;1.91;97;0;1.7;2.0;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;IYR   3-iodo-tyrosine;GOL   glycerol;Structual basis of iodo-tyrosine recognition by engineered archeal tyrosyl-tRNA synthetase;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.50;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh6;2;1zh0;2;b;1;594;97;97;612;100;100;1.21;1.24;99;0;2.5;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh6;2;4pbt;1;b;1;608;99;98;614;100;99;0.71;0.73;98;0;2.5;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh6;2;2hgz;1;b;1;607;99;99;612;100;100;0.65;0.66;98;0;2.5;2.5;diffraction;diffraction;628;612;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;PBF   para-(benzoyl)-phenylalanine;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh6;2;4hjx;1;b;1;603;98;98;612;100;100;0.87;0.90;97;0;2.5;2.91;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;F2Y   3,5-difluoro-l-tyrosine;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh6;2;4hk4;1;b;1;551;90;89;607;99;98;2.17;2.24;96;0;2.5;2.298;diffraction;diffraction;628;624;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;PEG   di(hydroxyethyl)ether;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh6;2;4hjr;1;b;1;568;93;92;613;100;100;1.93;1.97;97;0;2.5;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;no/data;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh6;2;4nd6;1;b;1;557;91;92;602;98;99;1.95;2.00;97;0;2.5;2.0;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;4AF   4-acetyl-l-phenylalanine| BME   beta-mercaptoethanol;GOL   glycerol;Crystal Structure of p-acetylphenylalanine-tRNA synthetase in complex with p-acetylphenylalanine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh0;2;4pbt;1;b;1;594;97;96;614;100;99;1.27;1.31;97;0;1.9;1.9;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;7.8;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh0;2;2hgz;1;c;1;598;97;98;612;100;100;1.08;1.12;97;0;1.9;2.5;diffraction;diffraction;628;612;Tyrosyl-tRNA synthetase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;PBF   para-(benzoyl)-phenylalanine;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh0;2;4hjx;1;c;1;597;97;97;612;100;100;1.11;1.16;97;0;1.9;2.91;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;F2Y   3,5-difluoro-l-tyrosine;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh0;2;4hk4;1;b;1;562;92;91;609;99;99;1.97;2.06;97;0;1.9;2.298;diffraction;diffraction;628;624;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;PEG   di(hydroxyethyl)ether;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh0;2;4hjr;1;b;1;562;91;91;609;99;99;1.99;2.05;96;0;1.9;2.5;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;no/data;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;1zh0;2;4nd6;1;b;1;575;94;95;598;97;99;1.37;1.46;98;0;1.9;2.0;diffraction;diffraction;628;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;NAL   beta-(2-naphthyl)-alanine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;GOL   glycerol;Crystal Structure of L-3-(2-napthyl)alanine-tRNA synthetase in complex with L-3-(2-napthyl)alanine;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbt;1;2hgz;1;b;1;609;98;100;612;99;100;0.49;0.49;97;0;1.9;2.5;diffraction;diffraction;628;612;Tyrosine--tRNA ligase;Tyrosyl-tRNA synthetase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;PBF   para-(benzoyl)-phenylalanine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.5;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbt;1;4hjx;1;b;1;607;98;99;612;99;100;0.62;0.64;98;0;1.9;2.91;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbt;1;4hk4;1;b;1;561;90;91;616;99;100;2.14;2.19;97;0;1.9;2.298;diffraction;diffraction;628;624;Tyrosine--tRNA ligase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;PEG   di(hydroxyethyl)ether;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbt;1;4hjr;1;b;1;572;92;93;615;99;100;1.89;1.92;98;0;1.9;2.5;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;no/data;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4pbt;1;4nd6;1;b;1;565;91;93;602;97;99;1.77;1.81;96;0;1.9;2.0;diffraction;diffraction;628;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;P4G   1-ethoxy-2-(2-ethoxyethoxy)ethane| GOL   glycerol| 2LQ   4-{[(1r,4e)-cyclooct-4-en-1-ylcarbonyl]amino}-l-phenylalanine;GOL   glycerol;Crystal structure of the M. jannaschii G2 tRNA synthetase variant bound to 4-trans-cyclooctene-amidopheylalanine (Tco-amF);Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.8;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2hgz;1;4hjx;1;b;1;606;99;99;610;100;100;0.58;0.60;96;0;2.5;2.91;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCOCCUS JANNASCHII DSM 2661;PBF   para-(benzoyl)-phenylalanine;F2Y   3,5-difluoro-l-tyrosine;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Crystal structure of F2YRS complexed with F2Y;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;no/data;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2hgz;1;4hk4;1;b;1;556;91;90;608;99;98;2.09;2.14;96;0;2.5;2.298;diffraction;diffraction;612;624;Tyrosyl-tRNA synthetase;Tyrosine--tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;PBF   para-(benzoyl)-phenylalanine;PEG   di(hydroxyethyl)ether;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2hgz;1;4hjr;1;b;1;566;92;92;611;100;99;1.94;1.97;96;0;2.5;2.5;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;PBF   para-(benzoyl)-phenylalanine;no/data;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;2hgz;1;4nd6;1;b;1;563;92;93;600;98;99;1.76;1.81;97;0;2.5;2.0;diffraction;diffraction;612;628;Tyrosyl-tRNA synthetase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;PBF   para-(benzoyl)-phenylalanine;GOL   glycerol;Crystal structure of a p-benzoyl-L-phenylalanyl-tRNA synthetase;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;8.5;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hjx;1;4hk4;1;c;1;553;90;90;609;100;99;2.17;2.24;98;0;2.91;2.298;diffraction;diffraction;628;624;Tyrosine-tRNA ligase;Tyrosine--tRNA ligase;METHANOCOCCUS JANNASCHII DSM 2661;METHANOCALDOCOCCUS JANNASCHII;F2Y   3,5-difluoro-l-tyrosine;PEG   di(hydroxyethyl)ether;Crystal structure of F2YRS complexed with F2Y;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;no/data;100;6.1;90;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hjx;1;4hjr;1;c;1;565;92;92;612;100;100;1.98;2.02;100;0;2.91;2.5;diffraction;diffraction;628;628;Tyrosine-tRNA ligase;Tyrosine-tRNA ligase;METHANOCOCCUS JANNASCHII DSM 2661;METHANOCALDOCOCCUS JANNASCHII DSM 2661;F2Y   3,5-difluoro-l-tyrosine;no/data;Crystal structure of F2YRS complexed with F2Y;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;no/data;100;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hjx;1;4nd6;1;b;1;568;93;94;604;99;100;1.74;1.81;96;0;2.91;2.0;diffraction;diffraction;628;628;Tyrosine-tRNA ligase;Tyrosine-tRNA ligase;METHANOCOCCUS JANNASCHII DSM 2661;METHANOCALDOCOCCUS JANNASCHII;F2Y   3,5-difluoro-l-tyrosine;GOL   glycerol;Crystal structure of F2YRS complexed with F2Y;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;no/data;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hk4;1;4hjr;1;b;1;604;98;98;615;100;100;0.92;0.94;98;0;2.298;2.5;diffraction;diffraction;624;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII DSM 2661;PEG   di(hydroxyethyl)ether;no/data;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Crystal structure of F2YRS;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;7.9;100;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hk4;1;4nd6;1;c;1;539;87;89;600;97;99;2.30;2.48;94;0;2.298;2.0;diffraction;diffraction;624;628;Tyrosine--tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII;METHANOCALDOCOCCUS JANNASCHII;PEG   di(hydroxyethyl)ether;GOL   glycerol;Crystal structure of apo Tyrosine-tRNA ligase mutant protein;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;6.1;90;8.1;77;1u7x_A;2ag6_A;1.69;2.74
4pbs;2;4hjr;1;4nd6;1;c;1;534;87;88;596;97;98;2.33;2.48;92;0;2.5;2.0;diffraction;diffraction;628;628;Tyrosine-tRNA ligase;Tyrosine-tRNA ligase;METHANOCALDOCOCCUS JANNASCHII DSM 2661;METHANOCALDOCOCCUS JANNASCHII;no/data;GOL   glycerol;Crystal structure of F2YRS;Crystal structure of apo 3-nitro-tyrosine tRNA synthetase (5B) in the open form;Q57834;tyrS MJ0389;PF00579;Q57834;tyrS MJ0389;PF00579;c;7.9;100;8.1;77;1u7x_A;2ag6_A;1.69;2.74
2pnc;2;2pnc;1;1tu5;1;b;1;1240;99;98;1246;100;98;0.51;0.51;100;0;2.4;2.37;diffraction;diffraction;1492;1492;Copper amine oxidase, liver isozyme;Copper amine oxidase, liver isozyme;BOS TAURUS;BOS TAURUS;TPQ   5-(2-carboxy-2-aminoethyl)-2-hydroxy-1,4-benzoquinone| NAG   n-acetyl-d-glucosamine| CU   copper (ii) ion| CA   calcium ion| CL   chloride ion| CLU   2,6-dichloro-n-imidazolidin-2-ylideneaniline;TPQ   5-(2-carboxy-2-aminoethyl)-2-hydroxy-1,4-benzoquinone| NDG   2-(acetylamino)-2-deoxy-a-d-glucopyranose| NAG   n-acetyl-d-glucosamine| CU   copper (ii) ion| CA   calcium ion| CL   chloride ion;Crystal Structure of Bovine Plasma Copper-Containing Amine Oxidase in Complex with Clonidine;Crystal structure of bovine plasma copper-containing amine oxidase;Q29437;no/data;PF01179,PF02727,PF02728;Q29437;no/data;PF01179,PF02727,PF02728;b;7.4;100;4.7;100;2pnc_B;1tu5_A;0.57;0.51
4aoa;2;4aoa;1;4ao9;1;b;1;861;100;99;862;100;100;0.17;0.17;100;0;2.28;1.5;diffraction;diffraction;908;908;BETA-PHENYLALANINE AMINOTRANSFERASE;BETA-PHENYLALANINE AMINOTRANSFERASE;VARIOVORAX PARADOXUS;VARIOVORAX PARADOXUS;IK2   4'-deoxy-4'-acetylyamino-pyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| GOL   glycerol;Biochemical properties and crystal structure of a novel beta- phenylalanine aminotransferase from Variovorax paradoxus;Biochemical properties and crystal structure of a novel beta- phenylalanine aminotransferase from Variovorax paradoxus;H8WR05;no/data;PF00202;H8WR05;no/data;PF00202;b;no/data;100;no/data;100;4aoa_B;4ao9_B;0.26;0.17
4oy3;2;4oy3;1;4bmy;1;b;1;427;93;96;441;96;99;1.26;1.30;96;0;1.2;1.65;diffraction;diffraction;462;502;Aminodeoxyfutalosine nucleosidase;MTA/SAH NUCLEOSIDASE;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SAH   s-adenosyl-l-homocysteine| CL   chloride ion;SO4   sulfate ion;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with S-Adenosylhomocysteine in the active site;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Q9ZMY2;mtnN mtn jhp_0082;PF01048;O24915;mtnN mtn HP_0089;PF01048;b;7.5;100;no/data;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4oy3;1;4bmx;1;b;1;443;96;97;453;98;99;1.03;1.07;96;0;1.2;1.76;diffraction;diffraction;462;502;Aminodeoxyfutalosine nucleosidase;MTA/SAH NUCLEOSIDASE;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SAH   s-adenosyl-l-homocysteine| CL   chloride ion;TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| ADE   adenine;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with S-Adenosylhomocysteine in the active site;Native structure of futalosine hydrolase of Helicobacter pylori strain 26695;Q9ZMY2;mtnN mtn jhp_0082;PF01048;O24915;mtnN mtn HP_0089;PF01048;b;7.5;100;no/data;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4oy3;1;4ojt;1;b;1;460;100;100;460;100;100;0.13;0.13;100;0;1.2;1.5;diffraction;diffraction;462;462;Aminodeoxyfutalosine nucleosidase;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SAH   s-adenosyl-l-homocysteine| CL   chloride ion;2WP   (2s)-2-amino-4-({[(2s,3s,4r,5s)-3,4,5-trihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid| ADE   adenine;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with S-Adenosylhomocysteine in the active site;Helicobacter pylori MTAN complexed with S-ribosylhomocysteine and adenine;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;7.5;100;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4oy3;1;3nm4;1;b;1;442;96;98;450;98;100;0.95;0.99;100;0;1.2;1.7;diffraction;diffraction;462;460;Aminodeoxyfutalosine nucleosidase;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SAH   s-adenosyl-l-homocysteine| CL   chloride ion;EDO   1,2-ethanediol| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with S-Adenosylhomocysteine in the active site;Helicobacter pylori MTAN;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;7.5;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4oy3;1;4bmz;1;b;1;458;99;99;460;100;99;0.51;0.52;96;0;1.2;1.79;diffraction;diffraction;462;502;Aminodeoxyfutalosine nucleosidase;MTA/SAH NUCLEOSIDASE;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SAH   s-adenosyl-l-homocysteine| CL   chloride ion;MTA   5'-deoxy-5'-methylthioadenosine;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with S-Adenosylhomocysteine in the active site;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Q9ZMY2;mtnN mtn jhp_0082;PF01048;O24915;mtnN mtn HP_0089;PF01048;b;7.5;100;no/data;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4oy3;1;3nm5;1;b;1;457;99;100;458;100;100;0.40;0.40;100;0;1.2;1.8;diffraction;diffraction;462;460;Aminodeoxyfutalosine nucleosidase;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SAH   s-adenosyl-l-homocysteine| CL   chloride ion;FMC   (1s)-1-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-d-ribitol;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with S-Adenosylhomocysteine in the active site;Helicobacter pylori MTAN complexed with Formycin A;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;7.5;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4oy3;1;3nm6;1;b;1;457;99;100;458;100;100;0.26;0.26;100;0;1.2;1.602;diffraction;diffraction;462;460;Aminodeoxyfutalosine nucleosidase;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SAH   s-adenosyl-l-homocysteine| CL   chloride ion;ADE   adenine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| EDO   1,2-ethanediol;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with S-Adenosylhomocysteine in the active site;Helicobacter pylori MTAN complexed with adenine and tris;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;7.5;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4oy3;1;4p54;1;b;1;460;100;100;460;100;100;0.10;0.10;100;0;1.2;1.65;diffraction;diffraction;462;462;Aminodeoxyfutalosine nucleosidase;Aminodeoxyfutalosine nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SAH   s-adenosyl-l-homocysteine| CL   chloride ion;MTA   5'-deoxy-5'-methylthioadenosine| CL   chloride ion;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with S-Adenosylhomocysteine in the active site;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with 5'-methylthioadenosine in the active site.;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;7.5;100;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmy;1;4bmx;1;b;1;436;98;95;441;99;96;0.76;0.78;100;0;1.65;1.76;diffraction;diffraction;502;502;MTA/SAH NUCLEOSIDASE;MTA/SAH NUCLEOSIDASE;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SO4   sulfate ion;TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| ADE   adenine;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Native structure of futalosine hydrolase of Helicobacter pylori strain 26695;O24915;mtnN mtn HP_0089;PF01048;O24915;mtnN mtn HP_0089;PF01048;b;no/data;100;no/data;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmy;1;4ojt;1;b;1;426;96;92;441;99;95;1.29;1.34;96;0;1.65;1.5;diffraction;diffraction;502;462;MTA/SAH NUCLEOSIDASE;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SO4   sulfate ion;2WP   (2s)-2-amino-4-({[(2s,3s,4r,5s)-3,4,5-trihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid| ADE   adenine;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Helicobacter pylori MTAN complexed with S-ribosylhomocysteine and adenine;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmy;1;3nm4;1;b;1;433;97;96;439;99;97;0.83;0.85;96;0;1.65;1.7;diffraction;diffraction;502;460;MTA/SAH NUCLEOSIDASE;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SO4   sulfate ion;EDO   1,2-ethanediol| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Helicobacter pylori MTAN;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmy;1;4bmz;1;b;1;430;97;93;441;99;95;1.10;1.15;100;0;1.65;1.79;diffraction;diffraction;502;502;MTA/SAH NUCLEOSIDASE;MTA/SAH NUCLEOSIDASE;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SO4   sulfate ion;MTA   5'-deoxy-5'-methylthioadenosine;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;O24915;mtnN mtn HP_0089;PF01048;O24915;mtnN mtn HP_0089;PF01048;b;no/data;100;no/data;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmy;1;3nm5;1;b;1;425;96;93;437;98;95;1.14;1.18;97;0;1.65;1.8;diffraction;diffraction;502;460;MTA/SAH NUCLEOSIDASE;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SO4   sulfate ion;FMC   (1s)-1-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-d-ribitol;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Helicobacter pylori MTAN complexed with Formycin A;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmy;1;3nm6;1;b;1;424;95;93;439;99;96;1.29;1.33;96;0;1.65;1.602;diffraction;diffraction;502;460;MTA/SAH NUCLEOSIDASE;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SO4   sulfate ion;ADE   adenine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| EDO   1,2-ethanediol;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Helicobacter pylori MTAN complexed with adenine and tris;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmy;1;4p54;1;b;1;427;96;92;441;99;95;1.28;1.33;96;0;1.65;1.65;diffraction;diffraction;502;462;MTA/SAH NUCLEOSIDASE;Aminodeoxyfutalosine nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;SO4   sulfate ion;MTA   5'-deoxy-5'-methylthioadenosine| CL   chloride ion;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with 5'-methylthioadenosine in the active site.;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmx;1;4ojt;1;b;1;443;97;96;453;99;98;1.05;1.10;96;0;1.76;1.5;diffraction;diffraction;502;462;MTA/SAH NUCLEOSIDASE;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| ADE   adenine;2WP   (2s)-2-amino-4-({[(2s,3s,4r,5s)-3,4,5-trihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid| ADE   adenine;Native structure of futalosine hydrolase of Helicobacter pylori strain 26695;Helicobacter pylori MTAN complexed with S-ribosylhomocysteine and adenine;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmx;1;3nm4;1;b;1;449;98;100;451;98;100;0.42;0.42;96;0;1.76;1.7;diffraction;diffraction;502;460;MTA/SAH NUCLEOSIDASE;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| ADE   adenine;EDO   1,2-ethanediol| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Native structure of futalosine hydrolase of Helicobacter pylori strain 26695;Helicobacter pylori MTAN;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmx;1;4bmz;1;b;1;447;98;96;455;99;98;0.91;0.95;100;0;1.76;1.79;diffraction;diffraction;502;502;MTA/SAH NUCLEOSIDASE;MTA/SAH NUCLEOSIDASE;HELICOBACTER PYLORI;HELICOBACTER PYLORI;TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| ADE   adenine;MTA   5'-deoxy-5'-methylthioadenosine;Native structure of futalosine hydrolase of Helicobacter pylori strain 26695;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;O24915;mtnN mtn HP_0089;PF01048;O24915;mtnN mtn HP_0089;PF01048;b;no/data;100;no/data;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmx;1;3nm5;1;b;1;443;97;97;451;98;98;0.97;1.00;96;0;1.76;1.8;diffraction;diffraction;502;460;MTA/SAH NUCLEOSIDASE;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| ADE   adenine;FMC   (1s)-1-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-d-ribitol;Native structure of futalosine hydrolase of Helicobacter pylori strain 26695;Helicobacter pylori MTAN complexed with Formycin A;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmx;1;3nm6;1;b;1;441;96;96;451;98;98;1.03;1.06;96;0;1.76;1.602;diffraction;diffraction;502;460;MTA/SAH NUCLEOSIDASE;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| ADE   adenine;ADE   adenine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| EDO   1,2-ethanediol;Native structure of futalosine hydrolase of Helicobacter pylori strain 26695;Helicobacter pylori MTAN complexed with adenine and tris;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmx;1;4p54;1;b;1;443;97;96;452;99;98;1.02;1.06;96;0;1.76;1.65;diffraction;diffraction;502;462;MTA/SAH NUCLEOSIDASE;Aminodeoxyfutalosine nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| ADE   adenine;MTA   5'-deoxy-5'-methylthioadenosine| CL   chloride ion;Native structure of futalosine hydrolase of Helicobacter pylori strain 26695;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with 5'-methylthioadenosine in the active site.;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4ojt;1;3nm4;1;b;1;441;95;98;450;97;100;0.99;1.02;100;0;1.5;1.7;diffraction;diffraction;462;460;MTA/SAH nucleosidase;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;2WP   (2s)-2-amino-4-({[(2s,3s,4r,5s)-3,4,5-trihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid| ADE   adenine;EDO   1,2-ethanediol| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;Helicobacter pylori MTAN complexed with S-ribosylhomocysteine and adenine;Helicobacter pylori MTAN;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;7.5;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4ojt;1;4bmz;1;b;1;458;99;99;461;100;99;0.57;0.60;95;0;1.5;1.79;diffraction;diffraction;462;502;MTA/SAH nucleosidase;MTA/SAH NUCLEOSIDASE;HELICOBACTER PYLORI;HELICOBACTER PYLORI;2WP   (2s)-2-amino-4-({[(2s,3s,4r,5s)-3,4,5-trihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid| ADE   adenine;MTA   5'-deoxy-5'-methylthioadenosine;Helicobacter pylori MTAN complexed with S-ribosylhomocysteine and adenine;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Q9ZMY2;mtnN mtn jhp_0082;PF01048;O24915;mtnN mtn HP_0089;PF01048;b;7.5;100;no/data;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4ojt;1;3nm5;1;b;1;457;99;100;458;99;100;0.39;0.39;100;0;1.5;1.8;diffraction;diffraction;462;460;MTA/SAH nucleosidase;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;2WP   (2s)-2-amino-4-({[(2s,3s,4r,5s)-3,4,5-trihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid| ADE   adenine;FMC   (1s)-1-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-d-ribitol;Helicobacter pylori MTAN complexed with S-ribosylhomocysteine and adenine;Helicobacter pylori MTAN complexed with Formycin A;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;7.5;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4ojt;1;3nm6;1;b;1;458;99;100;458;99;100;0.20;0.20;100;0;1.5;1.602;diffraction;diffraction;462;460;MTA/SAH nucleosidase;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;2WP   (2s)-2-amino-4-({[(2s,3s,4r,5s)-3,4,5-trihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid| ADE   adenine;ADE   adenine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| EDO   1,2-ethanediol;Helicobacter pylori MTAN complexed with S-ribosylhomocysteine and adenine;Helicobacter pylori MTAN complexed with adenine and tris;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;7.5;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4ojt;1;4p54;1;b;1;462;100;100;462;100;100;0.10;0.10;100;0;1.5;1.65;diffraction;diffraction;462;462;MTA/SAH nucleosidase;Aminodeoxyfutalosine nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;2WP   (2s)-2-amino-4-({[(2s,3s,4r,5s)-3,4,5-trihydroxytetrahydrofuran-2-yl]methyl}sulfanyl)butanoic acid| ADE   adenine;MTA   5'-deoxy-5'-methylthioadenosine| CL   chloride ion;Helicobacter pylori MTAN complexed with S-ribosylhomocysteine and adenine;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with 5'-methylthioadenosine in the active site.;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;7.5;100;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;3nm4;1;4bmz;1;b;1;442;98;95;450;100;97;0.91;0.94;96;0;1.7;1.79;diffraction;diffraction;460;502;MTA/SAH nucleosidase;MTA/SAH NUCLEOSIDASE;HELICOBACTER PYLORI;HELICOBACTER PYLORI;EDO   1,2-ethanediol| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;MTA   5'-deoxy-5'-methylthioadenosine;Helicobacter pylori MTAN;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Q9ZMY2;mtnN mtn jhp_0082;PF01048;O24915;mtnN mtn HP_0089;PF01048;b;8.5;95;no/data;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;3nm4;1;3nm5;1;b;1;442;98;97;450;100;98;0.94;0.98;100;0;1.7;1.8;diffraction;diffraction;460;460;MTA/SAH nucleosidase;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;EDO   1,2-ethanediol| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;FMC   (1s)-1-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-d-ribitol;Helicobacter pylori MTAN;Helicobacter pylori MTAN complexed with Formycin A;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;8.5;95;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;3nm4;1;3nm6;1;b;1;441;98;96;450;100;98;0.99;1.03;100;0;1.7;1.602;diffraction;diffraction;460;460;MTA/SAH nucleosidase;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;EDO   1,2-ethanediol| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;ADE   adenine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| EDO   1,2-ethanediol;Helicobacter pylori MTAN;Helicobacter pylori MTAN complexed with adenine and tris;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;8.5;95;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;3nm4;1;4p54;1;b;1;441;98;96;450;100;97;0.98;1.01;100;0;1.7;1.65;diffraction;diffraction;460;462;MTA/SAH nucleosidase;Aminodeoxyfutalosine nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;EDO   1,2-ethanediol| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol;MTA   5'-deoxy-5'-methylthioadenosine| CL   chloride ion;Helicobacter pylori MTAN;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with 5'-methylthioadenosine in the active site.;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;8.5;95;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmz;1;3nm5;1;b;1;457;98;100;458;99;100;0.39;0.39;96;0;1.79;1.8;diffraction;diffraction;502;460;MTA/SAH NUCLEOSIDASE;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;MTA   5'-deoxy-5'-methylthioadenosine;FMC   (1s)-1-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-d-ribitol;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Helicobacter pylori MTAN complexed with Formycin A;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmz;1;3nm6;1;b;1;456;98;100;458;99;100;0.45;0.46;96;0;1.79;1.602;diffraction;diffraction;502;460;MTA/SAH NUCLEOSIDASE;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;MTA   5'-deoxy-5'-methylthioadenosine;ADE   adenine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| EDO   1,2-ethanediol;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Helicobacter pylori MTAN complexed with adenine and tris;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;4bmz;1;4p54;1;b;1;458;99;99;461;99;100;0.56;0.59;96;0;1.79;1.65;diffraction;diffraction;502;462;MTA/SAH NUCLEOSIDASE;Aminodeoxyfutalosine nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;MTA   5'-deoxy-5'-methylthioadenosine;MTA   5'-deoxy-5'-methylthioadenosine| CL   chloride ion;Structure of futalosine hydrolase mutant of Helicobacter pylori strain 26695;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with 5'-methylthioadenosine in the active site.;O24915;mtnN mtn HP_0089;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;no/data;100;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;3nm5;1;3nm6;1;b;1;457;100;100;458;100;100;0.31;0.31;100;0;1.8;1.602;diffraction;diffraction;460;460;MTA/SAH nucleosidase;MTA/SAH nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;FMC   (1s)-1-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-d-ribitol;ADE   adenine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| EDO   1,2-ethanediol;Helicobacter pylori MTAN complexed with Formycin A;Helicobacter pylori MTAN complexed with adenine and tris;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;8.5;95;8.5;95;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;3nm5;1;4p54;1;b;1;457;100;99;458;100;99;0.39;0.39;100;0;1.8;1.65;diffraction;diffraction;460;462;MTA/SAH nucleosidase;Aminodeoxyfutalosine nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;FMC   (1s)-1-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-d-ribitol;MTA   5'-deoxy-5'-methylthioadenosine| CL   chloride ion;Helicobacter pylori MTAN complexed with Formycin A;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with 5'-methylthioadenosine in the active site.;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;8.5;95;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4oy3;2;3nm6;1;4p54;1;b;1;458;100;99;458;100;99;0.23;0.23;100;0;1.602;1.65;diffraction;diffraction;460;462;MTA/SAH nucleosidase;Aminodeoxyfutalosine nucleosidase;HELICOBACTER PYLORI;HELICOBACTER PYLORI;ADE   adenine| TRS   2-amino-2-hydroxymethyl-propane-1,3-diol| EDO   1,2-ethanediol;MTA   5'-deoxy-5'-methylthioadenosine| CL   chloride ion;Helicobacter pylori MTAN complexed with adenine and tris;Crystal Structure of the Helicobacter pylori MTAN-D198N mutant with 5'-methylthioadenosine in the active site.;Q9ZMY2;mtnN mtn jhp_0082;PF01048;Q9ZMY2;mtnN mtn jhp_0082;PF01048;b;8.5;95;7.5;100;4ojt_A;3nm4_B;1.33;1.34
4b5d;5;4b5d;1;4afg;1;b;1;1050;100;99;1054;100;99;0.43;0.43;100;0;2.195;2.001;diffraction;diffraction;1150;1150;CAPITELLA TELETA ACHBP;CAPITELLA TELETA ACHBP;CAPITELLA TELETA;CAPITELLA TELETA;NAG   n-acetyl-d-glucosamine| SW4   2-[(1r,2s)-2-[5-[[(2s)-azetidin-2-yl]methoxy]pyridin-3-yl]cyclopropyl]ethanol;NAG   n-acetyl-d-glucosamine| BMA   beta-d-mannose| MAN   alpha-d-mannose| QMR   varenicline;Capitella teleta AChBP in complex with psychonicline (3-((2(S)- Azetidinyl)methoxy)-5-((1S,2R)-2-(2-hydroxyethyl)cyclopropyl)pyridine);Capitella teleta AChBP in complex with varenicline;I6L8L2;no/data;PF02931;I6L8L2;no/data;PF02931;b;no/data;100;no/data;100;4afg_D;4afh_C;0.62;0.50
4b5d;5;4b5d;1;4afh;1;b;1;1050;100;99;1055;100;99;0.46;0.47;100;0;2.195;1.88;diffraction;diffraction;1150;1150;CAPITELLA TELETA ACHBP;ACHBP;CAPITELLA TELETA;CAPITELLA TELETA;NAG   n-acetyl-d-glucosamine| SW4   2-[(1r,2s)-2-[5-[[(2s)-azetidin-2-yl]methoxy]pyridin-3-yl]cyclopropyl]ethanol;NAG   n-acetyl-d-glucosamine| BMA   beta-d-mannose| MAN   alpha-d-mannose| L0B   alpha-lobeline;Capitella teleta AChBP in complex with psychonicline (3-((2(S)- Azetidinyl)methoxy)-5-((1S,2R)-2-(2-hydroxyethyl)cyclopropyl)pyridine);Capitella teleta AChBP in complex with lobeline;I6L8L2;no/data;PF02931;I6L8L2;no/data;PF02931;b;no/data;100;no/data;100;4afg_D;4afh_C;0.62;0.50
4b5d;5;4afg;1;4afh;1;b;1;1055;100;99;1060;100;100;0.48;0.50;100;0;2.001;1.88;diffraction;diffraction;1150;1150;CAPITELLA TELETA ACHBP;ACHBP;CAPITELLA TELETA;CAPITELLA TELETA;NAG   n-acetyl-d-glucosamine| BMA   beta-d-mannose| MAN   alpha-d-mannose| QMR   varenicline;NAG   n-acetyl-d-glucosamine| BMA   beta-d-mannose| MAN   alpha-d-mannose| L0B   alpha-lobeline;Capitella teleta AChBP in complex with varenicline;Capitella teleta AChBP in complex with lobeline;I6L8L2;no/data;PF02931;I6L8L2;no/data;PF02931;b;no/data;100;no/data;100;4afg_D;4afh_C;0.62;0.50
3sh1;5;3sh1;2;3sio;2;b;1;1063;99;98;1069;100;99;0.51;0.51;97;0;2.9;2.32;diffraction;diffraction;1150;1150;Soluble acetylcholine receptor;Soluble acetylcholine receptor;APLYSIA CALIFORNICA;APLYSIA CALIFORNICA;MG   magnesium ion| NAG   n-acetyl-d-glucosamine| MLK   methyllycaconitine| MPD   (4s)-2-methyl-2,4-pentanediol| MRD   (4r)-2-methylpentane-2,4-diol| ACT   acetate ion| BMA   beta-d-mannose;NAG   n-acetyl-d-glucosamine| MRD   (4r)-2-methylpentane-2,4-diol| MLK   methyllycaconitine| BMA   beta-d-mannose| MAN   alpha-d-mannose| MPD   (4s)-2-methyl-2,4-pentanediol;Ac-AChBP ligand binding domain mutated to human alpha-7 nAChR;Ac-AChBP ligand binding domain (not including beta 9-10 linker) mutated to human alpha-7 nAChR;Q8WSF8;no/data;PF02931;Q8WSF8;no/data;PF02931;b;6.5;100;4.6;100;3sh1_A;3sio_I;0.57;0.51
4hza;2;4hza;1;4dfh;1;b;1;231;93;93;244;98;98;1.65;1.74;83;0;1.7;1.85;diffraction;diffraction;256;256;Poliovirus receptor-related protein 2;Poliovirus receptor-related protein 2;HOMO SAPIENS;HOMO SAPIENS;no/data;no/data;Crystal Structure of the Immunoglobulin variable domain of Nectin-2 in monoclinic form;Crystal structure of cell adhesion molecule nectin-2/CD112 variable domain;Q92692;NECTIN2 HVEB PRR2 PVRL2;PF08205,PF07686;Q92692;NECTIN2 HVEB PRR2 PVRL2;PF08205,PF07686;c;5.5;100;5.5;100;4dfh_A;3r0n_A;0.89;1.74
4hza;2;4hza;1;3r0n;1;b;1;244;98;95;248;100;97;0.88;0.91;100;0;1.7;1.3;diffraction;diffraction;256;256;Poliovirus receptor-related protein 2;Poliovirus receptor-related protein 2;HOMO SAPIENS;HOMO SAPIENS;no/data;MG   magnesium ion| CL   chloride ion;Crystal Structure of the Immunoglobulin variable domain of Nectin-2 in monoclinic form;Crystal Structure of the Immunoglobulin variable domain of Nectin-2;Q92692;NECTIN2 HVEB PRR2 PVRL2;PF08205,PF07686;Q92692;NECTIN2 HVEB PRR2 PVRL2;PF08205,PF07686;c;5.5;100;8.5;100;4dfh_A;3r0n_A;0.89;1.74
4hza;2;4dfh;1;3r0n;1;b;1;245;99;96;248;100;97;0.82;0.83;100;0;1.85;1.3;diffraction;diffraction;256;256;Poliovirus receptor-related protein 2;Poliovirus receptor-related protein 2;HOMO SAPIENS;HOMO SAPIENS;no/data;MG   magnesium ion| CL   chloride ion;Crystal structure of cell adhesion molecule nectin-2/CD112 variable domain;Crystal Structure of the Immunoglobulin variable domain of Nectin-2;Q92692;NECTIN2 HVEB PRR2 PVRL2;PF08205,PF07686;Q92692;NECTIN2 HVEB PRR2 PVRL2;PF08205,PF07686;c;5.5;100;8.5;100;4dfh_A;3r0n_A;0.89;1.74
1de5;4;1de5;1;1de6;1;b;1;1661;100;100;1664;100;100;0.32;0.32;100;0;2.2;2.1;diffraction;diffraction;1704;1704;L-RHAMNOSE ISOMERASE;L-RHAMNOSE ISOMERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;RNT   l-rhamnitol| ZN   zinc ion;RNS   l-rhamnose| ZN   zinc ion| MN   manganese (ii) ion;L-RHAMNOSE ISOMERASE;L-RHAMNOSE ISOMERASE;P32170;rhaA b3903 JW5561;PF06134;P32170;rhaA b3903 JW5561;PF06134;b;6.4;195;no/data;195;1de5_A;1d8w_D;0.45;0.46
1de5;4;1de5;1;1d8w;1;b;1;1599;96;99;1606;96;100;0.45;0.46;100;0;2.2;1.6;diffraction;diffraction;1704;1704;L-RHAMNOSE ISOMERASE;L-RHAMNOSE ISOMERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;RNT   l-rhamnitol| ZN   zinc ion;MSE   selenomethionine| ZN   zinc ion;L-RHAMNOSE ISOMERASE;L-RHAMNOSE ISOMERASE;P32170;rhaA b3903 JW5561;PF06134;P32170;rhaA b3903 JW5561;PF06134;b;6.4;195;6.4;190;1de5_A;1d8w_D;0.45;0.46
1de5;4;1de6;1;1d8w;1;b;1;1603;96;100;1605;96;100;0.27;0.27;100;0;2.1;1.6;diffraction;diffraction;1704;1704;L-RHAMNOSE ISOMERASE;L-RHAMNOSE ISOMERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;RNS   l-rhamnose| ZN   zinc ion| MN   manganese (ii) ion;MSE   selenomethionine| ZN   zinc ion;L-RHAMNOSE ISOMERASE;L-RHAMNOSE ISOMERASE;P32170;rhaA b3903 JW5561;PF06134;P32170;rhaA b3903 JW5561;PF06134;b;no/data;195;6.4;190;1de5_A;1d8w_D;0.45;0.46
3ku7;2;3ku7;1;3mcd;1;b;1;109;92;99;111;93;100;0.82;0.83;100;0;2.8;3.2;diffraction;diffraction;160;160;Cell division topological specificity factor;Cell division topological specificity factor;HELICOBACTER PYLORI;HELICOBACTER PYLORI;no/data;no/data;Crystal structure of Helicobacter pylori MinE, a cell division topological specificity factor;Crystal structure of Helicobacter pylori MinE, a cell division topological specificity factor;O25099;minE HP_0332;PF03776;O25099;minE HP_0332;PF03776;a;6.5;100;6.5;100;3mcd_A;3mcd_B;1.80;0.83
1lwh;2;1lwh;1;1lwj;1;b;1;872;99;99;882;100;100;0.75;0.77;100;0;2.6;2.5;diffraction;diffraction;882;882;4-alpha-glucanotransferase;4-ALPHA-GLUCANOTRANSFERASE;THERMOTOGA MARITIMA;THERMOTOGA MARITIMA;CA   calcium ion;ACG   modified acarbose pentasaccharide| CA   calcium ion;CRYSTAL STRUCTURE OF T. MARITIMA 4-ALPHA-GLUCANOTRANSFERASE;CRYSTAL STRUCTURE OF T. MARITIMA 4-ALPHA-GLUCANOTRANSFERASE/ACARBOSE COMPLEX;P80099;mgtA TM_0364;PF00128,PF09178;P80099;mgtA TM_0364;PF00128,PF09178;b;6.5;100;6.5;100;1lwh_A;1lwj_B;0.77;0.77
4ea7;3;4ea7;1;4eaa;1;b;1;621;100;99;621;100;99;0.12;0.12;100;0;1.0;1.45;diffraction;diffraction;660;660;Perosamine N-acetyltransferase;Perosamine N-acetyltransferase;CAULOBACTER VIBRIOIDES;CAULOBACTER VIBRIOIDES;COA   coenzyme a| JB2   gdp-perosamine| CL   chloride ion;JB2   gdp-perosamine| COA   coenzyme a| NA   sodium ion| CL   chloride ion;X-ray crystal structure of PerB from Caulobacter crescentus in complex with CoA and GDP-perosamine at 1.0 Angstrom resolution;X-ray crystal structure of the H141N mutant of perosamine N-acetyltransferase from Caulobacter crescentus in complex with CoA and GDP-perosamine;O85353;wbqR;PF00132,PF17836;O85353;wbqR;PF00132,PF17836;b;7.5;100;7.5;100;4eaa_A;4ea8_A;0.17;0.21
4ea7;3;4ea7;1;4ea8;1;b;1;621;100;100;621;100;100;0.17;0.17;100;0;1.0;1.0;diffraction;diffraction;660;660;Perosamine N-acetyltransferase;Perosamine N-acetyltransferase;CAULOBACTER VIBRIOIDES;CAULOBACTER VIBRIOIDES;COA   coenzyme a| JB2   gdp-perosamine| CL   chloride ion;COA   coenzyme a| JB3   gdp-n-acetylperosamine| CL   chloride ion;X-ray crystal structure of PerB from Caulobacter crescentus in complex with CoA and GDP-perosamine at 1.0 Angstrom resolution;X-ray crystal structure of PerB from Caulobacter crescentus in complex with coenzyme A and GDP-N-acetylperosamine at 1 Angstrom resolution;O85353;wbqR;PF00132,PF17836;O85353;wbqR;PF00132,PF17836;b;7.5;100;7.5;100;4eaa_A;4ea8_A;0.17;0.21
4ea7;3;4ea7;1;4eab;1;b;1;621;100;99;621;100;99;0.14;0.14;100;0;1.0;1.35;diffraction;diffraction;660;660;Perosamine N-acetyltransferase;Perosamine N-acetyltransferase;CAULOBACTER VIBRIOIDES;CAULOBACTER VIBRIOIDES;COA   coenzyme a| JB2   gdp-perosamine| CL   chloride ion;JB2   gdp-perosamine| COA   coenzyme a| NA   sodium ion| CL   chloride ion;X-ray crystal structure of PerB from Caulobacter crescentus in complex with CoA and GDP-perosamine at 1.0 Angstrom resolution;X-ray crystal structure of the H141A mutant of GDP-perosamine N-acetyl transferase from Caulobacter crescentus in complex with CoA and GDP-perosamine;O85353;wbqR;PF00132,PF17836;O85353;wbqR;PF00132,PF17836;b;7.5;100;7.5;100;4eaa_A;4ea8_A;0.17;0.21
4ea7;3;4ea7;1;4ea9;1;b;1;621;100;100;621;100;100;0.15;0.15;100;0;1.0;0.9;diffraction;diffraction;660;660;Perosamine N-acetyltransferase;Perosamine N-acetyltransferase;CAULOBACTER VIBRIOIDES;CAULOBACTER VIBRIOIDES;COA   coenzyme a| JB2   gdp-perosamine| CL   chloride ion;JBT   gdp-n-acetylperosamine-coenzyme a| CL   chloride ion;X-ray crystal structure of PerB from Caulobacter crescentus in complex with CoA and GDP-perosamine at 1.0 Angstrom resolution;X-ray structure of GDP-perosamine N-acetyltransferase in complex with transition state analog at 0.9 Angstrom resolution;O85353;wbqR;PF00132,PF17836;O85353;wbqR;PF00132,PF17836;b;7.5;100;7.5;100;4eaa_A;4ea8_A;0.17;0.21
4ea7;3;4eaa;1;4ea8;1;b;1;620;98;100;621;99;100;0.21;0.21;100;0;1.45;1.0;diffraction;diffraction;660;660;Perosamine N-acetyltransferase;Perosamine N-acetyltransferase;CAULOBACTER VIBRIOIDES;CAULOBACTER VIBRIOIDES;JB2   gdp-perosamine| COA   coenzyme a| NA   sodium ion| CL   chloride ion;COA   coenzyme a| JB3   gdp-n-acetylperosamine| CL   chloride ion;X-ray crystal structure of the H141N mutant of perosamine N-acetyltransferase from Caulobacter crescentus in complex with CoA and GDP-perosamine;X-ray crystal structure of PerB from Caulobacter crescentus in complex with coenzyme A and GDP-N-acetylperosamine at 1 Angstrom resolution;O85353;wbqR;PF00132,PF17836;O85353;wbqR;PF00132,PF17836;b;7.5;100;7.5;100;4eaa_A;4ea8_A;0.17;0.21
4ea7;3;4eaa;1;4eab;1;b;1;630;100;100;630;100;100;0.13;0.13;100;0;1.45;1.35;diffraction;diffraction;660;660;Perosamine N-acetyltransferase;Perosamine N-acetyltransferase;CAULOBACTER VIBRIOIDES;CAULOBACTER VIBRIOIDES;JB2   gdp-perosamine| COA   coenzyme a| NA   sodium ion| CL   chloride ion;JB2   gdp-perosamine| COA   coenzyme a| NA   sodium ion| CL   chloride ion;X-ray crystal structure of the H141N mutant of perosamine N-acetyltransferase from Caulobacter crescentus in complex with CoA and GDP-perosamine;X-ray crystal structure of the H141A mutant of GDP-perosamine N-acetyl transferase from Caulobacter crescentus in complex with CoA and GDP-perosamine;O85353;wbqR;PF00132,PF17836;O85353;wbqR;PF00132,PF17836;b;7.5;100;7.5;100;4eaa_A;4ea8_A;0.17;0.21
4ea7;3;4eaa;1;4ea9;1;b;1;621;99;100;621;99;100;0.15;0.16;100;0;1.45;0.9;diffraction;diffraction;660;660;Perosamine N-acetyltransferase;Perosamine N-acetyltransferase;CAULOBACTER VIBRIOIDES;CAULOBACTER VIBRIOIDES;JB2   gdp-perosamine| COA   coenzyme a| NA   sodium ion| CL   chloride ion;JBT   gdp-n-acetylperosamine-coenzyme a| CL   chloride ion;X-ray crystal structure of the H141N mutant of perosamine N-acetyltransferase from Caulobacter crescentus in complex with CoA and GDP-perosamine;X-ray structure of GDP-perosamine N-acetyltransferase in complex with transition state analog at 0.9 Angstrom resolution;O85353;wbqR;PF00132,PF17836;O85353;wbqR;PF00132,PF17836;b;7.5;100;7.5;100;4eaa_A;4ea8_A;0.17;0.21
4ea7;3;4ea8;1;4eab;1;b;1;621;100;99;621;100;99;0.16;0.16;100;0;1.0;1.35;diffraction;diffraction;660;660;Perosamine N-acetyltransferase;Perosamine N-acetyltransferase;CAULOBACTER VIBRIOIDES;CAULOBACTER VIBRIOIDES;COA   coenzyme a| JB3   gdp-n-acetylperosamine| CL   chloride ion;JB2   gdp-perosamine| COA   coenzyme a| NA   sodium ion| CL   chloride ion;X-ray crystal structure of PerB from Caulobacter crescentus in complex with coenzyme A and GDP-N-acetylperosamine at 1 Angstrom resolution;X-ray crystal structure of the H141A mutant of GDP-perosamine N-acetyl transferase from Caulobacter crescentus in complex with CoA and GDP-perosamine;O85353;wbqR;PF00132,PF17836;O85353;wbqR;PF00132,PF17836;b;7.5;100;7.5;100;4eaa_A;4ea8_A;0.17;0.21
4ea7;3;4ea8;1;4ea9;1;b;1;621;100;100;621;100;100;0.16;0.16;100;0;1.0;0.9;diffraction;diffraction;660;660;Perosamine N-acetyltransferase;Perosamine N-acetyltransferase;CAULOBACTER VIBRIOIDES;CAULOBACTER VIBRIOIDES;COA   coenzyme a| JB3   gdp-n-acetylperosamine| CL   chloride ion;JBT   gdp-n-acetylperosamine-coenzyme a| CL   chloride ion;X-ray crystal structure of PerB from Caulobacter crescentus in complex with coenzyme A and GDP-N-acetylperosamine at 1 Angstrom resolution;X-ray structure of GDP-perosamine N-acetyltransferase in complex with transition state analog at 0.9 Angstrom resolution;O85353;wbqR;PF00132,PF17836;O85353;wbqR;PF00132,PF17836;b;7.5;100;7.5;100;4eaa_A;4ea8_A;0.17;0.21
4ea7;3;4eab;1;4ea9;1;b;1;621;99;100;621;99;100;0.12;0.12;100;0;1.35;0.9;diffraction;diffraction;660;660;Perosamine N-acetyltransferase;Perosamine N-acetyltransferase;CAULOBACTER VIBRIOIDES;CAULOBACTER VIBRIOIDES;JB2   gdp-perosamine| COA   coenzyme a| NA   sodium ion| CL   chloride ion;JBT   gdp-n-acetylperosamine-coenzyme a| CL   chloride ion;X-ray crystal structure of the H141A mutant of GDP-perosamine N-acetyl transferase from Caulobacter crescentus in complex with CoA and GDP-perosamine;X-ray structure of GDP-perosamine N-acetyltransferase in complex with transition state analog at 0.9 Angstrom resolution;O85353;wbqR;PF00132,PF17836;O85353;wbqR;PF00132,PF17836;b;7.5;100;7.5;100;4eaa_A;4ea8_A;0.17;0.21
3kr5;6;3kr5;2;3kqz;2;b;1;3048;99;99;3062;99;100;0.48;0.49;100;0;2.56;2.39;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM;CO3   carbonate ion| ZN   zinc ion| BEY   (2s)-3-[(r)-[(1s)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid| SO4   sulfate ion| 1PE   pentaethylene glycol;CO3   carbonate ion| ZN   zinc ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Structure of a protease 4;Structure of a protease 2;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kr5;2;3kqx;2;b;1;3019;98;98;3062;99;100;0.84;0.84;100;0;2.56;2.01;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM;CO3   carbonate ion| ZN   zinc ion| BEY   (2s)-3-[(r)-[(1s)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid| SO4   sulfate ion| 1PE   pentaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Structure of a protease 4;Structure of a protease 1;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kr5;2;4k3n;2;b;1;3044;99;99;3070;100;99;0.64;0.64;100;0;2.56;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM 3D7;CO3   carbonate ion| ZN   zinc ion| BEY   (2s)-3-[(r)-[(1s)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid| SO4   sulfate ion| 1PE   pentaethylene glycol;ZN   zinc ion| CO3   carbonate ion| 1OT   {(r)-amino[4-(1h-pyrazol-1-yl)phenyl]methyl}phosphonic acid| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Structure of a protease 4;Phosphonic Arginine Mimetics as Inhibitors of the M17 Aminopeptidases from Plasmodium falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kr5;2;4r6t;1;b;1;2993;97;97;3059;99;99;1.03;1.07;96;0;2.56;2.6;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM 3D7;CO3   carbonate ion| ZN   zinc ion| BEY   (2s)-3-[(r)-[(1s)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid| SO4   sulfate ion| 1PE   pentaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| R5T   tert-butyl {(1s)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}carbamate| 1PE   pentaethylene glycol| DMS   dimethyl sulfoxide;Structure of a protease 4;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kr5;2;3t8w;2;b;1;3029;98;98;3071;100;99;0.82;0.85;98;0;2.56;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM;CO3   carbonate ion| ZN   zinc ion| BEY   (2s)-3-[(r)-[(1s)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid| SO4   sulfate ion| 1PE   pentaethylene glycol;CO3   carbonate ion| ZN   zinc ion| DGZ   n-((2r,3s,6s,18s,21s)-2-amino-18-(4-benzoylbenzyl)-21-carbamoyl-3-hydroxy-6-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-1-phenyl-11,14-dioxa-5,8,17,20-tetraazapentacosan-25-yl)hex-5-ynamide| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Structure of a protease 4;A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kr5;2;4r7m;1;b;1;3039;99;99;3066;100;100;0.66;0.66;100;0;2.56;2.85;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM 3D7;CO3   carbonate ion| ZN   zinc ion| BEY   (2s)-3-[(r)-[(1s)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid| SO4   sulfate ion| 1PE   pentaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 3MW   4-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| DMS   dimethyl sulfoxide;Structure of a protease 4;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kr5;2;4r76;1;b;1;3030;98;98;3064;100;100;0.74;0.74;100;0;2.56;2.5;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 family aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM FCB1/COLUMBIA;CO3   carbonate ion| ZN   zinc ion| BEY   (2s)-3-[(r)-[(1s)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid| SO4   sulfate ion| 1PE   pentaethylene glycol;ZN   zinc ion| CO3   carbonate ion| R5X   3-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of a protease 4;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kr5;2;3kr4;2;b;1;3056;99;99;3078;100;100;0.59;0.59;100;0;2.56;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM;CO3   carbonate ion| ZN   zinc ion| BEY   (2s)-3-[(r)-[(1s)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid| SO4   sulfate ion| 1PE   pentaethylene glycol;CO3   carbonate ion| ZN   zinc ion| BES   2-(3-amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid| MG   magnesium ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of a protease 4;Structure of a protease 3;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kr5;2;4x2t;2;b;1;3018;98;98;3061;99;100;0.83;0.85;98;0;2.56;2.729;diffraction;diffraction;3168;3114;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM (ISOLATE 3D7);CO3   carbonate ion| ZN   zinc ion| BEY   (2s)-3-[(r)-[(1s)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid| SO4   sulfate ion| 1PE   pentaethylene glycol;ZN   zinc ion| TOD   (2s)-({(2r)-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)ethanoic acid| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of a protease 4;X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M17 Leucyl Aminopeptidase from P. falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.6;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqz;2;3kqx;2;b;1;3044;99;99;3070;100;100;0.65;0.65;100;0;2.39;2.01;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM;CO3   carbonate ion| ZN   zinc ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Structure of a protease 2;Structure of a protease 1;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqz;2;4k3n;2;b;1;3036;99;98;3065;100;99;0.68;0.69;100;0;2.39;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM 3D7;CO3   carbonate ion| ZN   zinc ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| 1OT   {(r)-amino[4-(1h-pyrazol-1-yl)phenyl]methyl}phosphonic acid| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Structure of a protease 2;Phosphonic Arginine Mimetics as Inhibitors of the M17 Aminopeptidases from Plasmodium falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqz;2;4r6t;1;b;1;3020;98;98;3057;100;99;0.78;0.78;100;0;2.39;2.6;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM 3D7;CO3   carbonate ion| ZN   zinc ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| R5T   tert-butyl {(1s)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}carbamate| 1PE   pentaethylene glycol| DMS   dimethyl sulfoxide;Structure of a protease 2;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqz;2;3t8w;2;b;1;3025;99;98;3068;100;99;0.83;0.87;97;0;2.39;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM;CO3   carbonate ion| ZN   zinc ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;CO3   carbonate ion| ZN   zinc ion| DGZ   n-((2r,3s,6s,18s,21s)-2-amino-18-(4-benzoylbenzyl)-21-carbamoyl-3-hydroxy-6-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-1-phenyl-11,14-dioxa-5,8,17,20-tetraazapentacosan-25-yl)hex-5-ynamide| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Structure of a protease 2;A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqz;2;4r7m;1;b;1;3032;99;98;3061;100;99;0.68;0.69;100;0;2.39;2.85;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM 3D7;CO3   carbonate ion| ZN   zinc ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 3MW   4-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| DMS   dimethyl sulfoxide;Structure of a protease 2;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqz;2;4r76;1;b;1;3025;99;98;3060;100;99;0.75;0.76;99;0;2.39;2.5;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 family aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM FCB1/COLUMBIA;CO3   carbonate ion| ZN   zinc ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| R5X   3-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of a protease 2;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqz;2;3kr4;2;b;1;3036;99;99;3062;100;99;0.64;0.65;100;0;2.39;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM;CO3   carbonate ion| ZN   zinc ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;CO3   carbonate ion| ZN   zinc ion| BES   2-(3-amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid| MG   magnesium ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of a protease 2;Structure of a protease 3;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqz;2;4x2t;2;b;1;3031;99;99;3064;100;100;0.72;0.75;98;0;2.39;2.729;diffraction;diffraction;3168;3114;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM (ISOLATE 3D7);CO3   carbonate ion| ZN   zinc ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| TOD   (2s)-({(2r)-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)ethanoic acid| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of a protease 2;X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M17 Leucyl Aminopeptidase from P. falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.6;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqx;2;4k3n;2;b;1;3046;99;99;3065;100;99;0.55;0.56;100;0;2.01;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM 3D7;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| 1OT   {(r)-amino[4-(1h-pyrazol-1-yl)phenyl]methyl}phosphonic acid| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Structure of a protease 1;Phosphonic Arginine Mimetics as Inhibitors of the M17 Aminopeptidases from Plasmodium falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqx;2;4r6t;1;b;1;3038;99;99;3057;100;99;0.56;0.57;100;0;2.01;2.6;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM 3D7;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| R5T   tert-butyl {(1s)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}carbamate| 1PE   pentaethylene glycol| DMS   dimethyl sulfoxide;Structure of a protease 1;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqx;2;3t8w;2;b;1;3046;99;99;3068;100;99;0.59;0.65;99;0;2.01;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;CO3   carbonate ion| ZN   zinc ion| DGZ   n-((2r,3s,6s,18s,21s)-2-amino-18-(4-benzoylbenzyl)-21-carbamoyl-3-hydroxy-6-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-1-phenyl-11,14-dioxa-5,8,17,20-tetraazapentacosan-25-yl)hex-5-ynamide| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Structure of a protease 1;A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqx;2;4r7m;1;b;1;3044;99;99;3066;100;100;0.60;0.63;99;0;2.01;2.85;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM 3D7;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 3MW   4-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| DMS   dimethyl sulfoxide;Structure of a protease 1;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqx;2;4r76;1;b;1;3042;99;99;3060;100;99;0.54;0.56;100;0;2.01;2.5;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 family aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM FCB1/COLUMBIA;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| R5X   3-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of a protease 1;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqx;2;3kr4;2;b;1;3047;99;99;3062;100;99;0.49;0.50;100;0;2.01;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;CO3   carbonate ion| ZN   zinc ion| BES   2-(3-amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid| MG   magnesium ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of a protease 1;Structure of a protease 3;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kqx;2;4x2t;2;b;1;3042;99;99;3064;100;100;0.59;0.62;98;0;2.01;2.729;diffraction;diffraction;3168;3114;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM (ISOLATE 3D7);ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| TOD   (2s)-({(2r)-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)ethanoic acid| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of a protease 1;X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M17 Leucyl Aminopeptidase from P. falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.6;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4k3n;2;4r6t;1;b;1;3054;99;99;3066;99;100;0.44;0.45;100;0;2.0;2.6;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM 3D7;ZN   zinc ion| CO3   carbonate ion| 1OT   {(r)-amino[4-(1h-pyrazol-1-yl)phenyl]methyl}phosphonic acid| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| R5T   tert-butyl {(1s)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}carbamate| 1PE   pentaethylene glycol| DMS   dimethyl sulfoxide;Phosphonic Arginine Mimetics as Inhibitors of the M17 Aminopeptidases from Plasmodium falciparum;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4k3n;2;3t8w;2;b;1;3057;99;99;3079;100;100;0.59;0.63;98;0;2.0;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM;ZN   zinc ion| CO3   carbonate ion| 1OT   {(r)-amino[4-(1h-pyrazol-1-yl)phenyl]methyl}phosphonic acid| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;CO3   carbonate ion| ZN   zinc ion| DGZ   n-((2r,3s,6s,18s,21s)-2-amino-18-(4-benzoylbenzyl)-21-carbamoyl-3-hydroxy-6-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-1-phenyl-11,14-dioxa-5,8,17,20-tetraazapentacosan-25-yl)hex-5-ynamide| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Phosphonic Arginine Mimetics as Inhibitors of the M17 Aminopeptidases from Plasmodium falciparum;A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4k3n;2;4r7m;1;b;1;3039;98;99;3073;100;100;0.73;0.80;98;0;2.0;2.85;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM 3D7;ZN   zinc ion| CO3   carbonate ion| 1OT   {(r)-amino[4-(1h-pyrazol-1-yl)phenyl]methyl}phosphonic acid| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 3MW   4-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| DMS   dimethyl sulfoxide;Phosphonic Arginine Mimetics as Inhibitors of the M17 Aminopeptidases from Plasmodium falciparum;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4k3n;2;4r76;1;b;1;3059;99;99;3072;99;100;0.46;0.49;99;0;2.0;2.5;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 family aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM FCB1/COLUMBIA;ZN   zinc ion| CO3   carbonate ion| 1OT   {(r)-amino[4-(1h-pyrazol-1-yl)phenyl]methyl}phosphonic acid| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| R5X   3-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| SO4   sulfate ion| 1PE   pentaethylene glycol;Phosphonic Arginine Mimetics as Inhibitors of the M17 Aminopeptidases from Plasmodium falciparum;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4k3n;2;3kr4;2;b;1;3067;99;100;3076;100;100;0.39;0.41;99;0;2.0;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM;ZN   zinc ion| CO3   carbonate ion| 1OT   {(r)-amino[4-(1h-pyrazol-1-yl)phenyl]methyl}phosphonic acid| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;CO3   carbonate ion| ZN   zinc ion| BES   2-(3-amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid| MG   magnesium ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Phosphonic Arginine Mimetics as Inhibitors of the M17 Aminopeptidases from Plasmodium falciparum;Structure of a protease 3;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4k3n;2;4x2t;2;b;1;3064;99;100;3072;99;100;0.36;0.37;100;0;2.0;2.729;diffraction;diffraction;3168;3114;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM (ISOLATE 3D7);ZN   zinc ion| CO3   carbonate ion| 1OT   {(r)-amino[4-(1h-pyrazol-1-yl)phenyl]methyl}phosphonic acid| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| TOD   (2s)-({(2r)-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)ethanoic acid| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Phosphonic Arginine Mimetics as Inhibitors of the M17 Aminopeptidases from Plasmodium falciparum;X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M17 Leucyl Aminopeptidase from P. falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.6;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4r6t;1;3t8w;2;b;1;3046;99;99;3066;100;99;0.57;0.59;99;0;2.6;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| R5T   tert-butyl {(1s)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}carbamate| 1PE   pentaethylene glycol| DMS   dimethyl sulfoxide;CO3   carbonate ion| ZN   zinc ion| DGZ   n-((2r,3s,6s,18s,21s)-2-amino-18-(4-benzoylbenzyl)-21-carbamoyl-3-hydroxy-6-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-1-phenyl-11,14-dioxa-5,8,17,20-tetraazapentacosan-25-yl)hex-5-ynamide| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4r6t;1;4r7m;1;b;1;3046;99;99;3067;100;100;0.59;0.59;100;0;2.6;2.85;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM 3D7;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| R5T   tert-butyl {(1s)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}carbamate| 1PE   pentaethylene glycol| DMS   dimethyl sulfoxide;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 3MW   4-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| DMS   dimethyl sulfoxide;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4r6t;1;4r76;1;b;1;3067;100;100;3071;100;100;0.24;0.24;100;0;2.6;2.5;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 family aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM FCB1/COLUMBIA;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| R5T   tert-butyl {(1s)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}carbamate| 1PE   pentaethylene glycol| DMS   dimethyl sulfoxide;ZN   zinc ion| CO3   carbonate ion| R5X   3-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4r6t;1;3kr4;2;b;1;3019;98;98;3062;100;99;0.83;0.88;96;0;2.6;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| R5T   tert-butyl {(1s)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}carbamate| 1PE   pentaethylene glycol| DMS   dimethyl sulfoxide;CO3   carbonate ion| ZN   zinc ion| BES   2-(3-amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid| MG   magnesium ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Structure of a protease 3;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4r6t;1;4x2t;2;b;1;3017;98;98;3066;100;100;0.89;0.95;95;0;2.6;2.729;diffraction;diffraction;3168;3114;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM (ISOLATE 3D7);ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| R5T   tert-butyl {(1s)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}carbamate| 1PE   pentaethylene glycol| DMS   dimethyl sulfoxide;ZN   zinc ion| TOD   (2s)-({(2r)-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)ethanoic acid| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M17 Leucyl Aminopeptidase from P. falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.6;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3t8w;2;4r7m;1;b;1;3012;98;98;3074;100;100;1.00;1.05;95;0;2.0;2.85;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM 3D7;CO3   carbonate ion| ZN   zinc ion| DGZ   n-((2r,3s,6s,18s,21s)-2-amino-18-(4-benzoylbenzyl)-21-carbamoyl-3-hydroxy-6-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-1-phenyl-11,14-dioxa-5,8,17,20-tetraazapentacosan-25-yl)hex-5-ynamide| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 3MW   4-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| DMS   dimethyl sulfoxide;A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3t8w;2;4r76;1;b;1;3033;98;99;3065;99;100;0.71;0.77;98;0;2.0;2.5;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 family aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM FCB1/COLUMBIA;CO3   carbonate ion| ZN   zinc ion| DGZ   n-((2r,3s,6s,18s,21s)-2-amino-18-(4-benzoylbenzyl)-21-carbamoyl-3-hydroxy-6-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-1-phenyl-11,14-dioxa-5,8,17,20-tetraazapentacosan-25-yl)hex-5-ynamide| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| CO3   carbonate ion| R5X   3-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| SO4   sulfate ion| 1PE   pentaethylene glycol;A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3t8w;2;3kr4;2;b;1;3048;99;99;3071;99;100;0.61;0.64;98;0;2.0;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM;CO3   carbonate ion| ZN   zinc ion| DGZ   n-((2r,3s,6s,18s,21s)-2-amino-18-(4-benzoylbenzyl)-21-carbamoyl-3-hydroxy-6-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-1-phenyl-11,14-dioxa-5,8,17,20-tetraazapentacosan-25-yl)hex-5-ynamide| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;CO3   carbonate ion| ZN   zinc ion| BES   2-(3-amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid| MG   magnesium ion| SO4   sulfate ion| 1PE   pentaethylene glycol;A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases;Structure of a protease 3;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3t8w;2;4x2t;2;b;1;3059;99;100;3069;99;100;0.40;0.42;99;0;2.0;2.729;diffraction;diffraction;3168;3114;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM (ISOLATE 3D7);CO3   carbonate ion| ZN   zinc ion| DGZ   n-((2r,3s,6s,18s,21s)-2-amino-18-(4-benzoylbenzyl)-21-carbamoyl-3-hydroxy-6-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-1-phenyl-11,14-dioxa-5,8,17,20-tetraazapentacosan-25-yl)hex-5-ynamide| SO4   sulfate ion| 1PE   pentaethylene glycol| 2PE   nonaethylene glycol;ZN   zinc ion| TOD   (2s)-({(2r)-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)ethanoic acid| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol;A bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases;X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M17 Leucyl Aminopeptidase from P. falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.6;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4r7m;1;4r76;1;b;1;3049;99;99;3076;100;100;0.66;0.70;98;0;2.85;2.5;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 family aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM FCB1/COLUMBIA;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 3MW   4-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| DMS   dimethyl sulfoxide;ZN   zinc ion| CO3   carbonate ion| R5X   3-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4r7m;1;3kr4;2;b;1;3049;99;99;3066;100;100;0.53;0.53;100;0;2.85;2.0;diffraction;diffraction;3168;3168;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM;ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 3MW   4-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| DMS   dimethyl sulfoxide;CO3   carbonate ion| ZN   zinc ion| BES   2-(3-amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid| MG   magnesium ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Structure of a protease 3;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4r7m;1;4x2t;2;b;1;3032;98;99;3063;99;100;0.71;0.73;98;0;2.85;2.729;diffraction;diffraction;3168;3114;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM 3D7;PLASMODIUM FALCIPARUM (ISOLATE 3D7);ZN   zinc ion| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol| 3MW   4-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| DMS   dimethyl sulfoxide;ZN   zinc ion| TOD   (2s)-({(2r)-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)ethanoic acid| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M17 Leucyl Aminopeptidase from P. falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.6;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4r76;1;3kr4;2;b;1;3053;99;99;3064;100;100;0.41;0.41;100;0;2.5;2.0;diffraction;diffraction;3168;3168;M17 family aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM FCB1/COLUMBIA;PLASMODIUM FALCIPARUM;ZN   zinc ion| CO3   carbonate ion| R5X   3-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| SO4   sulfate ion| 1PE   pentaethylene glycol;CO3   carbonate ion| ZN   zinc ion| BES   2-(3-amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid| MG   magnesium ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;Structure of a protease 3;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.5;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;4r76;1;4x2t;2;b;1;3034;99;99;3059;99;100;0.64;0.67;98;0;2.5;2.729;diffraction;diffraction;3168;3114;M17 family aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM FCB1/COLUMBIA;PLASMODIUM FALCIPARUM (ISOLATE 3D7);ZN   zinc ion| CO3   carbonate ion| R5X   3-amino-n-{(1r)-2-(hydroxyamino)-2-oxo-1-[4-(1h-pyrazol-1-yl)phenyl]ethyl}benzamide| SO4   sulfate ion| 1PE   pentaethylene glycol;ZN   zinc ion| TOD   (2s)-({(2r)-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)ethanoic acid| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of the m17 leucyl aminopeptidase from malaria complexed with a hydroxamic acid-based inhibitor;X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M17 Leucyl Aminopeptidase from P. falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.6;100;3kr4_A;4x2t_C;2.27;1.07
3kr5;6;3kr4;2;4x2t;2;b;1;3036;99;99;3061;99;100;0.63;0.66;98;0;2.0;2.729;diffraction;diffraction;3168;3114;M17 leucyl aminopeptidase;M17 leucyl aminopeptidase;PLASMODIUM FALCIPARUM;PLASMODIUM FALCIPARUM (ISOLATE 3D7);CO3   carbonate ion| ZN   zinc ion| BES   2-(3-amino-2-hydroxy-4-phenyl-butyrylamino)-4-methyl-pentanoic acid| MG   magnesium ion| SO4   sulfate ion| 1PE   pentaethylene glycol;ZN   zinc ion| TOD   (2s)-({(2r)-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}amino)(phenyl)ethanoic acid| CO3   carbonate ion| SO4   sulfate ion| 1PE   pentaethylene glycol;Structure of a protease 3;X-ray crystal structure of the orally available aminopeptidase inhibitor, Tosedostat, bound to the M17 Leucyl Aminopeptidase from P. falciparum;Q8IL11;PF3D7_1446200;PF00883;Q8IL11;PF3D7_1446200;PF00883;a;8.5;100;8.6;100;3kr4_A;4x2t_C;2.27;1.07
2y6v;2;2y6v;2;2y6u;1;b;1;734;97;99;741;98;100;0.69;0.75;100;0;2.83;1.9;diffraction;diffraction;796;796;PEROXISOMAL MEMBRANE PROTEIN LPX1;PEROXISOMAL MEMBRANE PROTEIN LPX1;SACCHAROMYCES CEREVISIAE;SACCHAROMYCES CEREVISIAE;CME   s,s-(2-hydroxyethyl)thiocysteine| CSO   s-hydroxycysteine| PO4   phosphate ion;CME   s,s-(2-hydroxyethyl)thiocysteine| CSO   s-hydroxycysteine| GOL   glycerol;Peroxisomal alpha-beta-hydrolase Lpx1 (Yor084w) from Saccharomyces cerevisiae (crystal form I);Peroxisomal alpha-beta-hydrolase Lpx1 (Yor084w) from Saccharomyces cerevisiae (crystal form II);Q12405;LPX1 YOR084W YOR3120W;PF12697;Q12405;LPX1 YOR084W YOR3120W;PF12697;b;no/data;100;no/data;100;2y6v_A;2y6v_B;1.06;0.75
2f78;2;2f78;1;2f6p;1;b;1;420;96;95;433;99;98;1.24;1.26;100;0;2.05;2.001;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;BEZ   benzoic acid;MSE   selenomethionine| SO4   sulfate ion| ACT   acetate ion| NA   sodium ion;BenM effector binding domain with its effector benzoate;BenM effector binding domain- SeMet derivative;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;no/data;100;no/data;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f78;1;2f97;1;b;1;417;96;97;430;99;100;1.23;1.28;100;0;2.05;2.2;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;BEZ   benzoic acid;ACT   acetate ion| PG4   tetraethylene glycol| PEG   di(hydroxyethyl)ether;BenM effector binding domain with its effector benzoate;Effector Binding Domain of BenM (crystals generated from high pH conditions);O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;no/data;100;9;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f78;1;2f8d;1;b;1;421;97;96;432;99;98;1.11;1.16;100;0;2.05;2.7;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;BEZ   benzoic acid;PO4   phosphate ion| BEZ   benzoic acid| GOL   glycerol;BenM effector binding domain with its effector benzoate;BenM effector-Binding domain crystallized from high pH conditions;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;no/data;100;10;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f78;1;2f7a;1;b;1;414;95;94;431;99;98;1.40;1.43;100;0;2.05;1.9;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;BEZ   benzoic acid;ACT   acetate ion| SO4   sulfate ion| CCU   (2z,4z)-hexa-2,4-dienedioic acid| BEZ   benzoic acid;BenM effector binding domain with its effector benzoate;BenM effector binding domain with its effector, cis,cis-muconate;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;no/data;100;no/data;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f78;1;2f6g;1;b;1;427;98;97;433;99;99;0.85;0.88;100;0;2.05;1.908;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;BEZ   benzoic acid;SO4   sulfate ion| CL   chloride ion;BenM effector binding domain with its effector benzoate;BenM effector binding domain;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;no/data;100;no/data;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f6p;1;2f97;1;b;1;413;93;96;429;97;99;1.36;1.41;100;0;2.001;2.2;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;MSE   selenomethionine| SO4   sulfate ion| ACT   acetate ion| NA   sodium ion;ACT   acetate ion| PG4   tetraethylene glycol| PEG   di(hydroxyethyl)ether;BenM effector binding domain- SeMet derivative;Effector Binding Domain of BenM (crystals generated from high pH conditions);O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;no/data;100;9;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f6p;1;2f8d;1;b;1;411;93;94;430;97;98;1.48;1.53;100;0;2.001;2.7;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;MSE   selenomethionine| SO4   sulfate ion| ACT   acetate ion| NA   sodium ion;PO4   phosphate ion| BEZ   benzoic acid| GOL   glycerol;BenM effector binding domain- SeMet derivative;BenM effector-Binding domain crystallized from high pH conditions;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;no/data;100;10;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f6p;1;2f7a;1;b;1;425;96;96;437;99;99;1.18;1.22;100;0;2.001;1.9;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;MSE   selenomethionine| SO4   sulfate ion| ACT   acetate ion| NA   sodium ion;ACT   acetate ion| SO4   sulfate ion| CCU   (2z,4z)-hexa-2,4-dienedioic acid| BEZ   benzoic acid;BenM effector binding domain- SeMet derivative;BenM effector binding domain with its effector, cis,cis-muconate;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;no/data;100;no/data;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f6p;1;2f6g;1;b;1;433;98;99;439;99;100;0.82;0.84;100;0;2.001;1.908;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;MSE   selenomethionine| SO4   sulfate ion| ACT   acetate ion| NA   sodium ion;SO4   sulfate ion| CL   chloride ion;BenM effector binding domain- SeMet derivative;BenM effector binding domain;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;no/data;100;no/data;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f97;1;2f8d;1;b;1;428;99;98;432;100;98;0.64;0.65;100;0;2.2;2.7;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;ACT   acetate ion| PG4   tetraethylene glycol| PEG   di(hydroxyethyl)ether;PO4   phosphate ion| BEZ   benzoic acid| GOL   glycerol;Effector Binding Domain of BenM (crystals generated from high pH conditions);BenM effector-Binding domain crystallized from high pH conditions;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;9;100;10;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f97;1;2f7a;1;b;1;405;94;92;425;98;96;1.52;1.56;100;0;2.2;1.9;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;ACT   acetate ion| PG4   tetraethylene glycol| PEG   di(hydroxyethyl)ether;ACT   acetate ion| SO4   sulfate ion| CCU   (2z,4z)-hexa-2,4-dienedioic acid| BEZ   benzoic acid;Effector Binding Domain of BenM (crystals generated from high pH conditions);BenM effector binding domain with its effector, cis,cis-muconate;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;9;100;no/data;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f97;1;2f6g;1;b;1;418;97;95;430;100;98;1.16;1.22;100;0;2.2;1.908;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;ACT   acetate ion| PG4   tetraethylene glycol| PEG   di(hydroxyethyl)ether;SO4   sulfate ion| CL   chloride ion;Effector Binding Domain of BenM (crystals generated from high pH conditions);BenM effector binding domain;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;9;100;no/data;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f8d;1;2f7a;1;b;1;405;92;92;429;98;97;1.66;1.71;100;0;2.7;1.9;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;PO4   phosphate ion| BEZ   benzoic acid| GOL   glycerol;ACT   acetate ion| SO4   sulfate ion| CCU   (2z,4z)-hexa-2,4-dienedioic acid| BEZ   benzoic acid;BenM effector-Binding domain crystallized from high pH conditions;BenM effector binding domain with its effector, cis,cis-muconate;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;10;100;no/data;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f8d;1;2f6g;1;b;1;418;95;95;431;98;98;1.21;1.26;100;0;2.7;1.908;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;PO4   phosphate ion| BEZ   benzoic acid| GOL   glycerol;SO4   sulfate ion| CL   chloride ion;BenM effector-Binding domain crystallized from high pH conditions;BenM effector binding domain;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;10;100;no/data;100;2f97_A;2f7a_A;1.51;1.71
2f78;2;2f7a;1;2f6g;1;b;1;425;96;97;435;99;99;1.06;1.10;100;0;1.9;1.908;diffraction;diffraction;464;464;HTH-type transcriptional regulator benM;HTH-type transcriptional regulator benM;ACINETOBACTER BAYLYI;ACINETOBACTER BAYLYI;ACT   acetate ion| SO4   sulfate ion| CCU   (2z,4z)-hexa-2,4-dienedioic acid| BEZ   benzoic acid;SO4   sulfate ion| CL   chloride ion;BenM effector binding domain with its effector, cis,cis-muconate;BenM effector binding domain;O68014;benM benR ACIAD1435;PF00126,PF03466;O68014;benM benR ACIAD1435;PF00126,PF03466;b;no/data;100;no/data;100;2f97_A;2f7a_A;1.51;1.71
3tl6;6;3tl6;1;3u40;1;b;1;1346;99;96;1356;100;97;0.59;0.61;100;0;2.65;2.05;diffraction;diffraction;1452;1452;Purine nucleoside phosphorylase;Purine nucleoside phosphorylase;ENTAMOEBA HISTOLYTICA;ENTAMOEBA HISTOLYTICA;SO4   sulfate ion;ADN   adenosine| NO3   nitrate ion| PO4   phosphate ion;Crystal structure of purine nucleoside phosphorylase from Entamoeba histolytica;Crystal structure of a purine nucleoside phosphorylase from Entamoeba histolytica bound to adenosine;C4LXG4;CL6EHI_130960 EHI_130960;PF01048;C4LXG4;CL6EHI_130960 EHI_130960;PF01048;a;5.5;100;7.5;100;3tl6_B;3u40_F;1.13;0.61
4okd;2;4okd;1;4j7r;1;b;1;1578;99;99;1588;100;99;0.56;0.58;100;0;2.4;2.3;diffraction;diffraction;1680;1680;Isoamylase;Isoamylase;CHLAMYDOMONAS REINHARDTII;CHLAMYDOMONAS REINHARDTII;GLC   alpha-d-glucose;no/data;Crystal Structure of Chlamydomonas reinhardtii Isoamylase 1 (ISA1) in complex with maltoheptaose;Crystal Structure of Chlamydomonas reinhardtii Isoamylase 1 (ISA1);Q7X8Q2;Isa1;PF00128,PF02922;Q7X8Q2;Isa1;PF00128,PF02922;b;7.0;100;7.0;100;4okd_A;4j7r_B;0.61;0.58
4kz1;2;4kz1;1;4mei;1;c;1;269;99;99;270;100;99;0.51;0.51;96;0;2.55;2.85;diffraction;diffraction;362;362;VirB8 protein;VirB8 protein;BARTONELLA GRAHAMII;BARTONELLA TRIBOCORUM;no/data;no/data;Crystal structure of the soluble domain of VirB8 from Bartonella grahamii;Crystal structure of a VirB8 Type IV secretion system machinery soluble domain from Bartonella tribocorum;C6AER9;virB8 Bgr_14870;PF04335;A9IWN6;virB8 BT_1695;PF04335;b;7.5;100;7.0;100;4kz1_A;4mei_A;0.33;0.51
1e5e;4;1e5e;1;1e5f;1;b;1;1571;100;100;1572;100;100;0.16;0.16;100;0;2.18;2.18;diffraction;diffraction;1616;1616;METHIONINE GAMMA-LYASE;METHIONINE GAMMA-LYASE;TRICHOMONAS VAGINALIS;TRICHOMONAS VAGINALIS;SO4   sulfate ion| PPJ   n-(hydroxy{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)norvaline| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| GOL   glycerol;METHIONINE GAMMA-LYASE (MGL) FROM TRICHOMONAS VAGINALIS IN COMPLEX WITH PROPARGYLGLYCINE;METHIONINE GAMMA-LYASE (MGL) FROM TRICHOMONAS VAGINALIS;A2FEV4;TVAG_041600;PF01053;O15564;mgl1;PF01053;b;5.60;100;5.60;100;1e5e_A;1e5f_B;0.38;0.16
4rpn;2;4rpn;2;4rns;2;b;1;433;99;100;434;99;100;0.30;0.30;100;0;2.272;2.7;diffraction;diffraction;446;446;PCP degradation transcriptional activation protein;PCP degradation transcriptional activation protein;SPHINGOBIUM CHLOROPHENOLICUM;SPHINGOBIUM CHLOROPHENOLICUM;PCI   pentachlorophenol;no/data;PcpR inducer binding domain complex with pentachlorophenol;PcpR inducer binding domain (apo-form);P52679;pcpR;PF00126,PF03466;P52679;pcpR;PF00126,PF03466;b;5.0;100;8.5;100;4rpn_B;4rpo_A;0.64;0.31
4rpn;2;4rpn;2;4rpo;1;b;1;437;100;100;438;100;100;0.31;0.31;100;0;2.272;1.95;diffraction;diffraction;446;446;PCP degradation transcriptional activation protein;PCP degradation transcriptional activation protein;SPHINGOBIUM CHLOROPHENOLICUM;SPHINGOBIUM CHLOROPHENOLICUM;PCI   pentachlorophenol;T6C   2,4,6-trichlorophenol| DMS   dimethyl sulfoxide| GOL   glycerol;PcpR inducer binding domain complex with pentachlorophenol;PcpR inducer binding domain (Complex with 2,4,6-trichlorophenol);P52679;pcpR;PF00126,PF03466;P52679;pcpR;PF00126,PF03466;b;5.0;100;7.5;100;4rpn_B;4rpo_A;0.64;0.31
4rpn;2;4rns;2;4rpo;1;b;1;433;100;99;434;100;99;0.28;0.28;100;0;2.7;1.95;diffraction;diffraction;446;446;PCP degradation transcriptional activation protein;PCP degradation transcriptional activation protein;SPHINGOBIUM CHLOROPHENOLICUM;SPHINGOBIUM CHLOROPHENOLICUM;no/data;T6C   2,4,6-trichlorophenol| DMS   dimethyl sulfoxide| GOL   glycerol;PcpR inducer binding domain (apo-form);PcpR inducer binding domain (Complex with 2,4,6-trichlorophenol);P52679;pcpR;PF00126,PF03466;P52679;pcpR;PF00126,PF03466;b;8.5;100;7.5;100;4rpn_B;4rpo_A;0.64;0.31
1o9q;2;1o9q;1;1obk;1;b;1;824;100;100;824;100;100;0.14;0.14;100;0;1.8;2.2;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;no/data;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9q;1;1och;1;b;1;824;100;100;824;100;100;0.03;0.03;100;0;1.8;1.8;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;CSD   3-sulfinoalanine;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9q;1;1obj;1;b;1;824;100;100;824;100;100;0.15;0.15;100;0;1.8;1.9;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;no/data;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9q;1;1o9p;1;b;1;824;100;100;824;100;100;0.17;0.17;100;0;1.8;1.8;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;MLA   malonic acid;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9q;1;1ocm;1;b;1;823;100;100;824;100;100;0.20;0.20;100;0;1.8;1.9;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;POP   pyrophosphate 2-;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9q;1;1obl;1;b;1;824;100;100;824;100;100;0.13;0.13;100;0;1.8;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;MLA   malonic acid;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9q;1;1ock;1;b;1;821;100;100;824;100;100;0.41;0.41;100;0;1.8;1.8;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;no/data;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9q;1;1o9n;1;b;1;821;100;100;824;100;100;0.46;0.46;100;0;1.8;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;no/data;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9q;1;1o9o;1;b;1;824;100;100;824;100;100;0.14;0.14;100;0;1.8;2.3;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;MLM   3-amino-3-oxopropanoic acid;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9q;1;1ocl;1;b;1;823;100;100;824;100;100;0.22;0.22;100;0;1.8;2.0;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;MLA   malonic acid;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9q;1;1obi;1;b;1;823;100;100;824;100;100;0.18;0.18;100;0;1.8;2.2;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSO   s-hydroxycysteine;no/data;Crystal structure of the S155C mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obk;1;1och;1;b;1;824;100;100;824;100;100;0.14;0.14;100;0;2.2;1.8;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;CSD   3-sulfinoalanine;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obk;1;1obj;1;b;1;823;100;100;824;100;100;0.22;0.22;100;0;2.2;1.9;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;no/data;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obk;1;1o9p;1;b;1;823;100;100;824;100;100;0.25;0.25;100;0;2.2;1.8;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLA   malonic acid;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obk;1;1ocm;1;b;1;823;100;100;824;100;100;0.26;0.26;100;0;2.2;1.9;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;POP   pyrophosphate 2-;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obk;1;1obl;1;b;1;824;100;100;824;100;100;0.16;0.16;100;0;2.2;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLA   malonic acid;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obk;1;1ock;1;b;1;822;100;100;824;100;100;0.36;0.36;100;0;2.2;1.8;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;no/data;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obk;1;1o9n;1;b;1;820;99;99;824;100;100;0.52;0.52;100;0;2.2;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;no/data;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obk;1;1o9o;1;b;1;823;100;100;824;100;100;0.19;0.19;100;0;2.2;2.3;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLM   3-amino-3-oxopropanoic acid;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obk;1;1ocl;1;b;1;823;100;100;824;100;100;0.20;0.20;100;0;2.2;2.0;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLA   malonic acid;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obk;1;1obi;1;b;1;823;100;100;824;100;100;0.18;0.18;100;0;2.2;2.2;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;no/data;crystal structure of the R158Q mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1och;1;1obj;1;b;1;824;100;100;824;100;100;0.15;0.15;100;0;1.8;1.9;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSD   3-sulfinoalanine;no/data;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1och;1;1o9p;1;b;1;824;100;100;824;100;100;0.17;0.17;100;0;1.8;1.8;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSD   3-sulfinoalanine;MLA   malonic acid;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1och;1;1ocm;1;b;1;823;100;100;824;100;100;0.20;0.20;100;0;1.8;1.9;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSD   3-sulfinoalanine;POP   pyrophosphate 2-;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1och;1;1obl;1;b;1;824;100;100;824;100;100;0.13;0.13;100;0;1.8;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSD   3-sulfinoalanine;MLA   malonic acid;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1och;1;1ock;1;b;1;821;100;100;824;100;100;0.41;0.41;100;0;1.8;1.8;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSD   3-sulfinoalanine;no/data;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1och;1;1o9n;1;b;1;821;100;100;824;100;100;0.45;0.46;100;0;1.8;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSD   3-sulfinoalanine;no/data;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1och;1;1o9o;1;b;1;824;100;100;824;100;100;0.14;0.14;100;0;1.8;2.3;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSD   3-sulfinoalanine;MLM   3-amino-3-oxopropanoic acid;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1och;1;1ocl;1;b;1;823;100;100;824;100;100;0.22;0.22;100;0;1.8;2.0;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSD   3-sulfinoalanine;MLA   malonic acid;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1och;1;1obi;1;b;1;823;100;100;824;100;100;0.18;0.18;100;0;1.8;2.2;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;CSD   3-sulfinoalanine;no/data;Crystal structure of the S155C mutant of malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obj;1;1o9p;1;b;1;824;100;100;824;100;100;0.17;0.17;100;0;1.9;1.8;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLA   malonic acid;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obj;1;1ocm;1;b;1;823;100;100;824;100;100;0.20;0.20;100;0;1.9;1.9;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;POP   pyrophosphate 2-;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obj;1;1obl;1;b;1;823;100;100;824;100;100;0.20;0.20;100;0;1.9;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLA   malonic acid;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obj;1;1ock;1;b;1;820;100;100;824;100;100;0.48;0.48;100;0;1.9;1.8;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;no/data;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obj;1;1o9n;1;b;1;821;100;100;824;100;100;0.45;0.45;100;0;1.9;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;no/data;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obj;1;1o9o;1;b;1;824;100;100;824;100;100;0.17;0.17;100;0;1.9;2.3;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLM   3-amino-3-oxopropanoic acid;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obj;1;1ocl;1;b;1;822;100;100;824;100;100;0.30;0.31;100;0;1.9;2.0;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLA   malonic acid;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obj;1;1obi;1;b;1;823;100;100;824;100;100;0.22;0.22;100;0;1.9;2.2;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;no/data;Crystal structure of the T150A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9p;1;1ocm;1;b;1;823;100;100;824;100;100;0.18;0.18;100;0;1.8;1.9;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;POP   pyrophosphate 2-;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9p;1;1obl;1;b;1;823;100;100;824;100;100;0.18;0.18;100;0;1.8;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;MLA   malonic acid;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9p;1;1ock;1;b;1;820;100;100;824;100;100;0.49;0.49;100;0;1.8;1.8;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;no/data;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9p;1;1o9n;1;b;1;822;100;100;824;100;100;0.38;0.39;100;0;1.8;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;no/data;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9p;1;1o9o;1;b;1;824;100;100;824;100;100;0.15;0.15;100;0;1.8;2.3;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;MLM   3-amino-3-oxopropanoic acid;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9p;1;1ocl;1;b;1;822;100;100;824;100;100;0.31;0.31;100;0;1.8;2.0;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;MLA   malonic acid;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9p;1;1obi;1;b;1;823;100;100;824;100;100;0.23;0.23;100;0;1.8;2.2;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;no/data;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ocm;1;1obl;1;b;1;823;100;100;824;100;100;0.22;0.22;100;0;1.9;2.0;diffraction;diffraction;824;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;POP   pyrophosphate 2-;MLA   malonic acid;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ocm;1;1ock;1;b;1;820;100;100;824;100;100;0.49;0.49;100;0;1.9;1.8;diffraction;diffraction;824;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;POP   pyrophosphate 2-;no/data;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ocm;1;1o9n;1;b;1;821;100;100;824;100;100;0.40;0.41;100;0;1.9;2.0;diffraction;diffraction;824;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;POP   pyrophosphate 2-;no/data;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ocm;1;1o9o;1;b;1;823;100;100;824;100;100;0.20;0.20;100;0;1.9;2.3;diffraction;diffraction;824;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;POP   pyrophosphate 2-;MLM   3-amino-3-oxopropanoic acid;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ocm;1;1ocl;1;b;1;822;100;100;824;100;100;0.32;0.32;100;0;1.9;2.0;diffraction;diffraction;824;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;POP   pyrophosphate 2-;MLA   malonic acid;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ocm;1;1obi;1;b;1;823;100;100;824;100;100;0.27;0.27;100;0;1.9;2.2;diffraction;diffraction;824;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;POP   pyrophosphate 2-;no/data;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COVALENTLY COMPLEXED WITH PYROPHOSPHATE FROM BRADYRHIZOBIUM JAPONICUM;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obl;1;1ock;1;b;1;822;100;100;824;100;100;0.37;0.37;100;0;2.0;1.8;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;no/data;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obl;1;1o9n;1;b;1;820;100;100;824;100;100;0.46;0.47;100;0;2.0;2.0;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;no/data;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obl;1;1o9o;1;b;1;824;100;100;824;100;100;0.15;0.15;100;0;2.0;2.3;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;MLM   3-amino-3-oxopropanoic acid;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obl;1;1ocl;1;b;1;823;100;100;824;100;100;0.19;0.19;100;0;2.0;2.0;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;MLA   malonic acid;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1obl;1;1obi;1;b;1;823;100;100;824;100;100;0.18;0.18;100;0;2.0;2.2;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;no/data;crystal structure of the S133A mutant of Malonamidase E2 complexed with malonate from Bradyrhizobium japonicum;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ock;1;1o9n;1;b;1;816;99;99;824;100;100;0.70;0.70;100;0;1.8;2.0;diffraction;diffraction;824;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;no/data;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ock;1;1o9o;1;b;1;821;100;100;824;100;100;0.44;0.44;100;0;1.8;2.3;diffraction;diffraction;824;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLM   3-amino-3-oxopropanoic acid;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ock;1;1ocl;1;b;1;823;100;100;824;100;100;0.24;0.24;100;0;1.8;2.0;diffraction;diffraction;824;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLA   malonic acid;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ock;1;1obi;1;b;1;822;100;100;824;100;100;0.38;0.38;100;0;1.8;2.2;diffraction;diffraction;824;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;no/data;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 FROM BRADYRHIZOBIUM JAPONICUM;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9n;1;1o9o;1;b;1;821;100;100;824;100;100;0.43;0.44;100;0;2.0;2.3;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLM   3-amino-3-oxopropanoic acid;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9n;1;1ocl;1;b;1;819;99;99;824;100;100;0.55;0.55;100;0;2.0;2.0;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;MLA   malonic acid;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9n;1;1obi;1;b;1;820;100;100;824;100;100;0.48;0.48;100;0;2.0;2.2;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;no/data;no/data;Crystal structure of the K62A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9o;1;1ocl;1;b;1;823;100;100;824;100;100;0.26;0.26;100;0;2.3;2.0;diffraction;diffraction;828;824;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLM   3-amino-3-oxopropanoic acid;MLA   malonic acid;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1o9o;1;1obi;1;b;1;823;100;100;824;100;100;0.20;0.20;100;0;2.3;2.2;diffraction;diffraction;828;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLM   3-amino-3-oxopropanoic acid;no/data;Crystal structure of the S131A mutant of Malonamidase E2 complexed with malonamate from Bradyrhizobium japonicum;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
1o9q;2;1ocl;1;1obi;1;b;1;823;100;100;824;100;100;0.23;0.23;100;0;2.0;2.2;diffraction;diffraction;824;828;MALONAMIDASE E2;MALONAMIDASE E2;BRADYRHIZOBIUM JAPONICUM;BRADYRHIZOBIUM JAPONICUM;MLA   malonic acid;no/data;THE CRYSTAL STRUCTURE OF MALONAMIDASE E2 COMPLEXED WITH MALONATE FROM BRADYRHIZOBIUM JAPONICUM;Crystal structure of the G130A mutant of Malonamidase E2 from Bradyrhizobium japonicum;Q9ZIV5;no/data;PF01425;Q9ZIV5;no/data;PF01425;b;7.00;100;7.00;100;1obk_A;1o9n_B;0.46;0.70
2uv6;2;2uv6;1;2uv7;1;b;1;286;100;100;286;100;100;0.18;0.18;99;0;2.0;2.0;diffraction;diffraction;304;304;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;HOMO SAPIENS;HOMO SAPIENS;AMP   adenosine monophosphate;AMP   adenosine monophosphate;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;P54619;PRKAG1;PF00571;P54619;PRKAG1;PF00571;b;8.00;100;no/data;100;2uv7_A;2uv5_A;0.39;0.40
2uv6;2;2uv6;1;2uv5;1;b;1;285;100;100;286;100;100;0.32;0.32;99;0;2.0;1.69;diffraction;diffraction;304;304;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;HOMO SAPIENS;HOMO SAPIENS;AMP   adenosine monophosphate;AMZ   aminoimidazole 4-carboxamide ribonucleotide;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;P54619;PRKAG1;PF00571;P54619;PRKAG1;PF00571;b;8.00;100;8.00;100;2uv7_A;2uv5_A;0.39;0.40
2uv6;2;2uv6;1;2uv4;1;b;1;286;100;100;286;100;100;0.28;0.28;99;0;2.0;1.33;diffraction;diffraction;304;304;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;HOMO SAPIENS;HOMO SAPIENS;AMP   adenosine monophosphate;AMP   adenosine monophosphate;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;P54619;PRKAG1;PF00571;P54619;PRKAG1;PF00571;b;8.00;100;8.00;100;2uv7_A;2uv5_A;0.39;0.40
2uv6;2;2uv7;1;2uv5;1;b;1;285;100;100;286;100;100;0.39;0.40;99;0;2.0;1.69;diffraction;diffraction;304;304;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;HOMO SAPIENS;HOMO SAPIENS;AMP   adenosine monophosphate;AMZ   aminoimidazole 4-carboxamide ribonucleotide;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;P54619;PRKAG1;PF00571;P54619;PRKAG1;PF00571;b;no/data;100;8.00;100;2uv7_A;2uv5_A;0.39;0.40
2uv6;2;2uv7;1;2uv4;1;b;1;285;100;100;286;100;100;0.36;0.36;99;0;2.0;1.33;diffraction;diffraction;304;304;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;HOMO SAPIENS;HOMO SAPIENS;AMP   adenosine monophosphate;AMP   adenosine monophosphate;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;P54619;PRKAG1;PF00571;P54619;PRKAG1;PF00571;b;no/data;100;8.00;100;2uv7_A;2uv5_A;0.39;0.40
2uv6;2;2uv5;1;2uv4;1;b;1;286;100;100;286;100;100;0.21;0.21;100;0;1.69;1.33;diffraction;diffraction;304;304;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;5'-AMP-ACTIVATED PROTEIN KINASE SUBUNIT GAMMA-1;HOMO SAPIENS;HOMO SAPIENS;AMZ   aminoimidazole 4-carboxamide ribonucleotide;AMP   adenosine monophosphate;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;Crystal Structure of a CBS domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP;P54619;PRKAG1;PF00571;P54619;PRKAG1;PF00571;b;8.00;100;8.00;100;2uv7_A;2uv5_A;0.39;0.40
3ahd;2;3ahd;1;3ahe;1;b;1;1604;100;100;1604;100;100;0.10;0.10;100;0;1.9;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;MG   magnesium ion| THD   2-[3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2-(1,2-dihydroxyethyl)-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;Phosphoketolase from Bifidobacterium Breve complexed with 2-acetyl-thiamine diphosphate;Phosphoketolase from Bifidobacterium Breve complexed with dihydroxyethyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahd;1;3ahj;1;b;1;1604;100;100;1604;100;100;0.10;0.10;100;0;1.9;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;MG   magnesium ion| TPP   thiamine diphosphate| EDO   1,2-ethanediol;Phosphoketolase from Bifidobacterium Breve complexed with 2-acetyl-thiamine diphosphate;H553A mutant of Phosphoketolase from Bifidobacterium Breve;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahd;1;3ahc;1;b;1;1604;100;100;1604;100;100;0.09;0.09;100;0;1.9;1.7;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;MG   magnesium ion| TPP   thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;Phosphoketolase from Bifidobacterium Breve complexed with 2-acetyl-thiamine diphosphate;Resting form of Phosphoketolase from Bifidobacterium Breve;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahd;1;3ahg;1;b;1;1603;100;100;1604;100;100;0.15;0.15;100;0;1.9;1.9;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;MG   magnesium ion| HTD   2-[(9ar)-2,7-dimethyl-9a,10-dihydro-5h-pyrimido[4,5-d][1,3]thiazolo[3,2-a]pyrimidin-8-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol;Phosphoketolase from Bifidobacterium Breve complexed with 2-acetyl-thiamine diphosphate;H64A mutant of Phosphoketolase from Bifidobacterium Breve complexed with a tricyclic ring form of thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahd;1;3ahh;1;b;1;1603;100;100;1604;100;100;0.14;0.14;100;0;1.9;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| PG4   tetraethylene glycol;Phosphoketolase from Bifidobacterium Breve complexed with 2-acetyl-thiamine diphosphate;H142A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahd;1;3ahi;1;b;1;1604;100;100;1604;100;100;0.08;0.08;100;0;1.9;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;Phosphoketolase from Bifidobacterium Breve complexed with 2-acetyl-thiamine diphosphate;H320A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahe;1;3ahj;1;b;1;1603;100;100;1604;100;100;0.13;0.13;100;0;2.1;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| THD   2-[3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2-(1,2-dihydroxyethyl)-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;MG   magnesium ion| TPP   thiamine diphosphate| EDO   1,2-ethanediol;Phosphoketolase from Bifidobacterium Breve complexed with dihydroxyethyl thiamine diphosphate;H553A mutant of Phosphoketolase from Bifidobacterium Breve;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahe;1;3ahc;1;b;1;1604;100;100;1604;100;100;0.11;0.11;100;0;2.1;1.7;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| THD   2-[3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2-(1,2-dihydroxyethyl)-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;MG   magnesium ion| TPP   thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;Phosphoketolase from Bifidobacterium Breve complexed with dihydroxyethyl thiamine diphosphate;Resting form of Phosphoketolase from Bifidobacterium Breve;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahe;1;3ahg;1;b;1;1603;100;100;1604;100;100;0.18;0.18;100;0;2.1;1.9;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| THD   2-[3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2-(1,2-dihydroxyethyl)-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;MG   magnesium ion| HTD   2-[(9ar)-2,7-dimethyl-9a,10-dihydro-5h-pyrimido[4,5-d][1,3]thiazolo[3,2-a]pyrimidin-8-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol;Phosphoketolase from Bifidobacterium Breve complexed with dihydroxyethyl thiamine diphosphate;H64A mutant of Phosphoketolase from Bifidobacterium Breve complexed with a tricyclic ring form of thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahe;1;3ahh;1;b;1;1603;100;100;1604;100;100;0.15;0.15;100;0;2.1;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| THD   2-[3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2-(1,2-dihydroxyethyl)-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| PG4   tetraethylene glycol;Phosphoketolase from Bifidobacterium Breve complexed with dihydroxyethyl thiamine diphosphate;H142A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahe;1;3ahi;1;b;1;1604;100;100;1604;100;100;0.12;0.12;100;0;2.1;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| THD   2-[3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-2-(1,2-dihydroxyethyl)-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;Phosphoketolase from Bifidobacterium Breve complexed with dihydroxyethyl thiamine diphosphate;H320A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahj;1;3ahc;1;b;1;1604;100;100;1604;100;100;0.12;0.12;100;0;2.1;1.7;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| TPP   thiamine diphosphate| EDO   1,2-ethanediol;MG   magnesium ion| TPP   thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;H553A mutant of Phosphoketolase from Bifidobacterium Breve;Resting form of Phosphoketolase from Bifidobacterium Breve;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahj;1;3ahg;1;b;1;1604;100;100;1604;100;100;0.12;0.12;100;0;2.1;1.9;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| TPP   thiamine diphosphate| EDO   1,2-ethanediol;MG   magnesium ion| HTD   2-[(9ar)-2,7-dimethyl-9a,10-dihydro-5h-pyrimido[4,5-d][1,3]thiazolo[3,2-a]pyrimidin-8-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol;H553A mutant of Phosphoketolase from Bifidobacterium Breve;H64A mutant of Phosphoketolase from Bifidobacterium Breve complexed with a tricyclic ring form of thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahj;1;3ahh;1;b;1;1603;100;100;1604;100;100;0.15;0.15;100;0;2.1;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| TPP   thiamine diphosphate| EDO   1,2-ethanediol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| PG4   tetraethylene glycol;H553A mutant of Phosphoketolase from Bifidobacterium Breve;H142A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahj;1;3ahi;1;b;1;1604;100;100;1604;100;100;0.11;0.11;100;0;2.1;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| TPP   thiamine diphosphate| EDO   1,2-ethanediol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;H553A mutant of Phosphoketolase from Bifidobacterium Breve;H320A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahc;1;3ahg;1;b;1;1603;100;100;1604;100;100;0.15;0.15;100;0;1.7;1.9;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| TPP   thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;MG   magnesium ion| HTD   2-[(9ar)-2,7-dimethyl-9a,10-dihydro-5h-pyrimido[4,5-d][1,3]thiazolo[3,2-a]pyrimidin-8-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol;Resting form of Phosphoketolase from Bifidobacterium Breve;H64A mutant of Phosphoketolase from Bifidobacterium Breve complexed with a tricyclic ring form of thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahc;1;3ahh;1;b;1;1603;100;100;1604;100;100;0.14;0.14;100;0;1.7;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| TPP   thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| PG4   tetraethylene glycol;Resting form of Phosphoketolase from Bifidobacterium Breve;H142A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahc;1;3ahi;1;b;1;1603;100;100;1604;100;100;0.13;0.13;100;0;1.7;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| TPP   thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| 2PE   nonaethylene glycol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;Resting form of Phosphoketolase from Bifidobacterium Breve;H320A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahg;1;3ahh;1;b;1;1603;100;100;1604;100;100;0.18;0.18;100;0;1.9;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| HTD   2-[(9ar)-2,7-dimethyl-9a,10-dihydro-5h-pyrimido[4,5-d][1,3]thiazolo[3,2-a]pyrimidin-8-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| PG4   tetraethylene glycol;H64A mutant of Phosphoketolase from Bifidobacterium Breve complexed with a tricyclic ring form of thiamine diphosphate;H142A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahg;1;3ahi;1;b;1;1603;100;100;1604;100;100;0.16;0.16;100;0;1.9;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| HTD   2-[(9ar)-2,7-dimethyl-9a,10-dihydro-5h-pyrimido[4,5-d][1,3]thiazolo[3,2-a]pyrimidin-8-yl]ethyl trihydrogen diphosphate| NA   sodium ion| EDO   1,2-ethanediol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;H64A mutant of Phosphoketolase from Bifidobacterium Breve complexed with a tricyclic ring form of thiamine diphosphate;H320A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3ahd;2;3ahh;1;3ahi;1;b;1;1603;100;100;1604;100;100;0.15;0.15;100;0;2.1;2.1;diffraction;diffraction;1690;1690;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase;BIFIDOBACTERIUM BREVE;BIFIDOBACTERIUM BREVE;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol| PG4   tetraethylene glycol;MG   magnesium ion| HTL   2-acetyl-thiamine diphosphate| NA   sodium ion| EDO   1,2-ethanediol;H142A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;H320A mutant of Phosphoketolase from Bifidobacterium Breve complexed with acetyl thiamine diphosphate;D6PAH1;xfp;PF03894,PF09363,PF09364;D6PAH1;xfp;PF03894,PF09363,PF09364;b;9.0;100;9.0;100;3ahg_A;3ahh_A;0.18;0.18
3kgw;2;3kgw;1;3kgx;1;b;1;767;99;99;771;100;100;0.52;0.54;100;0;1.65;1.8;diffraction;diffraction;786;786;Alanine-glyoxylate aminotransferase;Alanine-glyoxylate aminotransferase;MUS MUSCULUS;MUS MUSCULUS;PLP   pyridoxal-5'-phosphate| CL   chloride ion| EDO   1,2-ethanediol;CL   chloride ion| MG   magnesium ion| EDO   1,2-ethanediol;Crystal structure of Putative aminotransferase (AAH25799.1) from MUS MUSCULUS at 1.65 A resolution;Crystal structure of Putative aminotransferase (AAH25799.1) from MUS MUSCULUS at 1.80 A resolution;O35423;Agxt Agxt1;PF00266;O35423;Agxt Agxt1;PF00266;b;7.8;100;6.2;100;3kgw_A;3kgx_B;0.71;0.54
1yf1;10;1yf1;1;4mab;1;b;1;1598;97;89;1632;99;91;1.01;1.04;99;0;2.6;1.9;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;NA   sodium ion;GOL   glycerol| K   potassium ion| CL   chloride ion;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Resolving Cys to Ala variant of Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;5.5;100;6.5;no/data;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yf1;1;3emp;1;b;1;1585;96;98;1618;98;100;1.01;1.02;99;0;2.6;4.0;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;NA   sodium ion;no/data;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Crystal Structure of the S-acetanilide modified form of C165S AhpC;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;5.5;100;6.0;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yf1;1;4ql9;1;b;1;1612;98;97;1644;100;99;0.99;0.99;98;0;2.6;3.4;diffraction;diffraction;1860;1820;Alkyl hydroperoxide reductase subunit C;Alkylhydroperoxide Reductase subunit C;SALMONELLA TYPHIMURIUM;ESCHERICHIA COLI;NA   sodium ion;no/data;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-182) from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;5.5;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yf1;1;1n8j;1;b;1;1579;96;85;1636;99;88;1.32;1.36;99;0;2.6;2.17;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase C22 protein;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;NA   sodium ion;no/data;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Crystal Structure of AhpC with Active Site Cysteine mutated to Serine (C46S);P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;5.5;100;4.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yf1;1;1yex;1;b;1;1633;99;99;1650;100;100;0.70;0.71;99;0;2.6;2.3;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;NA   sodium ion;SO4   sulfate ion;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;5.5;100;6.0;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yf1;1;1yep;1;b;1;1631;99;99;1650;100;100;0.75;0.75;99;0;2.6;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;NA   sodium ion;SO4   sulfate ion;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Structural and biochemical analysis of the link between enzymatic activity and olgomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;5.5;100;6.5;103;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yf1;1;4ma9;1;b;1;1597;97;88;1635;99;90;1.08;1.12;99;0;2.6;1.82;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;NA   sodium ion;CL   chloride ion| GOL   glycerol| K   potassium ion;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Wild type Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;5.5;100;6.5;no/data;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yf1;1;1yf0;1;b;1;1630;99;99;1650;100;100;0.77;0.77;99;0;2.6;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;NA   sodium ion;SO4   sulfate ion;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;5.5;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yf1;1;4o5r;1;b;1;1608;97;97;1646;100;99;1.06;1.07;98;0;2.6;3.33;diffraction;diffraction;1860;1870;Alkyl hydroperoxide reductase subunit C;AhpC component, subunit of alkylhydroperoxide reductase;SALMONELLA TYPHIMURIUM;ESCHERICHIA COLI;NA   sodium ion;no/data;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Crystal structure of Alkylhydroperoxide Reductase subunit C from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;5.5;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4mab;1;3emp;1;b;1;1585;88;98;1614;90;100;0.93;0.96;100;0;1.9;4.0;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;SALMONELLA TYPHIMURIUM;GOL   glycerol| K   potassium ion| CL   chloride ion;no/data;Resolving Cys to Ala variant of Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;Crystal Structure of the S-acetanilide modified form of C165S AhpC;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;no/data;6.0;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4mab;1;4ql9;1;b;1;1583;88;95;1631;91;98;1.21;1.23;98;0;1.9;3.4;diffraction;diffraction;1860;1820;Alkyl hydroperoxide reductase subunit C;Alkylhydroperoxide Reductase subunit C;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;ESCHERICHIA COLI;GOL   glycerol| K   potassium ion| CL   chloride ion;no/data;Resolving Cys to Ala variant of Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-182) from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;6.5;no/data;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4mab;1;1n8j;1;b;1;1775;99;95;1794;100;96;0.73;0.74;99;0;1.9;2.17;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase C22 protein;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;SALMONELLA TYPHIMURIUM;GOL   glycerol| K   potassium ion| CL   chloride ion;no/data;Resolving Cys to Ala variant of Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;Crystal Structure of AhpC with Active Site Cysteine mutated to Serine (C46S);P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;no/data;4.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4mab;1;1yex;1;b;1;1616;90;98;1632;91;99;0.69;0.73;99;0;1.9;2.3;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;SALMONELLA TYPHIMURIUM;GOL   glycerol| K   potassium ion| CL   chloride ion;SO4   sulfate ion;Resolving Cys to Ala variant of Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;no/data;6.0;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4mab;1;1yep;1;b;1;1616;90;98;1630;91;99;0.65;0.68;100;0;1.9;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;SALMONELLA TYPHIMURIUM;GOL   glycerol| K   potassium ion| CL   chloride ion;SO4   sulfate ion;Resolving Cys to Ala variant of Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;Structural and biochemical analysis of the link between enzymatic activity and olgomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;no/data;6.5;103;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4mab;1;4ma9;1;b;1;1791;100;99;1794;100;99;0.27;0.27;100;0;1.9;1.82;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;GOL   glycerol| K   potassium ion| CL   chloride ion;CL   chloride ion| GOL   glycerol| K   potassium ion;Resolving Cys to Ala variant of Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;Wild type Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;no/data;6.5;no/data;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4mab;1;1yf0;1;b;1;1617;90;98;1633;91;99;0.69;0.73;99;0;1.9;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;SALMONELLA TYPHIMURIUM;GOL   glycerol| K   potassium ion| CL   chloride ion;SO4   sulfate ion;Resolving Cys to Ala variant of Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;no/data;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4mab;1;4o5r;1;b;1;1582;88;95;1632;91;98;1.24;1.26;98;0;1.9;3.33;diffraction;diffraction;1860;1870;Alkyl hydroperoxide reductase subunit C;AhpC component, subunit of alkylhydroperoxide reductase;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;ESCHERICHIA COLI;GOL   glycerol| K   potassium ion| CL   chloride ion;no/data;Resolving Cys to Ala variant of Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;Crystal structure of Alkylhydroperoxide Reductase subunit C from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;6.5;no/data;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;3emp;1;4ql9;1;b;1;1592;98;96;1618;100;98;0.89;0.89;98;0;4.0;3.4;diffraction;diffraction;1860;1820;Alkyl hydroperoxide reductase subunit C;Alkylhydroperoxide Reductase subunit C;SALMONELLA TYPHIMURIUM;ESCHERICHIA COLI;no/data;no/data;Crystal Structure of the S-acetanilide modified form of C165S AhpC;Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-182) from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;6.0;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;3emp;1;1n8j;1;b;1;1576;97;85;1614;100;87;1.08;1.11;100;0;4.0;2.17;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase C22 protein;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;no/data;no/data;Crystal Structure of the S-acetanilide modified form of C165S AhpC;Crystal Structure of AhpC with Active Site Cysteine mutated to Serine (C46S);P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.0;100;4.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;3emp;1;1yex;1;b;1;1595;99;97;1618;100;98;0.83;0.83;99;0;4.0;2.3;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;no/data;SO4   sulfate ion;Crystal Structure of the S-acetanilide modified form of C165S AhpC;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.0;100;6.0;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;3emp;1;1yep;1;b;1;1596;99;96;1618;100;98;0.82;0.82;100;0;4.0;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;no/data;SO4   sulfate ion;Crystal Structure of the S-acetanilide modified form of C165S AhpC;Structural and biochemical analysis of the link between enzymatic activity and olgomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.0;100;6.5;103;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;3emp;1;4ma9;1;b;1;1585;98;87;1615;100;89;0.96;0.99;100;0;4.0;1.82;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;no/data;CL   chloride ion| GOL   glycerol| K   potassium ion;Crystal Structure of the S-acetanilide modified form of C165S AhpC;Wild type Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.0;100;6.5;no/data;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;3emp;1;1yf0;1;b;1;1598;99;97;1618;100;98;0.78;0.79;99;0;4.0;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;no/data;SO4   sulfate ion;Crystal Structure of the S-acetanilide modified form of C165S AhpC;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.0;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;3emp;1;4o5r;1;b;1;1591;98;96;1618;100;97;0.90;0.91;98;0;4.0;3.33;diffraction;diffraction;1860;1870;Alkyl hydroperoxide reductase subunit C;AhpC component, subunit of alkylhydroperoxide reductase;SALMONELLA TYPHIMURIUM;ESCHERICHIA COLI;no/data;no/data;Crystal Structure of the S-acetanilide modified form of C165S AhpC;Crystal structure of Alkylhydroperoxide Reductase subunit C from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;6.0;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4ql9;1;1n8j;1;b;1;1567;95;84;1635;99;88;1.44;1.48;98;0;3.4;2.17;diffraction;diffraction;1820;1860;Alkylhydroperoxide Reductase subunit C;Alkyl hydroperoxide reductase C22 protein;ESCHERICHIA COLI;SALMONELLA TYPHIMURIUM;no/data;no/data;Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-182) from E. coli;Crystal Structure of AhpC with Active Site Cysteine mutated to Serine (C46S);A0A140NC97;ECBD_3047;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;100;4.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4ql9;1;1yex;1;b;1;1612;97;98;1644;99;100;0.98;0.99;98;0;3.4;2.3;diffraction;diffraction;1820;1860;Alkylhydroperoxide Reductase subunit C;Alkyl hydroperoxide reductase subunit C;ESCHERICHIA COLI;SALMONELLA TYPHIMURIUM;no/data;SO4   sulfate ion;Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-182) from E. coli;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;A0A140NC97;ECBD_3047;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;100;6.0;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4ql9;1;1yep;1;b;1;1606;97;97;1644;99;99;1.07;1.08;98;0;3.4;2.5;diffraction;diffraction;1820;1860;Alkylhydroperoxide Reductase subunit C;Alkyl hydroperoxide reductase subunit C;ESCHERICHIA COLI;SALMONELLA TYPHIMURIUM;no/data;SO4   sulfate ion;Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-182) from E. coli;Structural and biochemical analysis of the link between enzymatic activity and olgomerization in AhpC, a bacterial peroxiredoxin.;A0A140NC97;ECBD_3047;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;100;6.5;103;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4ql9;1;4ma9;1;b;1;1580;95;87;1633;98;90;1.27;1.31;98;0;3.4;1.82;diffraction;diffraction;1820;1860;Alkylhydroperoxide Reductase subunit C;Alkyl hydroperoxide reductase subunit C;ESCHERICHIA COLI;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;no/data;CL   chloride ion| GOL   glycerol| K   potassium ion;Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-182) from E. coli;Wild type Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;A0A140NC97;ECBD_3047;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;100;6.5;no/data;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4ql9;1;1yf0;1;b;1;1609;97;97;1644;99;100;1.02;1.03;98;0;3.4;2.5;diffraction;diffraction;1820;1860;Alkylhydroperoxide Reductase subunit C;Alkyl hydroperoxide reductase subunit C;ESCHERICHIA COLI;SALMONELLA TYPHIMURIUM;no/data;SO4   sulfate ion;Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-182) from E. coli;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;A0A140NC97;ECBD_3047;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4ql9;1;4o5r;1;b;1;1654;100;99;1658;100;100;0.35;0.35;100;0;3.4;3.33;diffraction;diffraction;1820;1870;Alkylhydroperoxide Reductase subunit C;AhpC component, subunit of alkylhydroperoxide reductase;ESCHERICHIA COLI;ESCHERICHIA COLI;no/data;no/data;Crystal structure of C-terminus truncated Alkylhydroperoxide Reductase subunit C (AhpC1-182) from E. coli;Crystal structure of Alkylhydroperoxide Reductase subunit C from E. coli;A0A140NC97;ECBD_3047;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;6.5;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1n8j;1;1yex;1;b;1;1589;85;96;1628;88;99;1.09;1.11;99;0;2.17;2.3;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase C22 protein;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;no/data;SO4   sulfate ion;Crystal Structure of AhpC with Active Site Cysteine mutated to Serine (C46S);Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;4.5;100;6.0;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1n8j;1;1yep;1;b;1;1589;85;96;1628;88;98;1.10;1.12;100;0;2.17;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase C22 protein;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;no/data;SO4   sulfate ion;Crystal Structure of AhpC with Active Site Cysteine mutated to Serine (C46S);Structural and biochemical analysis of the link between enzymatic activity and olgomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;4.5;100;6.5;103;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1n8j;1;4ma9;1;b;1;1796;97;99;1812;97;100;0.65;0.66;100;0;2.17;1.82;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase C22 protein;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;no/data;CL   chloride ion| GOL   glycerol| K   potassium ion;Crystal Structure of AhpC with Active Site Cysteine mutated to Serine (C46S);Wild type Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;4.5;100;6.5;no/data;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1n8j;1;1yf0;1;b;1;1590;85;96;1632;88;99;1.13;1.17;99;0;2.17;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase C22 protein;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;no/data;SO4   sulfate ion;Crystal Structure of AhpC with Active Site Cysteine mutated to Serine (C46S);Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;4.5;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1n8j;1;4o5r;1;b;1;1567;84;94;1636;88;98;1.45;1.49;98;0;2.17;3.33;diffraction;diffraction;1860;1870;Alkyl hydroperoxide reductase C22 protein;AhpC component, subunit of alkylhydroperoxide reductase;SALMONELLA TYPHIMURIUM;ESCHERICHIA COLI;no/data;no/data;Crystal Structure of AhpC with Active Site Cysteine mutated to Serine (C46S);Crystal structure of Alkylhydroperoxide Reductase subunit C from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;4.5;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yex;1;1yep;1;b;1;1647;100;100;1652;100;100;0.39;0.39;99;0;2.3;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;SO4   sulfate ion;SO4   sulfate ion;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Structural and biochemical analysis of the link between enzymatic activity and olgomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.0;100;6.5;103;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yex;1;4ma9;1;b;1;1612;98;89;1633;99;90;0.80;0.85;99;0;2.3;1.82;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;SO4   sulfate ion;CL   chloride ion| GOL   glycerol| K   potassium ion;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Wild type Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.0;100;6.5;no/data;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yex;1;1yf0;1;b;1;1648;100;100;1652;100;100;0.35;0.35;99;0;2.3;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;SO4   sulfate ion;SO4   sulfate ion;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.0;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yex;1;4o5r;1;b;1;1612;98;97;1646;100;99;1.01;1.01;98;0;2.3;3.33;diffraction;diffraction;1860;1870;Alkyl hydroperoxide reductase subunit C;AhpC component, subunit of alkylhydroperoxide reductase;SALMONELLA TYPHIMURIUM;ESCHERICHIA COLI;SO4   sulfate ion;no/data;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Crystal structure of Alkylhydroperoxide Reductase subunit C from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;6.0;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yep;1;4ma9;1;b;1;1610;97;89;1626;98;90;0.71;0.74;100;0;2.5;1.82;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;SO4   sulfate ion;CL   chloride ion| GOL   glycerol| K   potassium ion;Structural and biochemical analysis of the link between enzymatic activity and olgomerization in AhpC, a bacterial peroxiredoxin.;Wild type Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;103;6.5;no/data;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yep;1;1yf0;1;b;1;1649;100;100;1652;100;100;0.31;0.31;99;0;2.5;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA TYPHIMURIUM;SALMONELLA TYPHIMURIUM;SO4   sulfate ion;SO4   sulfate ion;Structural and biochemical analysis of the link between enzymatic activity and olgomerization in AhpC, a bacterial peroxiredoxin.;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;103;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yep;1;4o5r;1;b;1;1605;97;96;1646;100;99;1.11;1.12;98;0;2.5;3.33;diffraction;diffraction;1860;1870;Alkyl hydroperoxide reductase subunit C;AhpC component, subunit of alkylhydroperoxide reductase;SALMONELLA TYPHIMURIUM;ESCHERICHIA COLI;SO4   sulfate ion;no/data;Structural and biochemical analysis of the link between enzymatic activity and olgomerization in AhpC, a bacterial peroxiredoxin.;Crystal structure of Alkylhydroperoxide Reductase subunit C from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;6.5;103;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4ma9;1;1yf0;1;b;1;1608;89;97;1626;90;98;0.74;0.77;99;0;1.82;2.5;diffraction;diffraction;1860;1860;Alkyl hydroperoxide reductase subunit C;Alkyl hydroperoxide reductase subunit C;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;SALMONELLA TYPHIMURIUM;CL   chloride ion| GOL   glycerol| K   potassium ion;SO4   sulfate ion;Wild type Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;P0A251;ahpC STM0608;PF10417,PF00578;P0A251;ahpC STM0608;PF10417,PF00578;b;6.5;no/data;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;4ma9;1;4o5r;1;b;1;1579;87;95;1634;90;98;1.29;1.32;98;0;1.82;3.33;diffraction;diffraction;1860;1870;Alkyl hydroperoxide reductase subunit C;AhpC component, subunit of alkylhydroperoxide reductase;SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;ESCHERICHIA COLI;CL   chloride ion| GOL   glycerol| K   potassium ion;no/data;Wild type Salmonella Alkyl Hydroperoxide Reductase C in its substrate-ready conformation;Crystal structure of Alkylhydroperoxide Reductase subunit C from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;6.5;no/data;6.5;100;1yf1_B;1n8j_O;1.03;1.49
1yf1;10;1yf0;1;4o5r;1;b;1;1610;97;97;1646;100;99;1.05;1.05;98;0;2.5;3.33;diffraction;diffraction;1860;1870;Alkyl hydroperoxide reductase subunit C;AhpC component, subunit of alkylhydroperoxide reductase;SALMONELLA TYPHIMURIUM;ESCHERICHIA COLI;SO4   sulfate ion;no/data;Structural and biochemical analysis of the link between enzymatic activity and oligomerization in AhpC, a bacterial peroxiredoxin.;Crystal structure of Alkylhydroperoxide Reductase subunit C from E. coli;P0A251;ahpC STM0608;PF10417,PF00578;A0A140NC97;ECBD_3047;PF10417,PF00578;b;6.5;100;6.5;100;1yf1_B;1n8j_O;1.03;1.49
3ust;2;3ust;1;3qzy;1;b;1;444;90;91;472;96;97;1.73;1.79;96;0;2.1;2.14;diffraction;diffraction;534;520;AcMNPV orf92;Baculovirus sulfhydryl oxidase Ac92;BOMBYX MORI NPV;AUTOGRAPHA CALIFORNICA NUCLEOPOLYHEDROVIRUS;MSE   selenomethionine| FAD   flavin-adenine dinucleotide;IMD   imidazole| FAD   flavin-adenine dinucleotide| PO4   phosphate ion;Structure of BmNPV ORF075 (p33);Structure of Baculovirus Sulfhydryl Oxidase Ac92;O92452;Orf_75 p33 Bm(Br)Orf-80 bmnpvc2gp074 Bmnpvcubicgp078 Bmnpvguangxigp078 Bmnpvindiagp077 Bmnpvzhejianggp078;PF05214;P41480;P33 ORF92;PF05214;b;7.5;100;9;100;3qzy_A;3qzy_B;1.78;1.79
3ust;2;3ust;1;3p0k;1;b;1;480;97;93;490;99;95;1.02;1.10;98;0;2.1;1.47;diffraction;diffraction;534;532;AcMNPV orf92;sulfhydryl oxidase;BOMBYX MORI NPV;AUTOGRAPHA CALIFORNICA NUCLEOPOLYHEDROVIRUS;MSE   selenomethionine| FAD   flavin-adenine dinucleotide;IMD   imidazole| FAD   flavin-adenine dinucleotide| ACT   acetate ion;Structure of BmNPV ORF075 (p33);Structure of Baculovirus Sulfhydryl Oxidase Ac92;O92452;Orf_75 p33 Bm(Br)Orf-80 bmnpvc2gp074 Bmnpvcubicgp078 Bmnpvguangxigp078 Bmnpvindiagp077 Bmnpvzhejianggp078;PF05214;P41480;P33 ORF92;PF05214;b;7.5;100;4.4;100;3qzy_A;3qzy_B;1.78;1.79
3ust;2;3qzy;1;3p0k;1;b;1;454;93;88;479;98;93;1.61;1.66;100;0;2.14;1.47;diffraction;diffraction;520;532;Baculovirus sulfhydryl oxidase Ac92;sulfhydryl oxidase;AUTOGRAPHA CALIFORNICA NUCLEOPOLYHEDROVIRUS;AUTOGRAPHA CALIFORNICA NUCLEOPOLYHEDROVIRUS;IMD   imidazole| FAD   flavin-adenine dinucleotide| PO4   phosphate ion;IMD   imidazole| FAD   flavin-adenine dinucleotide| ACT   acetate ion;Structure of Baculovirus Sulfhydryl Oxidase Ac92;Structure of Baculovirus Sulfhydryl Oxidase Ac92;P41480;P33 ORF92;PF05214;P41480;P33 ORF92;PF05214;b;9;100;4.4;100;3qzy_A;3qzy_B;1.78;1.79
3g6b;2;3g6b;1;3g67;1;b;1;424;100;100;425;100;100;0.31;0.31;100;0;3.0;2.17;diffraction;diffraction;426;426;Methyl-accepting chemotaxis protein;Methyl-accepting chemotaxis protein;THERMOTOGA MARITIMA;THERMOTOGA MARITIMA;no/data;no/data;Crystal structure of a Soluble Chemoreceptor from Thermotoga maritima Asn217Ile mutant;Crystal Structure of a Soluble Chemoreceptor from Thermotoga maritima;Q7DFA3;TM_0014;PF00015;Q7DFA3;TM_0014;PF00015;b;7.5;100;no/data;100;3g6b_A;3g67_A;0.32;0.31
1tim;2;1tim;1;1su5;1;b;1;477;96;96;491;99;99;1.21;1.27;95;0;2.5;2.7;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1tpv;1;b;1;474;96;97;486;98;99;1.12;1.16;96;0;2.5;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;no/data;PGH   phosphoglycolohydroxamic acid;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1tpb;1;b;1;474;96;97;488;99;100;1.20;1.29;96;0;2.5;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;no/data;PGH   phosphoglycolohydroxamic acid;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1ssg;1;b;1;477;97;97;491;99;99;1.19;1.25;95;0;2.5;2.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1spq;1;b;1;470;95;98;482;98;100;1.09;1.12;96;0;2.5;2.16;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;PEG   di(hydroxyethyl)ether;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;9.1;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1tpw;1;b;1;474;96;97;490;99;100;1.26;1.36;96;0;2.5;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;no/data;PGH   phosphoglycolohydroxamic acid;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1tpc;1;b;1;474;96;97;488;99;100;1.20;1.29;96;0;2.5;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;no/data;PGH   phosphoglycolohydroxamic acid;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1tpu;1;b;1;474;96;97;488;99;100;1.19;1.27;96;0;2.5;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;no/data;PGH   phosphoglycolohydroxamic acid;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1sw0;1;b;1;476;96;96;489;99;99;1.13;1.17;96;0;2.5;1.71;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;PGA   2-phosphoglycolic acid;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1sw3;1;b;1;477;97;97;492;100;100;1.24;1.33;96;0;2.5;2.03;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;PGA   2-phosphoglycolic acid;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1tph;1;b;1;473;96;97;485;98;99;1.10;1.14;97;0;2.5;1.8;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;no/data;PGH   phosphoglycolohydroxamic acid;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1sq7;1;b;1;485;98;98;494;100;100;0.97;0.99;96;0;2.5;2.85;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;no/data;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;4p61;1;b;1;471;95;98;481;97;100;1.02;1.04;96;0;2.5;1.34;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;no/data;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;8tim;1;b;1;486;98;98;494;100;100;0.90;0.92;97;0;2.5;2.5;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;no/data;SO4   sulfate ion;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1tim;1;1sw7;1;b;1;473;96;97;486;98;99;1.14;1.18;95;0;2.5;2.22;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;PGA   2-phosphoglycolic acid;STRUCTURE OF TRIOSE PHOSPHATE ISOMERASE FROM CHICKEN MUSCLE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1tpv;1;b;1;486;98;99;490;99;100;0.62;0.62;98;0;2.7;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1tpb;1;b;1;486;98;99;490;99;100;0.65;0.65;98;0;2.7;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1ssg;1;b;1;493;100;100;494;100;100;0.37;0.37;99;0;2.7;2.9;diffraction;diffraction;494;494;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;5.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1spq;1;b;1;473;96;98;481;97;100;0.90;0.91;99;0;2.7;2.16;diffraction;diffraction;494;494;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PEG   di(hydroxyethyl)ether;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;9.1;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1tpw;1;b;1;485;98;99;490;99;100;0.69;0.69;98;0;2.7;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1tpc;1;b;1;486;98;99;490;99;100;0.60;0.61;98;0;2.7;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1tpu;1;b;1;486;98;99;490;99;100;0.63;0.63;98;0;2.7;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1sw0;1;b;1;490;99;99;494;100;100;0.64;0.64;99;0;2.7;1.71;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGA   2-phosphoglycolic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1sw3;1;b;1;489;99;99;494;100;100;0.68;0.68;99;0;2.7;2.03;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGA   2-phosphoglycolic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1tph;1;b;1;486;98;99;490;99;100;0.65;0.65;98;0;2.7;1.8;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1sq7;1;b;1;483;98;98;491;99;99;0.87;0.95;99;0;2.7;2.85;diffraction;diffraction;494;494;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;no/data;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;4p61;1;b;1;475;96;99;479;97;99;0.63;0.65;99;0;2.7;1.34;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;no/data;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;8tim;1;b;1;483;98;98;491;99;99;0.92;0.96;98;0;2.7;2.5;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;SO4   sulfate ion;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1su5;1;1sw7;1;b;1;489;99;100;490;99;100;0.28;0.28;99;0;2.7;2.22;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGA   2-phosphoglycolic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1tpb;1;b;1;490;100;100;490;100;100;0.15;0.15;99;0;1.9;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1ssg;1;b;1;487;99;99;490;100;99;0.55;0.55;98;0;1.9;2.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1spq;1;b;1;475;97;99;479;98;99;0.65;0.66;99;0;1.9;2.16;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PEG   di(hydroxyethyl)ether;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;9.1;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1tpw;1;b;1;489;100;100;490;100;100;0.25;0.25;100;0;1.9;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1tpc;1;b;1;490;100;100;490;100;100;0.16;0.16;99;0;1.9;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1tpu;1;b;1;490;100;100;490;100;100;0.14;0.14;100;0;1.9;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1sw0;1;b;1;490;100;99;490;100;99;0.21;0.21;98;0;1.9;1.71;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1sw3;1;b;1;490;100;99;490;100;99;0.16;0.16;98;0;1.9;2.03;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1tph;1;b;1;490;100;100;490;100;100;0.14;0.14;99;0;1.9;1.8;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1sq7;1;b;1;482;98;97;488;100;99;0.81;0.90;98;0;1.9;2.85;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;4p61;1;b;1;473;97;98;476;97;99;0.52;0.54;98;0;1.9;1.34;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;8tim;1;b;1;481;98;97;489;100;99;0.89;0.94;99;0;1.9;2.5;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;SO4   sulfate ion;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpv;1;1sw7;1;b;1;487;99;99;490;100;100;0.51;0.51;98;0;1.9;2.22;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;1ssg;1;b;1;487;99;99;490;100;99;0.56;0.56;98;0;1.9;2.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;1spq;1;b;1;475;97;99;480;98;100;0.71;0.75;99;0;1.9;2.16;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PEG   di(hydroxyethyl)ether;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;9.1;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;1tpw;1;b;1;489;100;100;490;100;100;0.26;0.26;99;0;1.9;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;1tpc;1;b;1;490;100;100;490;100;100;0.13;0.13;100;0;1.9;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;1tpu;1;b;1;490;100;100;490;100;100;0.17;0.17;99;0;1.9;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;1sw0;1;b;1;490;100;99;490;100;99;0.20;0.20;98;0;1.9;1.71;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;1sw3;1;b;1;490;100;99;490;100;99;0.14;0.14;99;0;1.9;2.03;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;1tph;1;b;1;490;100;100;490;100;100;0.09;0.09;100;0;1.9;1.8;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;1sq7;1;b;1;481;98;97;487;99;99;0.78;0.87;98;0;1.9;2.85;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;4p61;1;b;1;473;97;98;476;97;99;0.53;0.55;99;0;1.9;1.34;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;8tim;1;b;1;480;98;97;487;99;99;0.82;0.86;100;0;1.9;2.5;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;SO4   sulfate ion;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpb;1;1sw7;1;b;1;487;99;99;490;100;100;0.53;0.54;98;0;1.9;2.22;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;1spq;1;b;1;475;96;99;481;97;100;0.80;0.81;99;0;2.9;2.16;diffraction;diffraction;494;494;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PEG   di(hydroxyethyl)ether;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;9.1;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;1tpw;1;b;1;486;98;99;490;99;100;0.62;0.62;98;0;2.9;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;1tpc;1;b;1;487;99;99;490;99;100;0.54;0.54;98;0;2.9;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;1tpu;1;b;1;487;99;99;490;99;100;0.57;0.57;98;0;2.9;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;1sw0;1;b;1;491;99;99;494;100;100;0.56;0.56;99;0;2.9;1.71;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGA   2-phosphoglycolic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;1sw3;1;b;1;490;99;99;494;100;100;0.60;0.60;99;0;2.9;2.03;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGA   2-phosphoglycolic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;1tph;1;b;1;487;99;99;490;99;100;0.56;0.57;98;0;2.9;1.8;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;1sq7;1;b;1;484;98;98;491;99;99;0.86;0.95;99;0;2.9;2.85;diffraction;diffraction;494;494;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;no/data;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;4p61;1;b;1;476;96;99;479;97;99;0.59;0.60;99;0;2.9;1.34;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;no/data;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;8tim;1;b;1;485;98;98;494;100;100;0.94;1.02;98;0;2.9;2.5;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;SO4   sulfate ion;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1ssg;1;1sw7;1;b;1;489;99;100;490;99;100;0.32;0.32;99;0;2.9;2.22;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid| SO4   sulfate ion| GOL   glycerol;PGA   2-phosphoglycolic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.5;100;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1spq;1;1tpw;1;b;1;474;98;97;480;100;98;0.76;0.79;99;0;2.16;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PEG   di(hydroxyethyl)ether;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;9.1;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1spq;1;1tpc;1;b;1;475;99;97;480;100;98;0.72;0.76;99;0;2.16;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PEG   di(hydroxyethyl)ether;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;9.1;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1spq;1;1tpu;1;b;1;475;99;97;479;99;98;0.63;0.65;99;0;2.16;1.9;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PEG   di(hydroxyethyl)ether;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;9.1;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1spq;1;1sw0;1;b;1;477;99;97;481;100;97;0.62;0.63;99;0;2.16;1.71;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PEG   di(hydroxyethyl)ether;PGA   2-phosphoglycolic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;9.1;100;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1spq;1;1sw3;1;b;1;477;99;97;481;100;97;0.66;0.67;100;0;2.16;2.03;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PEG   di(hydroxyethyl)ether;PGA   2-phosphoglycolic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;9.1;100;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1spq;1;1tph;1;b;1;475;99;97;479;99;98;0.65;0.66;99;0;2.16;1.8;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PEG   di(hydroxyethyl)ether;PGH   phosphoglycolohydroxamic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;9.1;100;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1spq;1;1sq7;1;b;1;478;99;97;482;100;98;0.63;0.63;99;0;2.16;2.85;diffraction;diffraction;494;494;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PEG   di(hydroxyethyl)ether;no/data;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;9.1;100;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1spq;1;4p61;1;b;1;475;99;99;480;100;100;0.73;0.75;99;0;2.16;1.34;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PEG   di(hydroxyethyl)ether;no/data;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;9.1;100;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1spq;1;8tim;1;b;1;476;99;96;482;100;98;0.76;0.76;99;0;2.16;2.5;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PEG   di(hydroxyethyl)ether;SO4   sulfate ion;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;9.1;100;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1spq;1;1sw7;1;b;1;473;98;97;479;99;98;0.79;0.80;99;0;2.16;2.22;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PEG   di(hydroxyethyl)ether;PGA   2-phosphoglycolic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;9.1;100;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpw;1;1tpc;1;b;1;489;100;100;490;100;100;0.26;0.26;100;0;1.9;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpw;1;1tpu;1;b;1;489;100;100;490;100;100;0.27;0.27;99;0;1.9;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpw;1;1sw0;1;b;1;489;100;99;490;100;99;0.31;0.31;98;0;1.9;1.71;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpw;1;1sw3;1;b;1;489;100;99;490;100;99;0.27;0.27;99;0;1.9;2.03;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpw;1;1tph;1;b;1;489;100;100;490;100;100;0.25;0.25;100;0;1.9;1.8;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpw;1;1sq7;1;b;1;480;98;97;487;99;99;0.82;0.93;98;0;1.9;2.85;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpw;1;4p61;1;b;1;473;97;98;476;97;99;0.57;0.58;99;0;1.9;1.34;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpw;1;8tim;1;b;1;480;98;97;489;100;99;0.93;0.99;100;0;1.9;2.5;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;SO4   sulfate ion;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpw;1;1sw7;1;b;1;487;99;99;490;100;100;0.58;0.58;98;0;1.9;2.22;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;TRIOSEPHOSPHATE ISOMERASE DRINKS WATER TO KEEP HEALTHY;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpc;1;1tpu;1;b;1;490;100;100;490;100;100;0.18;0.18;99;0;1.9;1.9;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpc;1;1sw0;1;b;1;490;100;99;490;100;99;0.21;0.21;98;0;1.9;1.71;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpc;1;1sw3;1;b;1;490;100;99;490;100;99;0.17;0.17;98;0;1.9;2.03;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpc;1;1tph;1;b;1;490;100;100;490;100;100;0.14;0.14;99;0;1.9;1.8;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpc;1;1sq7;1;b;1;481;98;97;487;99;99;0.78;0.86;98;0;1.9;2.85;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpc;1;4p61;1;b;1;473;97;98;476;97;99;0.52;0.54;98;0;1.9;1.34;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpc;1;8tim;1;b;1;481;98;97;490;100;99;0.93;1.01;99;0;1.9;2.5;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;SO4   sulfate ion;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpc;1;1sw7;1;b;1;488;99;99;490;100;100;0.50;0.50;98;0;1.9;2.22;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;OFFSET OF A CATALYTIC LESION BY A BOUND WATER SOLUBLE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpu;1;1sw0;1;b;1;490;100;99;490;100;99;0.21;0.21;98;0;1.9;1.71;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpu;1;1sw3;1;b;1;490;100;99;490;100;99;0.17;0.17;99;0;1.9;2.03;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpu;1;1tph;1;b;1;490;100;100;490;100;100;0.16;0.16;100;0;1.9;1.8;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGH   phosphoglycolohydroxamic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpu;1;1sq7;1;b;1;482;98;97;488;100;99;0.80;0.90;98;0;1.9;2.85;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpu;1;4p61;1;b;1;473;97;98;476;97;99;0.53;0.55;99;0;1.9;1.34;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpu;1;8tim;1;b;1;481;98;97;488;100;99;0.86;0.91;100;0;1.9;2.5;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;SO4   sulfate ion;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1tpu;1;1sw7;1;b;1;487;99;99;490;100;100;0.51;0.51;98;0;1.9;2.22;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;S96P CHANGE IS A SECOND-SITE SUPPRESSOR FOR H95N SLUGGISH MUTANT TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw0;1;1sw3;1;b;1;494;100;100;494;100;100;0.18;0.18;99;0;1.71;2.03;diffraction;diffraction;496;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;PGA   2-phosphoglycolic acid;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;7.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw0;1;1tph;1;b;1;490;99;100;490;99;100;0.19;0.19;99;0;1.71;1.8;diffraction;diffraction;496;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;PGH   phosphoglycolohydroxamic acid;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw0;1;1sq7;1;b;1;485;98;98;491;99;99;0.79;0.88;100;0;1.71;2.85;diffraction;diffraction;496;494;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;no/data;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw0;1;4p61;1;b;1;476;96;99;479;97;99;0.56;0.57;99;0;1.71;1.34;diffraction;diffraction;496;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;no/data;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw0;1;8tim;1;b;1;485;98;98;494;100;100;0.97;1.06;99;0;1.71;2.5;diffraction;diffraction;496;494;Triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;SO4   sulfate ion;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw0;1;1sw7;1;b;1;488;99;99;490;99;100;0.50;0.50;99;0;1.71;2.22;diffraction;diffraction;496;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;PGA   2-phosphoglycolic acid;Triosephosphate isomerase from Gallus gallus, loop 6 hinge mutant K174L, T175W;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw3;1;1tph;1;b;1;490;99;100;490;99;100;0.12;0.12;99;0;2.03;1.8;diffraction;diffraction;496;494;Triosephosphate isomerase;TRIOSEPHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;PGH   phosphoglycolohydroxamic acid;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;no/data;no/data;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw3;1;1sq7;1;b;1;485;98;98;492;100;100;0.83;0.93;99;0;2.03;2.85;diffraction;diffraction;496;494;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;no/data;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw3;1;4p61;1;b;1;476;96;99;479;97;99;0.56;0.57;99;0;2.03;1.34;diffraction;diffraction;496;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;no/data;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw3;1;8tim;1;b;1;484;98;98;491;99;99;0.87;0.90;99;0;2.03;2.5;diffraction;diffraction;496;494;Triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;SO4   sulfate ion;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1sw3;1;1sw7;1;b;1;487;99;99;490;99;100;0.56;0.56;99;0;2.03;2.22;diffraction;diffraction;496;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGA   2-phosphoglycolic acid;PGA   2-phosphoglycolic acid;Triosephosphate isomerase from Gallus gallus, loop 6 mutant T175V;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7.5;295;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1tph;1;1sq7;1;b;1;481;98;97;487;99;99;0.78;0.86;99;0;1.8;2.85;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.2;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tph;1;4p61;1;b;1;473;97;98;477;97;99;0.60;0.68;99;0;1.8;1.34;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;no/data;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1tph;1;8tim;1;b;1;481;98;97;490;100;99;0.93;1.02;100;0;1.8;2.5;diffraction;diffraction;494;494;TRIOSEPHOSPHATE ISOMERASE;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;SO4   sulfate ion;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1tph;1;1sw7;1;b;1;487;99;99;490;100;100;0.53;0.53;98;0;1.8;2.22;diffraction;diffraction;494;496;TRIOSEPHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;PGH   phosphoglycolohydroxamic acid;PGA   2-phosphoglycolic acid;1.8 ANGSTROMS CRYSTAL STRUCTURE OF WILD TYPE CHICKEN TRIOSEPHOSPHATE ISOMERASE-PHOSPHOGLYCOLOHYDROXAMATE COMPLEX;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;no/data;no/data;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;1sq7;1;4p61;1;b;1;479;97;99;482;98;100;0.55;0.59;99;0;2.85;1.34;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;no/data;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.2;100;8.5;100;1spq_A;4p61_A;1.68;1.36
1tim;2;1sq7;1;8tim;1;b;1;490;99;99;494;100;100;0.61;0.62;99;0;2.85;2.5;diffraction;diffraction;494;494;Triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;no/data;SO4   sulfate ion;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.2;100;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;1sq7;1;1sw7;1;b;1;480;97;98;487;99;99;0.85;0.96;99;0;2.85;2.22;diffraction;diffraction;494;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;PGA   2-phosphoglycolic acid;Understanding protein lids: Structural analysis of active hinge mutants in triosephosphate isomerase;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;5.2;100;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;4p61;1;8tim;1;b;1;477;99;96;482;100;98;0.75;0.78;99;0;1.34;2.5;diffraction;diffraction;496;494;Triosephosphate isomerase;TRIOSE PHOSPHATE ISOMERASE;GALLUS GALLUS;GALLUS GALLUS;no/data;SO4   sulfate ion;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;TRIOSE PHOSPHATE ISOMERASE;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;8.5;100;7;290;1spq_A;4p61_A;1.68;1.36
1tim;2;4p61;1;1sw7;1;b;1;473;98;96;477;99;97;0.66;0.73;99;0;1.34;2.22;diffraction;diffraction;496;496;Triosephosphate isomerase;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;no/data;PGA   2-phosphoglycolic acid;CHICKEN TRIOSEPHOSPHATE ISOMERASE WITH LOOP6 MUTATIONS, V167P AND W168E.;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;8.5;100;5.5;295;1spq_A;4p61_A;1.68;1.36
1tim;2;8tim;1;1sw7;1;b;1;479;97;98;487;99;99;0.88;0.91;98;0;2.5;2.22;diffraction;diffraction;494;496;TRIOSE PHOSPHATE ISOMERASE;Triosephosphate isomerase;GALLUS GALLUS;GALLUS GALLUS;SO4   sulfate ion;PGA   2-phosphoglycolic acid;TRIOSE PHOSPHATE ISOMERASE;Triosephosphate isomerase from Gallus gallus, loop 6 mutant K174N, T175S, A176S;P00940;TPI1;PF00121;P00940;TPI1;PF00121;b;7;290;5.5;295;1spq_A;4p61_A;1.68;1.36
2j6r;2;2j6r;1;2j6g;1;b;1;504;99;97;508;100;98;0.66;0.66;97;0;1.9;1.55;diffraction;diffraction;532;532;K88 FIMBRIAL PROTEIN;FAEG;ESCHERICHIA COLI;ESCHERICHIA COLI;PO4   phosphate ion;ACT   acetate ion;FaeG from F4ac ETEC strain GIS26, produced in tobacco plant chloroplast;FaeG from F4ac ETEC strain 5_95, produced in tobacco plant chloroplast;P14190;faeG;no/data;Q6T3W5;no/data;no/data;b;no/data;100;no/data;100;2j6r_A;2j6g_A;0.62;0.66
3b6a;2;3b6a;1;2opt;1;b;1;401;95;97;412;98;100;1.17;1.19;100;0;3.05;2.05;diffraction;diffraction;468;468;ActR protein;ActII protein;STREPTOMYCES COELICOLOR;STREPTOMYCES COELICOLOR;ZCT   2,2'-[(1r,1'r,3s,3's)-6,6',9,9'-tetrahydroxy-1,1'-dimethyl-5,5',10,10'-tetraoxo-3,3',4,4',5,5',10,10'-octahydro-1h,1'h-8,8'-bibenzo[g]isochromene-3,3'-diyl]diacetic acid;no/data;Crystal structure of the Streptomyces coelicolor TetR family protein ActR in complex with actinorhodin;Crystal Structure of Apo ActR from Streptomyces coelicolor.;Q53901;actII;PF02909,PF00440;Q53901;actII;PF02909,PF00440;b;8.5;100;6.5;100;3b6a_A;2opt_B;1.37;1.19
3b6a;2;3b6a;1;3b6c;1;b;1;398;94;98;405;96;100;0.93;0.95;100;0;3.05;2.3;diffraction;diffraction;468;468;ActR protein;ActII protein;STREPTOMYCES COELICOLOR;STREPTOMYCES COELICOLOR;ZCT   2,2'-[(1r,1'r,3s,3's)-6,6',9,9'-tetrahydroxy-1,1'-dimethyl-5,5',10,10'-tetraoxo-3,3',4,4',5,5',10,10'-octahydro-1h,1'h-8,8'-bibenzo[g]isochromene-3,3'-diyl]diacetic acid;SDN   [(3s)-9-hydroxy-1-methyl-10-oxo-4,10-dihydro-3h-benzo[g]isochromen-3-yl]acetic acid;Crystal structure of the Streptomyces coelicolor TetR family protein ActR in complex with actinorhodin;Crystal structure of the Streptomyces coelicolor TetR family protein ActR in complex with (S)-DNPA;Q53901;actII;PF02909,PF00440;Q53901;actII;PF02909,PF00440;b;8.5;100;6.5;100;3b6a_A;2opt_B;1.37;1.19
3b6a;2;2opt;1;3b6c;1;b;1;397;96;98;405;98;100;1.01;1.11;97;0;2.05;2.3;diffraction;diffraction;468;468;ActII protein;ActII protein;STREPTOMYCES COELICOLOR;STREPTOMYCES COELICOLOR;no/data;SDN   [(3s)-9-hydroxy-1-methyl-10-oxo-4,10-dihydro-3h-benzo[g]isochromen-3-yl]acetic acid;Crystal Structure of Apo ActR from Streptomyces coelicolor.;Crystal structure of the Streptomyces coelicolor TetR family protein ActR in complex with (S)-DNPA;Q53901;actII;PF02909,PF00440;Q53901;actII;PF02909,PF00440;b;6.5;100;6.5;100;3b6a_A;2opt_B;1.37;1.19
2q29;4;2q29;1;2q27;1;b;1;2181;100;100;2182;100;100;0.16;0.16;100;0;1.82;2.12;diffraction;diffraction;2256;2256;oxalyl-CoA decarboxylase;oxalyl-CoA decarboxylase;ESCHERICHIA COLI;ESCHERICHIA COLI;MG   magnesium ion| ACO   acetyl coenzyme *a| TPP   thiamine diphosphate| MES   2-(n-morpholino)-ethanesulfonic acid;MG   magnesium ion| SO4   sulfate ion| TPP   thiamine diphosphate| EDO   1,2-ethanediol| MES   2-(n-morpholino)-ethanesulfonic acid;Crystal structure of oxalyl-coA decarboxylase from Escherichia coli in complex with acetyl coenzyme A;Crystal structure of oxalyl-coA decarboxylase from Escherichia coli;P0AFI0;oxc yfdU b2373 JW2370;PF02775,PF00205,PF02776;P0AFI0;oxc yfdU b2373 JW2370;PF02775,PF00205,PF02776;b;6;100;6.5;100;2q29_B;2q28_A;0.24;0.21
2q29;4;2q29;1;2q28;1;b;1;2182;100;99;2184;100;99;0.21;0.21;100;0;1.82;1.74;diffraction;diffraction;2256;2256;oxalyl-CoA decarboxylase;oxalyl-CoA decarboxylase;ESCHERICHIA COLI;ESCHERICHIA COLI;MG   magnesium ion| ACO   acetyl coenzyme *a| TPP   thiamine diphosphate| MES   2-(n-morpholino)-ethanesulfonic acid;MG   magnesium ion| SO4   sulfate ion| TPP   thiamine diphosphate| ADP   adenosine-5'-diphosphate| MES   2-(n-morpholino)-ethanesulfonic acid| EDO   1,2-ethanediol;Crystal structure of oxalyl-coA decarboxylase from Escherichia coli in complex with acetyl coenzyme A;Crystal structure of oxalyl-coA decarboxylase from Escherichia coli in complex with adenosine-5`-diphosphate;P0AFI0;oxc yfdU b2373 JW2370;PF02775,PF00205,PF02776;P0AFI0;oxc yfdU b2373 JW2370;PF02775,PF00205,PF02776;b;6;100;6.5;100;2q29_B;2q28_A;0.24;0.21
2q29;4;2q27;1;2q28;1;b;1;2182;100;99;2184;100;99;0.21;0.21;100;0;2.12;1.74;diffraction;diffraction;2256;2256;oxalyl-CoA decarboxylase;oxalyl-CoA decarboxylase;ESCHERICHIA COLI;ESCHERICHIA COLI;MG   magnesium ion| SO4   sulfate ion| TPP   thiamine diphosphate| EDO   1,2-ethanediol| MES   2-(n-morpholino)-ethanesulfonic acid;MG   magnesium ion| SO4   sulfate ion| TPP   thiamine diphosphate| ADP   adenosine-5'-diphosphate| MES   2-(n-morpholino)-ethanesulfonic acid| EDO   1,2-ethanediol;Crystal structure of oxalyl-coA decarboxylase from Escherichia coli;Crystal structure of oxalyl-coA decarboxylase from Escherichia coli in complex with adenosine-5`-diphosphate;P0AFI0;oxc yfdU b2373 JW2370;PF02775,PF00205,PF02776;P0AFI0;oxc yfdU b2373 JW2370;PF02775,PF00205,PF02776;b;6.5;100;6.5;100;2q29_B;2q28_A;0.24;0.21
2y0f;2;2y0f;1;4g9p;1;b;1;514;65;63;548;70;68;1.77;1.85;100;0;2.5;1.55;diffraction;diffraction;812;812;4-HYDROXY-3-METHYLBUT-2-EN-1-YL DIPHOSPHATE SYNTHASE;4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase;THERMUS THERMOPHILUS;THERMUS THERMOPHILUS;SF4   iron/sulfur cluster;SF4   iron/sulfur cluster| CDI   2c-methyl-d-erythritol 2,4-cyclodiphosphate| MES   2-(n-morpholino)-ethanesulfonic acid| CL   chloride ion| K   potassium ion;STRUCTURE OF GCPE (IspG) FROM THERMUS THERMOPHILUS HB27;Structure of the GcpE-MEcPP (IspG) complex from Thermus thermophilus;Q72H18;ispG gcpE TT_C1677;PF04551;Q72H18;ispG gcpE TT_C1677;PF04551;c;7.5;100;6.0;100;2y0f_A;2y0f_D;1.33;1.85
3o74;2;3o74;1;3o75;1;b;1;534;99;99;540;100;100;0.72;0.72;100;0;2.0;2.3;diffraction;diffraction;544;544;Fructose transport system repressor FruR;Fructose transport system repressor FruR;PSEUDOMONAS PUTIDA;PSEUDOMONAS PUTIDA;MSE   selenomethionine| GOL   glycerol;F1X   1-o-phosphono-beta-d-fructofuranose;Crystal structure of Cra transcriptional dual regulator from Pseudomonas putida;Crystal structure of Cra transcriptional dual regulator from Pseudomonas putida in complex with fructose 1-phosphate';Q88PQ6;cra PP_0792;PF00356,PF00532;Q88PQ6;cra PP_0792;PF00356,PF00532;b;6.5;100;6.5;100;3o74_B;3o75_A;0.72;0.72
1zk7;2;1zk7;1;1zx9;1;b;1;901;96;99;906;97;100;0.54;0.55;100;0;1.6;1.9;diffraction;diffraction;934;934;Mercuric reductase;Mercuric reductase;PSEUDOMONAS AERUGINOSA;PSEUDOMONAS AERUGINOSA;SO4   sulfate ion| FAD   flavin-adenine dinucleotide| GOL   glycerol;FAD   flavin-adenine dinucleotide;Crystal Structure of Tn501 MerA;Crystal Structure of Tn501 MerA;P00392;merA;PF00403,PF07992,PF02852;P00392;merA;PF00403,PF07992,PF02852;b;9.4;100;4.6;100;1zk7_A;1zx9_A;0.49;0.58
1zk7;2;1zk7;1;4k7z;1;b;1;926;99;99;930;100;100;0.46;0.48;100;0;1.6;1.5;diffraction;diffraction;934;934;Mercuric reductase;Mercuric reductase;PSEUDOMONAS AERUGINOSA;PSEUDOMONAS AERUGINOSA;SO4   sulfate ion| FAD   flavin-adenine dinucleotide| GOL   glycerol;no/data;Crystal Structure of Tn501 MerA;Crystal structure of the C136(42)A/C141(47)A double mutant of Tn501 MerA in complex with NADP and Hg2+;P00392;merA;PF00403,PF07992,PF02852;P00392;merA;PF00403,PF07992,PF02852;b;9.4;100;9.4;100;1zk7_A;1zx9_A;0.49;0.58
1zk7;2;1zk7;1;4k8d;1;b;1;921;99;99;926;99;99;0.50;0.51;100;0;1.6;1.86;diffraction;diffraction;934;934;Mercuric reductase;Mercuric reductase;PSEUDOMONAS AERUGINOSA;PSEUDOMONAS AERUGINOSA;SO4   sulfate ion| FAD   flavin-adenine dinucleotide| GOL   glycerol;no/data;Crystal Structure of Tn501 MerA;Crystal structure of the C558(464)A/C559(465)A double mutant of Tn501 MerA in complex with NADPH and Hg2+;P00392;merA;PF00403,PF07992,PF02852;P00392;merA;PF00403,PF07992,PF02852;b;9.4;100;9.4;100;1zk7_A;1zx9_A;0.49;0.58
1zk7;2;1zx9;1;4k7z;1;b;1;902;100;97;906;100;97;0.48;0.49;100;0;1.9;1.5;diffraction;diffraction;934;934;Mercuric reductase;Mercuric reductase;PSEUDOMONAS AERUGINOSA;PSEUDOMONAS AERUGINOSA;FAD   flavin-adenine dinucleotide;no/data;Crystal Structure of Tn501 MerA;Crystal structure of the C136(42)A/C141(47)A double mutant of Tn501 MerA in complex with NADP and Hg2+;P00392;merA;PF00403,PF07992,PF02852;P00392;merA;PF00403,PF07992,PF02852;b;4.6;100;9.4;100;1zk7_A;1zx9_A;0.49;0.58
1zk7;2;1zx9;1;4k8d;1;c;1;900;99;97;906;100;97;0.58;0.58;100;0;1.9;1.86;diffraction;diffraction;934;934;Mercuric reductase;Mercuric reductase;PSEUDOMONAS AERUGINOSA;PSEUDOMONAS AERUGINOSA;FAD   flavin-adenine dinucleotide;no/data;Crystal Structure of Tn501 MerA;Crystal structure of the C558(464)A/C559(465)A double mutant of Tn501 MerA in complex with NADPH and Hg2+;P00392;merA;PF00403,PF07992,PF02852;P00392;merA;PF00403,PF07992,PF02852;b;4.6;100;9.4;100;1zk7_A;1zx9_A;0.49;0.58
1zk7;2;4k7z;1;4k8d;1;b;1;931;100;100;932;100;100;0.28;0.28;99;0;1.5;1.86;diffraction;diffraction;934;934;Mercuric reductase;Mercuric reductase;PSEUDOMONAS AERUGINOSA;PSEUDOMONAS AERUGINOSA;no/data;no/data;Crystal structure of the C136(42)A/C141(47)A double mutant of Tn501 MerA in complex with NADP and Hg2+;Crystal structure of the C558(464)A/C559(465)A double mutant of Tn501 MerA in complex with NADPH and Hg2+;P00392;merA;PF00403,PF07992,PF02852;P00392;merA;PF00403,PF07992,PF02852;b;9.4;100;9.4;100;1zk7_A;1zx9_A;0.49;0.58
3qhs;6;3qhs;2;2y90;1;b;1;382;95;99;384;95;100;0.50;0.50;100;0;2.85;2.252;diffraction;diffraction;612;624;Protein hfq;PROTEIN HFQ;ESCHERICHIA COLI;ESCHERICHIA COLI;no/data;no/data;Crystal structure of full-length Hfq from Escherichia coli;Crystal structure of Hfq riboregulator from E. coli (P6 space group);P0A6X3;hfq b4172 JW4130;PF17209;P0A6X3;hfq b4172 JW4130;PF17209;a;6.5;100;no/data;100;3qhs_B;3qhs_G;1.10;0.50
4i7h;2;4i7h;1;4lmy;1;b;1;278;94;91;291;99;95;1.51;1.55;100;0;2.0;1.6;diffraction;diffraction;326;326;peroxide stress sensing regulator;Peroxide stress regulator PerR, FUR family;STREPTOCOCCUS PYOGENES;STREPTOCOCCUS PYOGENES;NI   nickel (ii) ion| ZN   zinc ion;ZN   zinc ion;Structural basis for peroxide sensing and gene regulation by PerR from Streptococcus pyogenes;Structure of GAS PerR-Zn-Zn;A0A0H2UT39;spf SpyM3_0147;PF01475;no/data;no/data;no/data;b;8.0;100;8.6;100;4i7h_B;4lmy_A;1.61;1.55
1js3;2;1js3;1;1js6;1;b;1;926;100;100;928;100;100;0.33;0.33;100;0;2.25;2.6;diffraction;diffraction;972;972;DOPA decarboxylase;DOPA decarboxylase;SUS SCROFA;SUS SCROFA;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| 142   carbidopa;PLP   pyridoxal-5'-phosphate;Crystal structure of dopa decarboxylase in complex with the inhibitor carbidopa;Crystal Structure of DOPA decarboxylase;P80041;DDC;PF00282;P80041;DDC;PF00282;b;6.5;100;6.5;100;1js3_B;1js6_A;0.34;0.33
2o9e;4;2o9e;1;2abm;2;b;1;906;98;100;908;98;100;0.36;0.36;99;0;2.2;3.2;diffraction;diffraction;936;924;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;HG   mercury (ii) ion;PO4   phosphate ion| 3PG   3-phosphoglyceric acid| AGA   (1s)-2-{[{[(2s)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(pentanoyloxy)methyl]ethyl octanoate| PEE   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine| BGL   b-2-octylglucoside| POQ   bis(((3s,4s,5r,6r)-5-(ethyl(phosphoryloxy))-3,4,6-trihydroxy-tetrahydro-2h-pyran-2-yl)methyl) hydrogen phosphate;Crystal Structure of AqpZ mutant T183C complexed with mercury;Crystal Structure of Aquaporin Z Tetramer Reveals both Open and Closed Water-conducting Channels;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;4.6;273;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2o9e;1;1rc2;1;b;1;915;99;99;920;99;100;0.50;0.51;99;0;2.2;2.5;diffraction;diffraction;936;924;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;HG   mercury (ii) ion;BGL   b-2-octylglucoside;Crystal Structure of AqpZ mutant T183C complexed with mercury;2.5 Angstrom Resolution X-ray Structure of Aquaporin Z;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;6.5;100;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2o9e;1;3nkc;1;b;1;921;99;100;924;100;100;0.39;0.39;97;0;2.2;3.1;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;HG   mercury (ii) ion;BOG   b-octylglucoside;Crystal Structure of AqpZ mutant T183C complexed with mercury;Crystal structure of AqpZ F43W,H174G,T183F;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2o9e;1;3nk5;2;b;1;926;100;99;928;100;100;0.29;0.30;97;0;2.2;2.4;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;HG   mercury (ii) ion;BOG   b-octylglucoside;Crystal Structure of AqpZ mutant T183C complexed with mercury;Crystal structure of AqpZ mutant F43W;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2o9e;1;3nka;1;b;1;919;99;100;920;99;100;0.24;0.24;98;0;2.2;2.5;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;HG   mercury (ii) ion;BOG   b-octylglucoside| GOL   glycerol;Crystal Structure of AqpZ mutant T183C complexed with mercury;Crystal structure of AqpZ H174G,T183F;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2o9e;1;2o9f;3;b;1;927;100;100;928;100;100;0.26;0.26;99;0;2.2;2.55;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;HG   mercury (ii) ion;no/data;Crystal Structure of AqpZ mutant T183C complexed with mercury;Crystal Structure of AqpZ mutant L170C;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2o9e;1;2o9d;3;b;1;927;100;99;928;100;100;0.27;0.29;99;0;2.2;2.3;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;HG   mercury (ii) ion;HSG   octyl alpha-l-altropyranoside| HSH   octyl beta-d-galactopyranoside;Crystal Structure of AqpZ mutant T183C complexed with mercury;Crystal Structure of AqpZ mutant T183C.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2o9e;1;2o9g;1;b;1;927;100;100;928;100;100;0.18;0.18;99;0;2.2;1.9;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;HG   mercury (ii) ion;BOG   b-octylglucoside| HG   mercury (ii) ion;Crystal Structure of AqpZ mutant T183C complexed with mercury;Crystal Structure of AqpZ mutant L170C complexed with mercury.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2abm;2;1rc2;1;b;1;904;100;98;908;100;98;0.44;0.44;100;0;3.2;2.5;diffraction;diffraction;924;924;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;PO4   phosphate ion| 3PG   3-phosphoglyceric acid| AGA   (1s)-2-{[{[(2s)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(pentanoyloxy)methyl]ethyl octanoate| PEE   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine| BGL   b-2-octylglucoside| POQ   bis(((3s,4s,5r,6r)-5-(ethyl(phosphoryloxy))-3,4,6-trihydroxy-tetrahydro-2h-pyran-2-yl)methyl) hydrogen phosphate;BGL   b-2-octylglucoside;Crystal Structure of Aquaporin Z Tetramer Reveals both Open and Closed Water-conducting Channels;2.5 Angstrom Resolution X-ray Structure of Aquaporin Z;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;4.6;273;6.5;100;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2abm;2;3nkc;1;b;1;905;100;98;908;100;98;0.37;0.37;99;0;3.2;3.1;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;PO4   phosphate ion| 3PG   3-phosphoglyceric acid| AGA   (1s)-2-{[{[(2s)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(pentanoyloxy)methyl]ethyl octanoate| PEE   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine| BGL   b-2-octylglucoside| POQ   bis(((3s,4s,5r,6r)-5-(ethyl(phosphoryloxy))-3,4,6-trihydroxy-tetrahydro-2h-pyran-2-yl)methyl) hydrogen phosphate;BOG   b-octylglucoside;Crystal Structure of Aquaporin Z Tetramer Reveals both Open and Closed Water-conducting Channels;Crystal structure of AqpZ F43W,H174G,T183F;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;4.6;273;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2abm;2;3nk5;2;b;1;906;100;97;908;100;97;0.34;0.34;99;0;3.2;2.4;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;PO4   phosphate ion| 3PG   3-phosphoglyceric acid| AGA   (1s)-2-{[{[(2s)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(pentanoyloxy)methyl]ethyl octanoate| PEE   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine| BGL   b-2-octylglucoside| POQ   bis(((3s,4s,5r,6r)-5-(ethyl(phosphoryloxy))-3,4,6-trihydroxy-tetrahydro-2h-pyran-2-yl)methyl) hydrogen phosphate;BOG   b-octylglucoside;Crystal Structure of Aquaporin Z Tetramer Reveals both Open and Closed Water-conducting Channels;Crystal structure of AqpZ mutant F43W;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;4.6;273;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2abm;2;3nka;1;b;1;906;100;98;908;100;99;0.35;0.35;99;0;3.2;2.5;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;PO4   phosphate ion| 3PG   3-phosphoglyceric acid| AGA   (1s)-2-{[{[(2s)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(pentanoyloxy)methyl]ethyl octanoate| PEE   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine| BGL   b-2-octylglucoside| POQ   bis(((3s,4s,5r,6r)-5-(ethyl(phosphoryloxy))-3,4,6-trihydroxy-tetrahydro-2h-pyran-2-yl)methyl) hydrogen phosphate;BOG   b-octylglucoside| GOL   glycerol;Crystal Structure of Aquaporin Z Tetramer Reveals both Open and Closed Water-conducting Channels;Crystal structure of AqpZ H174G,T183F;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;4.6;273;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2abm;2;2o9f;3;b;1;905;100;98;908;100;98;0.40;0.40;99;0;3.2;2.55;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;PO4   phosphate ion| 3PG   3-phosphoglyceric acid| AGA   (1s)-2-{[{[(2s)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(pentanoyloxy)methyl]ethyl octanoate| PEE   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine| BGL   b-2-octylglucoside| POQ   bis(((3s,4s,5r,6r)-5-(ethyl(phosphoryloxy))-3,4,6-trihydroxy-tetrahydro-2h-pyran-2-yl)methyl) hydrogen phosphate;no/data;Crystal Structure of Aquaporin Z Tetramer Reveals both Open and Closed Water-conducting Channels;Crystal Structure of AqpZ mutant L170C;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;4.6;273;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2abm;2;2o9d;3;b;1;906;100;97;908;100;97;0.37;0.37;99;0;3.2;2.3;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;PO4   phosphate ion| 3PG   3-phosphoglyceric acid| AGA   (1s)-2-{[{[(2s)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(pentanoyloxy)methyl]ethyl octanoate| PEE   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine| BGL   b-2-octylglucoside| POQ   bis(((3s,4s,5r,6r)-5-(ethyl(phosphoryloxy))-3,4,6-trihydroxy-tetrahydro-2h-pyran-2-yl)methyl) hydrogen phosphate;HSG   octyl alpha-l-altropyranoside| HSH   octyl beta-d-galactopyranoside;Crystal Structure of Aquaporin Z Tetramer Reveals both Open and Closed Water-conducting Channels;Crystal Structure of AqpZ mutant T183C.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;4.6;273;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2abm;2;2o9g;1;b;1;906;100;97;908;100;97;0.35;0.35;99;0;3.2;1.9;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;PO4   phosphate ion| 3PG   3-phosphoglyceric acid| AGA   (1s)-2-{[{[(2s)-2,3-dihydroxypropyl]oxy}(hydroxy)phosphoryl]oxy}-1-[(pentanoyloxy)methyl]ethyl octanoate| PEE   1,2-dioleoyl-sn-glycero-3-phosphoethanolamine| BGL   b-2-octylglucoside| POQ   bis(((3s,4s,5r,6r)-5-(ethyl(phosphoryloxy))-3,4,6-trihydroxy-tetrahydro-2h-pyran-2-yl)methyl) hydrogen phosphate;BOG   b-octylglucoside| HG   mercury (ii) ion;Crystal Structure of Aquaporin Z Tetramer Reveals both Open and Closed Water-conducting Channels;Crystal Structure of AqpZ mutant L170C complexed with mercury.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;4.6;273;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;1rc2;1;3nkc;1;b;1;912;99;99;916;99;99;0.46;0.47;99;0;2.5;3.1;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BGL   b-2-octylglucoside;BOG   b-octylglucoside;2.5 Angstrom Resolution X-ray Structure of Aquaporin Z;Crystal structure of AqpZ F43W,H174G,T183F;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;100;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;1rc2;1;3nk5;2;b;1;915;99;98;920;100;99;0.52;0.54;99;0;2.5;2.4;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BGL   b-2-octylglucoside;BOG   b-octylglucoside;2.5 Angstrom Resolution X-ray Structure of Aquaporin Z;Crystal structure of AqpZ mutant F43W;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;100;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;1rc2;1;3nka;1;b;1;909;98;99;912;99;99;0.39;0.40;99;0;2.5;2.5;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BGL   b-2-octylglucoside;BOG   b-octylglucoside| GOL   glycerol;2.5 Angstrom Resolution X-ray Structure of Aquaporin Z;Crystal structure of AqpZ H174G,T183F;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;100;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;1rc2;1;2o9f;3;b;1;915;99;99;920;100;99;0.51;0.52;99;0;2.5;2.55;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BGL   b-2-octylglucoside;no/data;2.5 Angstrom Resolution X-ray Structure of Aquaporin Z;Crystal Structure of AqpZ mutant L170C;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;100;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;1rc2;1;2o9d;3;b;1;917;99;98;924;100;99;0.62;0.66;99;0;2.5;2.3;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BGL   b-2-octylglucoside;HSG   octyl alpha-l-altropyranoside| HSH   octyl beta-d-galactopyranoside;2.5 Angstrom Resolution X-ray Structure of Aquaporin Z;Crystal Structure of AqpZ mutant T183C.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;100;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;1rc2;1;2o9g;1;b;1;915;99;98;920;100;99;0.50;0.52;99;0;2.5;1.9;diffraction;diffraction;924;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BGL   b-2-octylglucoside;BOG   b-octylglucoside| HG   mercury (ii) ion;2.5 Angstrom Resolution X-ray Structure of Aquaporin Z;Crystal Structure of AqpZ mutant L170C complexed with mercury.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;100;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nkc;1;3nk5;2;b;1;921;100;99;924;100;99;0.39;0.41;98;0;3.1;2.4;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside;BOG   b-octylglucoside;Crystal structure of AqpZ F43W,H174G,T183F;Crystal structure of AqpZ mutant F43W;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nkc;1;3nka;1;b;1;919;99;100;920;100;100;0.27;0.27;100;0;3.1;2.5;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside;BOG   b-octylglucoside| GOL   glycerol;Crystal structure of AqpZ F43W,H174G,T183F;Crystal structure of AqpZ H174G,T183F;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nkc;1;2o9f;3;b;1;921;100;99;924;100;100;0.42;0.43;97;0;3.1;2.55;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside;no/data;Crystal structure of AqpZ F43W,H174G,T183F;Crystal Structure of AqpZ mutant L170C;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nkc;1;2o9d;3;b;1;921;100;99;924;100;99;0.42;0.43;98;0;3.1;2.3;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside;HSG   octyl alpha-l-altropyranoside| HSH   octyl beta-d-galactopyranoside;Crystal structure of AqpZ F43W,H174G,T183F;Crystal Structure of AqpZ mutant T183C.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nkc;1;2o9g;1;b;1;921;100;99;924;100;99;0.38;0.39;97;0;3.1;1.9;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside;BOG   b-octylglucoside| HG   mercury (ii) ion;Crystal structure of AqpZ F43W,H174G,T183F;Crystal Structure of AqpZ mutant L170C complexed with mercury.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nk5;2;3nka;1;b;1;919;99;100;920;99;100;0.25;0.25;98;0;2.4;2.5;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside;BOG   b-octylglucoside| GOL   glycerol;Crystal structure of AqpZ mutant F43W;Crystal structure of AqpZ H174G,T183F;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;103;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nk5;2;2o9f;3;b;1;926;99;100;928;100;100;0.29;0.29;98;0;2.4;2.55;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside;no/data;Crystal structure of AqpZ mutant F43W;Crystal Structure of AqpZ mutant L170C;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nk5;2;2o9d;3;b;1;931;100;100;932;100;100;0.21;0.21;98;0;2.4;2.3;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside;HSG   octyl alpha-l-altropyranoside| HSH   octyl beta-d-galactopyranoside;Crystal structure of AqpZ mutant F43W;Crystal Structure of AqpZ mutant T183C.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nk5;2;2o9g;1;b;1;927;99;99;928;100;100;0.20;0.20;98;0;2.4;1.9;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside;BOG   b-octylglucoside| HG   mercury (ii) ion;Crystal structure of AqpZ mutant F43W;Crystal Structure of AqpZ mutant L170C complexed with mercury.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nka;1;2o9f;3;b;1;918;100;99;920;100;99;0.31;0.31;98;0;2.5;2.55;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside| GOL   glycerol;no/data;Crystal structure of AqpZ H174G,T183F;Crystal Structure of AqpZ mutant L170C;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nka;1;2o9d;3;b;1;919;100;99;920;100;99;0.27;0.27;98;0;2.5;2.3;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside| GOL   glycerol;HSG   octyl alpha-l-altropyranoside| HSH   octyl beta-d-galactopyranoside;Crystal structure of AqpZ H174G,T183F;Crystal Structure of AqpZ mutant T183C.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;3nka;1;2o9g;1;b;1;919;100;99;920;100;99;0.24;0.24;98;0;2.5;1.9;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;BOG   b-octylglucoside| GOL   glycerol;BOG   b-octylglucoside| HG   mercury (ii) ion;Crystal structure of AqpZ H174G,T183F;Crystal Structure of AqpZ mutant L170C complexed with mercury.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;103;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2o9f;3;2o9d;3;b;1;927;100;99;928;100;100;0.27;0.27;99;0;2.55;2.3;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;no/data;HSG   octyl alpha-l-altropyranoside| HSH   octyl beta-d-galactopyranoside;Crystal Structure of AqpZ mutant L170C;Crystal Structure of AqpZ mutant T183C.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2o9f;3;2o9g;1;b;1;927;100;99;928;100;100;0.23;0.23;100;0;2.55;1.9;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;no/data;BOG   b-octylglucoside| HG   mercury (ii) ion;Crystal Structure of AqpZ mutant L170C;Crystal Structure of AqpZ mutant L170C complexed with mercury.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2o9e;4;2o9d;3;2o9g;1;b;1;927;99;99;928;100;100;0.20;0.20;99;0;2.3;1.9;diffraction;diffraction;936;936;Aquaporin Z;Aquaporin Z;ESCHERICHIA COLI;ESCHERICHIA COLI;HSG   octyl alpha-l-altropyranoside| HSH   octyl beta-d-galactopyranoside;BOG   b-octylglucoside| HG   mercury (ii) ion;Crystal Structure of AqpZ mutant T183C.;Crystal Structure of AqpZ mutant L170C complexed with mercury.;P60844;aqpZ bniP b0875 JW0859;PF00230;P60844;aqpZ bniP b0875 JW0859;PF00230;b;6.5;no/data;6.5;no/data;1rc2_B;2o9d_B;0.64;0.66
2q7w;2;2q7w;1;4f5h;1;b;1;734;97;92;754;100;95;1.15;1.20;91;0;1.4;1.6;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;4.6;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;4f5i;1;b;1;745;99;93;754;100;94;0.75;0.76;94;0;1.4;2.2;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;4.6;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1x29;1;b;1;724;96;91;754;100;95;1.40;1.50;89;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;3pa9;1;b;1;745;99;94;753;100;95;0.72;0.76;96;0;1.4;1.7;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;P00509;aspC b0928 JW0911;PF00155;D3H0F7;aspC EC042_1019;PF00155;c;6.0;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;3paa;1;b;1;748;99;95;753;100;95;0.59;0.62;98;0;1.4;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;P00509;aspC b0928 JW0911;PF00155;D3H0F7;aspC EC042_1019;PF00155;c;6.0;100;8;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;4f5g;1;b;1;737;98;92;753;100;94;1.02;1.06;91;0;1.4;1.67;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;4f5m;1;b;1;724;96;91;748;99;94;1.27;1.37;92;0;1.4;1.65;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;4.6;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2qb3;1;b;1;746;99;98;752;100;98;0.60;0.65;97;0;1.4;1.45;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;4f5j;1;b;1;711;94;89;754;100;94;1.70;1.80;77;0;1.4;1.954;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;4f5f;1;b;1;720;95;90;745;99;93;1.29;1.41;89;0;1.4;2.25;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2d66;1;b;1;715;95;90;754;100;95;1.61;1.71;85;0;1.4;2.18;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Mutant MAB;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;6.0;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;4f5k;1;c;1;708;94;89;746;99;93;1.60;1.70;80;0;1.4;2.2;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1tok;1;b;1;732;97;92;754;100;95;1.21;1.24;96;0;1.4;1.85;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;4dbc;1;b;1;723;96;91;754;100;95;1.43;1.52;88;0;1.4;1.5;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1cq6;1;b;1;740;98;93;754;100;95;0.96;1.01;95;0;1.4;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2d7y;1;b;1;739;98;93;754;100;95;0.98;1.02;94;0;1.4;2.66;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2d7z;1;b;1;733;97;93;754;100;95;1.16;1.21;94;0;1.4;2.65;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;6.0;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1b4x;1;b;1;709;94;90;754;100;95;1.73;1.83;79;0;1.4;2.45;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2qbt;1;b;1;753;100;96;754;100;96;0.23;0.24;100;0;1.4;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2qb2;1;b;1;746;99;98;752;100;98;0.61;0.66;97;0;1.4;1.7;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1toj;1;b;1;729;97;92;754;100;95;1.28;1.35;93;0;1.4;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1toi;1;c;1;726;96;92;753;100;95;1.34;1.41;91;0;1.4;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;3qpg;1;b;1;740;98;93;754;100;95;0.97;0.99;98;0;1.4;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2d65;1;c;1;716;95;90;749;99;95;1.48;1.56;88;0;1.4;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;6.0;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1cq8;1;b;1;738;98;93;754;100;95;1.02;1.05;98;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ari;1;b;1;735;97;93;754;100;95;1.13;1.16;96;0;1.4;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1g4v;1;b;1;737;98;93;753;100;95;1.04;1.10;92;0;1.4;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;3uak;1;c;1;662;88;84;752;100;95;2.49;2.59;90;0;1.4;3.232;diffraction;diffraction;792;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;MSE   selenomethionine;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;6.0;100;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1g4x;1;b;1;742;98;94;754;100;95;0.90;0.94;95;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;5eaa;1;b;1;746;99;94;754;100;95;0.72;0.75;97;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2d64;1;b;1;729;97;92;754;100;95;1.29;1.35;92;0;1.4;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;6.0;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1spa;1;b;1;749;99;95;754;100;95;0.58;0.60;98;0;1.4;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;3aat;1;b;1;745;99;94;754;100;95;0.75;0.76;99;0;1.4;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1x28;1;b;1;722;96;91;751;100;95;1.40;1.49;89;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1g7w;1;b;1;746;99;94;754;100;95;0.74;0.76;98;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2d5y;1;c;1;718;95;91;750;99;95;1.46;1.55;89;0;1.4;1.98;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2d63;1;b;1;728;97;92;751;100;95;1.23;1.29;96;0;1.4;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2d61;1;c;1;739;98;93;754;100;95;0.98;1.00;98;0;1.4;2.01;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1g7x;1;b;1;709;94;90;754;100;95;1.73;1.83;78;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1cq7;1;c;1;733;97;92;754;100;95;1.19;1.25;94;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1c9c;1;b;1;720;95;91;746;99;94;1.33;1.47;91;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PP3   alanyl-pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;4f5l;1;b;1;734;97;92;750;99;94;1.02;1.10;92;0;1.4;1.4;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;3qn6;1;b;1;741;98;94;750;99;95;0.75;0.80;96;0;1.4;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1tog;1;b;1;726;96;92;754;100;95;1.37;1.42;94;0;1.4;2.31;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1asn;1;b;1;748;99;94;754;100;95;0.64;0.66;98;0;1.4;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1arh;1;b;1;742;98;94;754;100;95;0.87;0.90;96;0;1.4;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1asa;1;b;1;731;97;92;754;100;95;1.24;1.29;95;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ahe;1;c;1;731;97;92;754;100;95;1.23;1.31;91;0;1.4;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1aic;1;b;1;727;96;92;754;100;95;1.33;1.41;88;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1aaw;1;b;1;743;98;94;754;100;95;0.86;0.90;96;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1asb;1;b;1;734;97;93;753;100;95;1.12;1.15;97;0;1.4;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1qir;1;b;1;736;98;93;754;100;95;1.09;1.11;97;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1czc;1;b;1;726;96;92;751;100;95;1.29;1.38;91;0;1.4;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ase;1;b;1;734;97;93;754;100;95;1.15;1.20;97;0;1.4;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1asd;1;b;1;732;97;92;754;100;95;1.19;1.23;95;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1qit;1;c;1;732;97;92;754;100;95;1.21;1.26;94;0;1.4;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ahf;1;c;1;734;97;93;754;100;95;1.16;1.22;92;0;1.4;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1asm;1;c;1;719;95;91;751;100;95;1.47;1.59;94;0;1.4;2.35;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ars;1;b;1;746;99;94;754;100;95;0.71;0.74;97;0;1.4;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2aat;1;b;1;719;95;91;754;100;95;1.52;1.59;87;0;1.4;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;2qa3;1;b;1;752;100;98;752;100;98;0.16;0.17;100;0;1.4;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1arg;1;c;1;736;98;93;754;100;95;1.08;1.12;97;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ahy;1;b;1;736;98;93;754;100;95;1.09;1.13;94;0;1.4;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1asg;1;c;1;731;97;92;754;100;95;1.22;1.27;94;0;1.4;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1x2a;1;c;1;723;96;91;747;99;94;1.26;1.36;94;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1cze;1;c;1;719;95;91;750;99;95;1.45;1.54;87;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ahx;1;b;1;727;96;92;754;100;95;1.32;1.40;91;0;1.4;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ams;1;b;1;746;99;94;754;100;95;0.73;0.77;97;0;1.4;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1yoo;1;b;1;717;95;91;754;100;95;1.58;1.67;85;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1amr;1;c;1;733;97;93;754;100;95;1.17;1.22;95;0;1.4;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1bqa;1;b;1;747;99;94;754;100;95;0.69;0.70;98;0;1.4;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1asl;1;b;1;738;98;93;754;100;95;1.03;1.06;98;0;1.4;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1qis;1;b;1;735;98;93;754;100;95;1.11;1.14;96;0;1.4;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1aam;1;b;1;734;97;93;754;100;95;1.14;1.19;95;0;1.4;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1bqd;1;b;1;726;96;92;754;100;95;1.37;1.45;87;0;1.4;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1asc;1;b;1;734;97;93;749;99;95;1.01;1.12;96;0;1.4;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;4a00;1;b;1;751;100;95;754;100;95;0.47;0.49;98;0;1.4;2.34;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ix7;1;b;1;746;99;94;754;100;95;0.73;0.75;98;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1aia;1;b;1;747;99;94;754;100;95;0.65;0.67;98;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1amq;1;b;1;744;99;94;753;100;95;0.76;0.80;97;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1asf;1;c;1;723;96;91;746;99;94;1.25;1.41;94;0;1.4;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1aib;1;b;1;739;98;93;754;100;95;0.99;1.05;94;0;1.4;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ix8;1;b;1;735;98;93;754;100;95;1.11;1.17;92;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;3zzk;1;b;1;744;99;94;754;100;95;0.83;0.88;94;0;1.4;1.78;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1ix6;1;b;1;735;97;93;750;99;95;0.99;1.08;95;0;1.4;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;3zzj;1;b;1;742;98;94;753;100;95;0.84;0.89;94;0;1.4;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1toe;1;b;1;726;96;92;750;99;95;1.25;1.35;90;0;1.4;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2q7w;1;1art;1;b;1;732;97;92;754;100;95;1.20;1.25;94;0;1.4;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Structural Studies Reveals the Inactivation of E. coli L-aspartate aminotransferase (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms at pH 6.0;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;6.0;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;4f5i;1;b;1;791;99;99;797;100;100;0.59;0.60;97;0;1.6;2.2;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;4.6;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1x29;1;b;1;751;94;95;790;99;100;1.57;1.65;96;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;3pa9;1;b;1;782;98;99;790;99;100;0.72;0.72;96;0;1.6;1.7;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;P00509;aspC b0928 JW0911;PF00155;D3H0F7;aspC EC042_1019;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;3paa;1;b;1;782;98;99;790;99;100;0.71;0.72;96;0;1.6;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;P00509;aspC b0928 JW0911;PF00155;D3H0F7;aspC EC042_1019;PF00155;c;4.6;100;8;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;4f5g;1;b;1;790;99;99;796;100;100;0.62;0.63;98;0;1.6;1.67;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;4f5m;1;b;1;789;99;99;796;100;100;0.66;0.67;96;0;1.6;1.65;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;4.6;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2qb3;1;b;1;746;94;98;756;95;99;0.82;0.83;96;0;1.6;1.45;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;4f5j;1;b;1;790;99;99;796;100;100;0.60;0.60;98;0;1.6;1.954;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;4f5f;1;b;1;789;99;99;797;100;100;0.68;0.69;98;0;1.6;2.25;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2d66;1;b;1;746;94;94;786;99;99;1.60;1.68;92;0;1.6;2.18;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Mutant MAB;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;4f5k;1;b;1;789;99;99;796;100;100;0.64;0.64;98;0;1.6;2.2;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1tok;1;b;1;734;92;93;783;98;99;1.77;1.87;95;0;1.6;1.85;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;4dbc;1;b;1;745;94;94;783;98;99;1.55;1.63;95;0;1.6;1.5;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1cq6;1;b;1;768;96;97;792;99;100;1.22;1.26;96;0;1.6;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2d7y;1;b;1;769;97;97;792;99;100;1.19;1.23;95;0;1.6;2.66;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2d7z;1;b;1;749;94;95;789;99;100;1.59;1.67;94;0;1.6;2.65;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1b4x;1;b;1;769;97;97;792;99;100;1.19;1.24;96;0;1.6;2.45;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2qbt;1;b;1;773;97;98;788;99;100;0.96;0.99;94;0;1.6;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2qb2;1;b;1;755;95;99;764;96;100;0.78;0.79;96;0;1.6;1.7;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1toj;1;b;1;734;92;93;774;97;98;1.62;1.70;95;0;1.6;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1toi;1;b;1;731;92;92;775;97;98;1.70;1.79;94;0;1.6;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;3qpg;1;b;1;743;93;94;782;98;99;1.58;1.65;95;0;1.6;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2d65;1;b;1;744;93;94;785;98;99;1.62;1.69;91;0;1.6;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1cq8;1;b;1;744;93;94;783;98;99;1.58;1.66;95;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ari;1;b;1;748;94;94;790;99;100;1.64;1.72;96;0;1.6;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1g4v;1;b;1;780;98;99;792;99;100;0.85;0.86;95;0;1.6;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;3uak;1;c;1;698;88;88;787;99;99;2.43;2.52;90;0;1.6;3.232;diffraction;diffraction;812;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;MSE   selenomethionine;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;4.6;100;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1g4x;1;b;1;783;98;99;792;99;100;0.76;0.77;95;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;5eaa;1;b;1;777;97;98;792;99;100;0.97;0.99;96;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2d64;1;b;1;737;93;93;776;97;98;1.58;1.65;92;0;1.6;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1spa;1;b;1;777;97;98;792;99;100;0.98;1.00;96;0;1.6;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;3aat;1;b;1;770;97;97;791;99;100;1.16;1.19;96;0;1.6;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1x28;1;b;1;754;95;95;792;99;100;1.56;1.64;96;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1g7w;1;b;1;781;98;99;792;99;100;0.83;0.84;95;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2d5y;1;b;1;746;94;94;783;98;99;1.55;1.62;94;0;1.6;1.98;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2d63;1;b;1;743;93;94;780;98;98;1.54;1.60;93;0;1.6;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2d61;1;b;1;750;94;95;789;99;100;1.58;1.65;94;0;1.6;2.01;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1g7x;1;b;1;779;98;98;792;99;100;0.89;0.91;95;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1cq7;1;b;1;743;93;94;781;98;99;1.55;1.63;96;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1c9c;1;b;1;777;97;98;792;99;100;0.98;1.00;96;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PP3   alanyl-pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;4f5l;1;b;1;789;99;99;796;100;100;0.65;0.65;98;0;1.6;1.4;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;3qn6;1;b;1;772;97;98;788;99;100;0.99;1.02;94;0;1.6;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1tog;1;b;1;735;92;93;786;99;99;1.82;1.92;94;0;1.6;2.31;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1asn;1;b;1;779;98;98;792;99;100;0.90;0.92;96;0;1.6;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1arh;1;b;1;764;96;97;792;99;100;1.32;1.39;95;0;1.6;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1asa;1;b;1;743;93;94;791;99;100;1.75;1.86;95;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ahe;1;b;1;752;94;95;789;99;100;1.54;1.63;96;0;1.6;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1aic;1;b;1;777;98;98;792;99;100;0.96;0.99;96;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1aaw;1;b;1;776;97;98;792;99;100;1.01;1.05;96;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1asb;1;b;1;748;94;94;790;99;100;1.64;1.72;94;0;1.6;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1qir;1;b;1;747;94;94;789;99;100;1.63;1.71;95;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1czc;1;b;1;742;93;94;781;98;99;1.58;1.66;93;0;1.6;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ase;1;b;1;738;93;93;781;98;99;1.66;1.75;96;0;1.6;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1asd;1;b;1;744;93;94;787;99;99;1.65;1.73;94;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1qit;1;b;1;740;93;93;781;98;99;1.62;1.71;96;0;1.6;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ahf;1;b;1;753;95;95;791;99;100;1.54;1.64;95;0;1.6;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1asm;1;b;1;748;94;94;789;99;100;1.61;1.69;95;0;1.6;2.35;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ars;1;b;1;780;98;98;792;99;100;0.87;0.88;96;0;1.6;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2aat;1;b;1;766;96;97;792;99;100;1.27;1.30;96;0;1.6;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;2qa3;1;b;1;743;93;97;766;96;100;1.22;1.29;89;0;1.6;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1arg;1;b;1;749;94;95;789;99;100;1.61;1.68;95;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ahy;1;b;1;746;94;94;787;99;99;1.62;1.71;95;0;1.6;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1asg;1;b;1;742;93;94;783;98;99;1.62;1.70;96;0;1.6;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1x2a;1;b;1;749;94;95;791;99;100;1.63;1.72;96;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1cze;1;b;1;748;94;94;789;99;100;1.61;1.69;92;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ahx;1;c;1;746;94;94;792;99;100;1.71;1.82;96;0;1.6;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ams;1;b;1;775;97;98;792;99;100;1.03;1.05;96;0;1.6;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1yoo;1;b;1;746;94;94;786;99;99;1.61;1.67;90;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1amr;1;b;1;750;94;95;789;99;100;1.58;1.65;95;0;1.6;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1bqa;1;b;1;783;98;99;792;99;100;0.74;0.74;96;0;1.6;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1asl;1;b;1;751;94;95;792;99;100;1.62;1.70;96;0;1.6;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1qis;1;b;1;747;94;94;792;99;100;1.69;1.80;96;0;1.6;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1aam;1;b;1;768;96;97;791;99;100;1.19;1.23;96;0;1.6;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1bqd;1;b;1;782;98;99;792;99;100;0.79;0.79;96;0;1.6;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1asc;1;b;1;768;96;97;792;99;100;1.22;1.26;96;0;1.6;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;4a00;1;b;1;782;98;99;792;99;100;0.80;0.81;95;0;1.6;2.34;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ix7;1;b;1;767;96;97;792;99;100;1.25;1.30;96;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1aia;1;b;1;774;97;98;792;99;100;1.05;1.09;96;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1amq;1;b;1;778;98;98;792;99;100;0.92;0.93;96;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1asf;1;b;1;772;97;97;790;99;100;1.07;1.10;94;0;1.6;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1aib;1;b;1;773;97;98;792;99;100;1.08;1.13;96;0;1.6;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ix8;1;b;1;785;98;99;792;99;100;0.67;0.67;95;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;3zzk;1;b;1;775;97;98;792;99;100;1.02;1.05;95;0;1.6;1.78;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1ix6;1;b;1;784;98;99;792;99;100;0.69;0.70;96;0;1.6;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;3zzj;1;b;1;782;98;99;792;99;100;0.79;0.80;95;0;1.6;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1toe;1;b;1;765;96;97;792;99;100;1.31;1.35;96;0;1.6;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5h;1;1art;1;b;1;750;94;95;791;99;100;1.62;1.70;96;0;1.6;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Intercoversion of Substrate Specificity: E. coli Aspatate Aminotransferase to Tyrosine Aminotransferase: Chimera P3.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1x29;1;c;1;764;95;96;792;99;100;1.33;1.40;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;3pa9;1;b;1;785;98;99;790;99;100;0.58;0.58;96;0;2.2;1.7;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;P00509;aspC b0928 JW0911;PF00155;D3H0F7;aspC EC042_1019;PF00155;c;4.6;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;3paa;1;b;1;785;98;99;790;99;100;0.58;0.58;96;0;2.2;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;P00509;aspC b0928 JW0911;PF00155;D3H0F7;aspC EC042_1019;PF00155;c;4.6;85;8;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;4f5g;1;b;1;794;99;100;798;100;100;0.49;0.50;97;0;2.2;1.67;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;4f5m;1;b;1;791;99;99;796;100;100;0.57;0.57;96;0;2.2;1.65;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;4.6;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2qb3;1;b;1;749;94;98;756;94;99;0.66;0.67;96;0;2.2;1.45;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;4f5j;1;b;1;796;99;100;798;100;100;0.37;0.38;98;0;2.2;1.954;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;4f5f;1;b;1;797;100;100;799;100;100;0.36;0.36;98;0;2.2;2.25;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2d66;1;b;1;755;94;95;789;99;100;1.46;1.52;94;0;2.2;2.18;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Mutant MAB;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;4f5k;1;b;1;796;100;100;798;100;100;0.33;0.34;99;0;2.2;2.2;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1tok;1;c;1;752;94;95;792;99;100;1.59;1.68;96;0;2.2;1.85;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;4dbc;1;b;1;761;95;96;792;99;100;1.40;1.47;95;0;2.2;1.5;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1cq6;1;b;1;776;97;98;792;99;100;1.00;1.03;95;0;2.2;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2d7y;1;b;1;777;97;98;792;99;100;0.98;1.02;95;0;2.2;2.66;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2d7z;1;b;1;759;95;96;789;99;100;1.38;1.44;94;0;2.2;2.65;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1b4x;1;b;1;777;97;98;792;99;100;0.98;1.02;95;0;2.2;2.45;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2qbt;1;b;1;781;98;99;788;98;100;0.65;0.66;96;0;2.2;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2qb2;1;b;1;758;95;99;764;96;100;0.63;0.63;96;0;2.2;1.7;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1toj;1;b;1;752;94;95;789;99;100;1.53;1.61;95;0;2.2;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1toi;1;b;1;755;94;95;789;99;100;1.48;1.55;94;0;2.2;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;3qpg;1;b;1;758;95;96;789;99;100;1.39;1.46;94;0;2.2;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2d65;1;b;1;754;94;95;789;99;100;1.50;1.57;93;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1cq8;1;c;1;759;95;96;792;99;100;1.43;1.50;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ari;1;b;1;760;95;96;790;99;100;1.39;1.44;95;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1g4v;1;b;1;785;98;99;792;99;100;0.66;0.67;95;0;2.2;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;3uak;1;c;1;704;88;89;791;99;100;2.39;2.49;92;0;2.2;3.232;diffraction;diffraction;812;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;MSE   selenomethionine;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;4.6;85;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1g4x;1;b;1;786;98;99;792;99;100;0.63;0.64;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;5eaa;1;b;1;782;98;99;792;99;100;0.77;0.79;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2d64;1;b;1;754;94;95;789;99;100;1.49;1.56;93;0;2.2;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1spa;1;b;1;782;98;99;792;99;100;0.80;0.81;95;0;2.2;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;3aat;1;b;1;777;97;98;792;99;100;0.98;1.02;95;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1x28;1;b;1;764;96;96;790;99;100;1.28;1.32;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1g7w;1;b;1;785;98;99;792;99;100;0.67;0.68;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2d5y;1;b;1;759;95;96;790;99;100;1.41;1.47;94;0;2.2;1.98;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2d63;1;b;1;757;95;96;789;99;100;1.43;1.50;94;0;2.2;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2d61;1;b;1;760;95;96;792;99;100;1.42;1.49;95;0;2.2;2.01;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1g7x;1;b;1;784;98;99;792;99;100;0.72;0.73;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1cq7;1;b;1;760;95;96;790;99;100;1.38;1.44;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1c9c;1;b;1;782;98;99;792;99;100;0.80;0.82;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PP3   alanyl-pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;4f5l;1;b;1;795;99;100;798;100;100;0.43;0.44;99;0;2.2;1.4;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;3qn6;1;b;1;774;97;98;788;98;100;0.94;0.98;93;0;2.2;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1tog;1;b;1;747;93;94;788;98;99;1.62;1.70;94;0;2.2;2.31;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1asn;1;b;1;784;98;99;792;99;100;0.70;0.72;95;0;2.2;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1arh;1;b;1;771;96;97;792;99;100;1.15;1.20;95;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1asa;1;b;1;756;94;95;788;98;99;1.44;1.50;94;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ahe;1;b;1;764;95;96;792;99;100;1.33;1.40;95;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1aic;1;b;1;782;98;99;792;99;100;0.78;0.80;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1aaw;1;b;1;780;98;99;792;99;100;0.85;0.88;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1asb;1;b;1;761;95;96;792;99;100;1.40;1.45;95;0;2.2;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1qir;1;b;1;759;95;96;789;99;100;1.38;1.43;94;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1czc;1;b;1;759;95;96;790;99;100;1.40;1.47;93;0;2.2;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ase;1;b;1;755;94;95;790;99;100;1.49;1.56;95;0;2.2;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1asd;1;b;1;756;94;95;789;99;100;1.46;1.52;94;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1qit;1;b;1;757;95;96;789;99;100;1.42;1.48;94;0;2.2;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ahf;1;c;1;766;96;97;792;99;100;1.29;1.35;95;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1asm;1;b;1;760;95;96;791;99;100;1.40;1.47;95;0;2.2;2.35;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ars;1;b;1;785;98;99;792;99;100;0.68;0.69;95;0;2.2;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2aat;1;b;1;770;96;97;792;99;100;1.17;1.20;95;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;2qa3;1;b;1;749;94;98;766;96;100;1.05;1.10;90;0;2.2;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1arg;1;b;1;759;95;96;790;99;100;1.40;1.46;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ahy;1;b;1;760;95;96;789;99;100;1.35;1.40;94;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1asg;1;b;1;758;95;96;791;99;100;1.44;1.51;95;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1x2a;1;b;1;761;95;96;790;99;100;1.36;1.41;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1cze;1;b;1;758;95;96;790;99;100;1.42;1.48;93;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ahx;1;c;1;758;95;96;791;99;100;1.45;1.53;95;0;2.2;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ams;1;b;1;781;98;99;792;99;100;0.82;0.84;95;0;2.2;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1yoo;1;b;1;755;94;95;789;99;100;1.47;1.54;92;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1amr;1;b;1;761;95;96;790;99;100;1.35;1.40;95;0;2.2;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1bqa;1;b;1;787;98;99;792;99;100;0.56;0.57;95;0;2.2;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1asl;1;b;1;762;95;96;792;99;100;1.37;1.43;95;0;2.2;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1qis;1;b;1;758;95;96;789;99;100;1.40;1.46;94;0;2.2;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1aam;1;b;1;772;96;97;791;99;100;1.10;1.13;95;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1bqd;1;b;1;786;98;99;792;99;100;0.60;0.61;95;0;2.2;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1asc;1;b;1;776;97;98;792;99;100;1.01;1.03;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;4a00;1;b;1;785;98;99;792;99;100;0.64;0.65;95;0;2.2;2.34;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ix7;1;b;1;774;97;98;792;99;100;1.07;1.11;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1aia;1;b;1;780;98;99;792;99;100;0.86;0.89;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1amq;1;b;1;783;98;99;792;99;100;0.73;0.74;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1asf;1;b;1;780;97;98;792;99;100;0.88;0.91;95;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1aib;1;b;1;779;97;98;792;99;100;0.90;0.93;95;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ix8;1;b;1;787;98;99;792;99;100;0.56;0.57;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;3zzk;1;b;1;781;98;99;792;99;100;0.82;0.84;95;0;2.2;1.78;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1ix6;1;b;1;786;98;99;792;99;100;0.60;0.60;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;3zzj;1;b;1;785;98;99;792;99;100;0.64;0.64;95;0;2.2;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1toe;1;b;1;774;97;98;792;99;100;1.06;1.09;95;0;2.2;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5i;1;1art;1;b;1;762;95;96;792;99;100;1.38;1.44;95;0;2.2;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MPD   (4s)-2-methyl-2,4-pentanediol;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Substrate Specificity Conversion of E. coli Pyridoxal-5'-Phosphate Dependent Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P4.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;3pa9;1;b;1;769;97;97;790;100;100;1.14;1.18;100;0;2.2;1.7;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;P00509;aspC b0928 JW0911;PF00155;D3H0F7;aspC EC042_1019;PF00155;c;7.5;293;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;3paa;1;b;1;769;97;97;790;100;100;1.14;1.18;100;0;2.2;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;P00509;aspC b0928 JW0911;PF00155;D3H0F7;aspC EC042_1019;PF00155;c;7.5;293;8;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;4f5g;1;b;1;762;96;96;792;100;99;1.37;1.43;95;0;2.2;1.67;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;4f5m;1;b;1;758;96;95;791;100;99;1.45;1.52;99;0;2.2;1.65;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;4.6;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2qb3;1;b;1;746;94;98;756;95;99;0.79;0.80;100;0;2.2;1.45;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;4f5j;1;b;1;764;97;96;792;100;99;1.32;1.38;96;0;2.2;1.954;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;4f5f;1;b;1;766;97;96;792;100;99;1.27;1.33;96;0;2.2;2.25;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2d66;1;b;1;784;99;99;792;100;100;0.68;0.69;98;0;2.2;2.18;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Mutant MAB;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;293;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;4f5k;1;b;1;765;97;96;790;100;99;1.25;1.29;95;0;2.2;2.2;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1tok;1;b;1;788;99;99;792;100;100;0.52;0.52;98;0;2.2;1.85;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;4dbc;1;b;1;790;100;100;792;100;100;0.39;0.39;100;0;2.2;1.5;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1cq6;1;b;1;784;99;99;792;100;100;0.69;0.70;100;0;2.2;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2d7y;1;b;1;782;99;99;792;100;100;0.80;0.81;98;0;2.2;2.66;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2d7z;1;b;1;787;99;99;792;100;100;0.58;0.58;98;0;2.2;2.65;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;293;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1b4x;1;b;1;784;99;99;792;100;100;0.70;0.70;100;0;2.2;2.45;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2qbt;1;b;1;765;97;97;788;99;100;1.21;1.26;97;0;2.2;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2qb2;1;b;1;751;95;98;764;96;100;0.91;0.94;98;0;2.2;1.7;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1toj;1;b;1;787;99;99;792;100;100;0.56;0.56;98;0;2.2;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1toi;1;b;1;787;99;99;792;100;100;0.57;0.57;98;0;2.2;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;3qpg;1;b;1;789;100;100;792;100;100;0.42;0.42;100;0;2.2;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2d65;1;b;1;784;99;99;792;100;100;0.71;0.71;96;0;2.2;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;293;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1cq8;1;b;1;789;100;100;792;100;100;0.40;0.40;100;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ari;1;b;1;789;100;100;792;100;100;0.46;0.46;100;0;2.2;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1g4v;1;b;1;775;98;98;792;100;100;1.03;1.05;99;0;2.2;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;3uak;1;b;1;712;90;90;790;100;100;2.25;2.31;95;0;2.2;3.232;diffraction;diffraction;792;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;MSE   selenomethionine;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;7.5;293;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1g4x;1;b;1;769;97;97;792;100;100;1.20;1.24;99;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;5eaa;1;b;1;779;98;98;792;100;100;0.90;0.92;100;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2d64;1;b;1;784;99;99;792;100;100;0.70;0.71;96;0;2.2;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;293;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1spa;1;b;1;778;98;98;792;100;100;0.94;0.95;100;0;2.2;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;3aat;1;b;1;772;97;97;792;100;100;1.13;1.17;100;0;2.2;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1x28;1;b;1;792;100;100;792;100;100;0.15;0.15;100;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1g7w;1;b;1;770;97;97;792;100;100;1.17;1.21;99;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2d5y;1;b;1;787;99;99;792;100;100;0.57;0.58;98;0;2.2;1.98;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2d63;1;b;1;786;99;99;792;100;100;0.62;0.62;98;0;2.2;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2d61;1;b;1;787;99;99;792;100;100;0.55;0.55;98;0;2.2;2.01;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1g7x;1;b;1;773;98;98;792;100;100;1.09;1.11;99;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1cq7;1;b;1;790;100;100;792;100;100;0.37;0.37;100;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1c9c;1;b;1;779;98;98;792;100;100;0.91;0.93;100;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PP3   alanyl-pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;4f5l;1;b;1;765;97;96;792;100;99;1.30;1.36;95;0;2.2;1.4;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;3qn6;1;b;1;762;96;97;787;99;100;1.25;1.30;97;0;2.2;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1tog;1;b;1;782;99;99;792;100;100;0.78;0.79;98;0;2.2;2.31;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1asn;1;b;1;777;98;98;792;100;100;0.98;1.00;100;0;2.2;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1arh;1;b;1;783;99;99;792;100;100;0.73;0.73;99;0;2.2;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1asa;1;b;1;789;100;100;792;100;100;0.45;0.46;100;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ahe;1;b;1;790;100;100;792;100;100;0.37;0.37;98;0;2.2;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1aic;1;b;1;777;98;98;792;100;100;0.96;0.97;100;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1aaw;1;b;1;774;98;98;792;100;100;1.06;1.09;100;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1asb;1;b;1;788;99;99;792;100;100;0.51;0.51;100;0;2.2;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1qir;1;b;1;789;100;100;792;100;100;0.43;0.43;100;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1czc;1;b;1;787;99;99;792;100;100;0.53;0.54;96;0;2.2;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ase;1;b;1;788;99;99;792;100;100;0.50;0.50;100;0;2.2;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1asd;1;b;1;789;100;100;792;100;100;0.44;0.44;100;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1qit;1;b;1;789;100;100;792;100;100;0.42;0.42;100;0;2.2;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ahf;1;b;1;789;100;100;792;100;100;0.42;0.42;98;0;2.2;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1asm;1;b;1;789;100;100;792;100;100;0.44;0.44;100;0;2.2;2.35;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ars;1;b;1;776;98;98;792;100;100;1.00;1.02;100;0;2.2;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2aat;1;b;1;761;96;96;792;100;100;1.40;1.44;100;0;2.2;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;2qa3;1;b;1;744;94;97;760;96;99;1.02;1.05;97;0;2.2;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1arg;1;b;1;789;100;100;792;100;100;0.39;0.40;100;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ahy;1;b;1;790;100;100;792;100;100;0.36;0.36;98;0;2.2;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1asg;1;b;1;789;100;100;792;100;100;0.43;0.44;100;0;2.2;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1x2a;1;b;1;792;100;100;792;100;100;0.17;0.17;100;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1cze;1;b;1;787;99;99;792;100;100;0.55;0.55;96;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ahx;1;b;1;789;100;100;792;100;100;0.43;0.43;98;0;2.2;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ams;1;b;1;780;98;98;792;100;100;0.86;0.87;100;0;2.2;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1yoo;1;b;1;785;99;99;792;100;100;0.68;0.69;96;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1amr;1;b;1;790;100;100;792;100;100;0.38;0.38;100;0;2.2;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1bqa;1;b;1;771;97;97;792;100;100;1.15;1.18;99;0;2.2;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1asl;1;b;1;789;100;100;792;100;100;0.46;0.46;100;0;2.2;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1qis;1;b;1;789;100;100;792;100;100;0.40;0.40;100;0;2.2;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1aam;1;b;1;759;96;96;792;100;100;1.44;1.50;100;0;2.2;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1bqd;1;b;1;773;98;98;792;100;100;1.10;1.13;99;0;2.2;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1asc;1;b;1;779;98;98;792;100;100;0.91;0.92;100;0;2.2;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;4a00;1;b;1;775;98;98;792;100;100;1.04;1.06;99;0;2.2;2.34;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ix7;1;b;1;781;99;99;792;100;100;0.82;0.83;100;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1aia;1;b;1;780;99;99;792;100;100;0.86;0.87;100;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1amq;1;b;1;778;98;98;792;100;100;0.94;0.96;100;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1asf;1;b;1;772;97;97;792;100;100;1.12;1.16;100;0;2.2;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1aib;1;b;1;781;99;99;792;100;100;0.84;0.85;100;0;2.2;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ix8;1;b;1;766;97;97;792;100;100;1.29;1.34;99;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;3zzk;1;b;1;781;99;99;792;100;100;0.84;0.84;99;0;2.2;1.78;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1ix6;1;b;1;768;97;97;792;100;100;1.24;1.28;100;0;2.2;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;3zzj;1;b;1;774;98;98;792;100;100;1.05;1.08;99;0;2.2;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1toe;1;b;1;783;99;99;792;100;100;0.75;0.75;98;0;2.2;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1x29;1;1art;1;b;1;789;100;100;792;100;100;0.41;0.41;100;0;2.2;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PMG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-2-methyl-l-glutamic acid;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-2-methyl-L-glutamic acid;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;293;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;3paa;1;b;1;790;100;100;790;100;100;0.13;0.13;100;0;1.7;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;D3H0F7;aspC EC042_1019;PF00155;D3H0F7;aspC EC042_1019;PF00155;c;7.5;100;8;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;4f5g;1;b;1;783;99;98;790;100;99;0.65;0.65;96;0;1.7;1.67;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;4f5m;1;b;1;781;99;98;789;100;99;0.70;0.70;100;0;1.7;1.65;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;4.6;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2qb3;1;b;1;755;96;99;756;96;99;0.30;0.30;100;0;1.7;1.45;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;4f5j;1;b;1;784;99;98;790;100;99;0.63;0.63;96;0;1.7;1.954;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;4f5f;1;b;1;784;99;98;790;100;99;0.60;0.61;96;0;1.7;2.25;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2d66;1;b;1;759;96;96;790;100;100;1.41;1.47;98;0;1.7;2.18;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Mutant MAB;D3H0F7;aspC EC042_1019;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;4f5k;1;b;1;784;99;98;790;100;99;0.62;0.62;95;0;1.7;2.2;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1tok;1;b;1;757;96;96;790;100;100;1.44;1.49;98;0;1.7;1.85;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;4dbc;1;b;1;767;97;97;790;100;100;1.20;1.25;100;0;1.7;1.5;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Substrate Activation in Aspartate Aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1cq6;1;b;1;780;99;98;790;100;100;0.81;0.83;100;0;1.7;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2d7y;1;b;1;778;99;98;790;100;100;0.86;0.88;98;0;1.7;2.66;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Mutant MA;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2d7z;1;b;1;763;97;96;790;100;100;1.31;1.36;98;0;1.7;2.65;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;D3H0F7;aspC EC042_1019;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1b4x;1;b;1;780;99;98;790;100;100;0.79;0.82;100;0;1.7;2.45;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2qbt;1;b;1;767;97;97;788;100;100;1.16;1.23;90;0;1.7;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2qb2;1;b;1;763;97;100;764;97;100;0.23;0.23;100;0;1.7;1.7;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1toj;1;b;1;758;96;96;790;100;100;1.43;1.50;98;0;1.7;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1toi;1;b;1;759;96;96;790;100;100;1.40;1.48;98;0;1.7;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;3qpg;1;b;1;766;97;97;790;100;100;1.24;1.29;100;0;1.7;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2d65;1;b;1;757;96;96;790;100;100;1.45;1.51;96;0;1.7;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Mutant MABC;D3H0F7;aspC EC042_1019;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1cq8;1;b;1;765;97;97;790;100;100;1.26;1.32;100;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ari;1;b;1;765;97;97;790;100;100;1.26;1.31;100;0;1.7;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate aminotransferase, W140H mutant, maleate complex;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1g4v;1;b;1;786;100;99;790;100;100;0.47;0.48;99;0;1.7;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;3uak;1;c;1;704;89;89;789;100;100;2.36;2.46;95;0;1.7;3.232;diffraction;diffraction;792;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;MSE   selenomethionine;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;D3H0F7;aspC EC042_1019;PF00155;no/data;no/data;no/data;c;7.5;100;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1g4x;1;b;1;786;99;99;790;100;100;0.51;0.52;99;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;5eaa;1;b;1;785;99;99;790;100;100;0.57;0.58;100;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2d64;1;b;1;757;96;96;790;100;100;1.44;1.51;96;0;1.7;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;D3H0F7;aspC EC042_1019;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1spa;1;b;1;785;99;99;790;100;100;0.56;0.57;100;0;1.7;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;3aat;1;b;1;778;99;98;790;100;100;0.85;0.88;100;0;1.7;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1x28;1;b;1;770;97;97;790;100;100;1.12;1.16;100;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1g7w;1;b;1;785;99;99;790;100;100;0.57;0.57;99;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2d5y;1;b;1;763;97;96;790;100;100;1.30;1.35;98;0;1.7;1.98;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2d63;1;b;1;760;96;96;790;100;100;1.39;1.46;98;0;1.7;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2d61;1;b;1;764;97;96;790;100;100;1.28;1.33;98;0;1.7;2.01;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Mutant MA With Maleic Acid;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1g7x;1;b;1;785;99;99;790;100;100;0.56;0.57;99;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1cq7;1;b;1;766;97;97;790;100;100;1.23;1.28;100;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1c9c;1;b;1;784;99;99;790;100;100;0.59;0.60;100;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PP3   alanyl-pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;4f5l;1;b;1;783;99;98;790;100;99;0.64;0.65;95;0;1.7;1.4;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;3qn6;1;b;1;781;99;99;786;99;100;0.59;0.61;99;0;1.7;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1tog;1;b;1;753;95;95;790;100;100;1.54;1.61;98;0;1.7;2.31;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1asn;1;b;1;785;99;99;790;100;100;0.54;0.55;100;0;1.7;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1arh;1;b;1;776;98;98;790;100;100;0.94;0.97;99;0;1.7;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1asa;1;b;1;762;96;96;790;100;100;1.32;1.38;100;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ahe;1;b;1;768;97;97;790;100;100;1.16;1.22;98;0;1.7;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1aic;1;b;1;784;99;99;790;100;100;0.60;0.61;100;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1aaw;1;c;1;782;99;99;790;100;100;0.71;0.74;100;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1asb;1;b;1;766;97;97;790;100;100;1.24;1.28;100;0;1.7;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1qir;1;b;1;765;97;97;790;100;100;1.25;1.30;100;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1czc;1;b;1;764;97;96;790;100;100;1.29;1.34;96;0;1.7;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ase;1;c;1;762;96;96;790;100;100;1.34;1.39;100;0;1.7;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1asd;1;b;1;762;96;96;790;100;100;1.33;1.38;100;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1qit;1;b;1;763;97;96;790;100;100;1.29;1.35;100;0;1.7;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ahf;1;b;1;770;97;97;790;100;100;1.13;1.18;98;0;1.7;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1asm;1;b;1;765;97;97;790;100;100;1.25;1.30;100;0;1.7;2.35;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ars;1;b;1;786;100;99;790;100;100;0.48;0.49;100;0;1.7;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2aat;1;b;1;771;98;97;790;100;100;1.09;1.12;100;0;1.7;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;2qa3;1;b;1;761;96;99;765;97;100;0.54;0.57;98;0;1.7;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1arg;1;b;1;765;97;97;790;100;100;1.25;1.30;100;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ahy;1;b;1;765;97;97;790;100;100;1.25;1.30;98;0;1.7;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1asg;1;b;1;764;97;96;790;100;100;1.29;1.34;100;0;1.7;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1x2a;1;b;1;767;97;97;790;100;100;1.20;1.25;100;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1cze;1;b;1;763;97;96;790;100;100;1.30;1.35;96;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ahx;1;b;1;762;96;96;790;100;100;1.33;1.38;98;0;1.7;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ams;1;b;1;784;99;99;790;100;100;0.60;0.61;100;0;1.7;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1yoo;1;b;1;758;96;96;790;100;100;1.42;1.49;96;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1amr;1;b;1;767;97;97;790;100;100;1.20;1.24;100;0;1.7;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1bqa;1;b;1;786;100;99;790;100;100;0.48;0.49;99;0;1.7;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE P195A MUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1asl;1;b;1;767;97;97;790;100;100;1.20;1.24;100;0;1.7;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1qis;1;b;1;765;97;97;790;100;100;1.27;1.32;100;0;1.7;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1aam;1;b;1;772;98;97;788;100;99;1.01;1.03;100;0;1.7;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1bqd;1;b;1;786;100;99;790;100;100;0.49;0.49;99;0;1.7;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1asc;1;b;1;778;99;98;790;100;100;0.85;0.87;100;0;1.7;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;4a00;1;b;1;787;100;99;790;100;100;0.42;0.43;99;0;1.7;2.34;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Structure of an engineered aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ix7;1;b;1;778;98;98;790;100;100;0.86;0.89;100;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1aia;1;b;1;783;99;99;790;100;100;0.66;0.68;100;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1amq;1;b;1;786;100;99;790;100;100;0.49;0.50;100;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1asf;1;b;1;780;99;98;790;100;100;0.81;0.84;100;0;1.7;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1aib;1;b;1;782;99;99;790;100;100;0.70;0.72;100;0;1.7;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ix8;1;b;1;786;100;99;790;100;100;0.48;0.48;99;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Active Site Mutant V39F/N194A;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;3zzk;1;b;1;784;99;99;790;100;100;0.61;0.63;99;0;1.7;1.78;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Structure of an engineered aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1ix6;1;b;1;786;100;99;790;100;100;0.47;0.47;100;0;1.7;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Aspartate Aminotransferase Active Site Mutant V39F;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;3zzj;1;b;1;787;100;99;790;100;100;0.43;0.44;99;0;1.7;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Structure of an engineered aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1toe;1;b;1;776;98;98;790;100;100;0.94;0.96;98;0;1.7;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3pa9;1;1art;1;b;1;767;97;97;790;100;100;1.21;1.25;100;0;1.7;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 7.5;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;4f5g;1;b;1;783;99;98;790;100;99;0.65;0.65;96;0;1.9;1.67;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;4f5m;1;b;1;781;99;98;789;100;99;0.72;0.72;100;0;1.9;1.65;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;4.6;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2qb3;1;b;1;754;95;99;756;96;99;0.33;0.33;100;0;1.9;1.45;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;4f5j;1;b;1;784;99;98;790;100;99;0.63;0.63;96;0;1.9;1.954;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;4f5f;1;b;1;784;99;98;790;100;99;0.61;0.61;96;0;1.9;2.25;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2d66;1;b;1;759;96;96;790;100;100;1.40;1.47;98;0;1.9;2.18;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Mutant MAB;D3H0F7;aspC EC042_1019;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;8;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;4f5k;1;b;1;784;99;98;790;100;99;0.62;0.62;95;0;1.9;2.2;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1tok;1;b;1;758;96;96;790;100;100;1.43;1.49;98;0;1.9;1.85;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;4dbc;1;b;1;767;97;97;790;100;100;1.20;1.26;100;0;1.9;1.5;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Substrate Activation in Aspartate Aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1cq6;1;b;1;780;99;98;790;100;100;0.79;0.81;100;0;1.9;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2d7y;1;b;1;779;99;98;790;100;100;0.85;0.87;98;0;1.9;2.66;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Mutant MA;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2d7z;1;b;1;763;97;96;790;100;100;1.30;1.36;98;0;1.9;2.65;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;D3H0F7;aspC EC042_1019;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;8;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1b4x;1;b;1;780;99;99;790;100;100;0.78;0.81;100;0;1.9;2.45;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2qbt;1;b;1;786;99;100;788;100;100;0.37;0.39;99;0;1.9;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2qb2;1;b;1;763;97;100;764;97;100;0.27;0.27;100;0;1.9;1.7;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1toj;1;b;1;758;96;96;790;100;100;1.43;1.50;98;0;1.9;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1toi;1;b;1;759;96;96;790;100;100;1.40;1.48;98;0;1.9;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;3qpg;1;b;1;766;97;97;790;100;100;1.24;1.29;100;0;1.9;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2d65;1;b;1;757;96;96;790;100;100;1.44;1.51;96;0;1.9;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Mutant MABC;D3H0F7;aspC EC042_1019;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;8;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1cq8;1;b;1;765;97;97;790;100;100;1.25;1.31;100;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ari;1;b;1;765;97;97;790;100;100;1.25;1.30;100;0;1.9;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate aminotransferase, W140H mutant, maleate complex;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1g4v;1;b;1;787;100;99;790;100;100;0.47;0.47;99;0;1.9;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;3uak;1;c;1;704;89;89;788;100;99;2.35;2.43;95;0;1.9;3.232;diffraction;diffraction;792;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;MSE   selenomethionine;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;D3H0F7;aspC EC042_1019;PF00155;no/data;no/data;no/data;c;8;100;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1g4x;1;b;1;786;100;99;790;100;100;0.48;0.49;99;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;5eaa;1;b;1;785;99;99;790;100;100;0.54;0.55;100;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2d64;1;b;1;757;96;96;790;100;100;1.44;1.51;96;0;1.9;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;D3H0F7;aspC EC042_1019;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;8;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1spa;1;b;1;785;99;99;790;100;100;0.54;0.55;100;0;1.9;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;3aat;1;b;1;779;99;98;790;100;100;0.83;0.86;100;0;1.9;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1x28;1;b;1;770;97;97;790;100;100;1.12;1.16;100;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1g7w;1;b;1;785;99;99;790;100;100;0.53;0.53;99;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2d5y;1;b;1;763;97;96;790;100;100;1.30;1.35;98;0;1.9;1.98;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2d63;1;b;1;760;96;96;790;100;100;1.38;1.45;98;0;1.9;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2d61;1;b;1;764;97;97;790;100;100;1.27;1.32;98;0;1.9;2.01;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Mutant MA With Maleic Acid;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1g7x;1;b;1;785;99;99;790;100;100;0.54;0.54;99;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1cq7;1;b;1;766;97;97;790;100;100;1.22;1.27;100;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1c9c;1;b;1;785;99;99;790;100;100;0.56;0.57;100;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PP3   alanyl-pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;4f5l;1;b;1;783;99;98;790;100;99;0.64;0.65;95;0;1.9;1.4;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;3qn6;1;b;1;781;99;99;786;99;100;0.55;0.57;99;0;1.9;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1tog;1;b;1;753;95;95;790;100;100;1.53;1.59;98;0;1.9;2.31;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1asn;1;b;1;786;99;99;790;100;100;0.51;0.52;100;0;1.9;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1arh;1;b;1;776;98;98;790;100;100;0.93;0.96;99;0;1.9;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1asa;1;b;1;763;97;96;790;100;100;1.31;1.37;100;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ahe;1;b;1;768;97;97;790;100;100;1.17;1.22;98;0;1.9;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1aic;1;b;1;785;99;99;790;100;100;0.57;0.59;100;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1aaw;1;b;1;782;99;99;790;100;100;0.69;0.71;100;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1asb;1;b;1;766;97;97;790;100;100;1.23;1.26;100;0;1.9;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1qir;1;b;1;765;97;97;790;100;100;1.24;1.29;100;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1czc;1;b;1;764;97;96;790;100;100;1.29;1.34;96;0;1.9;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ase;1;b;1;762;96;96;790;100;100;1.33;1.39;100;0;1.9;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1asd;1;b;1;762;97;96;790;100;100;1.32;1.37;100;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1qit;1;b;1;764;97;96;790;100;100;1.29;1.34;100;0;1.9;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ahf;1;b;1;770;97;97;790;100;100;1.13;1.18;98;0;1.9;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1asm;1;b;1;766;97;97;790;100;100;1.24;1.29;100;0;1.9;2.35;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ars;1;b;1;786;100;99;790;100;100;0.47;0.48;100;0;1.9;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2aat;1;b;1;771;98;97;790;100;100;1.08;1.10;100;0;1.9;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;2qa3;1;b;1;744;94;97;762;96;99;1.08;1.22;93;0;1.9;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1arg;1;b;1;765;97;97;790;100;100;1.24;1.29;100;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ahy;1;b;1;765;97;97;790;100;100;1.24;1.29;98;0;1.9;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1asg;1;b;1;764;97;96;790;100;100;1.28;1.33;100;0;1.9;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1x2a;1;b;1;767;97;97;790;100;100;1.20;1.25;100;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1cze;1;b;1;763;97;96;790;100;100;1.29;1.35;96;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ahx;1;b;1;762;96;96;790;100;100;1.33;1.38;98;0;1.9;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ams;1;b;1;785;99;99;790;100;100;0.58;0.59;100;0;1.9;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1yoo;1;b;1;758;96;96;790;100;100;1.42;1.49;96;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1amr;1;b;1;767;97;97;790;100;100;1.19;1.23;100;0;1.9;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1bqa;1;b;1;787;100;99;790;100;100;0.45;0.45;99;0;1.9;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE P195A MUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1asl;1;b;1;768;97;97;790;100;100;1.19;1.23;100;0;1.9;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1qis;1;b;1;765;97;97;790;100;100;1.26;1.31;100;0;1.9;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1aam;1;b;1;773;98;98;790;100;100;1.04;1.06;100;0;1.9;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1bqd;1;b;1;787;100;99;790;100;100;0.45;0.45;99;0;1.9;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1asc;1;b;1;779;99;98;790;100;100;0.84;0.86;100;0;1.9;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;4a00;1;b;1;787;100;99;790;100;100;0.44;0.44;99;0;1.9;2.34;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Structure of an engineered aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ix7;1;b;1;779;99;98;790;100;100;0.84;0.86;100;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1aia;1;b;1;784;99;99;790;100;100;0.64;0.65;100;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1amq;1;b;1;786;100;99;790;100;100;0.47;0.48;100;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1asf;1;b;1;780;99;98;790;100;100;0.79;0.81;100;0;1.9;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1aib;1;b;1;783;99;99;790;100;100;0.68;0.70;100;0;1.9;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ix8;1;b;1;787;100;99;790;100;100;0.46;0.46;99;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Active Site Mutant V39F/N194A;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;3zzk;1;b;1;784;99;99;790;100;100;0.61;0.63;99;0;1.9;1.78;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Structure of an engineered aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1ix6;1;b;1;787;100;99;790;100;100;0.43;0.44;100;0;1.9;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Aspartate Aminotransferase Active Site Mutant V39F;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;3zzj;1;b;1;787;100;99;790;100;100;0.45;0.45;99;0;1.9;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Structure of an engineered aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1toe;1;b;1;775;98;98;790;100;100;0.96;0.98;98;0;1.9;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;3paa;1;1art;1;b;1;767;97;97;790;100;100;1.20;1.24;100;0;1.9;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;PJ7   4-aminofuran-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol| SO4   sulfate ion;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Mechanism of inactivation of E. coli aspartate aminotransferase by (S)-4-amino-4,5-dihydro-2-furancarboxylic acid (S-ADFA) pH 8.0;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;D3H0F7;aspC EC042_1019;PF00155;P00509;aspC b0928 JW0911;PF00155;c;8;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;4f5m;1;b;1;788;99;99;795;100;100;0.64;0.65;96;0;1.67;1.65;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;4.6;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2qb3;1;b;1;748;94;98;756;95;99;0.70;0.71;96;0;1.67;1.45;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;4f5j;1;b;1;796;100;100;798;100;100;0.32;0.32;99;0;1.67;1.954;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;4f5f;1;b;1;793;99;99;798;100;100;0.55;0.55;98;0;1.67;2.25;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2d66;1;b;1;756;95;95;789;99;100;1.44;1.50;93;0;1.67;2.18;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Mutant MAB;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;4f5k;1;b;1;796;100;100;798;100;100;0.38;0.38;99;0;1.67;2.2;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1tok;1;b;1;751;94;95;792;99;100;1.62;1.70;95;0;1.67;1.85;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;4dbc;1;b;1;760;95;96;792;99;100;1.42;1.48;95;0;1.67;1.5;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1cq6;1;b;1;775;97;98;792;99;100;1.02;1.05;95;0;1.67;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2d7y;1;b;1;777;97;98;792;99;100;0.98;1.01;94;0;1.67;2.66;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2d7z;1;b;1;758;95;96;790;99;100;1.41;1.48;94;0;1.67;2.65;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1b4x;1;b;1;776;97;98;792;99;100;1.01;1.05;95;0;1.67;2.45;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2qbt;1;b;1;750;94;95;779;98;99;1.35;1.47;89;0;1.67;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2qb2;1;b;1;757;95;99;764;96;100;0.68;0.69;96;0;1.67;1.7;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1toj;1;c;1;752;94;95;792;99;100;1.59;1.68;95;0;1.67;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1toi;1;b;1;755;95;95;789;99;100;1.48;1.55;94;0;1.67;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;3qpg;1;b;1;758;95;96;792;99;100;1.46;1.53;95;0;1.67;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2d65;1;b;1;754;95;95;789;99;100;1.49;1.55;92;0;1.67;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1cq8;1;b;1;759;95;96;792;99;100;1.45;1.52;95;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ari;1;b;1;759;95;96;792;99;100;1.44;1.50;95;0;1.67;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1g4v;1;b;1;785;98;99;792;99;100;0.68;0.69;95;0;1.67;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;3uak;1;c;1;708;89;89;790;99;100;2.31;2.39;91;0;1.67;3.232;diffraction;diffraction;812;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;MSE   selenomethionine;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;5.0;85;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1g4x;1;b;1;785;98;99;792;99;100;0.68;0.68;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;5eaa;1;b;1;782;98;99;792;99;100;0.80;0.81;95;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2d64;1;b;1;755;95;95;789;99;100;1.48;1.55;92;0;1.67;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1spa;1;b;1;782;98;99;792;99;100;0.79;0.81;95;0;1.67;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;3aat;1;b;1;776;97;98;792;99;100;1.00;1.03;95;0;1.67;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1x28;1;b;1;763;96;96;792;99;100;1.35;1.40;95;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1g7w;1;b;1;784;98;99;792;99;100;0.72;0.73;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2d5y;1;b;1;759;95;96;791;99;100;1.42;1.48;94;0;1.67;1.98;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2d63;1;b;1;757;95;96;789;99;100;1.43;1.49;93;0;1.67;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2d61;1;b;1;761;95;96;792;99;100;1.41;1.47;94;0;1.67;2.01;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1g7x;1;b;1;783;98;99;792;99;100;0.75;0.76;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1cq7;1;b;1;760;95;96;792;99;100;1.42;1.49;95;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1c9c;1;b;1;781;98;99;792;99;100;0.83;0.84;95;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PP3   alanyl-pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;4f5l;1;b;1;796;100;100;798;100;100;0.37;0.37;98;0;1.67;1.4;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;3qn6;1;b;1;767;96;97;784;98;99;1.03;1.13;93;0;1.67;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1tog;1;b;1;747;94;94;787;99;99;1.60;1.67;94;0;1.67;2.31;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1asn;1;b;1;783;98;99;792;99;100;0.75;0.76;95;0;1.67;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1arh;1;b;1;771;97;97;792;99;100;1.16;1.20;95;0;1.67;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1asa;1;b;1;756;95;95;792;99;100;1.51;1.57;95;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ahe;1;b;1;763;96;96;792;99;100;1.34;1.41;95;0;1.67;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1aic;1;b;1;781;98;99;792;99;100;0.82;0.84;95;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1aaw;1;b;1;779;98;98;792;99;100;0.90;0.93;95;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1asb;1;b;1;760;95;96;792;99;100;1.43;1.48;95;0;1.67;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1qir;1;b;1;759;95;96;792;99;100;1.45;1.51;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1czc;1;b;1;759;95;96;792;99;100;1.43;1.50;93;0;1.67;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ase;1;b;1;755;95;95;792;99;100;1.52;1.59;95;0;1.67;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1asd;1;b;1;755;95;95;792;99;100;1.53;1.59;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1qit;1;b;1;756;95;96;791;99;100;1.48;1.55;95;0;1.67;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ahf;1;b;1;765;96;97;792;99;100;1.30;1.36;95;0;1.67;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1asm;1;b;1;760;95;96;792;99;100;1.43;1.50;95;0;1.67;2.35;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ars;1;b;1;784;98;99;792;99;100;0.70;0.71;95;0;1.67;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2aat;1;b;1;769;96;97;792;99;100;1.21;1.24;95;0;1.67;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;2qa3;1;b;1;734;92;96;766;96;100;1.44;1.52;83;0;1.67;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1arg;1;b;1;759;95;96;792;99;100;1.44;1.50;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ahy;1;b;1;760;95;96;792;99;100;1.43;1.49;95;0;1.67;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1asg;1;b;1;758;95;96;792;99;100;1.47;1.53;95;0;1.67;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1x2a;1;b;1;760;95;96;792;99;100;1.42;1.48;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1cze;1;b;1;759;95;96;792;99;100;1.44;1.51;93;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ahx;1;b;1;756;95;95;790;99;100;1.47;1.54;95;0;1.67;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ams;1;b;1;781;98;99;792;99;100;0.84;0.85;95;0;1.67;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1yoo;1;b;1;754;95;95;788;99;99;1.46;1.52;91;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1amr;1;b;1;761;95;96;792;99;100;1.40;1.45;95;0;1.67;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1bqa;1;b;1;786;98;99;792;99;100;0.62;0.62;95;0;1.67;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1asl;1;b;1;761;95;96;792;99;100;1.39;1.44;95;0;1.67;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1qis;1;b;1;758;95;96;792;99;100;1.46;1.53;95;0;1.67;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1aam;1;b;1;770;97;97;792;99;100;1.16;1.20;95;0;1.67;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1bqd;1;b;1;785;98;99;792;99;100;0.66;0.66;95;0;1.67;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1asc;1;b;1;774;97;98;792;99;100;1.05;1.08;95;0;1.67;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;4a00;1;b;1;784;98;99;792;99;100;0.69;0.69;95;0;1.67;2.34;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ix7;1;b;1;774;97;98;792;99;100;1.07;1.10;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1aia;1;b;1;780;98;98;792;99;100;0.88;0.90;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1amq;1;b;1;783;98;99;792;99;100;0.76;0.77;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1asf;1;b;1;778;97;98;791;99;100;0.91;0.93;95;0;1.67;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1aib;1;b;1;778;98;98;792;99;100;0.92;0.95;95;0;1.67;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ix8;1;b;1;786;98;99;792;99;100;0.62;0.63;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;3zzk;1;b;1;780;98;99;792;99;100;0.85;0.87;95;0;1.67;1.78;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1ix6;1;b;1;785;98;99;792;99;100;0.66;0.66;95;0;1.67;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;3zzj;1;b;1;785;98;99;792;99;100;0.67;0.68;95;0;1.67;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1toe;1;b;1;774;97;98;792;99;100;1.07;1.10;95;0;1.67;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5g;1;1art;1;b;1;761;95;96;792;99;100;1.39;1.44;95;0;1.67;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Rational Design and Directed Evolution of E. coli Apartate Aminotransferase to Tyrosine Aminotransferase: Mutant P2.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2qb3;1;b;1;747;94;98;755;95;99;0.73;0.74;100;0;1.65;1.45;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;4f5j;1;b;1;790;99;99;795;100;100;0.57;0.57;96;0;1.65;1.954;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;4f5f;1;b;1;791;99;99;796;100;100;0.57;0.58;97;0;1.65;2.25;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2d66;1;b;1;749;94;95;787;99;99;1.56;1.64;96;0;1.65;2.18;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Mutant MAB;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;4f5k;1;b;1;787;99;99;795;100;100;0.70;0.70;95;0;1.65;2.2;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1tok;1;b;1;743;93;94;791;99;100;1.74;1.83;98;0;1.65;1.85;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;4dbc;1;b;1;754;95;95;791;99;100;1.54;1.62;99;0;1.65;1.5;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1cq6;1;b;1;770;97;97;791;99;100;1.15;1.18;99;0;1.65;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2d7y;1;b;1;772;97;97;791;99;100;1.10;1.13;98;0;1.65;2.66;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2d7z;1;b;1;753;95;95;788;99;99;1.50;1.57;97;0;1.65;2.65;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1b4x;1;b;1;772;97;97;791;99;100;1.10;1.14;99;0;1.65;2.45;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2qbt;1;b;1;778;98;99;787;99;100;0.74;0.75;100;0;1.65;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2qb2;1;b;1;755;95;99;763;96;100;0.70;0.71;100;0;1.65;1.7;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1toj;1;b;1;741;93;94;781;98;99;1.60;1.68;97;0;1.65;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1toi;1;b;1;746;94;94;786;99;99;1.60;1.69;98;0;1.65;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;3qpg;1;b;1;752;94;95;791;99;100;1.57;1.65;99;0;1.65;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2d65;1;b;1;748;94;94;788;99;99;1.60;1.68;95;0;1.65;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1cq8;1;b;1;751;94;95;791;99;100;1.59;1.67;99;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ari;1;b;1;752;94;95;791;99;100;1.58;1.65;99;0;1.65;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1g4v;1;b;1;781;98;99;791;99;100;0.80;0.81;99;0;1.65;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;3uak;1;b;1;701;88;88;787;99;99;2.39;2.46;95;0;1.65;3.232;diffraction;diffraction;812;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;MSE   selenomethionine;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;4.6;100;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1g4x;1;b;1;783;98;99;791;99;100;0.71;0.71;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;5eaa;1;b;1;778;98;98;791;99;100;0.91;0.92;99;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2d64;1;b;1;749;94;95;788;99;99;1.58;1.66;95;0;1.65;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1spa;1;b;1;776;98;98;791;99;100;0.96;0.98;99;0;1.65;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;3aat;1;b;1;770;97;97;791;99;100;1.14;1.17;99;0;1.65;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1x28;1;b;1;759;95;96;791;99;100;1.42;1.49;99;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1g7w;1;b;1;781;98;99;791;99;100;0.78;0.79;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2d5y;1;b;1;753;95;95;791;99;100;1.54;1.62;97;0;1.65;1.98;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2d63;1;b;1;750;94;95;787;99;99;1.54;1.61;97;0;1.65;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2d61;1;b;1;751;94;95;790;99;100;1.57;1.64;98;0;1.65;2.01;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1g7x;1;b;1;780;98;98;791;99;100;0.84;0.85;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1cq7;1;b;1;753;95;95;791;99;100;1.56;1.64;99;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1c9c;1;b;1;776;97;98;791;99;100;0.97;0.98;99;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PP3   alanyl-pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;4f5l;1;b;1;789;99;99;795;100;100;0.59;0.59;95;0;1.65;1.4;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;3qn6;1;b;1;756;95;96;781;98;99;1.27;1.40;93;0;1.65;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1tog;1;b;1;736;92;93;787;99;99;1.81;1.91;96;0;1.65;2.31;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1asn;1;b;1;779;98;98;791;99;100;0.85;0.86;99;0;1.65;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1arh;1;b;1;765;96;97;791;99;100;1.29;1.34;99;0;1.65;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1asa;1;b;1;748;94;94;791;99;100;1.66;1.74;99;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ahe;1;b;1;757;95;96;791;99;100;1.46;1.53;98;0;1.65;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1aic;1;b;1;777;98;98;791;99;100;0.93;0.95;99;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1aaw;1;b;1;776;97;98;791;99;100;0.98;1.00;99;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1asb;1;b;1;753;95;95;791;99;100;1.55;1.61;99;0;1.65;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1qir;1;b;1;750;94;95;791;99;100;1.62;1.69;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1czc;1;b;1;753;95;95;789;99;100;1.52;1.60;96;0;1.65;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ase;1;b;1;746;94;94;790;99;100;1.68;1.76;99;0;1.65;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1asd;1;b;1;748;94;94;791;99;100;1.66;1.74;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1qit;1;b;1;748;94;94;791;99;100;1.65;1.73;99;0;1.65;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ahf;1;b;1;760;95;96;791;99;100;1.40;1.47;98;0;1.65;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1asm;1;b;1;751;94;95;790;99;100;1.58;1.66;99;0;1.65;2.35;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ars;1;b;1;780;98;98;791;99;100;0.83;0.85;99;0;1.65;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2aat;1;b;1;765;96;97;791;99;100;1.28;1.32;99;0;1.65;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;2qa3;1;b;1;757;95;99;765;96;100;0.72;0.72;100;0;1.65;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1arg;1;b;1;751;94;95;790;99;100;1.58;1.66;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ahy;1;b;1;753;95;95;790;99;100;1.53;1.60;98;0;1.65;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1asg;1;b;1;750;94;95;789;99;100;1.57;1.64;99;0;1.65;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1x2a;1;b;1;755;95;95;790;99;100;1.49;1.56;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1cze;1;b;1;752;94;95;790;99;100;1.56;1.64;96;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ahx;1;b;1;752;94;95;791;99;100;1.58;1.67;98;0;1.65;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ams;1;b;1;775;97;98;791;99;100;0.98;1.00;99;0;1.65;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1yoo;1;b;1;750;94;95;788;99;99;1.56;1.64;94;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1amr;1;b;1;753;95;95;790;99;100;1.53;1.59;99;0;1.65;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1bqa;1;b;1;783;98;99;791;99;100;0.69;0.69;99;0;1.65;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1asl;1;b;1;753;95;95;791;99;100;1.55;1.61;99;0;1.65;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1qis;1;b;1;750;94;95;791;99;100;1.62;1.70;99;0;1.65;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1aam;1;b;1;769;97;97;791;99;100;1.18;1.21;99;0;1.65;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1bqd;1;b;1;782;98;99;791;99;100;0.75;0.75;99;0;1.65;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1asc;1;b;1;769;97;97;791;99;100;1.18;1.21;99;0;1.65;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;4a00;1;b;1;783;98;99;791;99;100;0.73;0.73;99;0;1.65;2.34;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ix7;1;b;1;766;96;97;791;99;100;1.25;1.29;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1aia;1;b;1;775;97;98;791;99;100;1.02;1.04;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1amq;1;b;1;778;98;98;791;99;100;0.89;0.90;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1asf;1;b;1;775;97;98;790;99;100;0.98;1.01;99;0;1.65;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1aib;1;b;1;774;97;98;791;99;100;1.04;1.08;99;0;1.65;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ix8;1;b;1;784;99;99;791;99;100;0.64;0.64;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;3zzk;1;b;1;777;98;98;791;99;100;0.94;0.96;99;0;1.65;1.78;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1ix6;1;b;1;783;98;99;791;99;100;0.73;0.73;99;0;1.65;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;3zzj;1;b;1;783;98;99;791;99;100;0.71;0.72;99;0;1.65;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1toe;1;b;1;772;97;98;791;99;100;1.08;1.11;98;0;1.65;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5m;1;1art;1;b;1;753;95;95;790;99;100;1.54;1.61;99;0;1.65;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Wild-Type E. coli Aspartate Aminotransferase: A Template For The Interconversion of Substrate Specificity and Activity To Tyrosine Aminotransferase By The JANUS Algorithm.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.6;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;4f5j;1;b;1;749;98;94;756;99;95;0.67;0.67;96;0;1.45;1.954;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;4f5f;1;b;1;750;98;94;756;99;95;0.63;0.63;97;0;1.45;2.25;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2d66;1;b;1;740;97;93;756;99;95;1.03;1.05;98;0;1.45;2.18;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Mutant MAB;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;4f5k;1;c;1;749;98;94;756;99;95;0.68;0.69;95;0;1.45;2.2;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1tok;1;b;1;737;96;93;756;99;95;1.11;1.13;98;0;1.45;1.85;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;4dbc;1;b;1;746;98;94;756;99;95;0.82;0.84;100;0;1.45;1.5;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1cq6;1;b;1;751;98;95;756;99;95;0.59;0.60;100;0;1.45;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2d7y;1;b;1;749;98;95;756;99;95;0.65;0.66;98;0;1.45;2.66;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2d7z;1;b;1;742;97;94;756;99;95;0.95;0.96;98;0;1.45;2.65;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1b4x;1;b;1;751;98;95;756;99;95;0.55;0.55;99;0;1.45;2.45;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2qbt;1;b;1;750;98;95;754;99;96;0.50;0.53;99;0;1.45;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2qb2;1;b;1;760;99;99;762;100;100;0.38;0.40;99;0;1.45;1.7;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1toj;1;b;1;740;97;93;756;99;95;1.04;1.06;98;0;1.45;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1toi;1;b;1;741;97;94;756;99;95;0.99;1.01;98;0;1.45;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;3qpg;1;b;1;745;97;94;756;99;95;0.85;0.87;100;0;1.45;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2d65;1;c;1;738;97;93;756;99;95;1.07;1.09;96;0;1.45;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1cq8;1;b;1;743;97;94;756;99;95;0.92;0.93;100;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ari;1;b;1;741;97;94;756;99;95;0.99;1.00;99;0;1.45;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1g4v;1;b;1;753;99;95;756;99;95;0.43;0.44;99;0;1.45;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;3uak;1;c;1;672;88;85;751;98;95;2.33;2.43;94;0;1.45;3.232;diffraction;diffraction;792;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;MSE   selenomethionine;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;7.5;100;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1g4x;1;b;1;751;98;95;756;99;95;0.59;0.60;99;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;5eaa;1;b;1;752;98;95;756;99;95;0.49;0.49;99;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2d64;1;b;1;739;97;93;756;99;95;1.05;1.07;96;0;1.45;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1spa;1;b;1;753;99;95;756;99;95;0.45;0.45;99;0;1.45;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;3aat;1;b;1;746;98;94;756;99;95;0.79;0.81;99;0;1.45;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1x28;1;b;1;747;98;94;756;99;95;0.78;0.79;100;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1g7w;1;b;1;750;98;95;756;99;95;0.65;0.65;99;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2d5y;1;b;1;741;97;94;756;99;95;0.98;0.99;98;0;1.45;1.98;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2d63;1;b;1;740;97;93;756;99;95;1.03;1.05;98;0;1.45;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2d61;1;b;1;741;97;94;756;99;95;0.97;0.99;98;0;1.45;2.01;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1g7x;1;b;1;750;98;95;756;99;95;0.61;0.61;99;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1cq7;1;b;1;744;97;94;756;99;95;0.90;0.91;100;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1c9c;1;b;1;752;98;95;756;99;95;0.53;0.53;100;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PP3   alanyl-pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;4f5l;1;b;1;749;98;94;756;99;95;0.67;0.67;95;0;1.45;1.4;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;3qn6;1;b;1;746;98;95;752;98;95;0.64;0.68;98;0;1.45;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1tog;1;b;1;733;96;93;756;99;95;1.22;1.25;98;0;1.45;2.31;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1asn;1;b;1;752;98;95;756;99;95;0.52;0.52;100;0;1.45;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1arh;1;b;1;749;98;95;756;99;95;0.68;0.68;99;0;1.45;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1asa;1;b;1;741;97;94;756;99;95;1.00;1.02;100;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ahe;1;b;1;747;98;94;756;99;95;0.77;0.78;98;0;1.45;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1aic;1;b;1;752;98;95;756;99;95;0.53;0.54;100;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1aaw;1;b;1;749;98;95;756;99;95;0.68;0.70;100;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1asb;1;b;1;741;97;94;756;99;95;0.98;0.99;99;0;1.45;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1qir;1;b;1;742;97;94;756;99;95;0.96;0.97;99;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1czc;1;b;1;742;97;94;756;99;95;0.95;0.96;96;0;1.45;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ase;1;b;1;740;97;93;756;99;95;1.02;1.04;100;0;1.45;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1asd;1;b;1;740;97;93;756;99;95;1.02;1.03;100;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1qit;1;b;1;741;97;94;756;99;95;0.98;0.99;99;0;1.45;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ahf;1;b;1;748;98;94;756;99;95;0.74;0.75;98;0;1.45;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1asm;1;b;1;742;97;94;756;99;95;0.94;0.96;100;0;1.45;2.35;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ars;1;b;1;753;99;95;756;99;95;0.45;0.45;100;0;1.45;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2aat;1;b;1;740;97;93;756;99;95;1.02;1.04;98;0;1.45;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;2qa3;1;b;1;748;98;98;754;99;98;0.63;0.68;97;0;1.45;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1arg;1;b;1;742;97;94;756;99;95;0.94;0.96;100;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ahy;1;b;1;743;97;94;756;99;95;0.91;0.93;98;0;1.45;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1asg;1;b;1;741;97;94;756;99;95;0.98;1.00;99;0;1.45;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1x2a;1;b;1;745;98;94;756;99;95;0.84;0.85;100;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1cze;1;b;1;742;97;94;756;99;95;0.97;0.99;96;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ahx;1;b;1;742;97;94;756;99;95;0.96;0.98;98;0;1.45;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ams;1;b;1;753;98;95;756;99;95;0.48;0.48;100;0;1.45;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1yoo;1;b;1;740;97;93;756;99;95;1.03;1.05;96;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1amr;1;b;1;743;97;94;756;99;95;0.91;0.92;100;0;1.45;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1bqa;1;b;1;751;98;95;756;99;95;0.58;0.59;100;0;1.45;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1asl;1;b;1;743;97;94;756;99;95;0.90;0.91;100;0;1.45;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1qis;1;b;1;742;97;94;756;99;95;0.95;0.96;99;0;1.45;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1aam;1;b;1;742;97;94;756;99;95;0.96;0.98;98;0;1.45;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1bqd;1;b;1;751;98;95;756;99;95;0.58;0.58;99;0;1.45;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1asc;1;b;1;749;98;95;756;99;95;0.68;0.69;98;0;1.45;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;4a00;1;b;1;754;99;95;756;99;95;0.37;0.37;99;0;1.45;2.34;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ix7;1;b;1;749;98;95;756;99;95;0.68;0.68;99;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1aia;1;b;1;752;98;95;756;99;95;0.54;0.54;100;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1amq;1;b;1;753;99;95;756;99;95;0.44;0.45;100;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1asf;1;b;1;747;98;94;756;99;95;0.79;0.81;99;0;1.45;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1aib;1;b;1;752;98;95;756;99;95;0.52;0.52;100;0;1.45;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ix8;1;b;1;750;98;95;756;99;95;0.60;0.61;99;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;3zzk;1;b;1;754;99;95;756;99;95;0.37;0.37;99;0;1.45;1.78;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1ix6;1;b;1;750;98;95;756;99;95;0.60;0.61;99;0;1.45;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;3zzj;1;b;1;754;99;95;756;99;95;0.39;0.40;99;0;1.45;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1toe;1;b;1;750;98;95;756;99;95;0.60;0.61;98;0;1.45;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2qb3;1;1art;1;b;1;743;97;94;756;99;95;0.92;0.93;100;0;1.45;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Structural Studies Reveal the Inactivation of E. coli L-Aspartate Aminotransferase by (s)-4,5-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 7.5);X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;4f5f;1;b;1;795;100;99;798;100;100;0.45;0.46;99;0;1.954;2.25;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;5.0;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2d66;1;b;1;758;95;96;789;99;100;1.41;1.48;93;0;1.954;2.18;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Mutant MAB;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;4f5k;1;b;1;796;100;100;798;100;100;0.39;0.39;99;0;1.954;2.2;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1tok;1;b;1;752;94;95;791;99;100;1.57;1.65;95;0;1.954;1.85;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;4dbc;1;b;1;762;95;96;792;99;100;1.38;1.44;96;0;1.954;1.5;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1cq6;1;b;1;776;97;98;792;99;100;1.00;1.03;96;0;1.954;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2d7y;1;b;1;778;97;98;792;99;100;0.95;0.98;95;0;1.954;2.66;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2d7z;1;b;1;761;95;96;792;99;100;1.40;1.48;94;0;1.954;2.65;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1b4x;1;b;1;777;97;98;792;99;100;0.98;1.02;96;0;1.954;2.45;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2qbt;1;b;1;756;95;96;788;99;100;1.43;1.51;84;0;1.954;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2qb2;1;b;1;757;95;99;764;96;100;0.65;0.65;96;0;1.954;1.7;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1toj;1;b;1;753;94;95;790;99;100;1.53;1.61;95;0;1.954;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1toi;1;b;1;756;95;96;789;99;100;1.44;1.51;94;0;1.954;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;3qpg;1;b;1;760;95;96;792;99;100;1.42;1.49;96;0;1.954;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2d65;1;b;1;756;95;95;789;99;100;1.45;1.52;92;0;1.954;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1cq8;1;b;1;760;95;96;792;99;100;1.41;1.48;96;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ari;1;b;1;761;95;96;792;99;100;1.39;1.45;96;0;1.954;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1g4v;1;b;1;785;98;99;792;99;100;0.65;0.66;95;0;1.954;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;3uak;1;c;1;709;89;89;790;99;100;2.31;2.38;92;0;1.954;3.232;diffraction;diffraction;812;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;MSE   selenomethionine;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;5.0;85;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1g4x;1;b;1;785;98;99;792;99;100;0.64;0.64;95;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;5eaa;1;b;1;783;98;99;792;99;100;0.77;0.78;96;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2d64;1;b;1;755;95;95;787;99;99;1.42;1.49;92;0;1.954;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1spa;1;b;1;782;98;99;792;99;100;0.80;0.81;96;0;1.954;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;3aat;1;b;1;776;97;98;792;99;100;0.99;1.02;96;0;1.954;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1x28;1;b;1;765;96;97;792;99;100;1.30;1.35;96;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1g7w;1;b;1;784;98;99;792;99;100;0.68;0.69;95;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2d5y;1;b;1;761;95;96;790;99;100;1.36;1.43;94;0;1.954;1.98;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2d63;1;b;1;758;95;96;789;99;100;1.39;1.46;94;0;1.954;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2d61;1;b;1;762;95;96;792;99;100;1.38;1.45;95;0;1.954;2.01;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1g7x;1;b;1;784;98;99;792;99;100;0.72;0.73;95;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1cq7;1;b;1;762;95;96;792;99;100;1.38;1.45;96;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1c9c;1;b;1;781;98;99;792;99;100;0.81;0.83;96;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PP3   alanyl-pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;4f5l;1;b;1;797;100;100;798;100;100;0.20;0.20;99;0;1.954;1.4;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;3qn6;1;b;1;779;98;99;788;99;100;0.74;0.76;95;0;1.954;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1tog;1;b;1;747;94;94;785;98;99;1.56;1.64;94;0;1.954;2.31;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1asn;1;b;1;784;98;99;792;99;100;0.71;0.72;96;0;1.954;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1arh;1;b;1;771;97;97;792;99;100;1.15;1.20;95;0;1.954;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1asa;1;b;1;758;95;96;792;99;100;1.47;1.54;96;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ahe;1;b;1;765;96;97;792;99;100;1.30;1.37;95;0;1.954;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1aic;1;b;1;782;98;99;792;99;100;0.80;0.82;96;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1aaw;1;b;1;780;98;99;792;99;100;0.86;0.88;96;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1asb;1;b;1;762;95;96;792;99;100;1.38;1.43;96;0;1.954;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1qir;1;b;1;760;95;96;792;99;100;1.42;1.49;96;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1czc;1;b;1;761;95;96;792;99;100;1.39;1.46;93;0;1.954;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ase;1;b;1;757;95;96;792;99;100;1.49;1.56;96;0;1.954;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1asd;1;b;1;757;95;96;791;99;100;1.47;1.54;96;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1qit;1;b;1;758;95;96;791;99;100;1.45;1.52;96;0;1.954;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ahf;1;b;1;767;96;97;792;99;100;1.26;1.32;95;0;1.954;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1asm;1;b;1;761;95;96;792;99;100;1.40;1.46;96;0;1.954;2.35;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ars;1;b;1;785;98;99;792;99;100;0.67;0.68;96;0;1.954;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2aat;1;b;1;769;96;97;792;99;100;1.19;1.22;96;0;1.954;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;2qa3;1;b;1;739;93;96;763;96;100;1.25;1.33;88;0;1.954;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1arg;1;b;1;761;95;96;792;99;100;1.40;1.47;96;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ahy;1;b;1;762;96;96;792;99;100;1.37;1.44;95;0;1.954;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1asg;1;b;1;760;95;96;792;99;100;1.43;1.50;96;0;1.954;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1x2a;1;b;1;762;96;96;792;99;100;1.37;1.43;96;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1cze;1;b;1;761;95;96;792;99;100;1.40;1.47;93;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ahx;1;b;1;759;95;96;790;99;100;1.41;1.48;95;0;1.954;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ams;1;b;1;781;98;99;792;99;100;0.82;0.84;96;0;1.954;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1yoo;1;b;1;756;95;95;787;99;99;1.40;1.47;91;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1amr;1;b;1;763;96;96;792;99;100;1.35;1.41;96;0;1.954;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1bqa;1;b;1;787;99;99;792;99;100;0.56;0.56;96;0;1.954;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1asl;1;b;1;763;96;96;792;99;100;1.35;1.41;96;0;1.954;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1qis;1;b;1;760;95;96;792;99;100;1.43;1.50;96;0;1.954;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1aam;1;b;1;771;97;97;792;99;100;1.14;1.18;96;0;1.954;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1bqd;1;b;1;786;99;99;792;99;100;0.60;0.61;96;0;1.954;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1asc;1;b;1;776;97;98;792;99;100;1.01;1.04;96;0;1.954;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;4a00;1;b;1;785;98;99;792;99;100;0.65;0.65;95;0;1.954;2.34;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ix7;1;b;1;774;97;98;792;99;100;1.07;1.11;96;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1aia;1;b;1;780;98;98;792;99;100;0.87;0.89;96;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1amq;1;b;1;783;98;99;792;99;100;0.74;0.75;96;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1asf;1;b;1;779;98;98;792;99;100;0.89;0.93;96;0;1.954;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1aib;1;b;1;779;98;98;792;99;100;0.91;0.94;96;0;1.954;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ix8;1;b;1;787;99;99;792;99;100;0.58;0.59;95;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;3zzk;1;b;1;781;98;99;792;99;100;0.83;0.85;95;0;1.954;1.78;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1ix6;1;b;1;786;98;99;792;99;100;0.63;0.64;96;0;1.954;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;3zzj;1;b;1;786;98;99;792;99;100;0.63;0.63;95;0;1.954;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1toe;1;b;1;776;97;98;792;99;100;1.01;1.03;95;0;1.954;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5j;1;1art;1;b;1;763;96;96;792;99;100;1.36;1.41;96;0;1.954;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Rational Design and Directed Evolution for Conversion of Substrate Specificity from E.coli Aspartate Aminotransferase to Tyrosine Aminotransferase: Mutant P5.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2d66;1;b;1;758;95;96;792;99;100;1.46;1.55;95;0;2.25;2.18;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Mutant MAB;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;4f5k;1;b;1;795;99;100;798;100;100;0.45;0.45;98;0;2.25;2.2;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1tok;1;c;1;754;94;95;792;99;100;1.55;1.62;96;0;2.25;1.85;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;4dbc;1;b;1;763;96;96;792;99;100;1.34;1.41;96;0;2.25;1.5;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1cq6;1;b;1;777;97;98;792;99;100;0.96;0.99;96;0;2.25;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2d7y;1;b;1;778;97;98;792;99;100;0.92;0.95;95;0;2.25;2.66;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2d7z;1;b;1;762;95;96;792;99;100;1.37;1.45;95;0;2.25;2.65;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1b4x;1;b;1;778;97;98;792;99;100;0.93;0.97;96;0;2.25;2.45;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2qbt;1;b;1;744;93;94;779;97;99;1.50;1.63;86;0;2.25;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2qb2;1;b;1;758;95;99;764;96;100;0.61;0.61;97;0;2.25;1.7;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1toj;1;b;1;753;94;95;788;99;99;1.48;1.56;96;0;2.25;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1toi;1;b;1;758;95;96;792;99;100;1.47;1.56;95;0;2.25;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;3qpg;1;b;1;762;95;96;792;99;100;1.39;1.45;96;0;2.25;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2d65;1;b;1;757;95;96;792;99;100;1.49;1.58;94;0;2.25;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1cq8;1;b;1;762;95;96;792;99;100;1.38;1.44;96;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ari;1;b;1;763;95;96;792;99;100;1.36;1.42;96;0;2.25;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1g4v;1;b;1;786;98;99;792;99;100;0.62;0.63;96;0;2.25;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;3uak;1;c;1;707;88;89;789;99;100;2.32;2.40;92;0;2.25;3.232;diffraction;diffraction;812;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;MSE   selenomethionine;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;5.0;85;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1g4x;1;b;1;786;98;99;792;99;100;0.60;0.61;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;5eaa;1;b;1;783;98;99;792;99;100;0.74;0.76;96;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2d64;1;c;1;757;95;96;792;99;100;1.49;1.58;94;0;2.25;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1spa;1;b;1;782;98;99;792;99;100;0.78;0.79;96;0;2.25;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;3aat;1;b;1;778;97;98;792;99;100;0.95;0.98;96;0;2.25;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1x28;1;b;1;767;96;97;792;99;100;1.25;1.30;96;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1g7w;1;b;1;785;98;99;792;99;100;0.64;0.65;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2d5y;1;b;1;763;95;96;792;99;100;1.36;1.43;94;0;2.25;1.98;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2d63;1;c;1;759;95;96;792;99;100;1.44;1.53;95;0;2.25;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2d61;1;b;1;763;96;96;792;99;100;1.35;1.41;95;0;2.25;2.01;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1g7x;1;b;1;785;98;99;792;99;100;0.68;0.69;95;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1cq7;1;b;1;763;96;96;792;99;100;1.35;1.41;96;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1c9c;1;b;1;782;98;99;792;99;100;0.78;0.80;96;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PP3   alanyl-pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;4f5l;1;b;1;796;100;100;798;100;100;0.32;0.32;98;0;2.25;1.4;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;3qn6;1;b;1;770;96;98;786;98;100;1.01;1.07;91;0;2.25;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1tog;1;b;1;747;93;94;785;98;99;1.57;1.64;94;0;2.25;2.31;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1asn;1;b;1;785;98;99;792;99;100;0.68;0.69;96;0;2.25;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1arh;1;b;1;772;97;97;792;99;100;1.13;1.18;96;0;2.25;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1asa;1;b;1;759;95;96;792;99;100;1.44;1.51;96;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ahe;1;b;1;766;96;97;792;99;100;1.27;1.33;95;0;2.25;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1aic;1;b;1;783;98;99;792;99;100;0.77;0.79;96;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1aaw;1;b;1;781;98;99;792;99;100;0.84;0.86;96;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1asb;1;b;1;764;96;96;792;99;100;1.34;1.39;96;0;2.25;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1qir;1;b;1;762;95;96;792;99;100;1.38;1.44;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1czc;1;b;1;763;96;96;792;99;100;1.35;1.42;93;0;2.25;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ase;1;b;1;758;95;96;792;99;100;1.46;1.53;96;0;2.25;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1asd;1;b;1;759;95;96;792;99;100;1.44;1.51;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1qit;1;b;1;760;95;96;792;99;100;1.42;1.49;96;0;2.25;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ahf;1;b;1;768;96;97;792;99;100;1.22;1.29;95;0;2.25;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1asm;1;b;1;763;95;96;792;99;100;1.36;1.43;96;0;2.25;2.35;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ars;1;b;1;785;98;99;792;99;100;0.64;0.65;96;0;2.25;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2aat;1;b;1;770;96;97;792;99;100;1.18;1.21;96;0;2.25;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;2qa3;1;b;1;756;95;99;766;96;100;0.79;0.82;94;0;2.25;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1arg;1;b;1;762;95;96;792;99;100;1.37;1.43;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ahy;1;b;1;764;96;96;792;99;100;1.33;1.40;95;0;2.25;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1asg;1;b;1;761;95;96;792;99;100;1.40;1.46;96;0;2.25;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1x2a;1;b;1;764;96;96;792;99;100;1.32;1.39;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1cze;1;b;1;762;95;96;792;99;100;1.37;1.43;93;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ahx;1;b;1;761;95;96;791;99;100;1.38;1.46;95;0;2.25;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ams;1;b;1;782;98;99;792;99;100;0.79;0.81;96;0;2.25;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1yoo;1;b;1;757;95;96;788;99;99;1.39;1.46;92;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1amr;1;b;1;764;96;97;792;99;100;1.32;1.37;96;0;2.25;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1bqa;1;b;1;788;99;99;792;99;100;0.53;0.53;96;0;2.25;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1asl;1;b;1;764;96;96;792;99;100;1.32;1.38;96;0;2.25;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1qis;1;b;1;761;95;96;792;99;100;1.39;1.46;96;0;2.25;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1aam;1;b;1;771;97;97;792;99;100;1.13;1.17;96;0;2.25;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1bqd;1;b;1;787;98;99;792;99;100;0.57;0.58;96;0;2.25;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1asc;1;b;1;776;97;98;792;99;100;1.00;1.03;96;0;2.25;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;4a00;1;b;1;786;98;99;792;99;100;0.63;0.63;96;0;2.25;2.34;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ix7;1;b;1;774;97;98;792;99;100;1.05;1.09;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1aia;1;b;1;781;98;99;792;99;100;0.83;0.86;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1amq;1;b;1;784;98;99;792;99;100;0.71;0.72;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1asf;1;b;1;780;98;98;792;99;100;0.86;0.89;96;0;2.25;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1aib;1;b;1;780;98;98;792;99;100;0.88;0.91;96;0;2.25;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ix8;1;b;1;787;99;99;792;99;100;0.54;0.55;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;3zzk;1;b;1;782;98;99;792;99;100;0.80;0.82;96;0;2.25;1.78;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1ix6;1;b;1;786;98;99;792;99;100;0.61;0.62;96;0;2.25;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;3zzj;1;b;1;786;98;99;792;99;100;0.62;0.62;96;0;2.25;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1toe;1;b;1;777;97;98;792;99;100;0.97;0.99;95;0;2.25;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5f;1;1art;1;b;1;764;96;96;792;99;100;1.32;1.38;96;0;2.25;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Structure of Aspartate Aminotransferase Conversion to Tyrosine Aminotransferase: Chimera P1.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;5.0;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;4f5k;1;b;1;759;96;95;789;100;99;1.39;1.44;92;0;2.18;2.2;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Aspartate Aminotransferase Mutant MAB;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;4.8;85;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1tok;1;b;1;780;98;98;792;100;100;0.87;0.87;97;0;2.18;1.85;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;4dbc;1;b;1;785;99;99;792;100;100;0.67;0.67;97;0;2.18;1.5;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Aspartate Aminotransferase Mutant MAB;Substrate Activation in Aspartate Aminotransferase;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1cq6;1;b;1;780;98;98;792;100;100;0.88;0.90;98;0;2.18;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2d7y;1;b;1;782;99;99;792;100;100;0.79;0.80;99;0;2.18;2.66;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;Aspartate Aminotransferase Mutant MA;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2d7z;1;b;1;791;100;100;792;100;100;0.22;0.22;100;0;2.18;2.65;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;no/data;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1b4x;1;b;1;780;98;98;792;100;100;0.87;0.88;97;0;2.18;2.45;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2qbt;1;b;1;742;94;94;777;98;99;1.49;1.56;90;0;2.18;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Aspartate Aminotransferase Mutant MAB;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2qb2;1;b;1;737;93;96;754;95;99;1.07;1.08;98;0;2.18;1.7;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Aspartate Aminotransferase Mutant MAB;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1toj;1;b;1;786;99;99;792;100;100;0.60;0.61;97;0;2.18;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Aspartate Aminotransferase Mutant MAB;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1toi;1;b;1;788;99;99;792;100;100;0.51;0.51;97;0;2.18;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Aspartate Aminotransferase Mutant MAB;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;3qpg;1;b;1;784;99;99;792;100;100;0.69;0.70;98;0;2.18;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Aspartate Aminotransferase Mutant MAB;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2d65;1;b;1;790;100;100;792;100;100;0.31;0.31;99;0;2.18;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;Aspartate Aminotransferase Mutant MABC;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;no/data;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1cq8;1;b;1;787;99;99;792;100;100;0.53;0.53;98;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ari;1;b;1;786;99;99;792;100;100;0.60;0.60;97;0;2.18;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;Aspartate aminotransferase, W140H mutant, maleate complex;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1g4v;1;b;1;767;97;97;792;100;100;1.25;1.30;97;0;2.18;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;3uak;1;b;1;731;92;92;791;100;100;1.96;2.01;94;0;2.18;3.232;diffraction;diffraction;792;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;MSE   selenomethionine;Aspartate Aminotransferase Mutant MAB;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;no/data;100;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1g4x;1;b;1;761;96;96;792;100;100;1.40;1.47;97;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;5eaa;1;b;1;773;98;98;792;100;100;1.10;1.13;97;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2d64;1;b;1;790;100;100;792;100;100;0.32;0.33;99;0;2.18;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Aspartate Aminotransferase Mutant MAB;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;no/data;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1spa;1;b;1;771;97;97;792;100;100;1.16;1.18;97;0;2.18;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Aspartate Aminotransferase Mutant MAB;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;3aat;1;b;1;766;97;97;792;100;100;1.29;1.34;97;0;2.18;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1x28;1;b;1;785;99;99;792;100;100;0.67;0.67;98;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Aspartate Aminotransferase Mutant MAB;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1g7w;1;b;1;762;96;96;792;100;100;1.38;1.43;97;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2d5y;1;b;1;790;100;100;792;100;100;0.38;0.38;97;0;2.18;1.98;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Aspartate Aminotransferase Mutant MAB;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2d63;1;b;1;791;100;100;792;100;100;0.21;0.21;99;0;2.18;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Aspartate Aminotransferase Mutant MAB;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2d61;1;b;1;790;100;100;792;100;100;0.33;0.33;99;0;2.18;2.01;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;Aspartate Aminotransferase Mutant MA With Maleic Acid;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1g7x;1;b;1;766;97;97;792;100;100;1.29;1.33;97;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1cq7;1;b;1;788;99;99;792;100;100;0.53;0.53;98;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1c9c;1;b;1;773;98;98;792;100;100;1.10;1.13;98;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PP3   alanyl-pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;4f5l;1;b;1;757;96;95;789;100;99;1.42;1.49;93;0;2.18;1.4;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Aspartate Aminotransferase Mutant MAB;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;3qn6;1;b;1;758;96;96;787;99;100;1.36;1.41;96;0;2.18;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Aspartate Aminotransferase Mutant MAB;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1tog;1;b;1;785;99;99;792;100;100;0.67;0.68;97;0;2.18;2.31;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Aspartate Aminotransferase Mutant MAB;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1asn;1;b;1;770;97;97;792;100;100;1.17;1.21;98;0;2.18;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1arh;1;b;1;782;99;99;792;100;100;0.80;0.80;97;0;2.18;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1asa;1;b;1;786;99;99;792;100;100;0.61;0.61;98;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ahe;1;b;1;787;99;99;792;100;100;0.57;0.57;97;0;2.18;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1aic;1;b;1;771;97;97;792;100;100;1.15;1.17;97;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1aaw;1;b;1;767;97;97;791;100;100;1.22;1.26;97;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1asb;1;b;1;786;99;99;792;100;100;0.59;0.60;97;0;2.18;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1qir;1;b;1;786;99;99;792;100;100;0.61;0.62;97;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1czc;1;b;1;788;100;100;792;100;100;0.49;0.49;97;0;2.18;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ase;1;b;1;785;99;99;792;100;100;0.65;0.65;98;0;2.18;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1asd;1;b;1;787;99;99;792;100;100;0.58;0.58;98;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1qit;1;b;1;786;99;99;792;100;100;0.63;0.64;97;0;2.18;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ahf;1;b;1;787;99;99;792;100;100;0.55;0.55;97;0;2.18;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1asm;1;b;1;786;99;99;792;100;100;0.59;0.60;98;0;2.18;2.35;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ars;1;b;1;768;97;97;792;100;100;1.22;1.26;98;0;2.18;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2aat;1;b;1;755;95;95;788;99;99;1.45;1.48;96;0;2.18;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;2qa3;1;b;1;713;90;93;754;95;98;1.65;1.76;85;0;2.18;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Aspartate Aminotransferase Mutant MAB;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1arg;1;b;1;787;99;99;792;100;100;0.57;0.57;98;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Aspartate Aminotransferase Mutant MAB;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ahy;1;b;1;787;99;99;792;100;100;0.57;0.57;97;0;2.18;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1asg;1;b;1;788;99;99;792;100;100;0.53;0.53;97;0;2.18;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1x2a;1;b;1;785;99;99;792;100;100;0.68;0.68;98;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Aspartate Aminotransferase Mutant MAB;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1cze;1;b;1;789;100;100;792;100;100;0.45;0.45;97;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ahx;1;b;1;786;99;99;792;100;100;0.60;0.61;97;0;2.18;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ams;1;b;1;773;98;98;792;100;100;1.09;1.11;98;0;2.18;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Aspartate Aminotransferase Mutant MAB;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1yoo;1;b;1;790;100;100;792;100;100;0.35;0.36;98;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1amr;1;b;1;787;99;99;792;100;100;0.56;0.56;98;0;2.18;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1bqa;1;b;1;763;96;96;792;100;100;1.34;1.40;97;0;2.18;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE P195A MUTANT;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1asl;1;b;1;785;99;99;792;100;100;0.68;0.68;98;0;2.18;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Aspartate Aminotransferase Mutant MAB;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1qis;1;b;1;786;99;99;792;100;100;0.61;0.61;97;0;2.18;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1aam;1;b;1;753;95;95;790;100;100;1.54;1.60;96;0;2.18;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1bqd;1;b;1;765;97;97;792;100;100;1.30;1.35;97;0;2.18;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Aspartate Aminotransferase Mutant MAB;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1asc;1;b;1;771;97;97;792;100;100;1.14;1.16;97;0;2.18;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Aspartate Aminotransferase Mutant MAB;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;4a00;1;b;1;765;97;97;792;100;100;1.31;1.35;97;0;2.18;2.34;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Aspartate Aminotransferase Mutant MAB;Structure of an engineered aspartate aminotransferase;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ix7;1;b;1;780;98;98;792;100;100;0.87;0.88;97;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Aspartate Aminotransferase Mutant MAB;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1aia;1;b;1;775;98;98;792;100;100;1.03;1.05;97;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1amq;1;b;1;770;97;97;792;100;100;1.17;1.20;98;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1asf;1;b;1;766;97;97;792;100;100;1.28;1.33;97;0;2.18;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1aib;1;b;1;775;98;98;792;100;100;1.02;1.03;97;0;2.18;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Aspartate Aminotransferase Mutant MAB;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ix8;1;b;1;758;96;96;792;100;100;1.48;1.56;97;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;Aspartate Aminotransferase Active Site Mutant V39F/N194A;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;3zzk;1;b;1;774;98;98;792;100;100;1.07;1.08;97;0;2.18;1.78;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Aspartate Aminotransferase Mutant MAB;Structure of an engineered aspartate aminotransferase;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1ix6;1;b;1;759;96;96;792;100;100;1.45;1.51;97;0;2.18;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate;Aspartate Aminotransferase Mutant MAB;Aspartate Aminotransferase Active Site Mutant V39F;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;3zzj;1;b;1;765;97;97;792;100;100;1.30;1.34;97;0;2.18;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Aspartate Aminotransferase Mutant MAB;Structure of an engineered aspartate aminotransferase;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1toe;1;b;1;779;98;98;792;100;100;0.90;0.91;97;0;2.18;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Aspartate Aminotransferase Mutant MAB;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;2d66;1;1art;1;b;1;786;99;99;792;100;100;0.59;0.59;98;0;2.18;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Aspartate Aminotransferase Mutant MAB;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;no/data;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1tok;1;c;1;755;95;95;792;99;100;1.52;1.59;95;0;2.2;1.85;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;4dbc;1;c;1;764;96;96;792;99;100;1.33;1.39;95;0;2.2;1.5;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1cq6;1;b;1;777;97;98;792;99;100;0.95;0.98;95;0;2.2;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2d7y;1;b;1;778;98;98;792;99;100;0.93;0.96;94;0;2.2;2.66;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2d7z;1;b;1;762;95;96;789;99;100;1.32;1.37;92;0;2.2;2.65;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.8;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1b4x;1;b;1;778;97;98;792;99;100;0.95;0.98;94;0;2.2;2.45;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2qbt;1;b;1;751;94;95;784;98;99;1.45;1.57;84;0;2.2;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2qb2;1;b;1;757;95;99;764;96;100;0.67;0.67;95;0;2.2;1.7;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1toj;1;c;1;756;95;95;792;99;100;1.51;1.60;95;0;2.2;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1toi;1;b;1;758;95;96;789;99;100;1.41;1.47;93;0;2.2;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;3qpg;1;b;1;761;95;96;790;99;100;1.35;1.40;95;0;2.2;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2d65;1;b;1;757;95;96;789;99;100;1.44;1.49;91;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.8;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1cq8;1;b;1;762;96;96;791;99;100;1.35;1.40;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ari;1;b;1;763;96;96;792;99;100;1.34;1.40;94;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1g4v;1;b;1;786;98;99;792;99;100;0.63;0.64;94;0;2.2;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;3uak;1;b;1;707;89;89;786;98;99;2.29;2.35;91;0;2.2;3.232;diffraction;diffraction;812;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;MSE   selenomethionine;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;4.8;85;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1g4x;1;b;1;785;98;99;792;99;100;0.67;0.67;94;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;5eaa;1;b;1;783;98;99;792;99;100;0.75;0.76;94;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2d64;1;b;1;757;95;96;789;99;100;1.43;1.49;91;0;2.2;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;4.8;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1spa;1;b;1;783;98;99;792;99;100;0.74;0.75;94;0;2.2;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;3aat;1;b;1;777;97;98;792;99;100;0.95;0.98;94;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1x28;1;b;1;767;96;97;792;99;100;1.25;1.30;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1g7w;1;b;1;784;98;99;792;99;100;0.69;0.70;94;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2d5y;1;b;1;762;95;96;789;99;100;1.31;1.36;92;0;2.2;1.98;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2d63;1;b;1;760;95;96;789;99;100;1.36;1.41;93;0;2.2;2.05;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2d61;1;b;1;764;96;96;792;99;100;1.33;1.39;94;0;2.2;2.01;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1g7x;1;b;1;784;98;99;792;99;100;0.72;0.72;94;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1cq7;1;c;1;764;96;96;792;99;100;1.33;1.39;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1c9c;1;b;1;783;98;99;792;99;100;0.77;0.78;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PP3   alanyl-pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;4f5l;1;b;1;795;100;100;798;100;100;0.41;0.41;99;0;2.2;1.4;diffraction;diffraction;812;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;3qn6;1;b;1;778;97;99;788;99;100;0.80;0.83;94;0;2.2;1.79;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1tog;1;b;1;751;94;95;791;99;100;1.60;1.68;95;0;2.2;2.31;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1asn;1;b;1;784;98;99;792;99;100;0.69;0.70;95;0;2.2;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1arh;1;b;1;773;97;98;792;99;100;1.10;1.14;94;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1asa;1;b;1;759;95;96;789;99;100;1.37;1.43;94;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ahe;1;b;1;767;96;97;792;99;100;1.26;1.32;94;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1aic;1;b;1;783;98;99;792;99;100;0.76;0.78;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1aaw;1;b;1;781;98;99;792;99;100;0.84;0.87;95;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1asb;1;b;1;764;96;96;792;99;100;1.34;1.38;94;0;2.2;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1qir;1;b;1;763;96;96;792;99;100;1.35;1.41;94;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1czc;1;b;1;763;96;96;792;99;100;1.36;1.42;92;0;2.2;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ase;1;b;1;760;95;96;792;99;100;1.42;1.49;95;0;2.2;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1asd;1;b;1;759;95;96;790;99;100;1.41;1.46;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1qit;1;b;1;760;95;96;790;99;100;1.37;1.42;94;0;2.2;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ahf;1;b;1;768;96;97;792;99;100;1.22;1.28;94;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1asm;1;b;1;763;96;96;790;99;100;1.31;1.36;95;0;2.2;2.35;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ars;1;b;1;785;98;99;792;99;100;0.64;0.65;95;0;2.2;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2aat;1;b;1;770;97;97;792;99;100;1.17;1.20;95;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;2qa3;1;c;1;722;90;94;753;94;98;1.45;1.61;88;0;2.2;1.75;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1arg;1;b;1;763;96;96;792;99;100;1.35;1.40;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ahy;1;b;1;763;96;96;790;99;100;1.31;1.35;94;0;2.2;2.3;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1asg;1;b;1;762;95;96;792;99;100;1.38;1.43;94;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1x2a;1;c;1;764;96;96;792;99;100;1.33;1.38;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1cze;1;b;1;762;96;96;792;99;100;1.37;1.43;92;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ahx;1;c;1;761;95;96;792;99;100;1.41;1.47;94;0;2.2;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ams;1;b;1;782;98;99;792;99;100;0.78;0.79;95;0;2.2;2.7;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1yoo;1;b;1;757;95;96;789;99;100;1.41;1.47;91;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1amr;1;b;1;765;96;97;792;99;100;1.30;1.35;95;0;2.2;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1bqa;1;b;1;786;99;99;792;99;100;0.58;0.59;95;0;2.2;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1asl;1;b;1;766;96;97;792;99;100;1.29;1.33;95;0;2.2;2.6;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1qis;1;b;1;762;96;96;792;99;100;1.37;1.43;94;0;2.2;1.9;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1aam;1;b;1;771;97;97;792;99;100;1.13;1.17;94;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1bqd;1;b;1;786;98;99;792;99;100;0.61;0.62;94;0;2.2;2.1;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1asc;1;b;1;778;97;98;792;99;100;0.95;0.98;94;0;2.2;2.4;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;4a00;1;b;1;785;98;99;792;99;100;0.65;0.65;94;0;2.2;2.34;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ix7;1;b;1;776;97;98;792;99;100;1.01;1.04;94;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1aia;1;b;1;781;98;99;792;99;100;0.82;0.84;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1amq;1;b;1;784;98;99;792;99;100;0.70;0.71;95;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1asf;1;b;1;780;98;98;792;99;100;0.88;0.91;94;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1aib;1;b;1;780;98;99;792;99;100;0.85;0.88;95;0;2.2;2.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ix8;1;b;1;786;98;99;792;99;100;0.63;0.63;94;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;3zzk;1;b;1;782;98;99;792;99;100;0.79;0.81;94;0;2.2;1.78;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1ix6;1;b;1;785;98;99;792;99;100;0.64;0.65;94;0;2.2;2.2;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;3zzj;1;b;1;785;98;99;792;99;100;0.64;0.65;94;0;2.2;2.5;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1toe;1;b;1;775;97;98;792;99;100;1.03;1.05;94;0;2.2;2.0;diffraction;diffraction;812;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4f5k;1;1art;1;b;1;765;96;97;792;99;100;1.30;1.34;95;0;2.2;1.8;diffraction;diffraction;812;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Substrate Specificity Conversion of Aspartate Aminotransferase to Tyrosine Aminotransferase By The JANUS Algorithm: Chimera P6.;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;4.8;85;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;4dbc;1;b;1;788;99;99;792;100;100;0.50;0.50;98;0;1.85;1.5;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Substrate Activation in Aspartate Aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1cq6;1;b;1;775;98;98;792;100;100;1.05;1.06;98;0;1.85;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2d7y;1;b;1;771;97;97;792;100;100;1.15;1.17;97;0;1.85;2.66;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2d7z;1;b;1;782;99;99;792;100;100;0.81;0.81;97;0;1.85;2.65;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1b4x;1;b;1;773;98;98;792;100;100;1.08;1.09;98;0;1.85;2.45;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2qbt;1;b;1;750;95;95;788;99;100;1.55;1.62;95;0;1.85;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2qb2;1;b;1;738;93;97;759;96;99;1.18;1.20;98;0;1.85;1.7;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1toj;1;b;1;788;99;99;792;100;100;0.52;0.52;100;0;1.85;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1toi;1;b;1;786;99;99;792;100;100;0.60;0.61;97;0;1.85;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;3qpg;1;b;1;789;100;100;792;100;100;0.46;0.46;98;0;1.85;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2d65;1;b;1;780;98;98;792;100;100;0.86;0.87;95;0;1.85;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1cq8;1;b;1;787;99;99;792;100;100;0.57;0.58;98;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ari;1;b;1;785;99;99;792;100;100;0.65;0.65;98;0;1.85;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1g4v;1;b;1;764;96;96;792;100;100;1.33;1.37;97;0;1.85;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;3uak;1;b;1;697;88;88;786;99;99;2.43;2.49;93;0;1.85;3.232;diffraction;diffraction;792;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;MSE   selenomethionine;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;7.5;100;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1g4x;1;b;1;756;95;95;792;100;100;1.52;1.58;97;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;5eaa;1;b;1;768;97;97;792;100;100;1.24;1.27;98;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2d64;1;b;1;780;99;99;792;100;100;0.86;0.87;95;0;1.85;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1spa;1;b;1;768;97;97;792;100;100;1.22;1.24;98;0;1.85;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;3aat;1;b;1;762;96;96;792;100;100;1.37;1.42;98;0;1.85;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1x28;1;b;1;786;99;99;792;100;100;0.59;0.59;98;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1g7w;1;b;1;757;96;96;792;100;100;1.48;1.54;97;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2d5y;1;b;1;782;99;99;792;100;100;0.80;0.80;96;0;1.85;1.98;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2d63;1;b;1;782;99;99;792;100;100;0.78;0.78;97;0;1.85;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2d61;1;b;1;783;99;99;792;100;100;0.74;0.74;97;0;1.85;2.01;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1g7x;1;b;1;760;96;96;792;100;100;1.41;1.46;97;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1cq7;1;b;1;786;99;99;792;100;100;0.59;0.59;98;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1c9c;1;b;1;767;97;97;792;100;100;1.25;1.28;98;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PP3   alanyl-pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;4f5l;1;b;1;754;95;94;792;100;99;1.56;1.63;95;0;1.85;1.4;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;3qn6;1;b;1;744;94;94;787;99;100;1.66;1.73;92;0;1.85;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1tog;1;b;1;784;99;99;792;100;100;0.72;0.73;100;0;1.85;2.31;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1asn;1;b;1;764;97;97;792;100;100;1.32;1.36;98;0;1.85;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1arh;1;b;1;774;98;98;792;100;100;1.06;1.07;97;0;1.85;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE, Y225R/R386A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1asa;1;b;1;787;99;99;792;100;100;0.54;0.54;98;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ahe;1;b;1;786;99;99;792;100;100;0.61;0.61;97;0;1.85;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1aic;1;b;1;765;97;97;792;100;100;1.30;1.33;98;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1aaw;1;b;1;762;96;96;792;100;100;1.37;1.41;98;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1asb;1;b;1;782;99;99;792;100;100;0.78;0.79;98;0;1.85;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1qir;1;b;1;787;99;99;792;100;100;0.54;0.54;98;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191Y MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1czc;1;b;1;784;99;99;792;100;100;0.71;0.72;95;0;1.85;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;PROTEIN (ASPARTATE AMINOTRANSFERASE);ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| GUA   glutaric acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH GLUTARIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ase;1;b;1;788;99;99;792;100;100;0.52;0.53;98;0;1.85;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;NOP   pyridoxal-5'-phosphate-n-oxide| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH PLP-N-OXIDE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1asd;1;b;1;787;99;99;792;100;100;0.56;0.56;98;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;MPL   n-methyl-pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;THE STRUCTURE OF WILD TYPE E. COLI ASPARTATE AMINOTRANSFERASE RECONSTITUTED WITH N-MEPLP;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1qit;1;b;1;788;99;99;792;100;100;0.50;0.50;98;0;1.85;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191W MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ahf;1;b;1;784;99;99;792;100;100;0.70;0.71;97;0;1.85;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate| IOP   indolylpropionic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1asm;1;b;1;787;99;99;792;100;100;0.56;0.57;98;0;1.85;2.35;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ars;1;b;1;765;97;97;792;100;100;1.31;1.34;98;0;1.85;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2aat;1;b;1;750;95;95;791;100;100;1.62;1.67;97;0;1.85;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;2.8-ANGSTROMS-RESOLUTION CRYSTAL STRUCTURE OF AN ACTIVE-SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;2qa3;1;b;1;734;93;96;760;96;99;1.31;1.35;96;0;1.85;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via two mechanisms (at pH6.5);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;6.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1arg;1;b;1;787;99;99;792;100;100;0.56;0.56;98;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PPD   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethylene)-amino]-succinic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate aminotransferase, phospho-5'-pyridoxyl aspartate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ahy;1;b;1;786;99;99;792;100;100;0.60;0.60;97;0;1.85;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1asg;1;b;1;786;99;99;792;100;100;0.61;0.61;98;0;1.85;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1x2a;1;b;1;788;100;100;792;100;100;0.47;0.47;98;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PDG   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-d-glutamic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-D-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1cze;1;b;1;784;99;99;792;100;100;0.72;0.72;95;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| SIN   succinic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE MUTANT ATB17/139S/142N WITH SUCCINIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ahx;1;b;1;786;99;99;792;100;100;0.61;0.61;97;0;1.85;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| HCI   hydrocinnamic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE HEXAMUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ams;1;b;1;771;97;97;792;100;100;1.16;1.18;98;0;1.85;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GUA   glutaric acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1yoo;1;b;1;780;99;99;792;100;100;0.85;0.86;95;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE MUTANT ATB17 WITH ISOVALERIC ACID;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1amr;1;b;1;786;99;99;792;100;100;0.61;0.61;98;0;1.85;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1bqa;1;b;1;758;96;96;792;100;100;1.47;1.52;98;0;1.85;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE P195A MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1asl;1;b;1;786;99;99;792;100;100;0.59;0.59;98;0;1.85;2.6;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLA   2-[(3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl)-amino]-2-methyl-succinic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;CRYSTAL STRUCTURES OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE IN TWO CONFORMATIONS: COMPARISON OF AN UNLIGANDED OPEN AND TWO LIGANDED CLOSED FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1qis;1;b;1;788;99;99;792;100;100;0.51;0.51;98;0;1.85;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE FROM ESCHERICHIA COLI, C191F MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1aam;1;b;1;746;94;94;788;99;99;1.65;1.72;97;0;1.85;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;THE STRUCTURAL BASIS FOR THE ALTERED SUBSTRATE SPECIFICITY OF THE R292D ACTIVE SITE MUTANT OF ASPARTATE AMINOTRANSFERASE FROM E. COLI;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1bqd;1;b;1;760;96;96;792;100;100;1.42;1.47;98;0;1.85;2.1;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE P138A/P195A DOUBLE MUTANT;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;290;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1asc;1;b;1;772;97;97;792;100;100;1.12;1.15;98;0;1.85;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE D223A(D222A) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;4a00;1;b;1;763;96;96;792;100;100;1.36;1.39;97;0;1.85;2.34;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PP3   alanyl-pyridoxal-5'-phosphate| PEG   di(hydroxyethyl)ether| GOL   glycerol;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ix7;1;b;1;771;97;97;792;100;100;1.14;1.16;98;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate Aminotransferase Active Site Mutant V39F maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1aia;1;b;1;769;97;97;792;100;100;1.20;1.23;98;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1amq;1;b;1;767;97;97;792;100;100;1.26;1.29;98;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAMINE 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN THREE FORMS;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1asf;1;b;1;760;96;96;792;100;100;1.42;1.47;98;0;1.85;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;THE STRUCTURAL BASIS FOR THE REDUCED ACTIVITY OF THE Y226F(Y225F) ACTIVE SITE MUTANT OF E. COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1aib;1;b;1;770;97;97;792;100;100;1.18;1.20;98;0;1.85;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| AKG   2-oxoglutaric acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;STRUCTURAL BASIS FOR THE CATALYTIC ACTIVITY OF ASPARTATE AMINOTRANSFERASE K258H LACKING THE PYRIDOXAL-5'-PHOSPHATE BINDING LYSINE RESIDUE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ix8;1;b;1;751;95;95;792;100;100;1.61;1.68;97;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate Aminotransferase Active Site Mutant V39F/N194A;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;3zzk;1;b;1;770;97;97;792;100;100;1.17;1.18;97;0;1.85;1.78;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| SO4   sulfate ion| GOL   glycerol;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1ix6;1;b;1;754;95;95;792;100;100;1.56;1.63;98;0;1.85;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate Aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Aspartate Aminotransferase Active Site Mutant V39F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;3zzj;1;b;1;762;96;96;792;100;100;1.38;1.41;97;0;1.85;2.5;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| SO4   sulfate ion| PEG   di(hydroxyethyl)ether| BME   beta-mercaptoethanol| GOL   glycerol;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Structure of an engineered aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1toe;1;b;1;774;98;98;792;100;100;1.05;1.06;97;0;1.85;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| SO4   sulfate ion;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;Unliganded structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;1tok;1;1art;1;b;1;787;99;99;792;100;100;0.58;0.58;98;0;1.85;1.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| MAE   maleic acid;PLP   pyridoxal-5'-phosphate| 0A0   2-methyl-l-aspartic acid;Maleic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;X-RAY CRYSTALLOGRAPHIC STUDY OF PYRIDOXAL 5'-PHOSPHATE-TYPE ASPARTATE AMINOTRANSFERASES FROM ESCHERICHIA COLI IN OPEN AND CLOSED FORM;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;100;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1cq6;1;b;1;782;99;99;792;100;100;0.79;0.80;100;0;1.5;2.7;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PY4   2-[o-phosphonopyridoxyl]-amino- butyric acid;Substrate Activation in Aspartate Aminotransferase;ASPARTATE AMINOTRANSFERASE COMPLEX WITH C4-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;2d7y;1;b;1;780;98;98;792;100;100;0.88;0.89;98;0;1.5;2.66;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate;Substrate Activation in Aspartate Aminotransferase;Aspartate Aminotransferase Mutant MA;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;2d7z;1;b;1;787;99;99;792;100;100;0.58;0.58;97;0;1.5;2.65;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Activation in Aspartate Aminotransferase;Aspartate Aminotransferase Mutant MAB Complexed with Maleic Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;no/data;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1b4x;1;b;1;781;99;99;792;100;100;0.81;0.82;99;0;1.5;2.45;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Activation in Aspartate Aminotransferase;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION, WITH BOUND MALEATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;2qbt;1;b;1;764;96;97;787;99;100;1.20;1.26;99;0;1.5;1.75;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Substrate Activation in Aspartate Aminotransferase;Structural Studies Reveal The Inactivation of E. coli L-aspartate aminotransferase by (S)-4,5-amino-dihydro-2-thiophenecarboxylic acid (SADTA) via Two Mechanisms (at pH 8.0);P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;8.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;2qb2;1;b;1;750;95;98;764;96;100;0.95;0.97;100;0;1.5;1.7;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;KST   n~6~-(5-carboxy-3-thienyl)-l-lysine| SO4   sulfate ion| PSZ   4-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]thiophene-2-carboxylic acid| PMP   4'-deoxy-4'-aminopyridoxal-5'-phosphate| GOL   glycerol;Substrate Activation in Aspartate Aminotransferase;Structural Studies Reveal the Inactivation of E. coli L-aspartate aminotransferase by (s)-4,5-dihydro-2thiophenecarboylic acid (SADTA) via two mechanisms (at pH 7.0).;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1toj;1;b;1;789;100;100;792;100;100;0.46;0.46;98;0;1.5;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Substrate Activation in Aspartate Aminotransferase;Hydrocinnamic acid-bound structure of SRHEPT mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1toi;1;b;1;789;100;100;792;100;100;0.45;0.45;98;0;1.5;1.9;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Substrate Activation in Aspartate Aminotransferase;Hydrocinnamic acid-bound structure of Hexamutant + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;3qpg;1;b;1;791;100;100;792;100;100;0.23;0.24;100;0;1.5;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate transaminase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;SO4   sulfate ion| EDO   1,2-ethanediol| CL   chloride ion| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;Substrate Activation in Aspartate Aminotransferase;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;2d65;1;b;1;784;99;99;792;100;100;0.69;0.70;96;0;1.5;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Activation in Aspartate Aminotransferase;Aspartate Aminotransferase Mutant MABC;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;no/data;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1cq8;1;b;1;790;100;100;792;100;100;0.38;0.38;100;0;1.5;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE (2.6.1.1);ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PY6   2-[o-phosphonopyridoxyl]-amino-hexanoic acid;Substrate Activation in Aspartate Aminotransferase;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C6-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1ari;1;b;1;788;99;99;792;100;100;0.50;0.50;99;0;1.5;2.3;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Activation in Aspartate Aminotransferase;Aspartate aminotransferase, W140H mutant, maleate complex;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.5;277;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1g4v;1;b;1;773;98;98;792;100;100;1.09;1.13;99;0;1.5;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate;Substrate Activation in Aspartate Aminotransferase;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/Y225F;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;3uak;1;c;1;710;90;90;791;100;100;2.29;2.36;95;0;1.5;3.232;diffraction;diffraction;792;812;Aspartate aminotransferase;De Novo designed cysteine esterase ECH14;ESCHERICHIA COLI;SYNTHETIC CONSTRUCT;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;MSE   selenomethionine;Substrate Activation in Aspartate Aminotransferase;Crystal Structure of De Novo designed cysteine esterase ECH14, Northeast Structural Genomics Consortium Target OR54;P00509;aspC b0928 JW0911;PF00155;no/data;no/data;no/data;c;7.5;no/data;5.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1g4x;1;b;1;766;97;97;792;100;100;1.29;1.34;99;0;1.5;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate;Substrate Activation in Aspartate Aminotransferase;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;5eaa;1;b;1;776;98;98;792;100;100;0.99;1.02;99;0;1.5;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate;Substrate Activation in Aspartate Aminotransferase;ASPARTATE AMINOTRANSFERASE FROM E. COLI, C191S MUTATION;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.50;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;2d64;1;b;1;784;99;99;792;100;100;0.69;0.70;96;0;1.5;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Activation in Aspartate Aminotransferase;Aspartate Aminotransferase Mutant MABC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;Q304P7,P00509;aspC,aspC b0928 JW0911;PF00155;c;7.5;no/data;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1spa;1;b;1;776;98;98;792;100;100;0.98;1.01;99;0;1.5;2.0;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;NPL   n-methyl-4-deoxy-4-amino-pyridoxal-5-phosphate;Substrate Activation in Aspartate Aminotransferase;ROLE OF ASP222 IN THE CATALYTIC MECHANISM OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE: THE AMINO ACID RESIDUE WHICH ENHANCES THE FUNCTION OF THE ENZYME-BOUND COENZYME PYRIDOXAL 5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;3aat;1;b;1;770;97;97;792;100;100;1.18;1.23;99;0;1.5;2.8;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;SO4   sulfate ion| PLP   pyridoxal-5'-phosphate;Substrate Activation in Aspartate Aminotransferase;ACTIVITY AND STRUCTURE OF THE ACTIVE-SITE MUTANTS R386Y AND R386F OF ESCHERICHIA COLI ASPARTATE AMINOTRANSFERASE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;no/data;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1x28;1;b;1;789;100;100;792;100;100;0.43;0.43;100;0;1.5;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PGU   n-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-l-glutamic acid;Substrate Activation in Aspartate Aminotransferase;Crystal Structure of e.coli AspAT complexed with N-phosphopyridoxyl-L-glutamic acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.5;297;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1g7w;1;b;1;767;97;97;792;100;100;1.26;1.31;99;0;1.5;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate;Substrate Activation in Aspartate Aminotransferase;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;2d5y;1;b;1;786;99;99;792;100;100;0.61;0.62;98;0;1.5;1.98;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Activation in Aspartate Aminotransferase;Aspartate Aminotransferase Mutant MC With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;2d63;1;b;1;786;99;99;792;100;100;0.61;0.61;98;0;1.5;2.05;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate| IVA   isovaleric acid;Substrate Activation in Aspartate Aminotransferase;Aspartate Aminotransferase Mutant MA With Isovaleric Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;no/data;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;2d61;1;b;1;787;99;99;792;100;100;0.55;0.55;98;0;1.5;2.01;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate| MAE   maleic acid;Substrate Activation in Aspartate Aminotransferase;Aspartate Aminotransferase Mutant MA With Maleic Acid;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.5;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1g7x;1;b;1;770;97;97;792;100;100;1.18;1.21;99;0;1.5;2.2;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PLP   pyridoxal-5'-phosphate;Substrate Activation in Aspartate Aminotransferase;ASPARTATE AMINOTRANSFERASE ACTIVE SITE MUTANT N194A/R292L/R386L;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.0;293;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1cq7;1;b;1;790;100;100;792;100;100;0.38;0.38;100;0;1.5;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PY5   2-[o-phosphonopyridoxyl]-amino-pentanoic acid;Substrate Activation in Aspartate Aminotransferase;ASPARTATE AMINOTRANSFERASE (E.C. 2.6.1.1) COMPLEXED WITH C5-PYRIDOXAL-5P-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1c9c;1;b;1;776;98;98;792;100;100;1.01;1.03;100;0;1.5;2.4;diffraction;diffraction;792;792;Aspartate aminotransferase;ASPARTATE AMINOTRANSFERASE;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;PP3   alanyl-pyridoxal-5'-phosphate;Substrate Activation in Aspartate Aminotransferase;ASPARTATE AMINOTRANSFERASE COMPLEXED WITH C3-PYRIDOXAL-5'-PHOSPHATE;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;8.0;298;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;4f5l;1;b;1;763;96;96;792;100;99;1.36;1.43;95;0;1.5;1.4;diffraction;diffraction;792;812;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| EDO   1,2-ethanediol;Substrate Activation in Aspartate Aminotransferase;A Theoretical Optimized Mutant for the Conversion of Substrate Specificity and Activity of Aspartate Aminotransferase to Tyrosine Aminotransferase: Chimera P7.;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;5.0;100;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;3qn6;1;b;1;767;97;97;788;99;100;1.16;1.19;99;0;1.5;1.79;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;3QN   (e)-n~6~-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-lysine| SO4   sulfate ion| EDO   1,2-ethanediol;Substrate Activation in Aspartate Aminotransferase;Crystal Structures of Escherichia coli Aspartate Aminotransferase Reconstituted with 1-Deaza-Pyridoxal 5'-Phosphate: Internal Aldimine and Stable L-Aspartate External Aldimine;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.5;no/data;3qn6_A;1ahy_A;2.07;2.59
2q7w;2;4dbc;1;1tog;1;b;1;783;99;99;792;100;100;0.75;0.76;98;0;1.5;2.31;diffraction;diffraction;792;792;Aspartate aminotransferase;Aspartate aminotransferase;ESCHERICHIA COLI;ESCHERICHIA COLI;SO4   sulfate ion| EDO   1,2-ethanediol| 3QP   (e)-n-{2-hydroxy-3-methyl-6-[(phosphonooxy)methyl]benzylidene}-l-aspartic acid;LLP   (2s)-2-amino-6-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid| HCI   hydrocinnamic acid;Substrate Activation in Aspartate Aminotransferase;Hydrocinnamic acid-bound structure of SRHEPT + A293D mutant of E. coli aspartate aminotransferase;P00509;aspC b0928 JW0911;PF00155;P00509;aspC b0928 JW0911;PF00155;c;7.5;no/data;7.5;100;3qn6_A;1ahy_A;2.07;2.59
